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PART	I:	General	introduction	
	
1.	The	role	of	the	(epi)genetic	landscape	in	normal	development	
1.1	Deciphering	the	‘code’	of	the	epigenome		
The	 revolutionary	 concept	 of	 the	 ‘epigenetic	 landscape’,	 raised	 by	 Conrad	
Waddington	more	than	fifty	years	ago,	was	fundamental	in	the	understanding	of	the	
processes	 controlling	 and	 driving	 the	 development	 of	 a	 multicellular	 organism,	
consisting	 of	 a	 large	 diversity	 of	 different	 cell	 types	 that	 arise	 from	 the	 pool	 of	
pluripotent	stem	cells,	exerting	distinct	cellular	functions	while	harboring	a	(nearly)	
identical	genetic	program.	The	transition	from	stem	cells	to	a	fully	differentiated	cell	
type	requires	orchestration	and	fine-tuning	of	transcriptional	programs	conveyed	by	
transcription	factors	interacting	with	various	DNA	regulatory	elements	embedded	in	
a	 specific	 epigenetic	 constellation,	 whereas	 mutations	 affecting	 the	 genetic	
information	of	the	cell	would	rewire	or	distort	the	cellular	differentiation	path1,2.	The	
epigenetic	landscape	therefore	plays	a	crucial	role	in	the	spatio-temporal	regulation	
of	 gene	expression	 to	 safeguard	normal	 development	 and	homeostasis.	 Important	
phenomena	such	as	X-chromosome	inactivation	and	paternal/maternal	imprinting	of	
loci	are	classic	examples	of	epigenetically	controlled	processes	required	for	accurate	
gene	 dosage	 regulation3-5.	 X-chromosome	 inactivation	 in	 females	 is	 a	 process	 that	
randomly	silences	one	of	 the	 two	X-chromosomes	during	early	embryogenesis	and	
involves	coating	of	the	chromosome	by	the	non-coding	RNA	XIST	as	well	as	DNA	and	
histone	methylation5.	
	
The	epigenetic	code	 is	a	constellation	of	DNA	methylation	patterns	 in	combination	
with	a	variety	of	post-translational	modifications	on	the	N-terminal	tails	of	the	core	
histone	proteins	H2A,	H2B,	H3	and	H4.	The	core	histones	assemble	into	octamers	to	
form	nucleosomes	covered	with	stretches	of	genomic	DNA	of	about	147bp	 in	size.	
The	 nucleosome	 is	 a	 repeating	 unit	 within	 the	 chromatin	 fiber	 and	 this	 structural	
organization	 allows	DNA	 compaction6.	 	 Along	 the	 chromatin	 template,	 domains	 of	
euchromatin	 and	 heterochromatin	 can	 be	 distinguished,	 delineating	 active	 and	
transcriptionally	 silent	 regions	 respectively5,	 as	 demarcated	 by	 specific	 epigenetic	
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modifications	and	nucleosome	positioning	at	these	sites.	The	chemical	modification	
of	 the	 DNA	 backbone	 by	 cytosine	 methylation	 forms	 the	 basis	 of	 the	 epigenetic	
landscape.	Methyl-binding	domain	(MBD)	proteins	(MBD1,	MBD2,	MD3,	MBD4	and	
MecP2)	 mediate	 transcriptional	 silencing	 by	 recruiting	 histone	 deacetylases	 and	
histone	 methyltransferases	 that	 mediate	 the	 formation	 of	 a	 compact	 chromatin	
structure7.	 In	 mammals,	 DNA-methylation	 patterns	 are	 newly	 established	 by	 the	
DNA	 methyltransferase	 3	 (DNMT3)	 family	 members	 and	 maintained	 over	 mitotic	
divisions	 by	 DNMT18.	 DNA	 methylation	 occurs	 at	 about	 70-80%	 of	 all	 CpG	
dinucleotides	genome-wide8.	Clusters	of	CpG	sites	mainly	occur	at	promoter	regions,	
termed	 CpG	 islands.	 Unmethylated	 CpG	 islands,	 together	 with	 gene	 body	
methylation,	 mark	 regions	 of	 active	 gene	 expression9.	 For	 a	 long	 time,	 cytosine	
methylation	was	considered	as	a	stable	modification10.	Instead,	it	is	now	known	that	
also	DNA	demethylation	plays	an	important	role	in	normal	development	and	cancer,	
underlying	 genomic	 instability11.	 Demethylation	 of	 the	 DNA	 template	 can	 occur	
either	 actively	 or	 passively.	 Passive	 DNA	 demethylation	 can	 occur	 during	 DNA	
replication.	 Instead,	 active	 DNA	 demethylation	 is	 a	 consequence	 of	 the	 catalytic	
activity	 of	 the	 ‘Ten	 Eleven	 Translocation’	 (TET)	 protein	 family	 	 (TET1,	 TET2,	 TET3).	
These	 TET	 enzymes	 convert	 5-methylcytosine	 (5mC)	 to	 the	 intermediate	 5-
hydroxymethylcytosine	 (5hmC),	 which	 can	 be	 further	 oxidized	 to	 5-formylcytosine	
and	5-carboxylcytosine12.	These	oxidation	products	can	then	be	efficiently	removed	
from	 the	 DNA	 template	 by	 the	 activity	 of	 the	 ‘thymine	 DNA	 glycosylase’	 (TDG)	
enzyme	and	replaced	by	an	unmethylated	cytosine	residue	during	DNA	repair	(base	
excission	repair).	In	addition,	active	DNA	demethylation	can	also	be	the	consequence	
of	 the	 conversion	 of	 5hmC	 to	 5-hydroxymethyluridine	 by	 the	 ‘activation-induced	
cytidine	 deaminase’	 (AID)	 enzymes	 and	 coupled	 DNA	 repair12.	 Passive	 DNA-
demethylation	 by	 TET	 enzymes	 is	 rather	 a	 consequence	 of	 the	 conversion	 they	
mediate	 of	 5mC	 to	 5hmC,	which	 inhibits	 the	 DNA	maintenance	methyltransferase	
DNMT1	from	further	DNA	association13.		
	
The	second	 layer	of	 the	epigenetic	 landscape	 is	embedded	within	a	 series	of	post-
translational	modifications	 (PTMs)	 that	 are	displayed	at	 the	N-terminal	 tails	of	 the	
core	histone	proteins	to	form	the	so-called	‘histone	code’14.	In	addition,	a	variety	of	
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histone	variants	can	replace	the	canonical	ones,	such	as	the	H2A	variant	H2AX,	which	
is	 incorporated	 into	 the	 nucleosomes	 at	 sites	 where	 DNA	 double-strand	 breaks	
occur15	 (Figure	 1A).	 There	 are	 at	 least	 eight	 different	 types	 of	 PTMs	 possible	 on	
histone	 tails	 such	as	 lysine	acetylation,	 lysine	and	arginine	methylation,	 serine	and	
threonine	phosphorylation	amongst	others,	that	can	be	of	different	forms	(eg	di-	or	
tri-methylation)16.	 Particular	 modifications	 can	 mark	 regions	 of	 active/inactive	
transcription.	 For	 example,	 active	 genes	 are	 marked	 by	 lysine	 acetylation	 at	 the	
histone	 H3	 and	 H4	 tails,	 tri-methylation	 of	 lysine	 4	 of	 histone	 H3	 (H3K4me3)	 and	
lysine	 36	 of	 histone	 H3	 (H3K36me3)	 amongst	 others.	 In	 contrast,	 transcriptionally	
silent	 regions	carry	high	 levels	of	 tri-methylation	of	H3	 lysine	9	 (H3K9me3)	and	27	
(H3K27me3)17.	 Moreover,	 histone	 modifications	 are	 also	 specific	 in	 demarcating	
various	 functional	 elements	 in	 the	 genome	 such	 as	 enhancers	 or	 transcribed	
regions18.	For	example,	H3K4me3	deposition	is	highly	correlated	to	the	presence	of	
unmethylated	CpG	islands	at	active	promoter	regions17	(Figure	1B).		
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Figure	 1:	 Histone	 PTMs	 (eg.	 methylation,	 acetylation,	 phosphorylation,	 …)	 and	 variants	 (eg.	 H3.3,	
H2AZ,	 …)	 (A)	 demarcate	 various	 functional	 elements	 in	 the	 genome	 (B):	 specific	 constellations	 of	
histone	 modifications	 discriminate	 inactive/active	 promoter	 and	 enhancer	 regions.	 Adapted	 from	
Tollervey	et	al.	(Epigenetics,	2012)3	and	Zhou	et	al.	(Nature	Reviews	Genetics,	2011)18.	
	
Histone	 modifications	 are	 dynamic	 in	 nature	 and	 a	 plethora	 of	 histone	 modifier	
enzymes	have	been	identified	in	the	last	decades	that	are	involved	in	the	deposition	
(‘writers’)	 or	 removal	 of	 the	 histone	 PTMs	 (‘erasers’)	 (Figure	 2).	 For	 example,	 the	
Polycomb	 group	 protein	 complex	 2	 (PRC2)	 component	 EZH2	 is	 a	 key	 regulatory	
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entity	 involved	 in	 gene	 silencing	 during	 normal	 differentiation	 by	 catalyzing	 the	
deposition	 of	 the	 H3K27me3	mark19.	 A	 third	 class	 of	 proteins	 can	 dock	 to	 certain	
histone	 modifications	 through	 a	 specific	 binding	 domain,	 but	 have	 no	 intrinsic	
enzymatic	activity	(‘readers’)	and	therefore	recruit	writers	and	erasers	to	control	the	
expression	 state	 of	 their	 targets.	 For	 example,	 the	 plant	 homeodomain	 (PHD)	 and	
chromodomain	 are	 the	 two	 most	 commonly	 found	 histone	 methyl-lysine	 binding	
domains20,21.			
	
	
Figure	 2:	 Histone	 modifier	 enzymes	 can	 be	 classified	 as	 epigenetic	 writers,	 readers	 and	 erasers.	
‘Writers’	and	‘erasers’	are	chromatin	modifiers	that	have	intrinsic	catalytic	activity	and	can	deposit	or	
remove	specific	histone	modifications	respectively.	Epigenetic	‘reader’	proteins	lack	the	capability	of	
catalyzing	the	deposition	of	post-translational	modifications	on	the	N-terminal	histone	tails,	but	can	
recognize	 and	 bind	 to	 a	 specific	 histone	 PTM	 through	 a	 specialized	 binding	 domain.	 Adapted	 from	
Fong	et	al.	(Haematologica,	2014)21.	
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Dynamic	 regulation	 of	 the	 chromatin	 template	 is	 important	 at	 the	 level	 of	
transcription,	translation	and	DNA-repair22.	Depending	on	the	constellation	or	cross-
talk	 between	 the	 different	 histone	 modifications	 at	 a	 specific	 site,	 different	
chromatin	modifiers	or	chromatin	remodelers	are	recruited	or	occluded	for	binding	
to	the	chromatin	template16.	Chromatin	remodeling	complexes	are	a	specific	class	of	
chromatin	 regulators	 that	 catalyze	 the	 eviction	 or	 deposition	 of	 nucleosomes	
coupled	to	ATP-hydrolysis.	Four	major	chromatin	remodeler	complexes	are	currently	
known:	the	‘Switching	defective/Sucrose	Non-Fermenting’	(SWI/SNF)	family,	‘Inositol	
requiring	 80’	 (INO80),	 ‘Imitation	 Switch’	 (ISWI)	 and	 the	 ‘Chromodomain	 helicase’	
(CHD)	 family23.	 Each	 of	 these	 chromatin	 remodeler	 complexes	 can	 exert	 diverse	
functions	 during	 normal	 human	 development.	 For	 example,	 INO80	 complexes	 are	
known	to	be	involved	in	cellular	processes	such	as	chromosome	segregation	and	cell	
cycle	 checkpoint	 control24.	 Also	 SWI-SNF	 complexes	 are	 crucial	 in	 mammalian	
development,	with	evidence	for	a	role	in	various	tissues	such	as	 in	development	of	
heart	and	muscles,	neuronal	development	and	hematopoiesis25.		
	
1.2	 Coordinated	 activity	 of	 hematopoietic	 master	 regulators	 within	 a	 dynamic	
epigenomic	landscape	is	essential	for	normal	hematopoietic	lineage	development		
Epigenetic	gene	expression	regulation	is	very	crucial	 in	the	context	of	a	plethora	of	
normal	 developmental	 programs,	 including	 the	process	 of	 hematopoiesis26.	During	
normal	 hematopoietic	 lineage	 specification,	 a	 series	 of	 gene	 expression	 programs	
are	 strictly	 orchestrated	 and	 fine-tuned	 to	 direct	 cell	 potential	 in	 a	 hierarchical	
manner	 to	 generate	 a	 specialized	 set	 of	 effector	 cells	 (Figure	 3).	 For	 example,	
generation	 of	 the	 T-cell	 repertoire	 requires	 homing	 of	 bone	 marrow	 derived	
hematopoietic	 progenitor	 cells	 to	 the	 thymus	microenvironment	 with	 subsequent	
proliferation	and	differentiation	across	different	developmental	phases	involving	the	
pool	 of	 early	 T-cell	 progenitors	 (ETP)	 that	 enter	 the	 thymus,	 over	 the	 double	
negative	stages	DN2a/2b	and	DN3a/3b	towards	the	development	of	double	positive	
(CD4+CD8+,	DP)	T-cells	expressing	a	 functional	alpha-beta	T-cell	 receptor	 (αβ	TCR+).	
Survival	 and	 proliferation	 of	 DN1	 and	 DN2	 cells	 is	 supported	 by	 the	 interleukin-7	
receptor	 (IL7R).	 During	 the	 DN3	 stage,	 a	 functional	 pre-TCR	 complex	 is	 generated	
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that	 leads	 to	 the	 generation	of	DN4	 stage	 cells.	 These	DN4	 cells	will	 express	 both	
CD4	and	CD8	molecules	at	their	surface	to	become	DP	stage	T-cells.	These	DP	cells	
will	eventually	undergo	further	TCR-rearrangements,	 leading	to	the	expression	of	a	
mature	TCR	αβ	receptor,	which	triggers	the	maturation	towards	single	positive	CD4	
or	CD8	T-cells27.	Naïve	CD4+	and	CD8+	single	positive	lymphocytes	emigrate	from	the	
thymus	 to	 the	 secondary	 lymphoid	 organs.	 There,	 CD4+	 T-cells	 will	 either	
differentiate	 into	 T-helper	 (Th)	 type	1	 or	 2	 cells,	whereas	CD8+	 cells	will	 evolve	 to	
cytotoxic	effector	T-cells.		
	
	
Figure	3:	Diagram	of	normal	hematopoietic	lineage	development	focusing	on	thymocyte	progenitors	
entering	the	thymus	microenvironment	with	indication	of	the	key	transcriptional	regulators	involved	
in	 different	 phases	 of	 lineage	 commitment.	 Blood	 lineage	 development	 is	 a	 hierarchical	
differentiation	process	starting	from	the	hematopoietic	stem	cell	(HSC)	that	gives	rise	to	the	branches	
of	 the	 lymphoid	 and	 myeloid	 lineages.	 From	 the	 common	 myeloid	 progenitor,	 amongst	 others	
monocytes	(purple)	arise	that	take	part	in	the	innate	immune	response.	Increased	PU.1	transcription	
factor	activity	will	 favor	monocytic	 commitment.	 In	contrast,	 the	common	 lymphoid	progenitor	will	
give	 rise	 to	 the	T-,	B-	and	NK-cell	 lineages.	The	transcription	 factor	E2A	 for	example	will	 trigger	 the	
initiation	 of	 B-lymphopoiesis.	 In	mammals,	 TCF1	 is	 exclusively	 expressed	 in	 T-lymphocytes	 and	 is	 a	
critical	gatekeeper	of	the	T-cell	fate	from	the	stage	of	thymus	seeding	to	the	development	of	effector	
T-cells.	Adapted	from	Yui	and	Rothenberg	(Nature	Reviews	Immunology,	2014)27.	
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The	most	important	factor	controlling	entrance	of	the	T-cell	developmental	program	
is	 NOTCH128.	 In	 humans,	 NOTCH1	 belongs	 to	 a	 family	 of	 four	 transmembrane	
receptors	(NOTCH1-4)	that	are	activated	by	ligands	that	either	belong	to	the	Serrate-
like	(Jagged	1	or	2)	or	the	Delta-like	ligand	(DLL1,	DLL3	and	DLL4)	families29.	Briefly,	
NOTCH1	signaling	is	triggered	by	activation	of	the	receptor	by	one	of	the	previously	
mentioned	 ligands,	which	 subsequently	 results	 in	 successive	 receptor	 cleavages	by	
ADAM-metalloproteases	 and	 the	 γ-secretase	 complex,	 ultimately	 leading	 to	 the	
formation	and	release	of	the	intracellular	NOTCH1	fragment	(ICN1)	(Figure	4).	Next,	
ICN1	will	translocate	to	the	nucleus	and	act	as	a	transcriptional	regulator	in	concert	
with	co-factors	such	as	‘Mastermind-like’	(MAML),	‘Suppressor	of	Hairless’	(CSL)	and	
‘Recombination	Signal	binding	Protein	for	Immunoglobulin	Kappa	J	region’	(RBPJκ)	to	
regulate	the	expression	of	canonical	targets	such	as	c-MYC,	DTX1,	HES1,	CCND330,31	
and	 IL7R32,33.	 The	 E3	 ubiquitin	 ligase	 ‘F-box	 and	WD	 repeat	 domain	 containing	 7’	
(FBXW7)	 is	 required	 for	 NOTCH1	 receptor	 turnover	 as	 it	 targets	 the	 receptor	 for	
proteasomal	degradation.	In	this	respect,	the	PEST	domain	of	the	NOTCH1	receptor	
tags	the	protein	for	FBXW7	mediated	proteasomal	degradation34.	A	‘PEST’	sequence	
is	composed	of	a	stretch	of	proline,	glutamic	acid,	serine	and	threonine	amino	acid	
residues	 that	 will	 target	 a	 protein	 for	 proteolytic	 degradation35.	 This	 signaling	
cascade	 is	 strongly	evolutionary	 conserved	and	mutations	 that	 affect	 this	pathway	
occur	in	a	variety	of	human	malignancies36.	For	the	NOTCH1	receptor	itself,	both	the	
heterodimerization	 domain	 as	 well	 as	 the	 PEST	 domain	 are	 hotspots	 for	 gain-of-
function	mutations37.	NOTCH1	signaling	is	crucial	to	drive	hematopoietic	progenitors	
into	the	T-cell	lineage	at	the	expense	of	development	towards	other	blood	lineages.	
Moreover,	it	also	assists	in	TCR-mediated	selection,	lineage	commitment	and	final	T-
cell	differentiation38.		
		
Chapter	1:	Introduction	
	 	 	11	
																																						
Figure	 4:	 The	 NOTCH1	 signaling	 pathway	 is	 an	 evolutionary	 conserved	 pathway	 in	 multicellular	
organisms.	 In	 brief,	 upon	 association	 of	 a	 suitable	 ligand	 (Delta	 or	 Serrate	 like	 family)	 to	 the	
transmembrane	 NOTCH1	 receptor,	 successive	 proteolytic	 cleavage	 reactions	 are	 initiated	 that	
eventually	 lead	to	the	formation	of	the	intracellular	NOTCH1	fragment	(ICN1).	This	ICN1	component	
can	 translocate	 to	 the	 nucleus	 and	 assembles	 towards	 a	 transcriptonal	 regulatory	 complex	 by	
association	with	its	co-factors	RBPJκ	and	MAML,	thereby	activating	the	expression	of	amongst	others	
canonical	 target	 genes	 such	 as	HES1,	DTX1,	NOTCH3,	CCND3,	…	 The	 ICN1	 fragment	 also	 contains	 a	
PEST	 domain	 (green)	 which	 targets	 this	 protein	 for	 proteolytic	 degradation	 upon	 recognition	 and	
association	with	the	FBXW7	E3	ubiquitin	ligase.	Adapted	from	Palomero	and	Ferrando	(Clinical	Cancer	
Research,	2008)33.	
	
In	 concert	 with	 NOTCH1,	 other	 master	 regulators	 are	 essential	 to	 guide	 the	
expression	 programs	 required	 for	 specification	 and	maintenance	 of	 T-cell	 identity.	
Several	 key	 transcriptional	 regulators	 are	 required	 across	 different	 T-cell	
developmental	phases	and	a	 specific	 active	 constellation	of	 transcription	 factors	 is	
required	 to	 establish	 the	 correct	 gene	 expression	 network	 for	 each	 stage.	 Three	
main	 transcriptional	 regulators	 are	 required	 to	 ensure	 correct	 T-cell	 specification:	
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BCL11B	plays	a	crucial	role	in	T-cell	lineage	commitment,	while	GATA3	and	TCF-1	are	
essential	 drivers	 in	 the	 T-cell	 differentiation	 process.	 	 GATA3	 exerts	 at	 least	 three	
major	roles	in	normal	T-cell	development:	specification	of	precursors	cells	to	the	T-
cell	 lineage,	 during	 TCR-αβ	 dependent	 positive	 selection	 and	 in	 the	maturation	 of	
Th2	 effector	 cells28.	 The	 key	 factors	 required	 at	 the	 final	 stages	 of	 T-cell	
differentiation	and	T-cell	maturation	are	the	transcriptional	regulators	HEB,	E2A	and	
LEF1	amongst	others	in	concert	with	BCL11B,	TCF-1	and	GATA327.	Both	E2A	and	HEB	
belong	 to	 the	 E	 protein	 family,	 binding	 to	 the	 E-box	 elements	 that	 are	 present	 in	
regulatory	elements	of	many	genes	encoding	key	T-cell	factors39.		
	
Gene	 expression	 regulation	 in	 the	 hematopoietic	 system	 not	 only	 involves	 the	
assembly	of	these	transcriptional	complexes	on	gene	regulatory	elements,	but	also	
depends	 on	 the	 accessibility	 of	 these	 regulators	 to	 their	 docking	 sites	 within	 the	
chromatin	template.	Coordinated	interaction	between	lineage-specific	transcription	
factors	and	 the	epigenetic	 landscape	 is	 thus	 required	 to	 secure	 correct	 checkpoint	
regulation40.	At	the	level	of	DNA-methylation,	DNMT1	has	an	essential	role	in	T-cell	
maturation,	as	deletion	of	Dnmt1	 in	double	negative	T-cells	 in	a	conditional	knock-
out	 mouse	 model,	 leads	 to	 massive	 de-methylation	 and	 a	 large	 reduction	 in	 cell	
numbers	of	double	positive	and	more	mature	T-cell	 stages41.	 Lineage	commitment	
also	 involves	 changes	 at	 the	 level	 of	 DNA-methylation.	 It	 has	 been	 shown	 that	
myeloid	lineage	commitment	involves	less	global	DNA-methylation	in	comparison	to	
the	lymphoid	lineage42.	For	example,	at	the	level	of	T-cell	development,	the	TCR-loci	
of	double-negative	stage	T-cells	are	methylated,	while	de-methylation	of	these	sites	
is	 required	 to	 allow	 recombination	 for	 the	 formation	 of	 a	 functional	 pre-TCR	
complex7.	In	addition,	also	integrity	of	the	chromatin	structure	is	essential	in	support	
of	normal	T-cell	development.	This	 is	nicely	 illustrated	by	 the	study	of	Gebuhr	and	
co-workers43	 showing	that	deficiency	 for	 the	SWI-SNF	ATPase	subunit	Brg1	 in	mice	
leads	to	a	block	at	the	DN	to	DP	stage	transition	and	impairs	processes	downstream	
of	pre-TCR	signaling.	 In	addition,	 it	has	been	shown	that	 loss	of	Snf5,	another	core	
component	 of	 the	 SWI-SNF	 complex,	 leads	 to	 development	 of	mature	 CD8+	 T-cell	
lymphoma	in	100%	of	the	Snf5	deficient	mice	within	a	couple	of	weeks	after	knock-
out44.	
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2.	The	epigenetic	basis	of	cancer	
	
2.1.	The	hallmarks	of	cancer	
The	 ‘Hallmarks	 of	 Cancer’	 concept	 as	 proposed	 by	 Hanahan	 and	 Weinberg	 has	
provided	a	 framework	 to	understand	 the	principles	of	 cancer	biology.	 The	authors	
were	 among	 the	 first	 to	make	 a	 synopsis	 starting	 from	 a	 bewildering	 and	 rapidly	
growing	amount	of	genetic	and	biological	data	on	the	causes	of	cancer	and	behavior	
of	 tumor	 cells45.	 The	 initially	 proposed	 six	 biological	 features	 acquired	 along	 the	
multi-step	process	of	tumor	formation	allow	cancer	cells	to	breech	multiple	cellular	
safeguards	 allowing	 for	 proliferation	 and	 cell	 renewal,	 unlimited	 growth,	
angiogenesis,	invasion	and	metastasis	and	evasion	of	cell	death46.	Ten	years	after	the	
initial	publication	and	 thousands	of	citations	 later,	 the	authors	added	a	number	of	
further	 essential	 cellular	 traits	 acquired	 by	 most	 if	 not	 all	 cancer	 cells	 i.e.	
maintenance	 of	 genomic	 stability,	 sustained	 energy	 supply	 related	 to	 the	 rewired	
metabolic	 cancer	 cell	 circuitry	 and	 tumor	 promoting	 inflammation45.	 In	 addition,	
tumor	cells	are	not	isolated	but	are	in	continuous	communication	to	their	immediate	
surrounding	 thus	 inducing	 the	 formation	 of	 a	 tumor	 microenvironment.	 This	
microenvironment	 is	 constituted	 of	 the	 tumor	 cells,	 the	 tumoral	 stroma,	 blood	
vessels,	inflammatory	cells	and	associated	tissue	cells47	and	plays	a	crucial	role	both	
locally	to	escape	from	immunological	defense	mechanisms	as	well	as	to	settle	distal	
metastasis48.	 Since	 the	 tumor	microenviroment	 plays	 a	 crucial	 role	 in	 oncogenesis	
and	 metastasis,	 this	 now	 also	 forms	 a	 novel	 target	 for	 cancer	 prevention	 and	
therapy47.	
	
2.	2.	Genetic	and	epigenetic	alterations	as	drivers	of	the	cancer	hallmarks		
The	 field	 of	 cancer	 genomics	 has	 rapidly	 evolved	 as	 a	 consequence	 of	 recent	
advances	 in	 sequencing	 technologies.	 Over	 the	 past	 decades,	 a	 comprehensive	
catalogue	 of	 somatic	 mutations	 has	 been	 established	 and	 underscored	 tumor	
heterogeneity	 across	 different	 tumor	 types	 and	 within	 a	 single	 tumor49.	 Tumors	
typically	acquire	a	series	of	mutations	over	time.	 ‘Gatekeeper’	mutations	arise	first	
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and	 confer	 a	 growth	 advantage	 to	 normal	 cells	 at	 the	 start	 of	 malignant	
transformation.	 Uncontrolled	 proliferation	 of	 the	 established	 tumor	 cells	 is	
eventually	 supported	 by	 so-called	 ‘driver’	 mutations.	 In	 keeping	 with	 the	 concept	
that	 cancer	 arises	 through	 (epi-)genetic	 alterations	 driving	 most	 if	 not	 all	 cancer	
hallmarks,	 the	 vast	 majority	 of	 tumor	 entities	 harbour	 multiple	 of	 these	 driver	
mutations.	 In	 addition,	 genomically	 unstable	 tumors	 and/or	 tumor	 cells	 arising	
through	 exposure	 to	 carcinogens	 (eg.	 smoke,	 UV-rays,	 …)	 like	 in	 lung	 cancer	 or	
melanoma	development,	can	exhibit	hundreds	or	more	additional	mutations	which	
have	no	immediate	obvious	cellular	advantage	and	are	called	passenger	mutations50.	
Most	of	the	driver	mutations	can	be	assigned	to	twelve	critical	signaling	pathways,	
such	as	the	RAS-signaling,	the	MAPK	cascade	and	the	NOTCH	pathway.	Cancer	cells	
not	 only	 display	mutations	 but	 also	 exhibit	 a	 variety	 of	 chromosomal	 aberrations,	
such	as	aneuploidy,	chromosomal	deletions,	 inversions	and	translocations	resulting	
in	 the	 aberrant	 activation	 of	 cellular	 proto-oncogenes,	 generation	 of	 novel	 fusion	
oncogenes	or	the	silencing	of	tumor	suppressor	genes.	
During	 recent	 years,	 a	 new	 dimension	 has	 been	 added	 to	 the	 field	 of	 cancer	
research.	 It	 is	 now	 clear	 that	 aberrant	 DNA-methylation	 patterns	 and	 changes	 in	
histone	 modification	 significantly	 contribute	 to	 tumorigenesis	 besides	 genetic	
mutations	 and	 genomic	 rearrangements.	 Bernstein	 and	 Vogelstein	 discovered	 the	
first	 epigenetic	 aberration	 in	 cancer	 cells:	 loss	 of	 DNA	 methylation9,51	 (Figure	 5).	
Indeed,	 CpG	 islands	 of	many	 oncogenes	 become	hypomethylated,	 leading	 to	 their	
aberrant	activation.	Moreover,	DNA	hypomethylation	is	intricately	linked	to	genomic	
instability52.	In	addition,	hypermethylation	occurs	leading	to	epigenetic	silencing	of	a	
range	of	tumor	suppressor	genes,	mainly	those	implicated	in	cell	cycle	regulation	(eg	
p16)	and	DNA	repair	(eg	MHL1	and	BRCA1)53.	Aberrant	methylation	might	be	directly	
caused	 by	 previous	 genetic	 alterations.	 This	 is	 nicely	 illustrated	 by	 the	 aberrant	
expression	 of	 the	 fusion	 protein	 PML-RARA	 in	 some	 types	 of	 leukemia,	 leading	 to	
recruitment	 of	 DNA-methyltransferases	 and	 histone	 deacetylases.	 In	 addition,	
changes	in	the	DNA-methylation	pattern	are	correlated	to	aberrations	in	the	histone	
modification	profile.	As	such,	CpG	island	hypermethylation	is	often	accompanied	by	
loss	of	acetylation	and	lysine	trimethylation	of	histone	H3	and	gain	of	trimethylation	
of	lysine	9	and	27.	
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Figure	 5:	 (A)	 DNA	methylation	 patterns	 under	 normal	 and	malignant	 conditions9,	white	 hexagons:	
unmethylated	 CpG	 sites,	 blue	 hexagons:	 methylated	 CpG	 sites.	 (B)	 Passive	 and	 active	 DNA	
demethylation	involving	TET-enzymatic	activity:	(left)	passive	demethylation	involves	the	conversion	
of	5-methylcytosine	 residues	 (blue	hexagons)	 to	5-hydroxymethylcytosine	 (green	hexagons)	by	TET-
enzymes,	which	will	 inhibit	DNMT1	from	cytosine	methylation	upon	replication,	eventually	resulting	
in	 replacement	 of	 5-hydroxymethylcytosine	 to	 unmethylated	 cytosine	 residues	 (white	 hexagons);	
(right)	Active	DNA	demethylation	involves	consecutive	action	of	the	TET	enzyme	family	to	convert	5-
methylcytosine	 (blue	 hexagon)	 to	 5-hydroxymethylcytosine	 and	 subsequent	 conversion	 towards	
further	oxidative	products	5-formylcytosine	(red	hexagon)		and	5-carboxylcytosine	(orange	hexagon).	
The	 latter	 cytosine	derivatives	will	 be	 the	 substrate	 for	 the	 ‘thymine	DNA	glycosylase’	 enzyme	and	
coupled	base	excision	repair	to	remove	these	oxidation	products	and	replace	them	by	unmethylated	
cytosine	residues	(white	hexagons)12.	
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DNA	methylation	drew	most	of	the	attention	in	the	epigenetic	cancer	research	field.	
For	a	 long	time,	5mC	was	the	only	epigenetic	modification	recognized	for	 the	DNA	
template.	 Now,	 the	 role	 of	 5hmC	 is	 also	 firmly	 established	 in	 the	 context	 of	
differentiation	 of	 various	 tissues,	 for	 example	 with	 strong	 enrichment	 of	 this	
modification	in	neuronal	tissue54	and	high	levels	in	pluripotent	cells55.	Interestingly,	a	
recent	 study	by	Hon	et	 al.56	 showed	 that	 5hmC	 is	 especially	 enriched	 at	 enhancer	
sites,	 thereby	 revealing	 a	 role	 for	 DNA	 demethylation	 in	 dynamic	 enhancer	
regulation	 during	 differentiation.	 Given	 the	 recent	 amazing	 discovery	 that	 nearly	
20%	 of	 all	 mutations	 across	 cancer	 types	 target	 various	 epigenetic	 regulators	
impacting	 on	 not	 only	 DNA	 methylation	 but	 also	 all	 aspects	 of	 chromatin	
modification	 and	 even	 upstream	metabolic	 pathways	 the	 interest	 in	 the	 study	 of	
cancer	 epigenetics	 was	 further	 boosted.	 Moreover,	 an	 increasing	 number	 of	
epigenetic	 drugs	 are	 under	 development	 or	 being	 tested,	 further	 fueling	 interest	
from	academic	research	and	pharma57.	Among	the	recently	described	mutations	are	
those	affecting	DNMT1	and	DNMT3,	with	a	high	frequency	of	DNMT3A	mutations	in	
AML	 (30%).	 Genetic	 changes	 in	 histone	 modifiers	 are	 rather	 cancer-specific58.	 In	
leukemia,	recurrent	translocations	affecting	histone	acetyltransferases/deacetylases	
and	histone	methyltransferase/demethylase	enzymes	underscored	their	importance	
in	 this	 pathology59.	 For	 example,	 translocations	 involving	 the	 histone	
methyltransferase	 ‘mixed	 lineage	 leukemia’	 (MLL)	 frequently	 occur	 in	 acute	
leukemia	 and	 lead	 to	 the	 generation	 of	 a	 variety	 of	 fusion	 proteins	 that	 cause	
aberrant	 H3K4me3	 methylation60.	 In	 myeloid	 leukemia,	 recurrent	 mutations	 and	
deletions	 are	 identified,	 affecting	 the	 genes	 encoding	 the	 epigenetic	 modifiers	
ASXL1,	DNMT3A,	EZH2,	IDH1/2,	MLL1/2	and	TET261.		
Genome-wide	 changes	 in	 5hmC	 contribute	 to	 malignant	 transformation	 in	
hematological	 cancers	 as	 well	 as	 in	 solid	 tumors	 (breast	 cancer,	 colon	 cancer,	
prostate	 cancer,	melanoma)11.	 From	all	 TET	 family	members,	mainly	 TET2	 fulfills	 a	
key	role	in	normal	hematopoietic	development62.	The	function	of	TET2	is	hampered	
by	 recurrent	 inactivating	 mutations	 both	 in	 myeloid	 and	 lymphoid	 hematological	
cancer	 types63.	 Recently,	 cooperative	 DNMT3A	 mutations	 were	 described	 to	 be	
cooperative	with	TET2	inactivation,	required	for	full-blown	leukemogenesis64.	
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While	most	of	the	mutations	 in	the	above	mentioned	genes	cause	 loss-of-function,	
the	 Polycomb	 group	 repressive	 complex	 2	 catalytic	 component	EZH2	 is	 frequently	
overexpressed	in	many	cancer	types	such	as	breast,	lung	and	prostate	cancer,	while	
acting	 as	 tumor	 suppressor	 in	 the	 context	 of	 some	 hematological	 malignancies	
characterized	by	EZH2	inactivating	mutations65.	Identifying	the	dependency	of	many	
cancer	types	on	somatic	alterations	in	various	chromatin	modifiers	has	triggered	the	
generation	of	targeted	epigenetic	therapeutic	strategies	such	as	EZH2	inhibitors.	
	
3.	 Genetic	 and	 epigenetic	 deregulation	 in	 T-cell	 acute	 lymphoblastic	
leukemia	
3.1	The	molecular-cytogenetic	profile	of	T-cell	acute	lymphoblastic	leukemia	
T-cell	 acute	 lymphoblastic	 leukemia	 originates	 from	 thymocytes	 that	 are	
developmentally	arrested	at	a	specific	maturation	stage	with	concomitant	aberrant	
clonal	expansion	of	these	blasts.	Leukemic	transformation	of	thymocyte	progenitor	
cells	is	a	paradigm	for	the	multi-step	nature	of	tumor	formation	in	which	a	plethora	
of	 genetic	 aberrations	 collectively	 contribute	 to	 the	 formation	 of	 a	 full-blown	
leukemia.	Various	cellular	processes	are	being	affected	such	as	cell	cycle	regulation,	
differentiation	 and	 cell	 survival,	 coupling	 back	 to	 the	 capabilities	 that	 need	 to	 be	
acquired	for	tumor	formation66.	From	a	molecular	perspective,	T-ALL	patients	can	be	
classified	 into	 genetic	 subtypes	 that	 are	 defined	 by	 the	 aberrant	 expression	 of	 a	
specific	 driver	 oncogene	 and	 are	 characterized	 by	 a	 unique	 gene	 expression	
signature67,68.	Structural	chromosomal	aberrations	are	identified	in	about	50%	of	all	
T-ALL	patients.	 Translocations	 involving	 the	TCR	 loci	on	14q11	 (TCR-α/δ)	 and	7q34	
(TCR-β)	 occur	 in	 35%	 of	 all	 T-ALLs.	 This	 results	 in	 the	 juxtaposition	 of	 control	
elements	 of	 the	 T-cell	 receptor	 (TCR)	 loci	 with	 oncogenes	 such	 as	 TAL1,	 LMO1/2,	
LYL1,	 TLX1,	 TLX3,	 MYB	 and	 HOXA69.	 Each	 of	 these	 translocations	 induce	 a	
developmental	 arrest	 of	 progenitor	 T-cells	 at	 a	 specific	 developmental	 stage	 that	
define	the	major	T-ALL	subtypes.	Both	LYL1	and	TAL1	are	ectopically	expressed	in	the	
thymus	 in	 T-ALL	 and	 interfere	with	 normal	 T-cell	 development	 by	 binding	 EA	 and	
HEB70.	 LYL1	expression	 defines	 the	 immature	 T-ALL	 subtype	 ‘early	 T-cell	 precursor	
acute	lymphoblastic	leukemia’	(ETP-ALL).	Additional	genetic	lesions	marking	ETP-ALL	
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are	 found	 in	RUNX1,	GATA3,	 ETV6	 and	MEF2C	 amongst	 others71.	 The	 latter	 T-ALL	
subtype	is	associated	with	a	poor	prognosis	(see	also	Part	II72).	Aberrant	expression	
of	LMO1	and	LMO2	occurs	in	45%	of	T-ALL	driven	by	their	juxtaposition	to	the	TCR-α	
locus.	The	aberrant	activation	of	HOXA	genes	in	T-ALL	occurs	due	a	cryptic	inversion	
inv(7)	or	the	translocation	t(7;7).	The	homeobox	transcription	factors	TLX1	and	TLX3	
cause	 a	 T-cell	 developmental	 arrest	 at	 the	 early	 cortical	 stage.	 Aberrant	 TLX1	
expression	 occurs	 in	 about	 10%	 of	 pediatric	 and	 30%	 of	 adult	 T-ALL67,73-75	 and	 is	
mainly	 driven	 through	 a	 t(10;14)(q24;q11)	 or	 t(7;10)(q34;q24)	 translocation,	 with	
juxtaposition	 to	 the	 TCR-α	 and	 TCR-β	 locus	 respectively.	 TLX1-driven	 leukemia	 is	
characterized	 by	 a	more	 favorable	 prognosis	 than	 all	 other	 T-ALL	 subtypes.	 TLX1-
expressing	T-ALL	presents	with	specific	genetic	alterations	 that	only	 rarely	occur	 in	
other	 genetic	 subgroups,	 such	 as	 PTPN2	 deletion76	 or	 mutations	 in	 PHF677.	
Overexpression	 of	 TLX3	 in	 T-ALL	 is	 driven	 by	 the	 translocation	 t(5;14)(q35;q32),	
juxtaposing	TLX3	 to	the	distal	 region	of	BCL11B	and	occurs	 in	25%	of	pediatric	and	
5%	of	adult	T-ALL.	Also	the	formation	of	fusion	genes	such	as	CALM-AF10	and	MLL-
ENL	 further	 contribute	 to	 deregulated	 T-cell	 differentiation	 through	 aberrant	
activation	of	HOXA	expression.	The	CALM-AF10	fusion	occurs	in	about	10%	of	T-ALL	
patients	and	is	associated	with	a	poor	prognosis78.	As	previously	mentioned,	the	MLL	
locus	participates	in	many	translocations	in	leukemia,	which	are	also	found	in	about	
4-8%	 of	 T-ALL.	 They	 represent	 a	 T-ALL	 molecular	 subtype	 that	 is	 associated	 with	
commitment	 to	 the	 γδ-lineage69.	 Other	 genetic	 abnormalities	 occur	 across	 the	
different	 T-ALL	 genetic	 subgroups	 and	 will	 interfere	 with	 cell	 cycle	 regulation	 (eg	
CDKN2A	 deletion),	 contribute	 to	 unlimited	 self-renewal	 capacity	 (eg	 mutations	 in	
NOTCH1,	FBXW7,	PTEN),	deregulate	crucial	 signaling	pathways	 (eg	 IL7R,	RAS,	PI3K-
AKT),	affect	translation	(eg	mutations	of	RPL5,	RPL10),	etc.	Deletion	of	the	CDKN2A	
locus,	including	both	tumor	suppressor	genes	p14	and	p16	occurs	in	70%	of	all	T-ALL	
patients66.	
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3.2	The	role	of	NOTCH1	signaling	in	T-ALL	
As	 previously	 described,	 NOTCH1	 is	 important	 in	 both	 T-cell	 lineage	 commitment	
and	 pre-TCR	 signaling38.	 Ablation	 of	 this	 signaling	 pathway	 results	 in	 a	 complete	
differentiation	 block	 of	 thymocytes	 at	 the	 earliest	 phases	 of	 thymocyte	
development79.	Hyperactivation	of	NOTCH1	 is	the	oncogenic	hallmark	of	T-ALL	that	
occurs	 across	 different	 genetic	 subgroups	 and	 is	 either	 established	 through	
mutations	 (>60%	 of	 all	 cases)	 or	 translocation	 of	 the	 TCR-β	 enhancer	 with	 the	
NOTCH1	 locus	 (1%	 of	 T-ALLs).	 Activating	 mutations	 are	 either	 found	 in	 the	
heterodimerization	 domain	 of	 the	 receptor	 (44%)	 or	 in	 the	 PEST-domain	 (30%)	 or	
both	 (17%	 of	 all	 cases).	 The	 E3	 ubiquitin	 ligase	 FBXW7	 is	 required	 for	 NOTCH1	
receptor	turnover	by	targeting	for	proteasomal	degradation	and	FBXW7	inactivating	
mutations,	which	 occur	 in	 about	 15%	 of	 all	 T-ALLs,	 can	 thus	 further	 contribute	 to	
hyperactivation	of	the	NOTCH1	pathway	in	T-ALL.	The	exceptional	high	prevalence	of	
NOTCH1	 aberrations	 in	 T-ALL	 provides	 opportunities	 for	 therapeutic	 targeting.	
Gamma-secretase	 inhibitors	 (GSI)	 are	 a	 classical	 example	 of	 small	 molecules	 that	
block	 oncogenic	 NOTCH1	 by	 interfering	 with	 the	 activity	 of	 the	 gamma-secretase	
complex	and	thus	preventing	the	formation	of	ICN1.	The	clinical	applicability	of	GSI	
compounds	has	been	hampered	by	induction	of	gastro-intestinal	toxicity	as	a	major	
side	 effect,	 as	 a	 consequence	 of	 NOTCH1	 inhibition	 in	 the	 gut.	 	 Interestingly,	
combination	 therapy	 of	 GSIs	 and	 glucocorticoids	 have	 shown	 to	 improve	 the	
therapeutic	 efficacy	 of	 GSI	 treatment	 (allow	 for	 reduced	 dosing)	 and	 diminish	 the	
toxic	side-effects	to	the	gastro-intestinal	system80,81.	Recently,	Pinell	and	co-workers	
proposed	that	therapeutic	targeting	of	ZMIZ1,	an	important	NOTCH1	co-factor,	could	
provide	 opportunities	 to	 interfere	 with	 hyperactive	 NOTCH1	 signaling,	 while	
circumventing	interference	with	intestinal	homeostasis82.		
It	 was	 shown	 that	 aberrant	 NOTCH1	 signaling	 also	 interferes	 with	 normal	 gene	
regulation	 at	 the	 level	 of	 the	 epigenome,	 as	 constitutive	 signaling	 through	 the	
NOTCH1	 receptor	 triggers	 global	 H3K27me3	 demethylation	 by	 antagonizing	 PRC2	
activity83.	Moreover,	the	histone	demethylase	JMJD3	facilitates	part	of	the	NOTCH1	
transcriptional	program	through	its	direct	interaction	with	ICN184	(see	also	3.4).		On	
the	other	hand,	 upstream	mechanisms	 that	 control	NOTCH1	activity	 could	 also	be	
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exploited	 for	 therapeutic	 purposes.	 For	 example,	 the	 cyclin	 C-CDK8	 complex	 is	
known	to	be	involved	in	transcriptional	regulation,	but	more	importantly	is	capable	
to	 control	 ICN1	 levels	 through	 phosphorylation,	 which	 subsequently	 promotes	 its	
degradation	by	FBXW7.	To	study	the	role	of	cyclin	C	(CCNC	gene)	in	T-ALL,	Li	et	al.85	
developed	an	in	vivo	conditional	knockout	model	and	crossed	it	with	an	Mx1-Cre	line	
to	ablate	cyclin	C	expression	specifically	in	the	hematopoietic	lineage.	The	resulting	
progeny	was	characterized	by	an	enlarged	thymus,	due	to	an	 increased	number	of	
thymocytes.	Moreover,	higher	levels	of	ICN1	were	present	in	both	precursor	T-cells	
and	 bone	marrow	 cells	 compared	 to	 those	 of	 the	 wild-type	mice.	 Primary	 T-ALLs	
show	 heterozygous	 loss	 in	 CCCNC,	 with	 the	 remaining	 allele	 being	 unaffected,	
suggesting	that	cyclin	C	acts	as	a	novel	haploinsufficient	tumor	suppressor	in	T-ALL.	
Finally,	 point	 mutations	 affecting	 the	 cyclin	 C-CDK	 phosphorylation	 sites	 of	 ICN1	
were	 found	 as	 another	 mechanism	 by	 which	 these	 hematological	 neoplasms	 can	
escape	phosphorylation	triggered	ICN1	degradation.			
	
3.3	The	genomic	landscape	of	TLX1	driven	leukemia	
Besides	NOTCH1,	also	 ‘T-cell	 leukemia	homeobox	1’	 (TLX1	or	HOX11)	and	TLX3	 are	
key	T-ALL	transcription	factor	oncogenes.	Physiologically,	the	TLX1	protein	has	a	role	
in	 splenogenesis86	 and	 neuronal	 development87.	 In	 T-ALL	 patients	 however,	 as	
previously	mentioned,	TLX1	is	ectopically	expressed	in	thymic	progenitor	cells	due	to	
translocations	 that	 juxtaposes	 TLX1	 to	 the	 T-cell	 receptor	 (TCR)-δ	 or	 TCR-β	
associated	 regulatory	 elements	 respectively	 (Figure	 6)67.	 This	 genetic	 aberration	
eventually	results	in	aneuploidy	(defective	mitotic	checkpoint	activation)	and	causes	
an	 arrest	 of	 developing	 thymocytes	 at	 the	 early	 cortical	 stage	 of	 T-cell	
development88-90.	Dadi	and	co-workers91	have	elegantly	shown	that	this	maturation	
block	involves	a	physical	association	between	TLX1	and	the	ETS1	protein,	forming	a	
repressive	 complex	 that	 blocks	 the	 activity	 of	 the	 TCR	 alpha	 enhancer	 region,	
eventually	interfering	with	correct	TCR	rearrangements	(Figure	6).	In	another	study,	
Della	 Gatta	 and	 colleagues92	 could	 show	 that	 besides	 ETS1,	 RUNX1	 also	 acts	 as	 a	
crucial	 regulator	within	 the	TLX1	 transcriptional	network.	 	 From	 this	 study,	RUNX1	
emerged	as	the	most	interconnected	hub	in	the	TLX1-TLX3	network,	identifying	this	
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factor	 as	 a	 key	 regulator	 of	 TLX1-TLX3	 driven	 transcriptional	 programs.	Moreover,	
RUNX1	is	most	significantly	downregulated	in	TLX1-positive	leukemia	and	recurrently	
mutated	 in	 T-ALL	 (about	 5%),	 underscoring	 RUNX1	 as	 an	 important	 tumor	
suppressor	in	this	T-ALL	subtype92.	TLX1	driven	tumors	show,	in	comparison	to	other	
T-ALL	subtypes,	a	gene	expression	signature	that	 is	primarily	characterized	by	gene	
repression,	 indicative	 for	 the	 role	 of	 TLX1	 as	 a	 transcriptional	 repressor	 in	 T-ALL.	
Many	of	 these	targets,	such	as	BRCA2	and	CHEK1,	are	 involved	 in	well-defined	key	
tumor	suppressor	activities	and	their	repression	by	TLX1	converges	towards	 loss	of	
mitotic	checkpoint	control	and	chromosomal	missegregation.	In	murine	TLX1-driven	
leukemia,	 78%	 of	 all	 tumors	 are	 aneuploid.	 Murine	 models	 of	 TLX1-induced	
leukemias	 exhibited	 a	 very	 long	 latency	 of	 leukemia	 onset	 (>30	weeks),	 indicative	
that	cooperating	mutations	are	required	to	establish	overt	leukemia93.		
Hyper-activating	NOTCH1	 mutations	 occur	 in	 over	 50%	 of	 all	 T-ALL	 patients	 while	
intriguingly	they	are	present	in	more	than	90%	of	all	TLX1-positive	cases94	suggesting	
a	 very	 strong	 interrelationship	 between	 TLX1	 driven	 leukemia	 formation	 and	 the	
cooperative	NOTCH1	mutations.	In	this	thesis,	we	provide	an	explanation	through	an	
unusual	transcriptional	antagonism	of	both	T-ALL	oncogenes	at	pre-leukemic	stages	
of	 T-ALL	 development.	 More	 specifically,	 TLX1	 downregulates	 most	 of	 the	 core	
components	 of	 the	 NOTCH1	 signaling	 pathway	 and	 therefore	 requires	 additional	
oncogenic	 NOTCH1	 activation	 in	 order	 for	 full-blown	 T-ALL	 development	 to	 occur	
(see	paper	1,	Chapter	3).		
	
As	indicated	above,	while	unexpectedly	repressing	NOTCH1	signaling,	TLX1	represses	
a	 plethora	 of	 T-ALL	 associated	 tumor	 suppressor	 genes,	 driving	 TLX1	 positive	
leukemia	to	a	fully	malignant	state95.	Inactivating	mutations	affect	the	expression	of	
several	 tumor	 suppressor	 genes	 such	 as	 BCL11B93,	 PTPN276,	 WT196	 and	 PHF677	
amongst	others.	Moreover,	 focal	deletions	of	Bcl11b,	Pten	and	Cdkn2a/b	are	often	
found	in	TLX1-driven	mouse	models	of	T-ALL93,95.		
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Figure	 6:	 TLX1	 is	 ectopically	 expressed	 in	 developing	 thymocytes	 due	 to	 a	 t(10;14)	 or	 t(7;10)	
translocation.	 TLX1	 forms	 a	 repressor	 complex	with	 RUNX1	 and	 ETS1	 at	 the	 TCR-α	 enhanceosome,	
thereby	 inducing	 a	 developmental	 arrest	 at	 the	 DN-DP	 T-cell	 stage	 transition	 and	 interferes	 with	
normal	 TCR-rearrangements	 ultimately	 leading	 to	 T-ALL	 blast	 formation.	 Adapted	 from	 Dadi	 et	 al.	
(Cancer	Cell,	2012)91		
	
	
3.4	The	T-ALL	epigenome	
Huether	 and	 co-workers	 have	 shown	 that	 T-cell	 acute	 lymphoblastic	 leukemia	 (T-
ALL),	 is	 characterized	 by	 one	 of	 the	 highest	 mutational	 frequencies	 in	 chromatin	
modifiers	across	a	large	panel	of	pediatric	cancer	entities97	and	thus	present	a	novel	
pool	of	oncogenes	and	tumor	suppressors	in	this	malignancy.	
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Like	in	other	cancer	types,	the	T-ALL	epigenome	is	affected	both	at	the	level	of	DNA	
methylation	 and	 chromatin	 modifications.	 Global	 methylation	 profiles	 have	 been	
shown	relevant	in	the	classification	of	leukemia	subtypes98.	In	T-ALL,	transcriptional	
silencing	 of	 tumor	 suppressors	 such	 as	CDKN1A/2B,	 SYK	 and	C/EBPA	 is	 associated	
with	 CpG	 island	 hypermethylation99.	 Moreover,	 adult	 T-ALL	 cases	 show	 a	 high	
frequency	 (18%)	 of	 DNMT3A	 mutations	 that	 are	 especially	 enriched	 in	 the	 ETP	
subtype100	 and	 are	 associated	 with	 a	 poor	 prognosis.	 Active	 DNA-demethylation	
involves	the	action	of	the	‘ten-eleven-translocation’	(TET)	protein	family	required	for	
the	 conversion	 of	 5-methylcytosine	 to	 5-hydroxymethylcytosine.	 While	 TET2	
mutations	are	recurrent	in	hematological	malignancies	such	as	AML,	so	far	only	TET1	
genetic	 lesion	 could	 be	 identified	 in	 about	 14%	of	 all	 T-ALL	 cases101.	 TET	 enzymes	
require	 2-oxoglutarate	 for	 their	 action,	 which	 can	 be	 produced	 by	 isocitrate	
dehydrogenase	enzymes	(IDH).	Both	IDH1	and	IDH2	mutations	have	been	identified	
in	 adult	 T-ALL102,103.	 	 Notably,	 like	 5mC,	 also	 the	 oxidative	 products	 5hmC,	 5-
formylcytosine	 and	 5-carboxylcytosine	 are	 involved	 in	 gene	 expression	 regulation.	
For	example,	Wang	and	co-workers	could	 show	that	 the	 levels	of	5-formylcytosine	
and	5-carboxylcytosine	can	affect	the	rate	of	RNA	Polymerase	II	driven	transcription,	
through	their	direct	interaction	with	the	polymerase	enzyme104.	In	addition,	the	role	
of	these	cytosine	(oxidative)	methylation	products	is	ever	expanding,	with	a	proven	
role	 as	 an	 epigenetic	 marker	 in	 DNA	 damage	 response105	 and	 CTCF-dependent	
splicing106.	
	
Epigenetic	 regulatory	 proteins	 such	 as	 CREBBP,	 EED,	 p300,	 EZH2,	 PHF6	 and	 SETD2	
are	 most	 recurrently	 mutated	 in	 pediatric	 ALL97.	 Both	 CREBBP	 and	 p300	 are	 co-
factors	 of	 histone	 acetyltransferases	 and	 are	 mutated	 in	 T-ALL107.	 The	 histone	
methyltransferase	SETD2	specifically	catalyzes	methylaton	of	lysine	36	of	histone	H3	
and	 is	 mutated	 in	 T-ALL,	 with	 48%	 of	 ETP-ALL	 cases	 harboring	 mutations	 in	
epigenetic	 regulators,	 including	 SETD271.	 Besides	 histone	 acetylation,	 also	
aberrations	 interfering	at	the	 level	of	histone	methylation	play	a	crucial	 role	 in	the	
pathogenesis	 of	 T-ALL.	 Ntziachristos	 and	 co-workers	 recently	 described	 the	
identification	of	inactivating	mutations	and	deletions	in	EZH2	and	SUZ12,	both	core	
components	 of	 the	 PRC2	 complex	 in	 25%	 of	 T-ALL	 cases83.	 These	 loss-of-function	
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mutations	 have	 been	 shown	 to	 be	 cooperative	 with	 hyperactivity	 of	 the	 NOTCH1	
signaling	 pathway	 in	 T-ALL,	 since	 abrogration	 of	 the	 PRC2	 complex	 function	
enhances	 the	 NOTCH1	 driven	 transcriptional	 program,	 in	 addition	 to	 global	
H3K27me3	 loss	 upon	 oncogenic	 NOTCH1	 signaling.	 In	 addition,	 also	 histone	
demethylation	has	been	shown	to	contribute	to	oncogenic	transformation.	Somatic	
mutations	in	the	lysine-specific	demethylase	6A	(KDM6A	or	UTX)	have	already	been	
identified	 in	a	plethora	of	other	cancers,	 such	as	 renal	cell	carcinoma	and	multiple	
myeloma108.	Recently,	In	T-ALL,	UTX	loss-of-function	mutations	were	identified	in	5%	
of	 T-ALL	 cases,	 with	 a	 skewed	 gender	 distribution	 towards	 males109,	 escaping	 X-
inactivation	in	female	T-ALL	and	normal	T-cells.	Remarkably,	whereas	UTX	acts	as	a	
tumor	 suppressor	 in	 T-ALL,	 the	 histone	 demethylase	 6B	 (KDM6B	 or	 JMJD3)	 was	
shown	 to	 exhibit	 oncogenic	 properties	 in	 T-ALL,	 crucial	 in	 both	 establishment	 and	
maintenance	 of	 the	 leukemic	 phenotype84,	 partially	 through	 its	 direct	 interaction	
with	 NOTCH1	 and	 its	 downstream	 transcriptional	 program.	 	 While	 these	 genes	
superficially	 seem	 to	 act	 in	 similar	 epigenetic	 processes	 (histone	 lysine	
demethylation),	 there	 seems	 to	 be	 strong	 context	 dependent	 action	 for	 the	 great	
diversity	of	epigenetic	regulators	as	reflected	from	specific	occurrence	of	either	gain	
or	loss-of-function	mutations	in	well-defined	cancer	entities.	
	
3.5	PHF6	as	a	novel	epigenetic	regulator	in	T-ALL	
In	 2010,	 inactivating	mutations	 and	 deletions	were	 identified	 in	 the	 X-linked	 gene	
PHF6	(Xq26.3)	(Figure	7)	in	16%	of	pediatric	and	38%	of	adult	T-ALLs	and	were	shown	
to	 be	 exclusively	 present	 in	male	 patients77.	 Later	 studies	 provided	 evidence	 that	
PHF6	mutations	 also	 occur	 in	 females110-112.	 Given	 the	 3:1	male	 to	 female	 ratio	 in	
which	T-ALL	occurs,	the	identification	of	an	X-linked	tumor	suppressor	is	of	particular	
interest.	Notably,	 these	PHF6	 aberrations	were	predominantly	 associated	with	 the	
TLX1+	 and	TLX3+	 T-ALL	 subgroups,	 adding	PHF6	 as	 an	 additional	 and	 critical	 tumor	
suppressor	 in	this	T-ALL	subtype.	 In	addition,	 it	was	shown	that	repression	of	PHF6	
may	also,	at	least	in	part,	be	the	result	of	activation	of	oncogenic	miRNAs	miR-20a,	
miR-26a	 and	miR-128b	 in	 T-ALL113,114.	Activating	NOTCH1	mutations	 are	present	 in	
more	than	80%	of	PHF6	mutated	cases112.	Furthermore,	also	JAK1	mutations	(>30%)	
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and	 SET-NUP214	 translocations	 (>40%)	 were	 significantly	 enriched	 within	 PHF6	
associated	 T-ALLs.	 Later,	 PHF6	 lesions	 were	 also	 identified,	 although	 to	 a	 minor	
extent,	 in	 other	 (hematological)	 tumor	 entities111	 such	 as	 acute	myeloid	 leukemia	
(AML,	 3%),	 hepatocellular	 carcinoma	 en	 chronic	 myeloid	 leukemia	 (CML)115,	 with	
PHF6	mutations	seven	times	more	prevalent	in	males	than	females	in	case	of	AML.	
Furthermore,	this	places	PHF6	aberrations	amongst	other	genetic	defects	such	as	the	
SET-NUP214	 and	 CALM-AF10	 translocations	 or	 FLT3	 mutations	 that	 are	 shared	
between	T-ALL	and	AML116.	 	 So	 far,	PHF6	 lesions	have	not	been	observed	 in	B-cell	
acute	lymphoblastic	leukemia	(B-ALL).	In	this	context,	it	is	of	interest	that	Meacham	
and	colleagues	could	actually	demonstrate	that	PHF6	deficiency	impaired	growth	of	
B-ALL	cells	through	the	use	of	a	genome-wide	in	vivo	loss-of-function	screen117,	thus	
mimicking	a	similar	duality	in	leukemia	formation	as	mentioned	above	for	NOTCH1.	
In	line	with	these	notions,	work	presented	in	this	thesis	shows	that	PHF6	acts	as	an	
important	 regulatory	 component	 in	 controlling	 lineage-specificity	 during	 normal	
hematopoietic	 development	 and	 ontogeny	 of	 hematological	 cancers	 (see	paper	 2,	
Chapter	3).	
	
While	 PHF6	 is	 expressed	 in	 the	 thymus,	 this	 protein	 also	 plays	 a	 key	 role	 in	 brain	
development.	 Historically,	PHF6	 germline	mutations	were	 shown	 to	 be	 the	 causal	
event	 of	 the	 Börjeson-Forssman-Lehmann	 syndrome	 (BFLS),	 an	 X-linked	 mental	
retardation	 syndrome,	 with	 patients	 presenting	 features	 such	 as	 tapered	 fingers,	
gynaecomastia	 and	 intellectual	 disability	 amongst	 others118-120.	 It	 is	 presumed	 that	
PHF6	is	implicated	in	BFLS	through	its	involvement	in	neuronal	migration	in	concert	
with	the	PAF1	transcription	elongation	complex121.	
BFLS	affects	predominantly	males,	while	female	carriers	usually	do	not	present	clear	
phenotypic	effects.	However,	de	novo	PHF6	mutations	were	recently	found	in	seven	
females	presenting	 a	BFLS	phenotype122.	 Importantly,	 a	 case	 study	by	Chao123	 and	
co-workers	described	a	BFLS	patient	that	also	developed	T-ALL	thus	suggesting	that	
PHF6	 can	 be	 involved	 in	 early	 stages	 of	 T-ALL	 oncogenesis	 and	 can	 predispose	 to	
leukemia	formation.		
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The	PHF6	gene	comprises	11	exons	(Figure	7)	and	produces	an	mRNA	transcript	of	
4.5	 kb,	 with	 an	 alternative	 splice	 variant	 that	 can	 be	 formed	 due	 to	 inclusion	 of	
intron	10118.	PHF6	is	highly	conserved	amongst	different	species,	but	absent	in	non-
vertebrates.	 During	 embryonic,	 fetal	 and	 post-natal	 phases	 of	 life,	 high	 levels	 of	
PHF6	 are	 present	 in	 the	 brain,	which	 are	 reduced	 again	 during	 adulthood.	 During	
these	 phases	 in	 life,	 also	 the	 intracellular	 location	 of	 the	 protein	 is	 shifted,	 with	
expression	 both	 in	 the	 nucleus	 and	 the	 cytoplasm	during	 development	 and	 finally	
towards	 an	 exclusive	 nuclear	 expression124.	 The	 PHF6	 protein	 (365	 amino	 acids)	 is	
structurally	 characterized	 by	 four	 nuclear	 localization	 sequences	 (NLS)	 (Figure	 7),	
which	 target	 PHF6	 towards	 the	 nucleus,	with	 an	 enrichment	 of	 the	 protein	 in	 the	
nucleolar	 compartments.	 Given	 that	 the	 nucleoli	 are	 the	 main	 sites	 of	 ribosome	
biogenesis,	the	subcellular	localization	of	PHF6	at	these	compartments	is	suggestive	
for	a	role	in	the	regulation	of	rDNA	transcription118,125.	Indeed,	Wang	and	co-workers	
recently	 showed	 that	 PHF6	 directly	 interacts	 with	 the	 transcription	 factor	 UBF,	
known	to	be	involved	in	RNA	polymerase	I	mediated	rRNA	generation.	Interaction	of	
PHF6	 with	 UBF	 leads	 to	 stabilized	 UBF	 expression	 and	 finally	 results	 in	 rDNA	
transcriptional	 silencing.	 Moreover,	 Wang	 et	 al	 could	 show	 that	 PHF6	 deficiency	
results	in	increased	DNA-damage	at	the	rDNA	loci,	which	subsequently	induces	a	cell	
cycle	 arrest	 at	 the	 G2/M	 phase125.	 Interestingly,	 Van	 Vlierberghe	 et	 al.	 previously	
suggested	that	PHF6	deficiency	 leads	to	 increased	γ-H2AX	 levels	that	are	 indicative	
for	 DNA	 double	 strand	 breaks77.	Moreover,	 the	 role	 of	 PHF6	 in	 the	 cell	 cycle	 and	
DNA-damage	response	(DDR)	is	further	supported	by	the	observation	that	the	PHF6	
protein	itself	is	also	subjected	to	phosphorylation,	both	during	mitosis126	and	during	
DDR	by	ATM	and	ATR	kinases127.	The	role	of	PHF6	in	the	process	of	DDR	could	be	an	
interesting	 entry	 point	 for	 therapy.	 One	 of	 the	 hallmarks	 of	 cancer	 involves	 the	
acquisition	 of	 limitless	 replicative	 potential45.	 When	 the	 control	 mechanisms	 of	
faithful	DNA	replication	are	hampered,	a	phenomenon	called	‘replicative	stress’128	is	
induced	 with	 concomitant	 accumulation	 of	 DNA	 damage.	 This	 makes	 the	 DDR	 an	
ideal	target	for	therapeutic	intervention129.	This	is	nicely	illustrated	by	a	recent	study	
of	Hähnel	et	al.130	focusing	on	KRAS-mutated	T-ALL.	It	was	previously	shown131	that	
over	half	of	all	 these	cases	harbour	activating	NOTCH1	mutations	and	 thus	benefit	
from	 treatment	 with	 GSI	 alone	 or	 combination	 strategies.	 Hähnel	 and	 colleagues	
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now	show	that	targeting	the	non-homologous	end-joining	pathway	(NHEJ),	which	is	
markedly	 upregulated	 in	 KRAS-mutated	 T-ALLs	 by	 e.g.	 use	 of	 PARP	 inhibitors	 is	 a	
sensitization	strategy	for	evoking	a	therapeutic	response	to	chemotherapy	 in	these	
cases130.	A	more	recent	study,	conducted	by	Sarmento	and	co-workers132,	provides	
evidence	 for	 the	pharmacological	 inhibition	of	 the	checkpoint	kinase	1	 (CHK1)	as	a	
novel	 therapeutic	 target	 for	 T-ALL	 patients.	 CHK1	 is	 a	 crucial	 factor	 in	 genomic	
surveillance	 and	 regulation	 of	 the	 cell	 cycle	 at	 the	 G2/M	 checkpoint.	 In	 T-ALL	
lymphoblasts,	CHK1	is	one	of	the	major	factors	that	protects	them	from	replicative	
stress	induced	upon	massive	proliferation	and	is	overexpressed	in	60%	of	primary	T-
ALLs.	 Pharmacological	 inhibition	 of	 CHK1	 shows	 anti-tumorigenic	 potential	 as	 it	
induces	 cell	 cycle	 arrest	 and	 cell	 death	 of	 T-ALL	 cells,	 with	 the	 response	 being	
dependent	on	ATM	and	caspase-3	activity.	
	
Besides	 NLS	motifs,	 PHF6	 also	 harbours	 two	 imperfect	 plant	 homeodomain	 (PHD)	
zinc	fingers	(Figure	7)77.	So	far,	about	14	members	of	the	PHD-finger	protein	family	
have	 been	 identified	 in	 yeast,	 50	 members	 in	 Drosophila	 and	 more	 than	 100	
members	in	the	human	genome133.	These	PHD	domains	are	about	50-80	amino	acids	
in	size	and	are	found	in	many	transcriptional	regulators	such	as	the	family	of	‘mixed	
lineage	leukemia’	 (MLL)	proteins	and	the	‘inhibitor	of	growth	family	member’	 (ING)	
protein	family134.	These	PHD	modules	can	recognize	the	N-terminal	tail	of	histone	H3	
and	 more	 in	 particular	 is	 targeted	 to	 the	 methylation	 on	 lysine	 (K)	 four	 (K4),	
methylation	of	arginine	 two	 (R2)	or	 the	acetylation	of	K14.	The	specificity	 towards	
the	 substrate	 can	 be	 different	 amongst	 various	 PHD-containing	 chromatin-
associating	factors.	The	two	PHD	zinc	fingers	in	the	protein	structure	of	PHF6	deviate	
in	composition	 from	the	standard	Cys4-His-Cys3	motif.	The	 terminal	 cysteine	 in	 the	
consensus	motif	is	in	PHF6	replaced	by	histidine	and	only	8	amino	acids	separate	the	
cysteine	 residues	at	position	 two	and	 three118.	Chromatin-associating	proteins	 that	
can	only	 recognize	 specific	 post-translational	modified	 (PTM)	histone	 residues	 and	
do	not	have	 intrinsic	 enzymatic	 activity	 are	 referred	 to	as	 ‘readers’135.	 Besides	 the	
PHD-motif,	also	other	domains	are	known	that	allow	recognition	of	a	specific	type	of	
PMT	on	 core	 histone	 proteins.	 A	well-known	 example	 is	 the	 bromodomain,	which	
allows	 proteins	 to	 recognize	 acetylated	 histone	 lysine	 residues136.	 Bromodomain	
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containing	 proteins,	 such	 as	 the	well-known	 example	 ‘bromodomain	 containing	 4’	
(BRD4),	are	currently	successfully	targeted	in	acute	leukemia	and	across	many	other	
malignancies137.	Two	other	classes	of	chromatin	 interacting	proteins,	referred	to	as	
‘writers’	(generate	these	PTMs)	or	‘erasers’	(remove	these	PTMs),	are	distinguished	
from	 reader	 proteins	 by	 the	 additional	 capacity	 of	 placing	 or	 removing	 chemical	
modification	 on	 core	 histone	 proteins138.	 This	 capacity	 requires	 the	 presence	 of	 a	
catalytic	 domain	 in	 the	 protein	 structure,	 such	 as	 the	 SET	 domain	 of	 the	 protein	
‘Enhancer	 of	 Zeste	 homolog	2’	 (EZH2),	which	 enables	 it	 to	 catalyze	methylation	of	
K27	residues	of	the	core	histones	to	establish	transcriptional	silencing139.	The	PHF6	
protein	can	thus	be	classified	as	a	‘reader’,	since	it	has	no	intrinsic	enzymatic	activity,	
but	is	hypothesized	to	rather	be	capable	of	recognizing	specific	histone	modifications	
(or	 combinations	 thereof)	 through	 its	 PHD	 domains133.	 In	 general	 these	 reader	
proteins	 then	 recruit	 ‘writer’	 or	 ‘erasers’	 to	 alter	 the	 chromatin	 structure	 at	 their	
target	 site.	 Interestingly,	 PHF8	 is	 another	 PHD-finger	 protein	 that	 shows	
commonalities	 with	 PHF6	 in	 various	 aspects.	 Amongst	 others,	 PHF8	 is	 involved	 in	
regulation	of	rDNA	transcription140,	control	of	cell	cycle	progression	(in	particular	the	
G2-M	 phase	 transition)141	 and	 is	 a	 mutated	 in	 X-linked	 mental	 retardation.	 In	
contrast	to	PHF6,	the	PHF8	protein	 is	classified	as	 	 ‘eraser’	protein,	as	 it	can	act	as	
H4K20me1	demethylase	through	the	presence	of	a	‘Jumonji	C’	(JmjC)	domain,	after	
docking	 to	 H3K4me3	 sites	 through	 its	 PHD-domains,	 to	 activate	 transcription142.	
Although	 PHF8	 has	 a	 known	 role	 in	 various	 cancer	 types143,144,	 the	 potential	
implication	of	PHF8	 in	hematological	malignancies	 is	 thus	 far	unknown.	Notably,	 a	
recent	 proteomics	 study	 by	 Yatim	 et	 al.145	 identified	 PHF8	 as	 a	 component	 of	 the	
NOTCH1	transcriptional	complex	 in	T-ALL	cells	promoting	 the	expression	of	several	
NOTCH1	 downstream	 target	 genes,	 providing	 a	 hint	 for	 potential	 implications	 of	
PHF8	in	T-ALL	as	well.	
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Figure	7:	The	PHF6	gene	resides	on	the	X-chromosome	(Xq26.3)		and	is	transcribed	into	a	transcript	
containing	11	exons.	The	protein	structure	of	PHF6	contains	4	nuclear	localisation	signals	(NLS)	and	2	
imperfect	 plant	 homeodomain	 (PHD)	 zinc	 fingers	 allowing	 the	 protein	 to	 dock	 to	 specific	 (yet	
unknown)	post-translational	modifications	on	the	N-termini	of	the	histone	tails.	
	
Transcriptional	 regulation	 at	 the	 level	 of	 chromatin	 also	 involves	 more	 profound	
architectural	 changes	 besides	 post-translational	 modification	 of	 core	 histone	
proteins	and	methylation	of	DNA	CpG	sites.	These	conformational	shifts	are	induced	
by	 chromatin	 remodeling	 complexes.	ATP-hydrolysis	provides	 the	energetic	driving	
force	 for	 these	 multi-protein	 scaffolds	 to	 force	 nucleosome	 sliding,	 removal	 or	
exchange146.	Well-known	 examples	 of	 these	 ATP-driven	 chromatin	 remodelers	 are	
the	‘SWItch/Sucrose	Non-Fermentable’	(SWI-SNF)	and	the	‘Nucleosome	Remodeling	
and	 Deacetylase’	 (Mi-2/NurD)	 complexes	 (Figure	 8)147.	 Both	 complexes	 have	 a	
known	 role	 in	 transcriptional	 regulation	 within	 the	 hematopoietic	 compartment,	
such	 as	 in	 normal	 T-cell	 development148,149.	 The	 SWI-SNF	 complex	 members	 are	
mutated	 in	 many	 different	 cancer	 types,	 such	 as	 colorectal	 and	 lung	 cancer150.	
Besides	 well-established	 members	 of	 the	 complex	 such	 as	 SMARCA4	 (BRG1)	 and	
ARID1A,	 novel	 subunits	 such	 as	 BCL11B	 and	 BRD9	 were	 recently	 described122.	
Interestingly,	 PHF6	 mutations	 were	 recently	 associated	 with	 Coffin-Siris	 (CSS)	 and	
Nicolaides-Baraitser	 (NCBRS)	 syndromes,	 two	 congenital	 disorders	 with	 associated	
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intellectual	 disability151,152.	 These	 syndromes	 were	 previously	 marked	 by	 de	 novo	
mutations	 in	 several	 members	 of	 the	 SWI-SNF	 nucleosome-remodeling	 complex.	
Notably,	like	PHF6,	also	other	X-linked	epigenetic	modifiers	have	been	associated	in	
the	 past	 with	 mental	 retardation	 syndromes,	 such	 as	 ATRX	 and	MECP2	 (besides	
PHF8)133.	 These	 findings	 further	 support	 the	 hypothesis	 that	 PHF6	 can	 be	 an	
important	 epigenetic	 modulator	 of	 gene	 expression	 in	 concert	 with	 NurD	 and/or	
SWI-SNF	 complexes,	 in	 keeping	 with	 the	 recent	 identification	 of	 a	 physical	
association	between	PHF6	and	members	of	the	NurD	complex153.	Moreover,	as	the	
NurD	complex	has	known	roles	in	both	brain154	function	and	lymphopoiesis149,	their	
interaction	is	suggestive	for	functional	cooperation	in	these	tissue	types.	 	
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Figure	8:	The	ATP-dependent	SWI-SNF	and	NurD	chromatin	remodeling	complexes147	(sp.uconn.edu)	
are	 involved	 in	 ATP-hydrolysis	 coupled	 reshaping	 of	 the	 chromatin	 structure,	 supporting	 the	
formation	 of	 either	 a	 hetero-	 (closed)	 or	 euchromatin	 (open)	 conformation:	 (upper	 panel)	 the	
catalytic	component	of	the	SWI-SNF	complex	is	BRG1	(SMARCA4)	and	the	remainder	constellation	of	
this	 complex	 is	 context-specific;	 (lower	 panel)	 it	 is	 already	 shown	 that	 PHF6	 is	 part	 of	 the	 NurD	
remodeling	 complex153	 in	 which	 several	 core	 compontens	mediate	 the	 transition	 from	 an	 open	 to	
closed	chromatin	conformation	eventually	 resulting	 in	gene	silencing.	The	exact	 role	of	PHF6	 in	 the	
function	of	this	complex	is	unknown	thus	far.		
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4.	The	role	of	long	non-coding	RNAs	in	normal	development	and	cancer	
Besides	 the	 multiple	 protein	 complexes	 that	 are	 involved	 in	 modulation	 of	 the	
epigenome,	 either	 through	 chromatin	 chemical	 modification	 (PTMs)	 or	 structural	
remodeling,	 an	 additional	 key	 layer	 of	 regulatory	 complexity	 should	 be	 taken	 into	
account	 to	 fully	 understand	 the	 network	 that	 controls	 correct	 epigenetic	 gene	
expression	regulation.	Recent	technological	advances	in	high-throughput	sequencing	
have	revolutionized	the	discovery	of	many	non-coding	RNA	species	throughout	the	
genome.	Although	the	function	for	the	majority	of	long	non-coding	RNAs	(lncRNAs)	
is	 still	unknown,	 it	 is	now	clear	 that	 these	RNA-species	comprise	 the	major	part	of	
the	 non-coding	 transcriptome	 and	 show	 a	 high	 versatility	 in	 their	 mechanism-of-
action	 to	 regulate	 gene	 expression	 (Figure	 9)155.	 The	 diversity	 of	 their	 folding	 or	
structure	 is	 crucial	 to	 support	 the	 interaction	 with	 protein	 complexes	 and	 the	
specific	functions	that	lncRNAs	are	able	to	execute156.	In	addition,	recent	discoveries	
have	proven	their	cell-type	specific	expression,	with	 important	 implications	both	 in	
normal	 development	 and	malignant	 transformation157	 (see	 also	Chapter	 I,	Part	 II)	
and	thereby	influencing	various	processes	such	as	genomic	stability,	cell	proliferation	
and	 survival158.	 	 There	 is	 currently	 no	 general	 way	 to	 assign	 the	 functional	
contribution	 of	 a	 particular	 lncRNA,	 given	 both	 our	 increased	 knowledge	 that	
transcriptional	regulation	is	very	complex	and	that	the	functional	diversity	that	RNA	
molecules	 display	 is	 huge.	 The	 potential	 importance	 of	 lncRNAs	 (and	 ncRNAs	 as	 a	
whole)	 in	 development	 is	 further	 supported	 by	 the	 intriguing	 observation	 that	
organism	complexity	 is	strongly	correlated	to	the	proportion	of	the	genome	that	 is	
non-coding159.	 A	 prototypical	 example	 is	 the	 lncRNA	HOTTIP,	 expressed	 from	 the	
HOX	loci	and	implicated	in	anatomic	patterning160.		
To	 exert	 their	 function,	 lncRNAs	 mainly	 interact	 with	 chromatin	 regulatory	
complexes161.	The	‘polycomb	repressive	complex	2’	(PRC2)	is	known	to	interact	with	
many	 lncRNAs.	 One	 particular	 notorious	 lncRNA	 that	 interacts	 with	 PRC2	 is	
XIST162,163,	 the	 key	 regulator	 controlling	 X-inactivation164.	 Yet	 another	 example	 is	
lncRNA	HOTAIR165,	transcribed	from	the	HOXC	locus,	which	plays	a	role	in	gastric	and	
metastatic	breast	cancer	amongst	others166.	Besides	the	interaction	of	lncRNAs	with	
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proteins,	 their	 interaction	 with	 other	 RNA	 species	 also	 plays	 a	 crucial	 role	 in	 the	
diversity	 of	 functions	 they	 execute	 and	 control	 of	 their	 actions.	 For	 instance,	 it	 is	
known	that	lncRNAs	can	be	bound	by	miRNAs.	In	this	way,	lncRNAs	can	act	as	miRNA	
sponges167,	 thereby	sequestering	 the	miRNA	away	 from	 its	endogenous	 target	and	
act	as	a	 ‘competing	endogenous	RNA’	(ceRNA),	as	nicely	 illustrated	for	the	PTENP1	
transcript	 interacting	 with	 miRNAs	 belonging	 to	 the	 miR-17-92	 cluster168	 or	
interaction	of	the	lncRNA	HULC	with	miR-372169.	
Given	tissue-specific	expression	of	many	lncRNAs,	they	may	represent	important	and	
powerful	biomarkers	in	diagnosis	and	monitoring	of	disease	and	are	currently	being	
scrutinzed	 to	 that	 end.	 This	 has	 been	 illustrated	 in	 prostate	 cancer	 where	
researchers	 identified	 lncRNA	PCA3	 as	 being	 highly	 prostate-specific170.	Moreover,	
certain	lncRNAs	for	the	same	reason	can	act	as	suitable	therapeutic	targets	as	their	
specific	 expression	will	 avoid	unwanted	 toxic	 side-effects	 in	normal	 tissues171.	 This	
was	nicely	illustrated	by	a	recent	study	of	Gutschner	and	colleagues	showing	that	in	
vivo	 perturbation	of	 the	 lncRNA	MALAT1	 in	 a	 lung	 cancer	mouse	 xenograft	model	
using	 anti-sense	 oligonucleotides	 (ASO)	 prevented	 metastasis172	 and	 also	 in	 the	
unpublished	work	in	melanoma	(Mestdagh	P	et	al.,	personal	communication,	paper	
under	 review).	 Taken	 together,	 a	 better	 understanding	 of	 the	 previously	 so-called	
‘dark	matter’	of	 the	genome	will	have	a	profound	 impact	on	our	understanding	of	
the	 complex	 regulation	 of	 various	 cellular	 processes	 such	 as	 replication,	
transcription,	splicing,	DNA	repair,	chromatin	conformation	and	so	on.	Together	with	
steadily	evolving	opportunities	for	genome	editing	and	RNA	therapeutics,	a	new	era	
of	revolutionized	targeted	therapy	is	now	emerging.		
An	important	feature	of	lncRNAs	that	will	also	be	crucial	to	tackle	in	the	near	future	
is	 the	 issue	 of	 lncRNA	 conservation.	 We	 do	 not	 only	 need	 to	 account	 for	 their	
sequence	conservation	across	 species,	but	also	 their	positional	 conservation,	given	
that	 positionally	 conserved	 lncRNAs	 which	 are	 expressed	 can	 be	 often	 found	 in	
proximity	of	protein	 coding	genes	 that	have	a	 crucial	 role	 in	development.	On	 the	
other	 hand,	 if	 a	 particular	 lncRNA	 is	 neither	 positionally	 nor	 sequence	 conserved,	
this	does	not	imply	that	this	lncRNA	lacks	any	important	funtionality	or	therapeutic	
potential.	 It	might	be	that	 the	 function	of	 the	 lncRNA	 is	 rather	dictated	by	 its	RNA	
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structural	 conformation	 and	 that	 structure	 is	 therefore	 the	main	 parameter	 to	 be	
evaluated	in	terms	of	evolutionary	conservation173,174.	
												 	
				
Figure	 9:	 Mechanistic	 diversity	 of	 transcriptional	 control	 mechanisms	 by	 lncRNAs	 in	 concert	 with	
chromatin	 remodeling	 complexes	 comprises	 four	main	modes-of-action:	 (A)	 lncRNA	 transcripts	 can	
induce	 conformational/allosteric	 changes	 that	 lead	 to	 the	 activation	 of	 interacting	 proteins,	 (B)	
lncRNAs	can	be	a	decoy	to	titrate	the	chromatin	remodeling	complex	away	from	the	DNA	template	
and	thereby	interfere	with	its	action,	(C)	 	 lncRNAs	can	guide	interacting	transcriptional	regulators	to	
their	site-of-action	either	in	cis	or	in	trans	to	distal	sites,	(D)	lcnRNAs	can	act	as	a	scaffold	facilitating	
the	 formation	 of	 a	 multiprotein	 complex.	 Adapted	 from	 Yang	 et	 al.	 (Biochim	 and	 Biophys	 Acta,	
2014)155		
	
A	more	detailed	review	concerning	T-ALL	genetics	and	development	of	novel	state-
of-the-art	targeted	therapies	are	described	in	the	review	‘Novel	biological	insights	in	
T-cell	acute	lymphoblastic	leukemia’	(see	Chapter	I,	Part	II).	 	
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Abstract	
T-cell	acute	lymphoblastic	leukemia	(T-ALL)	is	an	aggressive	type	of	blood	cancer	that	
accounts	for	about	15%	of	paediatric	and	25%	of	adult	ALL	cases	and	is	considered	a	
paradigm	for	the	multistep	nature	of	cancer	initiation	and	progression.	Genetic	and	
epigenetic	reprogramming	events,	which	transform	T-cell	precursors	into	malignant	
T-ALL	lymphoblasts,	have	been	extensively	characterized	over	the	past	decade.	
	
Despite	 our	 comprehensive	 understanding	 of	 the	 genomic	 landscape	 of	 human	 T-
ALL,	 leukemia	 patients	 are	 nowadays	 still	 treated	 by	 high-dose	 multi-agent	
chemotherapy	potentially	followed	by	hematopoietic	stem	cell	transplantation.	Even	
with	 such	 aggressive	 treatment	 regimens,	 which	 are	 often	 associated	 with	
considerable	acute	and	 long-term	side	effects,	about	15%	of	paediatric	and	40%	of	
adult	T-ALL	patients	still	relapse	due	to	acquired	therapy	resistance	and	present	with	
very	 dismal	 survival	 perspectives.	 Unfortunately,	 the	 molecular	 mechanisms	 by	
which	 residual	 T-ALL	 tumor	 cells	 survive	 chemotherapy	 and	 act	 as	 a	 reservoir	 for	
leukemic	progression	and	hematological	relapse	remain	poorly	understood.	
	
Nevertheless,	it	is	expected	that	enhanced	molecular	understanding	of	T-ALL	disease	
biology	will	ultimately	facilitate	a	targeted	therapy	driven	approach	that	can	reduce	
chemotherapy	associated	toxicities	and	improve	survival	of	refractory	T-ALL	patients	
through	personalized	salvage	therapy.	In	this	review,	we	summarize	recent	biological	
insights	 in	 the	 molecular	 pathogenesis	 of	 T-ALL	 and	 speculate	 how	 the	 genetic	
landscape	of	T-ALL	could	trigger	the	development	of	novel	therapeutic	strategies	for	
the	treatment	of	human	T-ALL.	
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Introduction	
Normal	 T-cell	 development	 is	 a	 strictly	 regulated,	 multi-step	 process	 in	 which	
hematopoietic	 progenitor	 cells	 differentiate	 into	 functionally	 diverse	 T-lymphocyte	
subsets	 after	 their	 migration	 into	 the	 thymus	 microenvironment.	 The	 different	
checkpoints,	 covering	 thymic	 colonization,	 lineage	 commitment	 and	 definitive	
differentiation1	are	orchestrated	by	diverse	transcriptional	regulatory	networks	and	
transitions	between	epigenetic	states2,3	in	response	to	cytokine	receptor	activation.	
During	 this	 fine-tuned	 developmental	 process,	 inappropriate	 activation	 of	 T-cell	
acute	lymphoblastic	leukemia	(T-ALL)	T-ALL	oncogenes	and	loss	of	tumor	suppressor	
gene	 activity	 will	 coordinately	 push	 thymic	 precursors	 into	 uncontrolled	 clonal	
expansion	and	cause	T-ALL.	
	
T-ALL	 is	 an	 aggressive	 hematological	 cancer	 that	 arises	 from	 the	 malignant	
transformation	of	T-cell	progenitors	and	occurs	in	about	15%	of	pediatric	and	25%	of	
adult	ALL	cases.	High-dose	multi-agent	chemotherapy	serves	as	the	current	standard	
of	 care	 for	 this	 tumor	 entity	 and	 is	 highly	 effective	 in	 the	 majority	 of	 childhood	
leukemia	 patients	 with	 overall	 survival	 rates	 reaching	 85%	 in	 most	 pediatric	
protocols.	Nevertheless,	 these	aggressive	 treatment	 regimens	are	often	associated	
with	severe	acute	toxicities	and	long-term	side	effects,	including	the	development	of	
secondary	 tumors	 later	 in	 life.	Notably,	 the	situation	 for	older	 leukemia	patients	 is	
less	 favorable	 as	 compared	 to	 children	 with	 at	 least	 40%	 of	 adult	 T-ALL	 patients	
failing	 current	 therapy.	 Despite	 the	 introduction	 of	 hematopoietic	 stem	 cell	
transplantations	 for	 refractory	 leukemias,	 the	 clinical	 outcome	 of	 these	 high-risk,	
primary	resistant	tumors	remains	extremely	poor4-6.	
	
Different	 studies	 have	 collectively	 shown	 that	 T-ALL	 can	 be	 divided	 in	 molecular	
genetic	subgroups	that	are	characterized	by	unique	gene	expression	signatures	and	
aberrant	 activation	 of	 specific	 T-ALL	 transcription	 factor	 oncogenes,	 including	
MEF2C,	HOXA,	 TLX1,	NKX2.1,	 TLX3,	 TAL1,	 LMO1	 and	 LMO26-10.	 Moreover,	 whole-
genome	 T-ALL	 profiling	 has	 provided	 a	 fairly	 complete	 and	 comprehensive	 list	 of	
additional	genetic	defects	that	are	shared	amongst	the	different	genetic	subclasses	
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and	 activate	 a	 plethora	 of	 oncogenic	 signaling	 cascades	 including	 interleukin	 7	
receptor	 (IL7R)/Janus	 Kinase	 (JAK)/Signal	 transducer	 and	 activator	 of	 transcription	
(STAT)11,	phosphatidylinositol	3-kinase	(PI3K)/AKT12-14	and	Ras/mitogen	extracellular-
signal-related	kinase	(MEK)/extracellular	signal-regulated	kinase	(ERK)15	signaling.	In	
addition,	 some	 of	 these	 cooperative	 genetic	 lesions	 also	 coordinately	 target	more	
general	 cellular	 pathways,	 as	 exemplified	 by	 aberrant	 activation	 of	 anti-apoptotic	
effector	pathways	and	enhanced	cap-dependent	translation	activity	in	human	T-ALL.	
Notably,	 this	 conversion	 towards	 aberrant	 activation	 of	 a	 discrete	 set	 of	 common	
cellular	or	signaling	pathways	provides	unique	opportunities	for	the	development	of	
targeted	therapies	in	the	context	of	human	T-ALL16,	17.	
	
Now	 that	 we	 acquired	 a	 detailed	molecular	 understanding	 of	 the	 genetic	 defects	
that	 drive	 human	 T-ALL	 at	 the	 coding	 level	 of	 the	 genome,	 we	 face	 a	 number	 of	
interesting	challenges	that	will	hopefully	be	addressed	 in	the	near	 future.	First,	we	
need	 to	 better	 understand	 how	 specific	 T-ALL	 oncogenes	 and	 tumor	 suppressors	
actually	cooperate	to	drive	overt	disease	and	full	 leukemic	transformation.	 Indeed,	
we	 lack	 a	 thorough	 understanding	 of	 the	 genetic	 interactions	 between	 genetic	
defects	that	preferentially	co-occur	 in	primary	human	T-ALL	samples.	Secondly,	the	
potential	contribution	of	the	exact	order	in	which	genetic	lesions	are	acquired	during	
disease	initiation,	progression	and/or	maintenance	should	be	further	investigated.	In	
addition,	it	is	still	unclear	whether	the	exact	cell	of	origin	for	T-cell	transformation	is	
truly	 different	 for	 the	 distinct	 molecular	 genetic	 subtypes	 of	 human	 T-ALL.	
Moreover,	 the	 existence	 of	 long-lived	 pre-leukemic	 stem	 cells	 (pre-LSCs)	 in	 the	
context	 of	 T-	 ALL	 is	 still	 under	 debate	 and	 the	 molecular	 mechanism	 that	 could	
regulate	pre-LSC	activity	of	thymic	precursors	remains	poorly	characterized.	Finally,	
epigenetic	mechanisms	and	 the	non-coding	part	of	 the	human	genome	provide	an	
additional	 layer	of	complexity	and	we	are	currently	only	starting	to	understand	the	
putative	 oncogenic	 contributions	 of	 deregulated	 microRNAs	 (miRNAs),	 long	 non-
coding	RNAs	(lncRNAs),	enhancer	activities,	chromatin	remodeling	and/or	epigenetic	
changes	in	the	context	of	malignant	T-cell	transformation.	
	
In	this	review,	we	summarize	recent	biological	insights	in	the	molecular	pathogenesis	
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of	 T-	 ALL	 and	 discuss	 the	 impact	 of	 these	 findings	 on	 some	 of	 the	 intriguing	
challenges	mentioned	above.	Moreover,	we	speculate	on	how	the	genetic	landscape	
of	 T-ALL	 could	 trigger	 the	 development	 of	 novel	 therapeutic	 strategies	 for	 the	
treatment	of	human	T-ALL.	
	
Genetic	heterogeneity	of	immature	T-ALL	subtypes	
More	than	a	decade	ago,	attempts	were	made	to	classify	human	T-ALL	into	different	
tumor	 entities	 based	 on	 their	 transcriptional	 signature.	 Indeed,	 depending	 on	 the	
expression	 of	 specific	 T-ALL	 transcription	 factor	 oncogenes,	 T-cell	 leukemia	 was	
classified	into	molecular	genetic	subgroups	reflecting	distinct	stages	of	arrest	during	
T-cell	development7.	
	
In	these	initial	studies,	early	immature	T-ALLs	were	recognized	as	a	transcriptionally	
distinct	 leukemic	 entity	 with	 high	 expression	 of	 the	 basic	 Helix-Loop-Helix	 (bHLH)	
transcription	 factor'	 lymphoblastic	 leukemia	 associated	 hematopoiesis	 regulator'	
(LYL1)	and	the	'LIM	domain–only	protein'	(LMO2)7.	In	addition,	leukemic	blasts	from	
these	so-called	LYL1+	T-ALLs	collectively	expressed	early	 lymphoid/myeloid	markers	
including	CD13,	CD33	and/or	CD34,	and	mostly	lacked	CD4	or	CD8	proteins	at	their	
surface.	 Although	 no	 unifying	molecular	 alterations	 could	 be	 identified	 in	 LYL1+
	
T-
ALLs,	 these	 leukemias	were	 characterized	 by	 a	 high	 frequency	 of	 deletions	 on	 the	
long	 arm	 of	 chromosome	 5	 and	 often	 lacked	 deletions	 on	 the	 short	 arm	 of	
chromosome	9	targeting	the	CDKN2A/CDKN2B	tumor	suppressor	locus7.	
	
Absence	 of	 these	 9p	 deletions,	 which	 occur	 in	 more	 than	 70%	 of	 other	 T-ALL	
subtypes18,	 is	 an	 intriguing	 feature	 of	 immature	 T-ALL	 that	might	 be	 linked	 to	 the	
epigenetic	 state	 of	 the	 cdkn2a	 locus	 during	 tumor	 progression.	 In	 primitive	
hematopoietic	precursor	cells,	the	polycomb	repressive	complex	2	(PRC2)	mediates	
silencing	 of	 the	 Ink4a-Arf	 locus19,	20,	 suggesting	 that	 leukemias	 that	 originate	 from	
hematopoietic	progenitors	 lack	 the	selective	pressure	 for	genomic	cdkn2a	deletion	
during	T-cell	transformation21,	22.	In	contrast,	this	permanent	silencing	is	not	present	
in	early	thymocytes	in	which	the	 Ink4a-Arf	 locus	can	be	re-activated	in	response	to	
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oncogenic	 signaling21.	 In	 such	 model,	 engagement	 of	 cdkn2a	 expression	 during	
tumor	 initiation	 creates	 a	 strong	 selective	 pressure	 for	 rare	 cells	 to	 bypass	 tumor	
suppression	by	deleting	cdkn2a	and	eventually,	to	emerge	as	clonal	malignancies22.	
Altogether,	these	studies	might	provide	an	explanation	for	the	unequal	distribution	
of	CDKN2A/CDKN2B	deletions	between	immature	and	mature	T-ALLs,	supporting	the	
view	that	the	cell	of	origin	for	some	early	immature	leukemias	might	have	features	
of	a	very	early	hematopoietic	progenitor.	More	recent	efforts	have	further	enhanced	
our	 molecular	 understanding	 of	 immature	 T-ALLs	 and	 provided	 a	 comprehensive	
overview	of	genetic	alterations	that	occur	in	this	particular	subtype	of	human	T-ALL.	
These	 studies	 showed	 that	 the	 genetic	 landscape	 of	 immature	 T-	 ALL	 is	 highly	
heterogeneous	with	aberrant	expression	of	the	MEF2C	gene23,	24,	genetic	alterations	
in	 hematopoietic	 transcription	 factors	 such	 as	 RUNX1,	 GATA3,	 BCL11B,	 PU.1	 and	
ETV624,	 activating	 mutations	 in	 critical	 mediators	 of	 cytokine	 receptor	 and	 Ras	
signaling,	including	NRAS,	KRAS,	FLT3,	IL7R,	JAK1,	JAK3,	SH2B3	and	BRAF;	mutations	
in	the	epigenetic	regulators	EZH2,	EED,	SUZ12,	MLL2,	BMI1,	SETD2	and	EP300;	and	
mutations	 in	 the	 dynamin	 coding	 gene	 DNM28,	 25.	 In	 addition,	 immature	 T-ALLs	
present	with	lower	frequencies	of	the	prototypical	NOTCH1	mutations,	which	occur	
in	 the	 majority	 of	 mature	 T-	 ALL	 patient	 samples	 and	 are	 considered	 one	 of	 the	
hallmarks	of	human	T-cell	transformation.	
	
For	 reasons	 not	 well	 understood,	 the	 relative	 percentage	 of	 immature	 T-ALLs	 in	
adults	 seems	 to	 be	 significantly	 higher	 as	 compared	 with	 children26	 and	 some	
molecular	 alterations	 are	 exclusively	 present	 in	 adult	 immature	 T-ALLs26.	 For	
example,	genetic	lesions	that	were	initially	identified	in	acute	myeloid	leukemia	and	
target	 genes	 implicated	 in	DNA	methylation,	 such	as	DNMT3A,	 IDH1	 and	 IDH2	 are	
uniquely	present	 in	adult	 immature	T-ALL	and	have	not	been	 reported	 in	pediatric	
patients.	In	that	context,	 it	was	recently	shown	that	DNMT3A	mutations	in	primary	
human	acute	myeloid	 leukemias	 (AMLs)	occur	 in	both	pre-leukemic	hematopoietic	
stem	 cells	 (HSCs)	 and	 committed	 T-cells,	 suggesting	 that	 DNMT3A	 mutant	 pre-
leukemic	HSCs	retain	the	ability	to	differentiate	into	multiple	cell	types27.	Therefore,	
DNMT3A	 mutations	 could	 act	 as	 an	 early	 leukemogenic	 event	 that	 enables	 the	
establishment	 of	 a	 pre-leukemic	 reservoir.	 Such	 DNMT3A	 mutant	 pre-HSCs	 could	
Chapter	1:	Introduction	
	 	 	55	
remain	 quiescent	 over	 a	 certain	 period	 in	 life	 and	 eventually	 progress	 towards	
malignant	 transformation	 in	 the	myeloid	 and/or	 early	 T-cell	 lineage	 depending	 on	
the	spectrum	of	acquired	secondary	hits.	Notably,	such	hierarchical	model	in	which	
pre-leukemic	 stem	cells	precede	 full	malignant	 transformation	has	been	previously	
proposed	 in	 the	 context	 of	 T-ALL28.	 The	 concept	 of	DNMT3A	mutant	 pre-leukemic	
HSCs,	which	emerge	in	ageing	adults,	could	partially	explain	why	DNMT3A	mutations	
are	not	 identified	 in	pediatric	early	T-cell	precursor	ALL	 (ETP-ALL)25,	but	are	mainly	
present	 in	early	 immature	adult	 T-ALLs	 26,	29.	Nevertheless,	 it	 is	 currently	unknown	
whether	 a	 similar	 model	 could	 be	 applied	 for	 other	 lesions	 that	 target	 the	 DNA	
methylation	machinery,	including	IDH1	and	IDH2	mutations.	
	
Thymocyte	 self	 renewal	 and	 pre-leukemic	 stem	 cells	 in	 T-ALL	
development	
Pre-leukemic	stem	cells	(pre-LSC)	are	a	population	of	progenitor	cells	that	harbour	a	
few	mutations,	 but	 not	 the	 entire	 complement	of	 genetic	 alterations	necessary	 to	
become	a	 leukemia.	 In	contrast	 to	 these	 fully	 transformed	 leukemic	cells,	pre-LSCs	
retain	the	ability	to	differentiate	into	the	full	spectrum	of	mature	daughter	cells.	In	
addition,	 their	 stem	 cell	 properties	 allow	 clonal	 expansion	 and	 subsequent	
acquisition	of	extra	oncogenic	driver	mutations,	eventually	leading	to	the	onset	of	a	
fully	transformed	tumor.	
	
McCormack	 and	 colleagues	 initially	 described	 a	 population	 of	 long-term	 self-
renewing	thymocytes	many	months	prior	to	the	generation	of	leukemia	in	the	CD2-
LMO2tg	 transgenic	 mouse	 model30	 that	 spontaneously	 develops	 T-ALL	 with	 an	
expression	profile	similar	 to	that	of	 immature	T-ALL	patients.	Unlike	the	thymus	of	
normal	mice,	which	is	continually	replenished	by	progenitors	from	the	bone	marrow,	
the	pre-leukemic	thymus	of	CD2-LMO2tg	transgenic	mice	was	self-sustaining	from	a	
young	age.	The	 self-renewal	 capacity	of	CD2-	 LMO2tg
	
thymocytes	was	 restricted	 to	
the	CD4-CD8-
	
double	negative	precursor	T-cells,	specifically	the	CD4-CD8-
	
CD44-CD25+	
(DN3)	subpopulation.	 In	addition,	 it	was	demonstrated	 that	 the	bHLH	transcription	
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factor	 Lyl1	 is	 an	 essential	 but	 not	 a	 sufficient	 factor	 to	 reprogram	 Lmo2	
overexpressing	 DN3	 cells	 into	 pre-LSCs31.	 More	 work	 will	 need	 to	 be	 done	 to	
decipher	the	exact	molecular	mechanism	explaining	how	LMO2	controls	thymocyte	
self-renewal.	LMO2	 itself	has	no	DNA	binding	capacity	and	depends	on	LYL1	for	 its	
transcriptional	 activity.	 LYL1	 as	 well	 requires	 binding	 with	 other	 helix-loop-helix	
proteins,	 including	 E2A,	 E47	 or	 'transcription	 factor	 12'	 (TCF12,	 HEB),	 to	 form	
heterodimers,	 which	 can	 recognize	 E-box	 sequences	 in	 specific	 target	 gene	
promoters.	Recently,	it	was	suggested	that	LMO2	and	'LIM	domain	binding	1'	(LDB1)	
are	 essential	 co-factors	 to	 bridge	 two	 of	 these	 heterodimer	 complexes	 as	 a	
prerequisite	for	binding	at	tandem	E-boxes	throughout	the	genome32.	
	
More	recently,	 it	was	shown	that	these	pre-LSCs	are	Notch1	dependent	and	supra-	
physiological	 levels	 of	 Notch1	 expanded	 the	 pool	 of	 pre-LSC	 and	 rendered	 them	
independent	 of	 the	 thymic	microenvironment33,	 34.	 Nevertheless,	 It	 remains	 to	 be	
determined	whether	gain	of	pre-leukemic	self-renewal	capacity	 is	a	true	obligatory	
trait	 for	 human	 T-ALL	 development.	 Moreover,	 it	 would	 be	 interesting	 to	 know	
whether	 other	 T-ALL	 specific	 transcription	 factor	 oncogenes,	 including	 NKX2.1,	
MEF2C,	 TLX1,	 TLX3	 or	 HOXA,	 also	 possess	 the	 intrinsic	 capacity	 to	 induce	 self-
renewal	in	T	cell	progenitors28.	
	
Finally,	 the	 pre-LSCs	 discussed	 above	 are	 more	 chemo/radioresistant	 and	 could	
reflect	 the	 population	 that	 would	 eventually	 give	 rise	 to	 tumor	 relapse	 after	
chemotherapy.	Recent	studies	indicate	that	pre-LSC	radioresistance	and	self-renewal	
capacity	are	regulated	via	distinct	molecular	pathways35.	Although	Kit	is	not	essential	
for	LMO2	mediated	leukemia	development,	Lmo2	transgenic	thymocytes	utilize	Kit-
dependent	signaling	pathways	to	enable	radioresistance.	
	
Prognostic	relevance	of	immature	subtypes	of	human	T-ALL	
From	 a	 clinical	 perspective,	 early	 work	 suggested	 that	 LYL1+	 T-ALLs	 could	 be	
associated	with	reduced	survival	rates	and	this	notion	was	further	supported	by	the	
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identification	of	early	T-	cell	specific	'V-Ets	avian	erythroblastosis	virus	E26	oncogene	
homolog'	 (ERG)	 and	 'brain	 and	 acute	 leukemia	 cytoplasmic'	 (BAALC)	 expression	 as	
poor	prognostic	markers	in	adult	T-ALL36.	In	addition,	absence	of	bi-allelic	deletion	of	
T-cell	 receptor	 γ,	 a	 marker	 for	 early	 arrest	 during	 T-cell	 differentiation,	 was	
associated	 with	 induction	 failure	 and	 poor	 clinical	 outcome	 in	 pediatric	 T-ALL37.	
Some	studies	have	suggested	that	RUNX138,	DNMT3A26,	IDH126	or	IDH226	mutations	
might	 confer	 poor	prognosis	within	 the	 immature	 subtype	of	 adult	 T-ALL.	 Further,	
specific	 immature	 subtypes	 characterized	 by	 aberrant	 HOXA	 gene	 activation,	
including	 SET-NUP214	 and	 CALM-AF10	 positive	 leukemias,	 were	 associated	 with	
higher	 levels	 of	 corticosteroid	 resistance39	 or	 dismal	 survival	 rates40.	 Finally,	 in	 an	
attempt	 to	 start	 integrating	 these	 molecular	 genetic	 findings	 into	 the	 clinic,	 the	
Group	for	Research	in	Adult	Acute	Lymphoblastic	Leukemia	(GRAALL)	implemented	a	
NOTCH1/FBXW7/RAS/PTEN-based	 oncogenetic	 risk	 classification,	 in	 which	 patients	
with	mutated	NOTCH1	 or	FBXW7	who	present	with	a	wild-type	RAS	 and	PTEN	 are	
considered	 low-risk,	 whereas	 all	 other	 adult	 T-ALLs	 are	 categorized	 in	 a	 high-risk	
category41.	Notably,	this	new	risk	classification	strategy	was	strongly	associated	with	
higher	cumulative	incidence	of	relapse	and	shorter	relapse-free	and	overall	survival	
in	 the	 multicenter	 GRAALL-2003	 and	 GRAALL-2005	 clinical	 trials42.	 Additional	
inclusion	of	poor	prognostic	genetic	markers,	such	as	mutational	status	of	DNMT3A,	
IDH1	 and	 IDH2	mutations,	 should	be	 considered	 to	 further	 improve	 this	novel	 risk	
stratification	 approach	 for	 adult	 T-ALL.	 Moreover,	 it	 should	 be	 noted	 that	 the	
prognostic	value	of	 this	novel	 risk	classification	strategy	might	not	be	applicable	 in	
pediatric	 treatment	 protocols	 given	 the	 high	 overall	 survival	 rates	 for	 T-ALL	 in	
children.	
	
More	recently,	early	T-cell	precursor	ALL	(ETP-ALL)	was	 identified	as	a	specific	sub-
entity	within	 immature	T-ALL	with	unique	 immunophenotypic	properties,	 including	
lack	of	CD1a	and	CD8	expression,	weak	CD5	positivity	and	expression	of	one	of	the	
stem	 cell/myeloid	markers	 CD13,	 CD117,	 CD33,	 'major	 histocompatibility,	 Class	 II,	
DR-Beta	(HLA-DR)	and/or	CD34.	Most	importantly,	the	initial	study	that	defined	ETP-
ALL	as	a	novel	 immature	subtype	of	pediatric	human	T-ALL,	 reported	an	extremely	
poor	clinical	course	for	these	patients	with	10-year	overall	survival	rates	of	19%	for	
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ETP-ALL	 patients	 as	 compared	with	 84%	 for	 other	 T-ALL	 subtypes43.	 Although	 the	
poor	clinical	characteristics	of	this	leukemic	subtype	were	subsequently	validated	in	
a	variety	of	 independent	patient	 series	 from	different	 international	pediatric	T-ALL	
treatment	protocols24,	43-46,	more	recent	work	has	started	to	question	the	prognostic	
relevance	 of	 this	 aggressive	 T-ALL	 subtype23,47.	 In	 that	 context,	 a	 recent	 and	 large	
study	 on	 1,144	 pediatric	 T-ALL	 patients	 enrolled	 in	 the	 Children’s	Oncology	Group	
(COG)	Study	AALL0434	suggested	that,	despite	significantly	higher	rates	of	induction	
failure,	pediatric	ETP-ALL	patients	as	defined	by	flow	cytometry	in	a	single	reference	
laboratory,	 show	 5-year	 event-free	 and	 overall	 survival	 rates	 identical	 to	 those	 of	
non-ETP-ALLs48.	These	discrepant	results	suggest	that	subtle	differences	in	treatment	
protocols	or	particular	 challenges	associated	with	accurate	assessment	of	 the	ETP-
ALL	immunophenotype	might	ultimately	affect	the	therapeutic	response	for	ETP-ALL	
observed	in	different	studies,	institutions	and/or	treatment	protocols.	Nevertheless,	
given	the	size	of	the	patient	population	included	in	the	COG	Study,	it	seems	unlikely	
that	the	ETP-ALL	immunophenotype,	as	originally	defined	by	Coustan-Smith	et	al.43,	
will	 eventually	 be	 implemented	 as	 a	 useful	 prognostic	marker	 to	 guide	 treatment	
decisions	for	pediatric	T-ALL.	
	
Novel	drivers	of	T-ALL	oncogenesis	
ZEB2	as	a	novel	transcription	factor	oncogene	in	early	immature	T-ALL	
Although	immature	T-ALL	has	been	identified	as	a	separate	T-ALL	disease	entity,	this	
genetic	subtype	is	relatively	heterogeneous;	only	few	oncogenic	transcription	factors	
implicated	in	immature	T-ALL	disease	biology	have	been	identified	to	date.	
	
The	 zinc	 finger	 E-box	 binding	 homeobox	 2	 protein	 (ZEB2/SIP1)	 has	 an	 established	
role	 in	 the	process	of	epithelial-mesenchymal	 transition	 (EMT)	and	 is	 implicated	 in	
both	 normal	 embryonic	 development	 and	 tumorigenesis49	 such	 as	 melanoma50,	
breast51	and	gastric	cancer52.	ZEB2	is	also	abundantly	expressed	in	the	hematopoietic	
system	and	 is	 essential	 for	 differentiation	 and	mobilization	of	 hematopoietic	 stem	
cells	 during	 embryonic	 development53.	 However,	 the	 role	 of	 ZEB2	 in	 normal	 T-cell	
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development	and	hematological	malignancies	has	not	been	thoroughly	investigated.	
Recently,	 Goossens	 et	 al.54	 identified	 the	 translocation,	 t(2;14)(q22;q32),	 as	 a	 rare	
but	recurrent	genetic	event	in	immature	T-ALL.	Detailed	cytogenetic	analysis	allowed	
mapping	 of	 the	 translocation	 breakpoint	 at	 14q32	 within	 the	 BCL11B	 locus	 and	
within	 close	 vicinity	 of	 the	 ZEB2	 gene	 at	 chromosomal	 band	 2q22.	 Notably,	
juxtaposition	of	BCL11B	near	putative	oncogenes	has	been	previously	reported	for	a	
number	 of	 T-ALL	 oncogenes	 including	 TLX3,	NKX2-5	 and	 PU.155,	 56.	 Therefore,	 this	
work	suggested	that	sustained	expression	of	the	EMT	regulator	ZEB2	could	act	as	a	
molecular	driver	of	 immature	T-ALL	development.	 It	 is	also	 interesting	to	note	that	
BCL11B	 haplo-insufficiency	 has	 also	 been	 implicated	 in	 T-cell	 leukemogenesis,	 as	
exemplified	by	loss-of-function	BCL11B	deletions	and	mutations	identified	in	primary	
T-ALLs57,	 58.	 Therefore,	 this	 particular	 chromosomal	 translocation	 might	 execute	 a	
dual	 function	 towards	 malignant	 T-cell	 transformation	 with	 concomitant	 loss	 of	
BCL11B	 and	 gain	of	ZEB2,	 a	 concept	 that	 also	 applies	 for	 the	other	BCL11B-driven	
translocations	mentioned	above.	
	
Using	a	conditional	ROSA26-based	Zeb2	gain-of-function	mouse	model,	Goossens	et	
al.54	 showed	 that	 hematopoietic	 overexpression	 of	 Zeb2	 resulted	 in	 spontaneous	
thymic	lymphoma	development	starting	at	5	months	of	age,	indicating	that	Zeb2	can	
act	 as	 a	 bona	 fide	 oncogene	 in	 hematologic	 T	 cell	 malignancies.	 Furthermore,	
breeding	of	 this	 tumor	model	 in	a	 tumor-prone	p53	null	background	revealed	 that	
Zeb2	 overexpression	 shortens	 tumor	 latency	 and	 drives	 a	 gene	 expression	 profile	
that	 resembles	 immature	 T-ALL,	 including	 the	 early	 T-cell/stem	 cell	 markers	 c-Kit,	
Baalc	 and	 Lyl1.	 Similar	 activation	 of	 a	 stem	 cell-like	 transcriptional	 program	 has	
previously	 been	 described	 in	 a	CD2-Lmo2tg	mouse	model59,	 in	which	 pre-leukemic	
thymocytes	 acquired	 Lmo2	 driven	 self-renewal	 capacity	 as	 a	 prerequisite	 of	 full	
clonal	 T	 cell	 transformation30.	 Similarly,	 transplantation	 experiments	 using	 Zeb2	
overexpressing	 lymphoblasts	 in	 immunodeficient	 mice	 showed	 that	 Zeb2	 driven	
tumors	 contained	 a	 higher	 fraction	 of	 leukemia-initiating	 cells	 as	 compared	 with	
controls,	 suggesting	 some	 putative	 communalities	 between	 the	 Zeb2	 and	 Lmo2	
driven	 tumor	 models	 as	 described	 above.	 Interestingly,	 ZEB	 proteins	 also	 bind	
tandem	 E-boxes60	 suggesting	 a	 potential	 overlap	 or	 competition	 for	 the	 same	
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regulatory	 sequences	 with	 the	 above	 described	 LYL1/LMO2	 transcriptional	
regulatory	complex32.	
	
Zeb2	 tumors	 were	 also	 characterized	 by	 enhanced	 JAK/STAT	 signaling	 through	
transcriptional	activation	of	IL7R.	This	association	between	ZEB2	and	IL7R/JAK/STAT	
activation	is	in	line	with	other	recent	studies	that	reported	alternative	in	vivo	models	
for	 immature	 T-ALL.	 Indeed,	 bone	 marrow	 transplantation	 of	 precursor	 cells	
expressing	gain-of-	function	IL7R61	or	JAK362	mutations	resulted	in	the	development	
of	 a	 transplantable	 murine	 immature	 T-ALL,	 reminiscent	 of	 the	 human	 disease.	
Altogether,	this	study	convincingly	identified	ZEB2	as	a	novel	oncogene	implicated	in	
immature	T-ALL,	but	 the	molecular	mechanisms	by	which	ZEB2	 regulates	 leukemic	
stem	 cell	 activity,	 in	 addition	 to	 the	 spectrum	 of	 direct	 ZEB2	 target	 genes	 that	
modulate	disease	initiation	or	progression	remain	to	be	established.	
	
The	role	of	non-coding	RNAs	in	T-ALL	
Over	 the	 last	 years,	 genome	wide	 profiling	 studies	 have	 extensively	 characterized	
oncogenic	 gene	 expression	 signatures	 of	 molecular	 genetic	 subtypes	 in	 human	 T-
ALL7-10.	 It	has	become	clear	 that	protein-coding	genes	only	 constitute	about	2%	of	
the	 entire	 genome,	 suggesting	 that	 the	 human	 transcriptome	 is	 predominantly	
composed	of	non-coding	RNAs63.	Besides	those	RNA	species	carrying	out	some	of	the	
main	housekeeping	 functions	 (such	as	 rRNAs,	 snoRNAs	and	 tRNAs),	diverse	classes	
such	as	miRNAs,	lncRNAs	and	circular	RNAs	constitute	novel	functional	effectors	and	
are	crucial	regulators	of	diverse	gene	expression	programs.	
	
MicroRNAs	in	the	pathogenesis	of	T-ALL	
MicroRNAs	(miRNAs)	are	a	well-known	class	of	small	non-coding	RNAs,	important	in	
both	 normal	 development	 and	 cancer64.	 The	 regulatory	 functions	 of	 miRNAs	 are	
essential	 to	 all	 levels	 of	 hematopoietic	 development65.	 With	 respect	 to	 T-ALL,	 a	
landmark	study	by	Mavrakis	et	al.66	identified	a	set	of	five	microRNAs	(miR-19b,	miR-
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20a,	miR-26a,	miR-92	and	miR-223)	that	cooperatively	suppress	a	network	of	tumor	
suppressor	 genes	 including	 PHF6,	 PTEN,	 BIM	 and	 FBXW7.	 Notably,	 each	 of	 these	
onco-miRNAs	were	 able	 to	 accelerate	 leukemia	 onset	 in	 a	Notch1-induced	murine	
bone	marrow	transplant	model	of	T-ALL,	confirming	their	in	vivo	potential.	This	study	
was	in	line	with	other	work	that	identified	the	miR-17-92	cluster	as	one	of	the	most	
prominent	oncogenic	miRNA	clusters	able	to	induce	overt	T-cell	leukemia	in	concert	
with	 activated	NOTCH167,	68.	 The	 role	 of	miR-223	 in	 oncogenic	 T-ALL	 signaling	was	
also	 emphasized	 by	 others69	 and	 could	 be	 further	 validated	 through	 the	
identification	of	miR-223	as	a	direct	 target	gene	of	 the	T-ALL	oncogenes	NOTCH170	
and	 TAL1,	 which	 contributes	 to	 T-ALL	 development	 by	 repression	 of	 the	 tumor	
suppressor	 gene	 FBXW771.	 Finally,	 another	 study	 identified	miR-128-3p	 as	 a	 novel	
oncogenic	miRNA	 in	 T-	 ALL	 that	 negatively	 regulates	 the	 expression	 of	 the	 tumor	
suppressor	PHF672	and	cooperates	with	activated	NOTCH1	signaling	to	accelerate	T-
ALL	formation	in	vivo72.	
	
In	 addition	 to	 oncogenic	 miRNAs	 that	 contribute	 to	 T-cell	 transformation	 by	
inactivation	of	specific	tumor	suppressor	genes,	Sanghvi	and	co-workers73	were	able	
to	 identify	 a	 set	 of	 so-called	 tumor	 suppressor	miRNAs	 (miR-29,	miR-31,	miR-150,	
miR-155	 and	 miR-200)	 in	 T-ALL.	 These	 miRNAs	 converged	 towards	 post-
transcriptional	 activation	 of	 the	MYB	 and	HBP1	 oncogenes.	 Another	 recent	 T-ALL	
study	 identified	 miR-193b	 as	 an	 additional	 tumor	 suppressor	 miRNA	 that	 also	
regulated	the	MYB	oncogene	expression	as	well	as		expression	of	the	anti-apoptotic	
factor	MCL174.	
Altogether,	 it	 is	 clear	 that	 a	 small	 subset	 of	 miRNAs	 has	 oncogenic	 or	 tumor	
suppressive	properties	 in	the	context	of	malignant	T-cell	 transformation	(Figure	1).	
Nevertheless,	a	comprehensive	overview	of	differential	miRNA	expression	between	
the	different	molecular	genetic	subgroups	in	human	T-ALL	remains	to	be	established.	
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Long	non-coding	RNAs	in	the	pathogenesis	of	T-ALL	
Long	non-coding	RNAs	(lncRNAs)	are	defined	as	transcripts	with	a	length	of	at	least	
200	nucleotides	that	 lack	protein-coding	potential	and	evolutionary	conservation75.	
They	 are	 positionally	 located	 as	 antisense,	 intronic,	 intergenic	 or	 overlapping	
transcripts	with	protein	coding	genes76.	The	functional	repertoire	of	lncRNAs	can	be	
very	 diverse,	 acting	mainly	 in	 concert	with	 chromatin	modifier	 enzymes.	 They	 can	
serve	 as	 scaffolds	 bridging	 between	multiple	 proteins,	 guides	 to	 target	 chromatin	
remodelers	 to	 their	 target	 sites	 or	 control	 devices	 which	 can	 induce	 protein	
conformational	 changes	 and	 thereby	 activate/inactivate	 the	 interacting	 protein	
complex77.	 Unlike	 miRNAs,	 the	 role	 of	 lncRNAs	 in	 normal	 and	 malignant	 T-cell	
development	is	only	starting	to	be	fully	explored.	
	
Last	 year,	 Trimarchi	 and	 colleagues	 published	 a	 pioneering	 study	 on	 the	
identification	of	a	set	of	 lncRNAs	under	control	of	aberrant	NOTCH1	signaling	 in	T-
ALL78.	They	identified	LUNAR1	as	an	oncogenic	lncRNA,	localized	in	the	nucleus,	that	
is	overexpressed	in	primary	T-ALLs	with	higher	expression	in	T-ALL	cases	that	harbor	
activating	 NOTCH1	 mutations.	 LUNAR1	 is	 located	 in	 cis	 to	 the	 IGF1R	 locus	 and	
promotes	 its	 expression	 through	 a	 direct	 interaction	 between	 LUNAR1	 and	 an	
intronic	 IGF1R	enhancer	element,	as	 shown	by	chromosome	conformation	capture	
analysis	 (Hi-C).	 Moreover,	 in	 vitro	 knockdown	 of	 LUNAR1	 significantly	 affected	
leukemic	cell	growth	due	to	decreased	'insulin-like	growth	factor	1	receptor'	(IGF1R)	
signaling.	 In	addition,	 the	 in	 vivo	 oncogenic	 capacity	of	 the	LUNAR1	 transcript	was	
further	 supported	 by	 xenograft	 assays,	 in	 which	 tumor	 cells	 that	 lost	 LUNAR1	
expression	 were	 outcompeted	 by	 the	 leukemic	 control	 population.	 Importantly,	
these	 initial	 findings	 were	 subsequently	 confirmed	 by	 a	 parallel	 study79	 in	 which	
LUNAR1	was	identified	as	the	top-candidate	of	NOTCH1	regulated	lncRNAs	in	T-ALL	
and	normal	T-cell	development.	These	studies	collectively	show	that	lncRNAs	act	as	
an	additional	 layer	of	complexity	 in	T-ALL	disease	biology	and	warrant	a	further	 in-
depth	analysis	of	lncRNA	profiles	in	an	extensive	series	of	disease	specimens.	
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Aberrant	enhancer	activity	in	malignant	T-cell	development	
Enhancers	 are	 gene	 regulatory	 elements	 that	 can	 act	 in	 cis	 or	 trans	 and	 ensure	
correct	 spatiotemporal	 gene	 expression.	 It	 is	 estimated	 that	 there	 are	 over	 one	
million	active	enhancers	present	in	all	human	cells80.	Hallmark	epigenetic	features	of	
enhancers	include	the	presence	of	H3K4me1	and	binding	by	p300,	with	the	absence	
or	 presence	 of	 H3K27ac	 further	 distinguishing	 between	 inactive	 and	 active	
enhancers81.	 Context	 and	 time-dependent	 binding	 of	 a	 diversity	 of	 transcription	
factors	 to	 these	 enhancer	 elements	 is	 crucial	 to	 ensure	 proper	 development	 and	
homeostasis82.	 Enhancer	 activity	 may	 act	 on	 genes	 in	 cis,	 but	 are	 often	 also	
implicated	in	long-range	interactions	through	chromatin	looping83.	
	
Recent	 studies	 have	 comprehensively	 mapped	 large	 enhancer	 regions	 that	 are	
marked	by	a	high	occupancy	of	'bromodomain	containing	4'	(BRD4),	p300,	H3K27ac	
and	 the	 Mediator	 complex;	 these	 are	 termed	 the	 super-enhancers84.	 These	 large	
enhancers	 resemble	 previously	 identified	 locus	 control	 regions	 and	 associate	with	
lineage	specific	transcription	factors	to	establish	a	correct	transcriptional	cell	identity	
program85.	 Moreover,	 given	 that	 these	 large	 enhancers	 are	 often	 aberrantly	
acquired	at	oncogenic	driver	genes,	accurate	localization	and	identification	of	these	
super-enhancers	can	help	in	identifying	relevant	cancer	genes	for	a	variety	of	tumor	
entities86.	
Two	parallel	T-ALL	studies	conducted	by	Mansour	et	al.87	and	Navarro	et	al.88	nicely	
illustrated	 the	 putative	 role	 of	 aberrant	 enhancer	 activity	 in	 the	 context	 of	 T-cell	
transformation.	Notably,	 these	 landmark	 publications	 identified	 a	 new	mechanism	
for	 oncogene	 activation	 in	 human	 T-ALL87,	 88,	 namely,	 somatic	 insertions	 in	 a	
regulatory	element	upstream	of	the	transcriptional	start	site	of	the	TAL1	oncogene87,	
88.	Indeed,	small	acquired	heterozygous	alterations	targeting	a	non-coding	region	of	
the	 human	 genome	 introduced	 a	 de	 novo	 recognition	 site	 for	 'V-myb	 avian	
myeloblastosis	viral	oncogene	homolog'	 (MYB)	near	 the	TAL1	 locus87.	 Interestingly,	
MYB	binding	at	this	particular	locus	resulted	in	the	creation	of	a	somatically	acquired	
super-enhancer	 and	 a	 concomitant	 epigenetic	 switch	 from	H3K27me3	 to	H3K27ac	
occupancy,	which	eventually	 caused	 increased	and	mono-allelic	TAL1	expression87.	
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Therefore,	these	studies	identified	a	novel	genetic	mechanism	for	the	generation	of	
oncogenic	 super-enhancers	 in	 malignant	 T	 cells87,	 88	 and	 their	 results	 suggest	 a	
general	 role	 for	MYB	 in	 the	 regulation	 of	 T-cell	 specific	 super-enhancer	 activity87.	
Additional	research	will	be	required	to	verify	if	similar	mechanisms	are	also	involved	
in	other	tumor	entities	and/or	activation	of	other	T-ALL	oncogenes.	
In	T-ALL,	it	was	previously	shown	that	a	proportion	of	relevant	NOTCH1	target	genes	
are	 also	 under	 control	 of	 long-range	 enhancers89.	 One	 interesting	 example	 is	 the	
massive	 binding	 of	 NOTCH1	 at	 a	 distal	 enhancer	 near	 the	MYC	 locus,	 which	 was	
recently	described	by	Herranz	et	al.90	and	subsequently	 independently	validated	by	
others91.	Most	notably,	conditional	deletion	of	this	single,	NOTCH1	controlled,	MYC	
enhancer	site	(N-Me)	abolished	the	initiation	and	maintenance	of	NOTCH1	induced	
leukemia	 in	 vivo90.	 Moreover,	 recurrent	 and	 focal	 duplications	 of	 the	N-Me	 locus	
were	found	in	5%	of	T-ALLs,	providing	an	alternative	example	of	genetic	alterations	
that	target	oncogenic	enhancer	activity	in	T-ALL90.	
	
Epigenetic	modulation	in	T-ALL	
Genome-wide	 or	 candidate-approach	 based	 studies	 recently	 identified	 recurrent	
genomic	 lesions	 in	 a	 variety	 of	 genes	 involved	 in	 DNA	 methylation	 or	 post-
translational	histone	modifications	 in	T-ALL.	Therefore,	disruption	of	the	epigenetic	
state	 and	 changes	 in	 the	 chromatine	 structure	 of	 normal	 thymocytes	 probably	
represent	crucial	mediators	of	malignant	T	cell	transformation.	The	reversible	nature	
of	 epigenetic	 modifications	 makes	 these	 DNA	 methyltransferases	 and	 histone	
modifier	enzymes	attractive	targets	for	therapeutic	intervention.	
	
The	PRC2	complex	functions	as	a	methyltransferase	that	regulates	H3K27me3	levels	
at	 specific	 target	 genes	 throughout	 the	genome.	Notably,	 the	 core	 components	of	
this	complex,	 including	EZH2,	EED	and	SUZ12,	were	 identified	as	 tumor	suppressor	
genes	 in	 T-	 ALL,	 with	mutations	 in	 about	 25%	 of	 adult	 T-ALL	 cases.	 Loss	 of	 PRC2	
activity	resulted	in	reduced	levels	of	H3K27me3	and	further	enhanced	the	NOTCH1	
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driven	oncogenic	transcriptional	program	during	malignant	T-cell	transformation92.	
	
'Lysine-speficic	 (K)	 demethylase	 6A'	 (KDM6A,	 UTX)	 is	 a	 H3K27	 demethylase	 that	
exerts	an	opposite	function	on	gene	transcription	as	compared	to	the	PRC2	complex.	
By	contrast,	some	studies	have	reported	loss-of-	function	mutations	targeting	UTX	in	
human	 T-ALL93-95,	 suggesting	 that	 both	 chromatin	 remodelers	 can	 exert	 tumor	
suppressor	functions	during	T-cell	 transformation.	 Interestingly,	Van	der	Meulen	et	
al.95	 exclusively	 identified	UTX	 mutations	 in	male	 T-ALL	 patients	 and	 showed	 that	
UTX	escapes	chromosome	X	inactivation	in	female	T-ALL	blasts,	providing	a	possible	
explanation	for	the	skewed	gender	distribution	observed	in	T-ALL.	These	findings	are	
also	clinically	relevant	given	that	T-ALL	driven	by	UTX	inactivation	exhibits	collateral	
sensitivity	 to	 pharmacological	 H3K27me3	 inhibition95.	 Finally,	 the	 critical	 role	 of	
unbalanced	H3K27me3	levels	in	the	initiation	and	maintenance	of	T-ALL	was	further	
exemplified	 by	 a	 recent	 study	 that	 identified	 an	 essential	 oncogenic	 role	 for	 the	
H3K27	 demethylase	 'Lysine-speficic	 (K)	 demethylase	 6B'	 (KDM6B,	 JMJD3)	 in	 the	
pathogenesis	of	T-ALL94.	 Indeed,	 JMJD3	was	critically	required	for	the	maintenance	
of	oncogenic	NOTCH1	signaling	during	T-cell	transformation	and	was	overexpressed	
in	primary	T-ALL.	JMJD3	inhibition	by	the	small	molecule	GSKJ4	could	restrain	T-ALL	
tumor	 growth	 and	 suggest	 that	 this	 epigenetic	 inhibitor	 could	 serve	 as	 another	
promising	therapeutic	strategy	for	the	treatment	of	T-	ALL94.	
	
Opportunities	for	targeted	therapy	in	T-ALL	
The	NOTCH1	signaling	pathway	
T-ALL	is	a	genetically	heterogeneous	disorder	in	which	multiple	oncogenic	and	loss-
of-	function	mutations	cooperate	to	establish	leukemia.	Nevertheless,	the	concept	of	
‘oncogene	 addiction’	 supports	 the	 idea	 that	 targeting	 single	 oncogenes	 should	 be	
sufficient	to	develop	effective	oncogene-based	therapeutic	opportunities96.	
	
The	 prototype	 example	 in	 the	 context	 of	 T-ALL	 is	 the	 inhibition	 of	 the	 proteolytic	
cleavage	 of	 the	 transmembrane	 NOTCH1	 receptor	 by	 the	 presenilin/γ-secretase	
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complex	 using	 γ-secretase	 inhibitors	 (GSI).	 Problematically,	 the	 accumulation	 of	
goblet	cells	in	the	digestive	system,	induced	by	GSI-treatment	through	upregulation	
of	'Kruppel-like	factor	4'	(KLF4)	levels,	leads	to	gastro-intestinal	toxicity.	Combination	
therapy	with	glucocorticoid	administration	effectively	reduces	the	toxic	effects	in	the	
gut97.	 It	 was	 recently	 shown	 that	 GSI-resistant	 T-ALLs	 could	 benefit	 from	 a	
combination	of	vincristine	and	GSI	treatment,	since	GSIs	were	shown	to	enhance	the	
apoptotic	 effect	 induced	 by	 the	 chemotherapeutic	 agent98.	 Similarly,	 a	 preclinical	
study	 using	 a	 clinically	 relevant	 GSI	 in	 combination	 with	 dexamethasone	 showed	
synergistic	results	in	glucocorticoid-	resistant	leukemias99.	
	
Alternative	strategies	 to	 target	 the	NOTCH1	pathway	are	still	being	developed	and	
include	 specific	NOTCH1	 inhibitory	antibodies	and	 stapled	peptides	 that	 target	 the	
NOTCH1	 transcriptional	 complex100,	101.	 For	 example,	 the	 synthetic	 peptide	 SAHM1	
that	directly	 interferes	 at	 the	 level	of	protein-protein	 interactions	 required	 for	 the	
NOTCH1	transcriptional	complex	shows	a	higher	potency	to	inhibit	NOTCH1	signaling	
in	comparison	to	GSI100.	
	
Other	strategies	involve	therapeutic	targeting	of	downstream	signaling	components	
of	the	NOTCH	pathway.	For	example,	pharmacological	inhibition	or	genetic	ablation	
of	 IGF1R,	 a	 direct	NOTCH1	 target	 gene,	 inhibits	 growth	 and	 viability	 of	 T-ALL	 cells	
and	 might	 influence	 the	 leukemia-initiating	 cell	 activity	 of	 NOTCH1	 induced	
tumors102.	Additionally,	 an	elegant	high-throughput	 compound	 screening	approach	
identified	 the	 sarco/endoplasmic	 reticulum	 calcium	 ATPase	 (SERCA)	 channels	 as	
novel	therapeutic	targets	in	NOTCH1	induced	T-ALL103.	SERCA	inhibition	by	the	small	
molecule	 thapsigargin	 selectively	 impaired	 NOTCH	 signaling	 and	 demonstrated	
antileukemic	 activity	 in	 both	 in	 vitro	 and	 in	 vivo	model	 systems103.	 Finally,	 Schnell	
and	 colleagues	 confirmed	 the	 critical	 role	 of	 HES1	 as	 downstream	 component	 of	
NOTCH1	signaling	in	T-ALL	and	revealed	that	perhexiline	could	evoke	a	strong	in	vitro	
and	 in	 vivo	 anti-leukemic	 response	 by	 reverting	 the	 HES1-driven	 gene	 expression	
signature,	providing	a	new	 lead	 for	 targeted	T-ALL	 treatment	 linked	to	hyperactive	
NOTCH1.	
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The	IL7R-JAK-STAT	pathway	as	a	therapeutic	target	
The	 IL7R-signaling	 pathway	 is	 strictly	 regulated	 during	 normal	 T-cell	 development,	
because	 it	 is	required	for	proliferation	and	survival	of	progenitor	T-cells.	Binding	of	
IL7	to	its	heterodimeric	receptor	(IL7R)	will	induce	phosphorylation	of	JAK1	and	JAK3	
as	 well	 as	 subsequent	 migration	 of	 dimerized	 STAT5	 to	 the	 nucleus	 where	 it	 will	
regulate	 target	 gene	 expression104.	 The	 anti-apoptotic	 effects	 of	 this	 pathway	 are	
mainly	mediated	 through	 the	 suppression	 of	 downstream	 'B-cell	 CLL/lymphoma	2'	
(BCL-2)	 expression105,	 whereas	 IL-7	 induced	 cell	 cycle	 progression	 requires	 down-	
regulation	of	p27.	
	
Two	independent	studies	described	somatic	gain-of-function	mutations	in	 IL7R	that	
caused	cytokine-independent	receptor	activation106,	107.	These	mutations	were	found	
in	about	10%	of	all	T-ALL	cases	and	are	specifically	associated	with	the	TLX1/3	T-ALL	
genetic	 subgroup.	 Alternatively,	 activation	 of	 JAK/STAT	 signaling	 can	 also	 be	
achieved	 by	 somatic	 JAK1	 or	 JAK3	 gain-of-function	 mutations25,	 108,	 or	 a	 rare	
translocation,	 t(9;12)(p24;p13),	 that	 drives	 expression	 of	 a	 chimeric	 ETV6-JAK2	
fusion	protein109,	110.	 Finally,	 inactivation	of	 the	 'protein	 tyrosine	phosphatase	non-
receptor	 type	 2'	 (PTPN2)	 gene	 has	 been	 observed	 in	 ~5%	 of	 T-ALL	 cases.	 Loss	 of	
PTPN2	 in	 leukemic	 T-cells	 resulted	 in	 increased	 proliferation	 upon	 IL7	 stimulation	
with	corresponding	activation	of	JAK1	and	STAT5111,	112.	
This	 genetic	 evidence	 combined	 with	 the	 transcriptional	 regulation	 of	 IL7R	 by	
activated	NOTCH	 signaling113	 and/or	 sustained	 ZEB2	 activity54,	marks	 this	 signaling	
axis	 as	 a	 highly	 attractive	 target	 for	 molecular	 therapy	 and	 therefore	 provides	 a	
strong	 rational	 for	 the	 use	 of	 clinical-stage	 JAK-	 or	 STAT-specific	 small	 molecule	
inhibitors	 in	 a	 significant	 fraction	 of	 human	 T-ALL	 patients	 (Figure	 2).	 Indeed,	
Goossens	et	et	al.	demonstrated	that	increased	IL7R	in	Zeb2	driven	immature	T-ALL	
is	associated	with	increased	cell	survival	and	secondary	leukemia	initiating	potential	
upon	 xenotransplantation,	which	 could	 be	 perturbed	 by	 administration	 of	 an	 IL7R	
blocking	antibody48.	
Recent	 efforts	 have	 been	 made	 to	 interfere	 with	 JAK-STAT	 signaling	 by	 chemical	
inhibitions	 and	 currently	 the	 JAK1/2	 inhibitor	 ruxolitinib	 and	 the	 JAK3	 inhibitor	
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tofacitinib	are	already	in	clinical	use	for	rheumatoid	arthritis114	and	myelofibrosis115.	
In	the	context	of	T-ALL,	Maude	et	al.116	nicely	demonstrated	aberrant	activation	of	
JAK/STAT	signaling	in	ETP-ALL	lymphoblasts	as	compared	with	more	mature	T-ALLs.	
Most	notably,	 JAK/STAT	pathway	activation	was	 found	to	be	a	universal	 feature	of	
immature	 leukemias	 irrespective	of	 IL7R,	 JAK1	 or	 JAK3	mutation	 status,	 suggesting	
that	 these	 tumors	 are	 strongly	 addicted	 to	 IL7	 signaling.	 Indeed,	 the	 broad	
therapeutic	 applicability	 of	 JAK	 inhibition	 in	 immature	 T-ALLs	was	 confirmed	by	 in	
vivo	drug	 treatment	experiments	 in	which	anti-tumoral	effects	 for	 ruxolitinib	were	
found	in	six	ETP-ALL	patient	derived	xenografts116.	
	
Pharmacological	BCL-2	inhibition	in	T-ALL	
As	 mentioned	 earlier,	 immature	 T-ALLs	 are	 often	 characterized	 by	 aberrant	
IL7R/JAK/STAT	activation	and	this	signaling	cascade	will	eventually	converge	towards	
STAT5-mediated	 activation	 of	 the	 anti-apoptotic	 factor	 BCL-2117.	 In	 addition,	 anti-
apoptotic	 genes	 show	 a	 spatiotemporal	 expression	 pattern	 during	 T-cell	
differentiation	with	the	highest	levels	of	BCL-2	in	early	T-cell	precursors118.	
	
Given	 this,	 pharmacological	 inhibition	of	BCL-2	has	been	 suggested	as	 a	promising	
new	 therapeutic	 strategy	 in	 immature	 subtypes	 of	 human	 T-ALL.	 Indeed,	 three	
independent	 studies118-120	 recently	 showed	 that	 immature	 T-ALLs	 display	 an	
increased	 sensitivity	 towards	 the	 highly	 specific	 BCL-2	 inhibitor	 ABT-199121.	 In	
addition,	 synergistic	 effects	 were	 reported	 between	 ABT-199	 and	 conventional	
chemotherapeutics	 that	 are	 currently	 used	 in	 T-ALL	 treatment	 schedules.	 Finally,	
preclinical	 models	 of	 patient	 derived	 xenografts	 confirmed	 ABT-199	 sensitivity	 in	
specific	T-ALL	subtypes	providing	additional	rationale	for	including	T-ALL	patients	in	
clinical	trials	using	this	particular	drug118-120.	
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The	PI3K-AKT-mTOR	pathway	
The	PI3K/AKT/'mammalian	 target	of	 rapamycin'	 (mTOR)	pathway	 controls	multiple	
cellular	responses	including	metabolic	regulation,	cell	growth	and	survival.	Activation	
of	 PI3K	 by	 growth	 factor	 stimuli	 results	 in	 the	 generation	 of	 phospatidylinositol	
triphosphate	 (PIP3)	 in	 the	plasma	membrane	and	subsequent	activation	of	 the	Akt	
kinase	 and	 downstream	 target	 proteins	 including	 mTOR.	 Importantly,	 the	
'phosphatase	 and	 tensin	 homologue'	 (PTEN)	 tumorsupressor	 negatively	 regulates	
PI3K/AKT/mTOR	signaling	by	dephosporylation	of	PIP3122.	
In	 human	 T-ALL,	 constitutive	 activation	 of	 the	 PI3K/AKT/mTOR	 signal	 transduction	
pathway	 is	 achieved	 by	 deletions	 or	 mutations	 targeting	 PTEN	 in	 about	 15%	 of	
cases123,	124	and	sporadic	gain-of-function	mutations	in	AKT,	PIK3R1	or	PIK3CA124-126.	
Moreover,	 normal	 and	malignant	 thymocytes	 rapidly	 activate	 the	 PI3K/AKT/mTOR	
pathway	 in	 response	 to	 IL7	 stimulation127,	 128.	 Therefore,	 IL7R	 gain-of-functions	
mutations106,	 107	 serve	 as	 an	 alternative	 route	 for	 enhanced	 PI3K/AKT/mTOR	
signaling	in	leukemic	T-cells.	Finally,	aberrant	NOTCH1	signaling	will	further	enhance	
PI3K/AKT/mTOR	 activation	 through	NOTCH1-mediated	 transcriptional	 upregulation	
of	the	 IL7R113	and	HES1-mediated	transcriptional	repression	of	PTEN123.	Notably,	 in	
some	T-ALL	cases,	loss	of	PTEN	can	occur	during	disease	progression	and	switch	the	
oncogene	 addiction	 from	NOTCH1	 towards	 constitutive	 AKT	 signaling123.	 However,	
PTEN	 inactivation	can	also	be	important	at	early	stages	of	leukemogenesis	where	it	
regulates	 the	 initial	 survival	 of	 the	 leukemia	 initiating	 cells129,	 130.	 Blackburn	 and	
colleagues	 used	 zebrafish	 as	 an	 in	 vivo	model	 to	 show	 that	 the	 Akt	 pathway	 is	
critically	 involved	 in	 expansion	of	 the	pool	 of	 leukemia	propagating	 cells	 that	may	
ultimately	give	rise	to	hematological	relapse131.	
	
Given	the	aberrant	activation	of	the	PI3K/AKT/mTOR	pathway,	this	signaling	cascade	
has	 been	 evaluated	 as	 novel	 therapeutic	 target	 in	 T-ALL.	 The	 mTOR	 inhibtor	
rapamycin	 showed	 promising	 results	 in	 pre-clinical	models132	 and	might	modulate	
glucocorticoid	resistance	in	T-ALL133.	However,	inhibition	of	mTOR	can	hyperactivate	
AKT	by	a	feedback	loop	between	mTOR,	PI3K	and	AKT134.	Therefore,	dual	PI3K/mTOR	
small	 molecule	 inhibitors	 have	 been	 developed135.	 They	 show	 strong	 cytotoxic	
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activity	 against	 T-ALL	 cell	 lines	 and	 lymphoblasts	 obtained	 from	 primary	 human	
leukemia	 patients136.	 In	 addition,	 direct	 AKT	 inhibition	 leads	 to	 rapid	 cell	 death	 in	
some	 T-ALL	 cell	 lines	 and	 primary	 patient	 samples123,	 137.	 At	 the	 level	 of	 PI3Ks,	
elegant	work	recently	showed	that	the	p110δ	and	p110γ	isoforms	of	PI3K	are	both	
critically	 required	 to	 sustain	 T-ALL	 development	 in	 a	 mouse	 model	 induced	 by	
conditional	loss	of	Pten	in	T-cells138.	Moreover,	a	specific	p110δ/p110γ	dual	inhibitor	
prolonged	 the	 survival	 of	 Pten	 null	 mice	 and	 showed	 promising	 effects	 in	 PTEN	
deificient	primary	human	T-ALL	tumor	cells138.	Therapeutic	targeting	of	cancer	cells	
by	exploiting	their	addiction	to	specific	PI3K	isoforms	might	be	particularly	relevant	
in	the	context	of	limiting	toxicities	that	would	be	associated	with	pan-PI3K	inhibitors.	
	
Targeting	general	transcription	machinery	in	T-ALL	
Impacting	on	 the	activity	of	 large	enhancers	may	provide	unique	opportunities	 for	
intervention	with	oncogenic	transcriptional	networks,	a	concept	that	has	now	been	
firmly	 established	 by	 the	 use	 of	 the	 BRD4	 inhibitor	 JQ1	 in	 a	 variety	 of	 pre-clinical	
tumor	 models,	 including	 T-ALL.	 Interestingly,	 chemical	 inhibition	 of	 CDK7,	 an	
important	component	of	the	transcription	factor	IIH	complex	(TFIIH)	which	regulates	
transcription	elongation	activity139,	has	recently	been	achieved	by	the	development	
of	 a	 novel	 CDK7	 inhibitor	 named	 THZ1.	 This	 molecule	 directly	 impacts	 on	 CDK7	
kinase	activity,	which	 is	required	for	regulation	of	the	TFIIH	complex	and	therefore	
globally	dampens	mRNA	transcription	of	a	 small	 set	of	 critical	genes	 involved	 in	T-
ALL	tumorigenesis140.	Besides	the	remarkable	in	vitro	and	in	vivo	anti-	tumor	activity	
observed	in	T-ALL140,	the	anti-cancer	effectiveness	of	the	THZ1	compound	was	also	
shown	for	other	tumor	entities	such	as	MYCN-driven	neuroblastoma141	and	small	cell	
lung	 cancer142.	 Nevertheless,	 the	 actual	 transcriptional	 response	 downstream	 of	
CDK7	 inhibition	 still	 needs	 to	 be	 further	 characterized	 for	 most	 tumors	 and	 the	
degree	of	overlap	with	JQ1	driven	BRD4	inhibition	remains	largely	unexplored.	
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Targeting	cap-dependent	translation	in	the	biology	T-ALL	
Translation	of	most	cellular	mRNAs	 is	mediated	by	a	cap	structure	at	 the	5'	end	of	
mRNAs.	 The	 initiation	 of	 this	 process,	 which	 is	 termed	 cap-dependent	 translation	
initiation,	 involves	a	tightly	controlled	multi-protein	initiation	complex	that	consists	
of	omnipresent	eukaryotic	initiating	factors,	including	the	cap-binding	protein	eIF4E	
and	the	RNA	helicase	eIF4A.	
	
Notably,	two	recent	key	publications	showed	that	T-ALL	cells	strictly	depend	on	cap-	
dependent	translation	for	their	survival143,	144.	Indeed,	sustained	expression	of	eIF4A	
or	 eIF4E	 was	 shown	 to	 accelerate	 tumor	 development	 in	 vivo	 and	 strong	 anti-
leukemic/apoptotic	effects	were	observed	using	eIF4A	 (silvestrol)	or	eIF4E	 (4EGI-1)	
specific	inhibitors143,	144.	This	critical	dependency	for	leukemic	survival	could	(at	least	
in	 part)	 be	 explained	 by	 a	 variety	 of	 signaling	 cascades	 that	 eventually	 converge	
towards	 enhanced	 cap-dependent	 translation	 activity	 in	 human	 T-ALL	 through	
aberrant	activation	of	mTORC1	and	mTORC2145.	Examples	of	such	signaling	pathways	
include	 aberrant	 NOTCH1	 activation,	 enhanced	 PI3K/Akt	 signaling	 through	 PTEN	
inactivation	 and	 aberrant	 receptor	 tyrosine	 kinase	 activity	 through	 IL7R	 or	 JAK	
mutations145.	 Moreover,	 enhanced	 cap-dependent	 translation	 in	 T-ALL	 will	
eventually	 result	 in	 more	 efficient	 translation	 of	 specific	 mRNAs	 with	 previously	
established	roles	in	the	pathogenesis	of	T-ALL	and	unique	structural	5’	untranslated	
region	(UTR)	features143,	144.	
	
Mechanisms	of	disease	relapse	in	T-ALL	
The	 biological	 basis	 for	 disease	 relapse	 in	 T-ALL	 is	 poorly	 understood.	 The	
identification	 and	 characterization	 of	 leukemia	 stem	 cells	 might	 provide	 novel	
insights	into	the	mechanisms	that	mediate	disease	recurrence	in	T-ALL	and	will	have	
important	implications	for	drug	development	and	pre-clinical	disease	modeling.	
Initial	 studies	have	shown	that	multiple	different	 leukemic	T-cell	 subpopulations	at	
diagnosis	have	intrinsic	repopulation	capacity	 in	 immunodeficient	recipient	mice146-
149.	 More	 importantly,	 pairwise	 genetic	 comparison	 of	 human	 T-ALL	 samples	 at	
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diagnosis	 with	 corresponding	 leukemic	 cells	 obtained	 after	 in	 vivo	 engraftment,	
showed	 that	 the	 xenograft	 leukemias	 often	 contained	 additional	 genetic	 defects	
targeting	known	T-ALL	oncogenes	and	tumor	suppressors	including	PTEN,	MYC,	MYB	
and	 CDKN2A150.	 Interestingly,	 these	 genetic	 abnormalities	 were	 present	 in	 minor	
leukemic	 subclones	 at	 diagnosis,	 suggesting	 a	 clonal	 relationship	 between	 the	
relapse	 clone	 and	 a	 chemoresistant	 subpopulation	 at	 diagnosis.	 Competitive	
engraftment	experiments	using	genetically	modified	primary	leukemia	cells	showed	
that,	for	example,	loss	of	PTEN	is	able	to	drive	enhanced	leukemia-	initiating	capacity	
in	a	primary	human	T-ALL	patient	samples150.	
	
These	 genomic	 analyses151	 suggest	 that	 relapse	 in	 T-ALL	 is	 mainly	 mediated	 by	
oncogenic	hits	that	are	already	present	in	minor	leukemic	subclones	at	diagnosis	and	
does	not	 simply	 result	 from	mutations	of	 specific	drug-resistance	genes.	However,	
this	 idea	has	 recently	been	 challenged	by	 the	 identification	of	mutations	 targeting	
the	 cytosolic	 5'-nucleotidase	 II	 (NT5C2)	 gene	 in	 about	 20%	 of	 relapsed	 T-cell	 ALL	
patients152,	153.	NT5C2	encodes	a	5'-	nucleotidase	enzyme	that	can	dephosphorylate	
thiopurine	nucleotides,	thereby	inactivating	the	purine	analogues	6-mercaptopurine	
(6-MP)	 and	 6-thioguanine	 (6-TG)	 which	 are	 routinely	 used	 in	 T-	 ALL	 maintenance	
therapy.	NT5C2	mutations	probably	represent	gain-of-function	alleles,	since	they	are	
clustered	 in	 specific	 regions	 of	 the	 NT5C2	 protein.	 Indeed,	 recombinant	 NT5C2	
mutant	 protein	 showed	 higher	 enzymatic	 activity	 and	 expression	 of	 NT5C2	
mutations	in	human	T-ALL	cell	lines	conferred	resistance	to	the	nucleoside	analogues	
6-MP	 and	 6-TG152.	 Together,	 these	 studies	 document	 an	 important	 role	 for	
nucleoside	analogue	metabolism	in	the	progression	and	chemoresistance	of	T-ALL.	
	
With	 the	 discovery	 of	 the	 chemo/radioresistant	 pre-leukemic	 stem	 cells,	 it	 is	
becoming	 increasingly	 clear	 that	 treatment	 of	 the	 bulk	 leukemic	 cells	may	 not	 be	
sufficient	to	discard	the	cell	of	origin.	Although	the	remaining	pre-LSCs	are	not	able	
to	 cause	 immediate	 overt	 leukemia,	 their	 clonal	 expansion	 would	 allow	 an	
accumulation	of	extra	oncogenic	hits,	causing	relapse	over	time.	Therefore	it	will	be	
important	 to	 further	 study	how	pre-LSCs	are	controlled	and	can	be	 therapeutically	
targeted.	Since	pre-LSCs	appear	to	be	dependent	on	Notch133,	 inhibition	of	NOTCH	
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signaling	 could	 serve	 as	 an	 attractive	 approach	 for	 targeting	 pre-LSCs	 more	
effectively	 and	 preventing	 relapse,	 irrespective	 of	 the	NOTCH1	mutation	 status	 of	
the	bulk	tumor	at	diagnosis34.	Alternatively,	targeting	the	Kit	signaling	pathway	may	
abolish	 their	 chemo/radioresistance	 and	 facilitate	 the	 eradication	 of	 leukemia-
initiating	cells	in	immature	T-cell	leukemias35.	
	
Conclusion	
T-ALL	originates	from	T-cell	precursors	at	different	stages	of	their	development	and	
is	 characterized	 by	 distinct	 and	 well-characterized	 molecular	 genetic	 subtypes.	
Children	 affected	 by	 this	 disease	 respond	 fairly	 well	 to	 high-dose	 chemotherapy	
regimens.	 Unfortunately,	 the	 clinical	 response	 in	 adults	 remains	 problematic	 and	
therapeutic	options	for	relapsed	T-ALL	patients	remain	scarce.	
Notably,	 the	 high	 survival	 rates	 reported	 in	 pediatric	 T-ALL	 protocols	 could	 result	
from	 overtreatment	 of	 a	 significant	 fraction	 of	 children.	 Therefore,	 and	 given	 the	
long-term	side	effects	associated	with	 intensive	chemotherapy,	risk	stratification	 in	
future	pediatric	T-ALL	treatment	protocols	should	be	further	optimized	based	on	our	
enhanced	 understanding	 of	 T-ALL	 disease	 biology.	 On	 the	 other	 hand,	 further	
reduction	 of	 chemotherapy	 can	 also	 be	 achieved	 by	 translation	 of	 our	 molecular	
genetic	findings	into	novel	targeted	therapies	for	the	treatment	of	human	T-ALL.	In	
that	 context,	 a	 variety	 of	 pre-clinical	 studies	 have	 reported	 promising	 therapeutic	
effects	for	particular	small	molecule	inhibitors	targeting	specific	oncogenic	pathways	
(Table	1).	Hopefully,	some	of	these	novel	therapeutic	strategies	can	be	implemented	
in	 daily	 clinical	 practice	 in	 complement	 with	 low	 dose	 chemotherapy.	 This	 will	
require	 an	 accurate	 definition	 of	 the	 specific	 T-ALL	 patient	 population	 that	 might	
benefit	from	these	novel	targeted	therapies.	 	
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Figures		
Figure	1.	miRNAs	implicated	in	T-ALL	disease	biology	
	
Figure	 1:	 Graphical	 illustration	 of	 miRNAs	 involved	 in	 the	 pathogenesis	 of	 T-ALL	 with	 tumor	
suppressor	miRNAs	targeting	oncogenes	and	oncomiRs	targeting	tumor	suppressor	genes.	 	
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Figure	2.	Molecular	mechanisms	for	IL7R/JAK/STAT	activation	in	T-ALL	
	
Figure	 2:	 Graphical	 overview	 of	 oncogenic	 mechanisms	 that	 can	 drive	 aberrant	 IL7R/JAK/STAT	
signaling	in	human	T-ALL.	The	left	panel	illustrates	indirect	mechanisms,	which	will	eventually	result	in	
enhanced	 IL7R	 expression	 and	 ligand-dependent	 pathway	 activation,	 including	 aberrant	 NOTCH1	
signaling	or	sustained	expression	of	ZEB2.	The	right	panel	documents	direct	mechanisms	of	pathway	
activation,	 which	 result	 in	 ligand	 independent	 stimulation,	 including	 activating	 IL7R,	 JAK1	 or	 JAK3	
mutations.	Therapeutic	targeting	of	this	oncogenic	signaling	pathway	could	be	achieved	by	the	JAK1/2	
inhibitor	ruxolitinib	or	the	JAK3	inhibitor	tofacitinib.	Moreover,	aberrant	IL7R/JAK/STAT	activation	will	
eventually	converge	towards	STAT5-mediated	activation	of	the	anti-apoptotic	factor	BCL-2.	Activation	
of	this	anti-apoptotic	factor	could	also	be	exploited	by	the	BH3	mimetic	BCL-2	inhibitor	ABT-199.	 	
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Tables	
	
Table	1.	Opportunities	for	targeted	therapy	in	T-ALL.	
	
Pathway	 Relevance	 Therapies	
NOTCH1  
 
Activating mutations in the 
NOTCH1 gene are present in over 
50% of T-ALL cases [6]. 
- NOTCH1	inhibitory	antibodies	and	
stapled	peptides	(ex.	SAHM1)	
- γ-secretase	inhibitors	(ex.	compound	E)	
- IGF1R	inhibitors	(ex.	BMS-536924)	
- SERCA	inhibitors	(ex.	thapsigargin)	
- HES1-signature	antagonists		
(ex.	perhexiline)	
 
IL7R-JAK-
STAT 
Activation of pathway in T-ALL 
by: 
- Gain-of-function	mutations	
in	IL7R,	JAK1,	JAK3	and	
STAT5B	or	loss	of	PTPN2	
- Overexpression	of	ZEB2	
- Activation	of	NOTCH1	
pathway	
- JAK1/JAK2	inhibitors	(ex.	ruxolitinib)	
- JAK3	inhibitors	(ex.	tofacitinib)	
- STAT5	inhibitors	
   
Mitochondrial 
apoptosis 
Overexpression of BCL-2 is 
typical for immature T-ALL. 
IL7R-JAK-STAT signaling also 
leads to BCL-2 upregulation 
- BCL-2	inhibitors	(ex.	ABT-199)	
   
PI3K-Akt-
mTOR 
Activation of pathway in T-ALL 
by: 
- Deletions	or	mutations	in	
PTEN	
- Gain-of-function	mutations	
in	AKT,	PIK3R1	or	PIK3CA	
- IL7	stimulation	
- mTOR	inhibitors	(ex.	rapamycin)	
- PI3Kγ/δ	inhibitors	(ex.	CAL-130)	
- dual	PI3K/mTOR	inhibitors	(ex.	PI-103)	
- AKT	inhibitors	(ex.	A443654)	
	
H3K27	
demethylation 
JMJD3 is overexpressed and 
oncogenic in T-ALL 
- JMJD3	inhibitors	(ex.	GSKJ4)	
	
General	
transcription	
Oncogenic driver genes are often 
associated with super-enhancers 
and are very strongly transcribed  
 
- BRD4	inhibitors	(ex.	JQ1)	
- CDK7	inhibitors	(ex.	THZ1)	
Cap-dependent	
translation	
T-ALL	cells	depend	on	cap-
dependent	translation	for	their	
survival 
- eIF4A	inhibitors	(ex.	silvestrol)	
- eIF4E	inhibitors	(ex.	4EGI-1)	
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Research	objectives	
	
Over	 the	 last	 decade,	 technological	 advances	 in	 next-generation	 sequencing	 have	
revolutionized	 the	 discovery	 and	 functional	 characterization	 of	 the	 genomic,	
transcriptomic	and	epigenomic	landscapes	that	drive	cancer	formation.	Interestingly,	
epigenetic	regulators	now	often	emerge	as	hubs	in	the	transcriptional	networks	that	
govern	malignant	transformation,	being	frequently	mutated	in	many	cancer	types.	
T-cell	 acute	 lymphoblastic	 leukemia	 (T-ALL)	 is	 an	 aggressive	 and	 genetically	
heterogeneous	 hematological	 disorder	 arising	 from	 uncontrolled	 clonal	 expansion	
and	arrested	differentiation	of	 thymocytes.	Although	a	plethora	of	 genetic	defects	
driving	 T-ALL	 formation	 and	progression	have	been	extensively	 studied	over	many	
years,	 the	 substantial	 contribution	 of	 epigenetic	 deregulation	 to	 acute	 T-cell	
leukemia	 has	 only	 recently	 been	 underscored	with	 the	 identification	 of	mutations	
affecting	 EZH2,	 UTX	 and	 PHF6	 and	 the	 elucidation	 of	 the	 putative	 oncogenic	
properties	of	JMJD3.		A	better	understanding	of	how	these	chromatin	modifiers	act	
in	concert	with	other	master	regulators	in	normal	T-cell	development	and	how	their	
deregulated	expression	 causes	 T-ALL	blast	 formation	and	expansion	will	 foster	 the	
development	and	implementation	of	novel	targeted	therapeutic	strategies	in	T-ALL.	
Interestingly,	to	aim	for	full	comprehension	of	transcriptional	regulatory	complexity,	
also	the	pool	of	non-coding	RNAs,	consisting	mainly	of	microRNAs	(miRNAs)	and	long	
non-coding	RNAs	(lncRNAs)	should	be	taken	into	account.	MiRNAs	have	been	shown	
to	be	directly	involved	in	cancer,	including	in	T-ALL.	Now,	lncRNAs	are	emerging	as	a	
class	 of	 non-coding	 RNAs	 displaying	 a	 versatile	 functional	 repertoire,	 mainly	 in	
concert	 with	 chromatin	 remodeling	 complexes	 and	 substantially	 contributing	 to	
various	 malignancies.	 Furthermore,	 the	 observation	 that	 many	 lncRNAs	 exhibit	 a	
tissue-specific	 expression,	 makes	 them	 ideal	 targets	 for	 therapeutic	 intervention	
with	reduced	toxic	effects.	
In	 this	 PhD	 thesis,	 I	 aimed	 to	 perform	 an	 in	 depth	 comprehensive	 and	 integrative	
analysis	 of	 the	 functional	 cross-talk	 between	 the	 known	 T-ALL	 driver	 oncogenes	
NOTCH1	 and	 TLX1,	 expand	 their	 respective	 transcriptional	 networks	 towards	 non-
coding	 RNAs	 and	 unravel	 the	 role	 of	 PHF6	 as	 a	 novel	 key	 epigenetic	 regulator	 in	
normal	and	malignant	T-cell	development.	 	
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Aim	1:	Landscaping	the	functional	consequences	of	the	genome-wide	TLX1	binding	
profile	in	T-ALL	
The	 ‘T-cell	 leukemia	 homeobox	 1’	 (HOX11,	 TLX1)	 gene	 encodes	 a	 homeobox	
transcription	factor	that	is	ectopically	expressed	in	a	subset	of	human	T-ALL	cases,	as	
a	 consequence	of	 chromosomal	 translocations	and	defines	one	of	 the	major	T-ALL	
subgroups.	 The	 current	understanding	of	 the	oncogenic	properties	downstream	of	
TLX1	 includes	 aneuploidy	 resulting	 from	 mitotic	 checkpoint	 deregulation,	 T-cell	
differentiation	 arrest	 caused	 by	 repression	 of	 TCRα	 enhancer	 activity	 and	
simultaneous	 inhibition	 of	 a	 plethora	 of	 T-ALL	 tumor	 suppressor	 genes.	 These	
studies	 provided	 important	 insights	 in	 the	 mechanisms	 that	 mediate	 T-cell	
transformation	downstream	of	TLX1,	but	were	solely	focused	on	TLX1	binding	at	the	
promoter	of	direct	target	genes.			
Therefore,	 I	 studied	 in	 more	 depth	 the	 functional	 consequences	 of	 genome-wide	
TLX1	binding	in	the	context	of	human	T-ALL	development	(paper	1,	Leukemia,	2015).	
To	 this	 end,	 an	 integrative	 genomic	 approach	 was	 applied	 to	 investigate	 the	
functional	 consequences	 of	 ectopic	 TLX1	 binding	 in	 the	 context	 of	 normal	 T	 cell	
development	as	well	as	in	the	process	of	malignant	T-cell	transformation.		
In	addition,	I	aimed	to	expand	this	network	under	control	of	TLX1	towards	long	non-
coding	RNAs	(lncRNAs)	(paper	6,	 in	preparation).	To	this	end,	we	performed	poly-A	
RNA-sequencing	 of	 an	 in	 vitro	 TLX1	 knockdown	 model	 system	 in	 ALL-SIL	
lymphoblasts	and	 from	a	primary	T-ALL	 cohort	of	64	patients.	Next,	we	 integrated	
H3K27ac	 ChIP-seq	 data	 to	 identify	 the	 set	 of	 TLX1	 regulated,	 super-enhancer	
associated	lncRNAs.	The	use	of	RNA-sequencing	as	a	discovery	tool,	allowed	us	also	
to	 retrieve	 a	 set	 of	 previously	 unannotated	 lncRNAs	 implicated	 in	 the	 the	 TLX1	
regulatory	network.	
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Aim	 2:	 Scrutinizing	 the	 role	 of	 PHF6	 as	 a	 novel	 master	 regulator	 of	 normal	
hematopoiesis	and	its	function	as	a	tumor	suppressor	in	T-ALL	pathogenesis	
In	2010,	our	research	team	was	involved	in	the	identification	of	a	novel	T-ALL	tumor	
suppressor	gene	PHF6.		In	collaboration	with	the	research	group	of	Adolfo	Ferrando		
(Columbia	 University	 Medical	 Center,	 New	 York,	 USA)	 a	 mutation	 screening	 was	
performed	 for	 X-linked	protein	 coding	 genes	 in	 T-ALL	patients.	 In	 16%	of	pediatric	
and	38%	of	adult	cases,	PHF6	mutations	and	deletions	were	identified.	Interestingly,	
in	the	context	of	hematological	malignancies,	PHF6	lesions	were	found	later	only	to	a	
minor	extent	also	in	acute	myeloid	leukemia	patients	and	not	in	B-cell	malignancies,	
underscoring	 the	role	of	PHF6	as	a	T-ALL	specific	 tumor	suppressor.	Notably,	PHF6	
deficiency	in	B-ALL	cells	leads,	in	contrast	to	a	T-ALL	context,	to	impaired	cell	growth.	
These	observations	 thus	 suggest	a	potential	 critical	 role	 for	PHF6	as	a	 regulator	of	
hematopoietic	 lineage	 commitment.	 To	 this	 end,	 we	 studied	 the	 effects	 of	 PHF6	
knockdown	 in	 CD34+	 thymocyte	 progenitors	 with	 respect	 to	 hematopoietic	
differentiation	 (paper	 2,	 in	 preparation).	 In	 addition,	 I	 aimed	 to	 unravel	 the	
functional	 interaction	between	TLX1	and	PHF6	in	T-ALL	formation	and	scrutinize	 its	
potential	 functional	 interaction	with	other	chromatin	 remodeling	complexes	at	 the	
level	of	transcriptional	networks.		(paper	3,	in	preparation).	
	
Aim	 3:	 Identification	 of	 TAL1	 as	 a	 novel	 driver	 of	 miRNA	 expression	 in	 T-ALL	
oncogenesis	
TAL1/SCL	is	a	crucial	regulator	 in	normal	hematopoietic	development	and	is	one	of	
the	 most	 frequently	 altered	 T-ALL	 oncogenes	 as	 a	 consequence	 of	 a	 t(1;14)	
translocation	(1-2%	of	all	cases)	or	SIL-TAL	fusion	due	to	an	interstitial	deletion	(15-
20%	 of	 T-ALLs).	 The	 transcriptional	 network	 under	 control	 of	 TAL1	 in	 normal	 and	
malignant	 T-cell	 development	 has	 already	 been	 extensively	 studied	 and	 requires	
amongst	 others	 interaction	 with	 the	 chromatin	 modifier	 enzyme	 ‘lysine	 specific	
demethylase	 1’	 (LSD1).	 We	 hypothesized	 that	 TAL1	 could	 also	 act	 as	 a	 crucial	
regulator	 of	miRNA	 expression	 in	 T-ALL	 (paper	 4,	 Leukemia,	 2013)	 and	 therefore	
scrutinized	the	miRNAs	that	are	under	control	of	TAL1	in	T-ALL	lymphoblasts.	
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Aim	 4:	 The	 role	 of	 long	 non-coding	 RNAs	 in	 the	 NOTCH1	 signaling	 pathway	 in	
normal	and	malignant	T-cell	development	
Besides	 the	 genetic	 alterations	 that	 discriminate	 the	 different	 T-ALL	 oncogenic	
subtypes,	 a	 set	 of	 mutations	 in	 T-ALL	 are	 prevalent	 in	 a	 subtype	 independent	
manner.		The	prototype	example	is	the	occurrence	of	activating	NOTCH1	mutations,	
present	 in	over	60%	of	all	T-ALL	cases.	The	NOTCH1	receptor	plays	a	crucial	role	 in	
normal	 and	 malignant	 T-cell	 development.	 Although	 the	 signaling	 cascade	
downstream	of	NOTCH1	has	been	studied	extensively	 in	 the	past,	 the	 role	of	non-
coding	RNAs	has	thus	far	not	been	explored.	Therefore,	we	aimed	to	identify	the	set	
of	lncRNAs	(paper	5,	Haematologica,	2014)	under	control	of	NOTCH1	in	both	thymic	
CD34+	and	CD4+CD8+	progenitor	cells	as	well	as	in	T-ALL	blasts.	
	
Statement	on	the	bio-informatics	analyses	throughout	this	doctoral	thesis	
Throughout	this		PhD	thesis,	a	plethora	of	bio-informatics	analyses	were	executed	to	
support	 or	 guide	 the	 experimental	 data	 that	 is	 described.	 I	 performed	 differential	
gene	expression	analyses	of	the	micro-array	expression	datasets	using	R	included	in	
this	 PhD	 thesis,	 as	well	 as	GSEA	 and	Gene	Ontology	 analyses	 on	 these	 expression	
datasets.	 With	 respect	 to	 data-mining	 of	 the	 RNA-seq	 and	 ChIP-seq	 datasets	
throughout	this	thesis,	 I	was	assisted	by	a	dedicated	bio-informatician,	Wouter	van	
Loocke,	who	 is	 therefore	 clearly	 stated	 as	 a	 prominent	 co-author	 on	many	 of	 the	
publications	(either	published	or	in	preparation)	included	in	this	doctoral	thesis.	
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ABSTRACT	
The	TLX1	transcription	factor	is	critically	involved	in	the	multi-step	pathogenesis	of	T-
cell	 acute	 lymphoblastic	 leukemia	 (T-ALL)	 and	 often	 cooperates	 with	 NOTCH1	
activation	 during	 malignant	 T-cell	 transformation.	 However,	 the	 exact	 molecular	
mechanism	 by	 which	 these	 T-cell	 specific	 oncogenes	 cooperate	 during	
transformation	 remains	 to	 be	 established.	 Here,	 we	 used	 chromatin	
immunoprecipitation	followed	by	sequencing	to	establish	the	genome-wide	binding	
pattern	 of	 TLX1	 in	 human	 T-ALL.	 This	 integrative	 genomics	 approach	 showed	 that	
ectopic	TLX1	expression	drives	repression	of	T-cell	specific	enhancers	and	mediates	
an	 unexpected	 transcriptional	 antagonism	 with	 NOTCH1	 at	 critical	 target	 genes,	
including	 IL7R	 and	NOTCH3.	 These	 phenomena	 coordinately	 trigger	 a	 TLX1	 driven	
pre-leukemic	phenotype	in	human	thymic	precursor	cells,	reminiscent	of	the	thymus	
regression	 observed	 in	 murine	 TLX1	 tumor	 models,	 and	 create	 a	 strong	 genetic	
pressure	 for	 acquiring	 activating	 NOTCH1	 mutations	 as	 a	 prerequisite	 for	 full	
leukemic	transformation.	In	conclusion,	our	results	uncover	a	functional	antagonism	
between	 cooperative	oncogenes	during	 the	 earliest	 phases	of	 tumor	development	
and	 provide	 novel	 insights	 in	 the	 multi-step	 pathogenesis	 of	 TLX1	 driven	 human	
leukemia.		
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INTRODUCTION	
T-cell	 leukemia	 homeobox	 1	 (TLX1,	 HOX11)	 is	 a	 homeobox	 transcription	 factor	
oncogene	that	is	ectopically	expressed	by	chromosomal	translocations	in	a	subset	of	
human	 T-cell	 acute	 lymphoblastic	 leukemia	 (T-ALL).	 TLX1	 activation	 is	 more	
prevalent	in	adult	than	in	pediatric	T-ALL	and	is	generally	associated	with	a	favorable	
prognosis1.	TLX1	driven	T-ALLs	show	a	unique	gene	expression	signature	related	to	
early	 cortical	 thymocytes	 with	 corresponding	 expression	 of	 CD1a,	 CD4	 and	 CD8	
surface	marker	proteins.	 Initial	studies	showed	that	TLX1	could	immortalize	murine	
hematopoietic	 precursors2,3,	 but	 its	 leukemic	 potential	 has	 only	 been	 fully	
established	 using	 TLX1	 transgenic	 mouse	 models	 that	 develop	 clonal	 T-cell	
malignancies	with	a	long	latency4,5.	These	TLX1	induced	murine	T-cell	tumors	share	
common	features	with	human	TLX1	positive	leukemia,	including	activation	of	Notch	
signaling,	 loss	 of	 the	Bcl11b	 tumor	 suppressor	 gene	 and	 a	 transcriptional	 program	
that	 disrupts	 the	 mitotic	 checkpoint	 and	 induces	 aneuploidy	 during	 T-cell	
transformation4.	 Of	 note,	 Lck-TLX1	 transgenic	 mice	 present	 with	 a	 pre-leukemic	
phenotype,	 in	 which	 TLX1	 positive	 T-cell	 precursors	 undergo	 a	 block	 in	
differentiation	and	show	enhanced	susceptibility	towards	apoptosis4.	The	decreased	
thymus	size	and	reduced	cellularity	observed	 in	TLX1	 transgenic	mice,	corresponds	
with	 earlier	 findings	 in	 the	 human	 context6
	
and	 might	 be	 associated	 with	
transcriptional	repression	of	the	TCRα	locus	by	the	TLX1-ETS1-RUNX1	complex7.		
NOTCH1	 is	 a	 critical	 regulator	 of	 T-cell	 development	 and	 serves	 as	 a	 prominent	
oncogene	 in	 the	 biology	 of	 T-ALL8.	 Critical	 NOTCH1	 target	 genes	 are	 often	 co-	
regulated	 by	 a	 transcription	 factor	 complex	 that	 contains	 NOTCH1,	 ETS1	 and	
RUNX19,10.	 Notably,	 binding	 of	 this	 complex	 regularly	 occurs	 near	 super-enhancer	
regions11,12,13
	
in	 the	 vicinity	 of	 genes	 that	 are	 critically	 involved	 in	 normal	 and	
malignant	T-cell	development9,10.	Activating	NOTCH1	mutations	occur	 in	more	than	
half	 of	 all	 T-ALLs8,	 but	 are	 particularly	 prevalent	 in	 TLX1	 positive	 human	 T-ALLs14.	
Moreover,	Notch1	mutations	are	almost	uniformly	identified	in	murine	T-cell	tumors	
that	 developed	 from	 TLX1	 transgenic	 mice4,5.	 Therefore,	 NOTCH1	 activation	 and	
aberrant	 expression	 of	 TLX1	 are	 considered	 collaborative	 events	 in	 the	multi-step	
pathogenesis	of	T-ALL.	However,	the	exact	molecular	mechanisms	by	which	these	T-
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cell	 specific	 oncogenes	 cooperate	during	malignant	 T-cell	 transformation	and	 their	
functional	relationship	remains	to	be	established.	
Here,	 we	 used	 an	 integrative	 genomic	 approach	 to	 study	 the	 role	 of	 the	 TLX1	
transcription	 factor	 oncogene	 in	 the	 multi-step	 pathogenesis	 of	 human	 T-ALL.	
Furthermore,	 we	 evaluated	 the	 functional	 relationship	 between	 the	 cooperative	
oncogenes	TLX1	and	NOTCH1	 in	T-ALL	to	understand	their	cooperative	mechanism-	
of-action	during	T-cell	transformation.	
	
METHODS	
Cell	lines	
ALL-SIL	 cells	 were	 obtained	 from	 the	 DSMZ	 cell	 line	 repository.	 Cells	 were	
maintained	in	RPMI-1640	medium	(Life	Technologies)	supplemented	with	20%	fetal	
bovine	serum,	1%	of	L-glutamine	(Life	Technologies)	and	1%	penicillin/streptomycin	
(Life	Technologies).	
	
Clinical	samples	
Bone	 marrow	 lymphoblast	 samples	 from	 64	 T-ALL	 patients	 (15	 immature,	 25	
TAL/LMO,	 17	 TLX1/TLX3	 and	 7	 HOXA)	 were	 collected	 with	 informed	 consent	
according	to	the	declaration	of	Helsinki	from	Saint-Louis	Hospital	(Paris,	France)	and	
the	 study	 was	 approved	 by	 the	 Institut	 Universitaire	 d’Hématologie	 Institutional	
Review	Board.	This	primary	T-ALL	cohort	was	previously	 investigated	and	the	high-	
quality	 RNA	 samples	 from	 this	 cohort	 were	 used	 for	 gene	 expression	 profiling15.	
Gene	 expression	 data	 is	 accessible	 on	 ArrayExpress	 under	 accession	 no.	 E-MTAB-	
59315.	
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SiRNA-mediated	knockdown,	RNA-isolation,	cDNA	synthesis	and	RT-qPCR	
ALL-SIL	cells	were	electroporated	 (250	V,	1000	μF)	using	a	Genepulser	Xcell	device	
(Biorad)	 with	 400	 nM	 of	 Silencer	 Select	 Negative	 Control	 1	 siRNA	 (Ambion,	 #)	 or	
siRNAs	 targeting	 TLX1	 (Silencer	 Select,	 Ambion).	 ALL-SIL	 cells	 were	 collected	 24h	
post-electroporation.	 Total	RNA	was	 isolated	using	 the	miRNeasy	mini	 kit	 (Qiagen)	
with	 DNA	 digestion	 on-column.	 By	 means	 of	 spectrophotometry,	 RNA	
concentrations	were	measured	 (Nanodrop	 1000)	 and	 RNA	 integrity	was	 evaluated	
(Experion,	 Bio-Rad).	 Next,	 cDNA	 synthesis	 was	 performed	 using	 the	 iScript	 cDNA	
synthesis	 Kit	 (Bio-Rad)	 followed	 by	 RT-qPCR	 using	 the	 LightCycler	 480	 (Roche).	
Finally,	qPCR	data	was	analyzed	according	to	the	ΔΔCt-method	using	the	qBasePLUS	
software	(Biogazelle).	
	
Western	blotting	
SDS-PAGE	 was	 performed	 according	 to	 standard	 protocols.	 For	 immunoblotting,	
following	 antibodies	 were	 used:	 rabbit	 polyclonal	 antibody	 to	 TLX1	 (1:500,	 Santa	
Cruz	 Biotechnology),	mouse	monoclonal	 antibody	 to	 alpha-tubulin	 (1:2000,	 Sigma-
Aldrich),	mouse	monoclonal	 antibody	 to	beta-actin	 (1:2000,	 Sigma-	Aldrich),	 rabbit	
polyclonal	antibody	to	ICN1	(1:1000,	Cell	Signaling)	and	rabbit	polyclonal	antibody	to	
c-MYC	(1:500,	Santa	Cruz	Biotechnology).	Protein	level	quantification	was	performed	
using	the	ImageJ	software.	
	
Micro-array	based	gene	expression	profiling	
RNA	samples	from	ALL-SIL	cells	as	well	as	CD34+	thymus	precursor	cells	were	profiled	
on	a	custom	designed	Agilent	micro-array	covering	all	protein	coding	genes	(33,128	
mRNA	 probes,	 Human	 Sureprint	 G3	 8x60k	 micro-arrays	 (Agilent))	 and	 12,000	
lncRNAs	 (23,042	 unique	 lncRNA	 probes)16.	 Expression	 data	were	 normalized	 using	
the	 VSN-package	 (Bioconductor	 release	 2.12)	 in	 R.	 Differential	 expression	 analysis	
was	 performed	 in	 R	 using	 Limma.	 All	 gene	 expression	 profiling	 data	 has	 been	
deposited	in	the	GEO	database	(GSE62144).	
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Compound	treatment	of	T-ALL	cell	lines	
ALL-SIL	 cells	 were	 seeded	 at	 a	 density	 of	 1*106
	
cells/ml	 and	 treated	 for	 12h	with	
either	DMSO	or	1	μM	of	JQ1	compound	(BPS	Bioscience).	ALL-SIL	cells	were	seeded	
at	 a	 density	 of	 1*106cells/ml	 and	 treated	 for	 48h	 with	 either	 DMSO	 or	 1	 μM	 of	
compound	E	(Enzo	Life	Sciences).	Cells	were	harvested	at	the	indicated	time-points	
and	RNA-isolation	was	performed	as	described	above.	
	
ChIP-seq	and	ChIP-qPCR	
The	 ChIP-protocol	 has	 been	 adapted	 from	 previous	 studies17.	 In	 brief,	 1*107	 cells	
were	cross-linked	with	1,1%	formaldehyde	(Sigma-Aldrich)	at	room	temperature	for	
10	 min	 and	 the	 cross-linking	 reaction	 was	 quenched	 with	 glycine	 (125	 mM	 final	
concentration,	 Sigma-Aldrich).	Nuclei	were	 isolated	 and	 chromatin	was	purified	by	
chemical	 lysis.	 Next,	 the	 purified	 chromatin	 was	 fragmented	 to	 200-300	 bp	
fragments	 by	 sonication	 (Covaris).	 Chromatin	 immunoprecipitation	was	 performed	
by	 incubation	of	 the	 chromatin	 fraction	overnight	with	100	μl	 of	 protein-A	 coated	
beads	(Thermo-	Scientific)	and	10	μg	of	fibrillarin-specific	(Abcam),	H3K27ac-specific	
antibody	 (Abcam)	 or	 TLX1-specific	 antibody	 (Santa-Cruz	 Biotechnology).	 The	 next	
day,	 beads	 were	 washed	 to	 remove	 non-specific	 binding	 events	 and	 enriched	
chromatin	fragments	were	eluted	from	the	beads,	followed	by	reverse	cross-linking	
by	 incubation	 at	 65°C	 overnight.	 DNA	 was	 subsequently	 purified	 by	
phenol/chloroform	 extraction,	 assisted	 by	 phase	 lock	 gel	 tubes	 (5Prime).	 DNA	
obtained	 from	 the	 ChIP-assays	 was	 adaptor-ligated,	 amplified	 and	 analyzed	 by	
Illumina	 Hiseq	 2000.	 Raw	 sequencing	 data	 was	 mapped	 to	 the	 human	 reference	
genome	(GRCh37/h19)	using	Bowtie18.	Peak	calling	was	performed	using	MACS	1.419.	
ChIP	seq	data	has	been	deposited	in	the	GEO	database	(GSE62144).	
Relative	 real-time	 PCR	 quantification	 of	 promoter	 sequences	 was	 normalized	 to	
HPRT1	 DNA	 levels	 (negative	 control	 region)	 in	 chromatin	 immunoprecipitates	
performed	 with	 TLX1-specific	 antibody	 (Santa	 Cruz	 Biotechnology)	 or	 fibrillarin-
specific	 antibody	 (negative	 control	 antibody)	 (Abcam).	 Additionally,	 real-time	 PCR	
quantification	was	 normalized	 in	 chromatin	 immunoprecipitates	 performed	with	 a	
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RUNX1	(Abcam)	and	ETS1	(Cell	signaling)	specific	antibodies	to	immunoprecipitation	
with	a	fibrillarin-specific	antibody.	ChIP-qPCR	primers	for	CHEK1,	BUB1,	BCL11B	and	
BRCA2	were	 used	 as	 described	 previously4.	 Enrichment	 was	 calculated	 using	 the	
ΔΔCt	method.	
	
Motif	enrichment	
A	 TLX1	 peak	 multi-fasta	 file	 (500	 bp	 centered	 around	 the	 peak	 summits)	 was	
produced	 using	 BedTools20	 and	 was	 subsequently	 submitted	 to	 the	 MEME-ChIP21
	
public	 server	 for	motif	 enrichment	 analysis.	 This	motif	 analysis	was	 performed	 on	
the	top	quartile	(25%	of	the	highest	scoring)	of	TLX1	ChIP-seq	peaks.	The	‘fasta-get-	
markov’	 module,	 included	 in	 the	 MEME	 suite,	 was	 used	 to	 create	 a	 background	
model	based	on	all	TLX1	peaks	as	called	by	MACS1.4.	
	
ChIP-seq	peak	heatmaps	
Public	ChIP-seq	data	for	ETS1,	RUNX1,	ICN1	and	BRD4	in	CUTLL19
	
were	downloaded	
from	GEO	series	GSE51800.	Fastq	files	were	aligned	to	the	reference	genome	(hg19)	
with	 Bowtie.	 HOMER22
	
was	 used	 to	 produce	 tag	 directories	 and	 heatmap	 data	
matrices	of	public	ChIP-seq	data	and	TLX1	ChIP-seq	data.	Heatmaps	were	produced	
in	 R.	 TSS-centered	heatmaps	were	ordered	based	on	 average	 linkage	 clustering	 of	
the	 rows	 in	 the	 TLX1	 heatmap.	 TLX1	 ChIP-seq	 peak	 heatmaps	 were	 ordered	 by	
descending	TLX1	peak	heights.	
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Thymocyte	transduction	and	culturing	on	OP9-DLL1	
Pediatric	thymus	samples	were	obtained	and	used	according	to	the	guidelines	of	the	
Medical	 Ethical	 Commission	 of	 the	 Ghent	 University	 Hospital	 (Belgium).	 CD34+
	
thymocytes	 were	 purified	 using	 magnetic	 activated	 cell	 sorting	 (MACS,	 Miltenyi	
Biotec)	and	cultured	for	24h	 in	complete	 IMDM,	supplemented	with	penicillin	 (100	
U/ml),	streptomycin	(100	μg/ml),	L-glutamine	(2	mM)	(all	from	Invitrogen)	and	10%	
heat-inactivated	FCS	(Biochrom)	in	the	presence	of	10	ng/ml	IL-7	and	SCF.	After	24h,	
cells	 were	 retrovirally	 transduced	 with	 either	 LZRS-IRES-EGFP	 (LIE)	 or	 LZRS-	 TLX1-
IRES-EGFP	(TLX1)	as	described	previously23.	For	the	double	transfection	experiments,	
retroviral	 transduction	 was	 performed	 using	 either	 MSCV-mCherry	 or	 MSCV-
mCherry-TLX1	 (TLX1)	 at	 24h.	 Next,	 mCherry+
	
cells	 were	 sorted	 and	 directly	
transduced	with	either	MSCV-EGFP	or	MSCV-EGFP-ICN1	at	48h.	Next,	equal	numbers	
of	 transduced	cells	were	 seeded	onto	confluent	OP9-GFP	or	OP9-DLL1	plates	 in	α-
MEM	media	supplemented	with	20%	heat-inactivated	FCS	plus	100	U/ml	penicillin,	
100	μg/ml	streptomycin,	2	mM	L-glutamine	and	the	T-lineage	supporting	cytokines	
SCF,	 Flt3-L	 and	 IL-7	 at	 5	 ng/ml	 each.	 Following	 72h	 of	 OP9	 co-culture,	 cells	 were	
harvested	 by	 forceful	 pipetting	 and	 stained	 with	 CD45-PE	 (Miltenyi)	 to	 purify	
CD45+EGFP+,	CD45+mCherry+
	
or	CD45+mCherry+EGFP+
	
human	transduced	leukocytes	
through	sorting	to	remove	contaminating	OP9	stromal	cells.	After	sorting,	part	of	the	
cells	were	lysed	in	700	μl	QIAzol	(Qiagen)	and	stored	at	-80°C	prior	to	RNA	isolation,	
while	 the	 other	 part	 was	 used	 to	 perform	 T-cell	 differentiation	 experiments	 as	
described	previousy24.	 To	evaluate	T	 cell	development,	 co-cultures	were	harvested	
at	indicated	time	points	by	forceful	pipetting,	stained	with	monoclonal	antibodies	as	
described	 previously26
	
and	 analyzed	 on	 a	 LSRII	 flow	 cytometer	 using	 FACSDiva	
software	(BD	Bioscience).	
	
Ectopic	TLX1	expression	in	CUTLL1	
CUTLL1	 cells	 were	 seeded	 at	 a	 density	 of	 1*10e6	 cells/ml	 in	 RPMI-1640	 medium	
supplemented	with	20%	fetal	bovine	serum	and	retrovirally	transduced	with	either	
LZRS-IRES-EGFP	 (control	 vector)	 or	 LZRS-TLX1-IRES-EGFP	 (TLX1).	 After	 72h,	
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transduced	cells	were	sorted	to	purify	EGFP+
	
CUTLL1	cells.	After	sorting,	cells	were	
lysed	in	700	μl	QIAzol	(Qiagen)	and	stored	at	-80°C	prior	to	RNA	isolation.	
 
RESULTS	
Genome-wide	binding	profile	of	TLX1	in	human	T-ALL	
To	identify	the	genome-wide	binding	pattern	of	TLX1	in	the	context	of	human	T-ALL,	
we	performed	chromatin	immunoprecipitation	followed	by	sequencing	(ChIP-seq)	in	
ALL-SIL,	 a	 human	 T-ALL	 cell	 line	 with	 ectopic	 TLX1	 expression	 as	 a	 result	 of	 the	
t(10;14)(q24;q11)	translocation.	This	analysis	 identified	18,187	unique	TLX1	binding	
peaks	(FDR<0.05)	with	a	distribution	of	19.8%	in	the	proximity	of	transcriptional	start	
sites	 (TSSs)	 of	 protein-coding	 genes,	 43.5%	 in	 intronic	 and	 36.7%	 in	 intergenic	
regions	 of	 the	 human	 genome	 (Supplementary	 Figure	 1a).	 Notably,	 genes	
characterized	 by	 the	 strongest	 TLX1	 binding	 events	 showed	 higher	 average	
expression	 levels	 as	 compared	 to	 genes	 with	 moderate	 or	 no	 TLX1	 binding	
(Supplementary	 Figure	 1b).	 The	 validity	 of	 our	 approach	 was	 confirmed	 by	 ChIP-	
qPCR	 analysis	 of	 TLX1	 binding	 at	 promoter	 regions	 of	 previously	 reported	 TLX1	
targets4,	including	BCL11B,	BUB1,	CHEK1	and	BRCA2	(Supplementary	Figure	1c).		
To	unravel	 the	transcriptional	consequences	of	TLX1	binding,	we	performed	micro-	
array	 gene	 expression	 analysis	 before	 and	 after	 TLX1	 knockdown	 in	 ALL-SIL	 cells	
using	2	independent	TLX1	targeting	siRNAs	(Figure	1a,	Supplementary	Figure	2a	and	
2b).	 Gene	 Set	 Enrichment	Analysis	 (GSEA)	 confirmed	 that	 TLX1	 binding	 peaks	 (top	
500	 and	 top	 1000	 scoring	 peaks)	 located	 near	 TSSs	 of	 protein-coding	 genes	 were	
significantly	enriched	in	genes	upregulated	after	TLX1	knockdown	in	ALL-SIL	(Figure	
1b	and	Supplementary	Figure	2c),	in	line	with	the	previously	recognized	role	of	TLX1	
as	 a	 transcriptional	 repressor	 in	 T-ALL4,25.	 In	 addition,	 this	 notion	 was	 further	
confirmed	 by	 a	 significantly	 higher	 number	 of	 TLX1	 bound	 genes	 that	 are	
upregulated	 as	 compared	 to	 downregulated	 after	 TLX1	 knockdown	 (Figure	 1c).	
Notably,	 the	 average	 gene	 expression	 levels	 of	 targets	 repressed	 by	 TLX1	 were	
higher	 in	 comparison	 to	 TLX1	 activated	 genes	 or	 those	 that	were	 not	 significantly	
differentially	expressed	upon	TLX1	knockdown	in	ALL-SIL	(Figure	1d).	Consistent	with	
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previous	 reports,	 we	 also	 obtained	 a	 significant	 enrichment	 of	 the	 TLX1	 binding	
peaks	 near	 TSSs	 in	 genes	 that	 are	 downregulated	 in	 both	 TLX1	 or	 TLX3	 driven	
primary	 T-ALLs,	 in	 keeping	with	 previously	 noted	 overlap	 between	 TLX1	 and	 TLX3	
transcriptional	programs4,25
	
(Figure	1e).	
Next,	we	evaluated	the	presence	of	co-factor	binding	sites	at	TLX1-bound	regions	by	
means	of	motif	analysis	(Figure	1f).	A	strong	enrichment	was	found	for	RUNX	family	
member	(E-value:	2.9e-288)	and	ETS	transcription	factor	motifs	(E-value:	1.5e-227),	
consistent	with	previously	published	data7,25.	Moreover,	but	 to	a	 lesser	extent,	we	
found	 enrichment	 for	 other	 co-factors	 previously	 linked	 to	 TLX1	 functionality,	
including	MEIS	and	PBX	transcription	factor	family	members26,27.	
The	genome-wide	binding	profiles	of	RUNX1	and	ETS1	were	previously	shown	to	be	
highly	overlapping	in	the	context	of	T-ALL9.	Moreover,	ETS1	cooperates	with	TLX1	at	
the	TCRα	locus	and	RUNX1	was	shown	to	act	as	a	central	hub	in	the	TLX1	regulatory	
network25.	 Given	 this,	 we	 integrated	 our	 TLX1	 ChIP-seq	 profiles	 with	 publically	
available	 ETS1	 and	 RUNX1	 ChIP-seq	 data9
	
and	 evaluated	 the	 extent	 of	 overlap	
between	these	transcription	factors	at	the	TSSs	of	genes	that	are	upregulated	after	
TLX1	knockdown	in	ALL-SIL	(bona	fide	TLX1	repressed	target	genes).	We	generated	a	
heatmap	 of	 the	 TLX1	 ChIP-seq	 binding	 profile	 for	 the	 top-500	 genes	 upregulated	
upon	TLX1	knockdown	by	clustering	of	TLX1	ChIP-seq	signals	within	a	10	kb	window	
surrounding	the	TSS	(Figure	1g).	Next,	ChIP-seq	binding	profiles	for	RUNX1	and	ETS1	
were	visualized	in	the	exact	same	gene	order	as	defined	by	the	TLX1	ChIP-seq	data	
(Figure	1g).	Similar	and	overlapping	patterns	observed	 in	 these	ChIP-seq	heatmaps	
support	our	motif	analysis	(Figure	1f)	and	confirm	a	high	degree	of	overlap	between	
TLX1,	 ETS1	 and	 RUNX1	 binding	 sites	 in	 the	 promoter	 of	 TLX1	 repressed	 genes.	 To	
verify	whether	these	overlapping	binding	patterns	between	TLX1,	RUNX1	and	ETS1	
also	 result	 in	 a	 similar	 transcriptional	 read-out,	 we	 performed	 siRNA-mediated	
knockdown	 for	 RUNX1	 and	 ETS1	 in	 ALL-SIL.	 The	 resulting	 gene	 signatures	 were	
scored	 to	 the	 transcriptional	profile	associated	with	TLX1	 inactivation	 in	ALL-SIL	by	
GSEA.	 This	 analysis	 points	 towards	 a	 common	 transcriptional	 regulatory	 network	
between	these	three	transcriptional	 regulators	 (Supplementary	 Figure	 3a	 and	3b).	
Furthermore,	ChIP-qPCR	analysis	in	ALL-SIL	confirmed	direct	binding	of	both	RUNX1	
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and	ETS1	at	 the	exact	 same	binding	 sites	 as	observed	 for	 TLX1	at	 canonical	 target	
genes,	 including	BCL11B,	CHEK1,	BRCA2	 and	BUB1	 (Supplementary	 Figure	 3c	 and	
3d).	 Overlapping	 binding	 patterns	 between	 TLX1,	 RUNX1	 and	 ETS1	 could	 not	 be	
observed	 using	 the	 top-500	 down-regulated	 genes	 upon	 TLX1	 knockdown	
(Supplementary	Figure	4).	
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Figure	1:	Characterizing	the	genome-wide	TLX1	binding	pattern.	(a)	Scatter	plot	showing	significantly	
down-	 (blue)	 and	 upregulated	 (red)	 genes	 (p-adj.	 value	 <	 0.05)	 upon	 TLX1	 knockdown	 in	 ALL-SIL	
leukemic	 cells,	 (b)	 GSEA	 shows	 a	 significant	 enrichment	 of	 the	 top-500	 scoring	 (FDR<0.05)	 TLX1	
binding	sites	in	proximity	(<=2kb)	of	the	TSS	amongst	the	TLX1	repressed	genes,	(c)	Barplot	showing	
the	distribution	of	TLX1	ChIP-seq	peaks	between	genes	up-	or	downregulated	upon	TLX1	knockdown	
in	ALL-SIL,	 (d)	Boxplot	showing	that	TLX1	repressed	genes	have	a	higher	average	expression	 level	 in	
comparison	to	genes	either	activated	by	TLX1	or	not	differentially	expressed	upon	TLX1	knockdown	in	
ALL-SIL	(e)	Validation	of	the	same	geneset	as	defined	in	(b)	in	a	primary	cohort	of	64	T-ALL	patients	(5	
TLX1+	 cases	 and	 12	 TLX3+	 cases),	 (f)	 MEME-ChIP	 motif	 analysis	 identifies	 RUNX	 and	 ETS	 family	
member	motifs	amongst	the	strongest	enriched	DNA-motifs	in	TLX1	binding	sites	identified	by	ChIP-
sequencing,	(g)	Heatmap	representation	of	ChIP-profiles	of	TLX1	in	ALL-SIL	cells	and	ETS1-RUNX1	sites	
in	 CUTLL1	 cells	 at	 the	 top-500	 upregulated	 genes	 upon	 TLX1	 knockdown,	 clustered	 according	 to	
average	linkage.	 	
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TLX1	binding	at	super-enhancers	in	human	T-ALL	
Recently,	 enhancer	 sites	 with	 broad	 binding	 of	 traditional	 enhancer	 associated	
histone	marks	(H3K27ac	and	H3K4me1)	and	co-occupation	of	the	transcriptional	co-	
activators	 BRD4	 and	 MED1	 were	 identified11,12.	 These	 so-called	 super-enhancers	
mark	the	binding	sites	for	transcription	factor	complexes	that	establish	a	unique	cell	
identity	 program	 and	 drive	 expression	 of	 both	 lineage	 identity	 genes	 as	 well	 as	
prominent	oncogenes	in	human	cancer.	
Given	the	role	of	TLX1	as	oncogenic	transcriptional	repressor,	we	wondered	whether	
TLX1	could	 interfere	with	super-enhancer	activity11,12
	
in	 the	context	of	TLX1-driven	
human	leukemia.	For	this,	we	performed	H3K27ac	ChIP-seq	analysis	in	the	T-ALL	cell	
line	 ALL-SIL	 and	 used	 the	 normalized	 H3K27ac	 cluster	 signals	 in	 function	 of	 the	
normalized	 ranks	 to	 identify	 super-enhancers	 in	 this	 TLX1	 driven	 tumor	 line,	 as	
previously	 described12
	
(Supplementary	 Figure	 5a).	 Next,	 we	 performed	 a	 similar	
analysis	based	on	TLX1	ChIP-seq	data	and	clustered	TLX1	peaks	within	12.5	kb	from	
each	 other.	 These	 TLX1	 clusters	 were	 superimposed	 on	 the	 H3K27ac	 super-	
enhancer	 plot,	 which	 revealed	 a	 large	 overlap	 between	 super-enhancer	 sites	 and	
TLX1	binding	clusters	 in	the	ALL-SIL	genome	(Figure	2a).	Notably,	 these	top-ranked	
super-enhancer	 sites	 were	 often	 located	 within	 the	 vicinity	 of	 crucial	 regulators	
involved	 in	 normal	 and	 malignant	 T-cell	 development,	 for	 example	 ZFP36L2	 and	
HIVEP3	(Figure	2b).	
To	further	confirm	true	super-enhancer	identity	of	TLX1	bound	super-enhancer	sites,	
we	 interrogated	 their	 responsiveness	 to	 treatment	 with	 the	 small-molecule	 BET-	
inhibitor	 JQ128.	 Response	 to	 treatment	 was	 verified	 by	 downregulation	 of	 c-MYC	
RNA	levels	(Supplementary	Figure	5b)	and	protein	levels	(Supplementary	Figure	5c).	
For	 this,	 we	 used	micro-array	 analysis	 to	 evaluate	 the	 transcriptional	 response	 of	
ALL-SIL	cells	upon	JQ1	treatment	(Supplementary	Figure	5d).	Notably,	GSEA	analysis	
showed	that	H3K27ac	defined	super-enhancers	characterized	by	co-binding	of	TLX1	
were	 significantly	enriched	 in	genes	downregulated	upon	 JQ1	 treatment	 in	ALL-SIL	
(Figure	2c).	In	addition,	the	same	TLX1	bound	super-enhancer	sites	were	significantly	
enriched	for	genes	that	are	upregulated	upon	TLX1	knockdown	(suppressed	by	TLX1;	
Chapter	3:	Results	
	 	 	118	
Figure	 2d),	 suggesting	 that	 TLX1	 interferes	 with	 enhancer	 function	 at	 these	 loci.	
Notably,	 the	core	enrichment	 for	 these	GSEA	analyses	 included	several	genes	with	
an	established	role	in	either	T-cell	development	(PTPN3,	RAG2,	BACH2,	HIVEP3,	CD2)	
or	T-ALL	pathogenesis	(ETV6,	MYB)	(Figure	2e).	The	response	of	these	genes	to	JQ1	
treatment	or	TLX1	knockdown,	respectively,	was	confirmed	by	RT-qPCR	(Figure	2f).	
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Figure	 2:	 The	 role	 of	 TLX1	 at	 (super)-enhancer	 sites.	 (a)	 Hockey-stick	 plot	 representing	 the	
normalized	rank	and	cluster	signal	of	clusters	of	H3K27ac	peaks	 (super-enhancers)	overlapping	with	
significant	TLX1	ChIP-seq	peak	clusters	(blue	dots),	overlapping	with	TLX1	binding	events	that	are	not	
organized	 in	 significant	 clusters	 (orange	 dots)	 or	 not	 overlapping	 with	 TLX1	 binding	 events	 (black	
dots),	 (b)	 Examples	 of	 H3K27ac	 defined	 super-enhancer	 sites	 characterized	 by	 large	 TLX1	 ChIP-seq	
peak	clusters	within	the	proximity	of	ZFP36L2	and	HIVEP3,	 (c)	GSEA	of	the	top-500	scoring	H3K27ac	
defined	super-enhancer	sites	with	significant	TLX1	clusters	(orange	and	blue	dots	from	a)	within	the	
set	of	genes	downregulated	by	JQ1	in	ALL-SIL,	(d)	GSEA	of	the	same	geneset	as	in	(c)	within	the	set	of	
genes	 upregulated	 upon	 TLX1	 knockdown	 in	 ALL-SIL,	 (e)	 Examples	 of	 H3K27ac	 and	 TLX1	 ChIP-seq	
signals	at	the	PTPN3	and	CD2	 loci,	both	significantly	enriched	in	the	GSEA	analyses	shown	in	(c)	and	
(d),	(f)	Confirmation	of	IGLL1	and	MYB	responsiveness	to	JQ1	treatment	and	TLX1	knockdown	in	ALL-
SIL	by	RT-qPCR.	 	
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Transcriptional	antagonism	between	the	cooperative	oncogenes	TLX1	and	NOTCH1	
Previous	studies	have	shown	that	NOTCH1,	ETS1	and	RUNX1	define	a	 transcription	
factor	 complex	 that	 co-regulates	 important	 NOTCH1	 target	 genes9,10.	 Moreover,	
binding	of	this	complex	can	also	occur	near	super-enhancer	regions	in	the	vicinity	of	
genes	 critically	 involved	 in	 normal	 and	malignant	 T-cell	 development9.	 Given	 that	
RUNX1	and	ETS1	often	co-occupy	TLX1	binding	sites	and	that	TLX1	can	also	associate	
with	regions	of	super-enhancer	activity,	we	wondered	whether	TLX1	could	interfere	
with	the	transcriptional	program	mediated	by	NOTCH1.	
To	 address	 this	 issue,	 we	 evaluated	 the	 relationship	 between	 the	 NOTCH1	
transcriptional	 program	 and	 the	 gene	 expression	 signature	 associated	 with	 TLX1	
knockdown	 in	 ALL-SIL.	 Surprisingly,	 GSEA	 analysis	 showed	 that	 NOTCH1	 positively	
regulated	 genes	 (down-regulated	 upon	 GSI	 treatment	 of	 ALL-SIL	 cells29;	
Supplementary	Figures	6a-c)	were	significantly	enriched	for	genes	repressed	by	TLX1	
(Figure	 3a).	 TLX1	 and	 ICN1	 binding	 near	 the	NOTCH3	 and	 IL7R	 loci	 are	 shown	 as	
representative	examples	for	overlapping	binding	events	of	these	factors	at	canonical	
NOTCH1	target	genes	 (Figure	 3b).	Notably,	next	 to	some	of	 the	canonical	NOTCH1	
targets	also	NOTCH1	 itself	 is	upregulated	upon	TLX1	knockdown	in	ALL-SIL,	at	both	
the	mRNA	and	protein	level	(Figure	3c).	The	TLX1-driven	repression	of	some	of	these	
NOTCH1	 target	 genes	was	 confirmed	 upon	 ectopic	 TLX1	 expression	 in	 the	 CUTLL1
	
cell	 line	 (as	 shown	 for	NOTCH3;	 Figure	 3d).	 Interestingly,	 strong	 and	 overlapping	
binding	of	TLX1	with	NOTCH1	was	also	observed	at	the	recently	identified	long-range	
acting	MYC-enhancer30
	
(Figure	 3e).	 Finally,	 alignment	 of	 the	 genome-wide	 ICN1,	
ETS1	and	RUNX1	ChIP-seq	peaks	in	CUTLL1	T-ALL	cells	with	those	of	TLX1	in	ALL-SIL	
cells	showed	a	striking	binding	overlap	for	these	transcription	factors	as	visualized	by	
ChIP-seq	 heatmaps	 (3	 kb	 centered	 around	 the	 TLX1	 summits;	 Figure	 3f	 and	
Supplementary	Figure	6d).	
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Figure	3:	Transcriptional	antagonism	between	cooperative	oncogenes	NOTCH1	and	TLX1	 in	T-ALL.	
(a)	GSEA	shows	that	the	top-500	downregulated	genes	upon	GSI	treatment	of	ALL-SIL	T-ALL	cells	are	
significantly	enriched	within	the	set	of	genes	that	are	upregulated	upon	TLX1	knockdown	in	ALL-SIL,	
(b)	ChIP-seq	profiles	of	ICN1	and	TLX1	showing	overlapping	binding	patterns	at	the	canonical	NOTCH1	
target	genes	NOTCH3	and	IL7R,	(c)	confirming	upregulation	of	NOTCH1	upon	TLX1	knockdown	in	ALL-
SIL	 cells,	 (d)	 Ectopic	 expression	 of	 TLX1	 in	 CUTLL1	 leads	 to	 reduced	 expression	 of	 the	 canonical	
NOTCH1	 target	 gene	NOTCH3	 as	 shown	 by	 RT-qPCR,	 (e)	 ChIP-seq	 profiles	 of	 ICN1	 and	 TLX1	 at	 the	
NOTCH3	and	IL7R	loci,	(e)	ChIP-seq	profiles	of	ICN1	and	TLX1	at	the	genomic	region	spanning	from	c-
MYC	 towards	 its	 recently	described	 long-range	enhancer	 site30	 and	visualization	of	 the	high-scoring	
and	overlapping	ICN1	and	TLX1	peak	at	this	specific	enhancer	site30
	
(f)	Heatmap	representation	of	the	
ChIP-seq	overlap	of	TLX1-ICN1-ETS1-RUNX1	sites	across	a	genome-wide	score-based	ranking	of	TLX1	
ChIP-seq	signals.	 	
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TLX1	broadly	interferes	with	normal	T-cell	development	
Previously,	 it	 has	 been	 shown	 that	 Lck-TLX1	 transgenic	mice	 are	 characterized	 by	
reduced	thymus	size	and	cellularity	as	a	pre-leukemic	phenotype	that	precedes	full	
leukemic	 transformation4.	 In	 addition,	 enforced	 TLX1	 expression	 in	 human	 cord	
blood	CD34+
	
progenitor	 cells	 disrupted	 primary	 T-cell	 differentiation	 and	 triggered	
enhanced	 thymocyte	 apoptosis6.	 These	 data	 suggest	 that	 ectopic	 induction	 of	 the	
TLX1	 oncogene	 in	 T-cell	 precursors	 negatively	 affects	 T-cell	 differentiation,	
proliferation	and	survival.	
To	 further	 study	 the	 role	 of	 TLX1	during	 the	 initial	 phases	 of	 tumor	 development,	
human	 thymus-derived	 CD34+
	
precursor	 T-cells	 were	 infected	 with	 a	 retroviral	
construct	that	drives	ectopic	TLX1	expression	and	cultured	on	a	feeder	layer	of	OP9	
stromal	 cells	 expressing	 the	NOTCH1	 ligand	DLL1	 (Figure	 4a).	 In	 line	with	previous	
results6,	ectopic	TLX1	expression	strongly	perturbed	normal	T-cell	development,	with	
a	drastic	reduction	 in	absolute	number	of	thymocytes	as	compared	to	control	cells	
(Figure	 4b).	Moreover,	at	day	12	of	 co-culture,	we	observed	a	drastic	 reduction	 in	
CD4+CD8+
	
double	 positive	 (17.1%	 vs.	 63,2%)	 (Figure	 4c)	 as	well	 as	 CD7+CD1a+
	
and	
CD3+
	
TCRγδ	 positive	 (0.7%	 vs.	 3.4%)	 T-cells	 overexpressing	 TLX1	 (Supplementary	
Figure	 7).	 In	 line	 with	 the	 transcriptional	 antagonism	 between	 TLX1	 and	 NOTCH1	
described	above,	thymocytes	that	ectopically	express	TLX1	also	showed	a	reduction	
in	IL7Rα	(CD127)	surface	expression	compared	with	controls	(Figure	4d).	Moreover,	
the	 previously	 established	 enhancer	 sites	 downstream	 of	 the	 IL7R	 locus	 showed	
overlapping	binding	of	ETS1,	RUNX1,	ICN1,	BRD4	and	TLX1	(Figure	4e).	
Cortical	thymocyte	maturation	arrest	in	TLX1	positive	human	T-ALL	has	been	linked	
to	 TLX1-mediated	 repression	of	 TCRα	enhancer	 activity	 and	 a	 subsequent	 block	 in	
TCR-Jα	 rearrangement7.	 Notably,	 our	 TLX1	 ChIP-seq	 data	 confirmed	 these	 findings	
with	TLX1	binding	at	the	TCRα	enhancer	site	in	the	TCRα	locus	(Figure	4e).	However,	
our	data	also	suggest	that	TLX1	may	be	implicated	in	a	more	global	repression	of	the	
T-cell	 recombination	 machinery	 including	 a	 broad	 pattern	 of	 TLX1	 binding	 at	 the	
TCRα	 and	 TCRβ	 locus	 (Figure	 4e)	 as	 well	 as	 simultaneous	 binding	 near	 critical	
regulators	of	V(D)J-recombination	including	RAG1	(Figure	4e).	
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Furthermore,	 gene	 expression	 profiling	 analysis	 of	 TLX1	 overexpressing	 versus	
control	human	CD34+
	
thymocytes	derived	from	two	representative	CD34+
	
donors	at	
72	 hours	 post	 transduction,	 confirmed	 genome-wide	 antagonistic	 effects	 between	
TLX1	 and	 NOTCH1	 in	 this	 independent	 in	 vitro	 model	 system.	 TLX1	 driven	
transcriptional	repression	of	NOTCH1,	NOTCH3,	 IL7R,	 IGLL1,	SHQ1,	RAG1	and	RAG2	
are	shown	as	representative	examples	(Figure	4f).	Moreover,	upregulation	of	some	
of	 these	 genes	 was	 also	 confirmed	 by	 RT-qPCR	 upon	 TLX1	 knockdown	 in	 ALL-SIL	
(Figure	4g).	
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Figure	4:	Ectopic	TLX1	expression	broadly	interferes	with	the	normal	T-cell	differentiation	program.	
(a)	 Schematic	 overview	 of	 the	 workflow	 used	 for	 retroviral	 infection	 of	 human	 thymic	 CD34+
	
progenitor	 T-cells	 with	 a	 TLX1	 overexpression	 construct	 followed	 by	 immunophenotypic	 and	
transcriptional	 characterization	 upon	 in	 vitro	 culturing	 on	 a	 feeder	 layer	 of	 OP9	 stromal	 cells	
expressing	 the	 NOTCH1	 ligand	 DLL1,	 (b)	 Bar	 plot	 showing	 the	 averaged	 absolute	 counts	 of	 EGFP-
positive	CD34+
	
T-	cell	progenitors	of	three	independent	donors	6,	12	and	18	days	post	infection	on	the	
in	vitro	OP9-DLL1	co-culture	system.	(c)	Flow	cytometry	profiles	of	CD34+
	
progenitor	T-cells	12	days	
post-transduction	 (representative	 example	 shown	 for	 three	 replicates)	 showing	 a	 CD4+CD8+
	
stage	
arrest	of	T-cell	progenitors	ectopically	expressing	TLX1,	(d)	Flow	cytometry	profile	showing	a	drastic	
reduction	 in	 of	 the	 percentage	 of	 IL7Rα	 surface	 positive	 (CD127+)	 T-cell	 progenitors	 ectopically	
expressing	TLX1,	(e)	TLX1	binding	profile	to	loci	critically	involved	in	T-cell	development	including	TCR	
loci,	RAG1	and	IL7R,	(f)	CD34+	T-cell	progenitors	(2	independent	donors)	transduced	either	with	empty	
vector	 or	 with	 the	 TLX1	 overexpression	 construct	 were	 profiled	 on	 a	 custom	 Agilent	 micro-array	
platform	 (see	 also	Materials	 and	methods).	 The	 average	 relative	 expression	 percentages	 in	 CD34+	
thymocytes	transduced	with	empty	vector	versus	CD34+
	
T-cell	progenitors	ectopically	expressing	TLX1	
from	both	 independent	experiments	are	shown	for	NOTCH1,	NOTCH3,	 IL7R,	 IGLL1,	SHQ1	and	RAG1,	
(g)	RT-qPCR	profiles	of	 IL7R	and	RAG2	confirming	upregulated	expression	of	these	genes	upon	TLX1	
knockdown	in	ALL-SIL.	 	
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To	further	study	the	functional	antagonism	between	TLX1	and	NOTCH1,	we	verified	
whether	ICN1	would	be	able	to	rescue	the	reduction	in	cell	counts	induced	by	TLX1	
ectopic	expression	in	T-cell	progenitor	cells.	To	this	end,	human	CD34+
	
progenitor	T-
cells	 from	 three	 independent	 donors	 were	 sequentially	 transduced	 with	 a	 TLX1	
and/or	ICN1	overexpression	constructs.	Absolute	total	cell	counts	were	measured	18	
and	 24	 days	 post-transduction	 (Figure	 5).	 As	 previously	 documented,	 TLX1	
overexpression	 induced	 a	 reduction	 in	 cell	 numbers.	 However	 and	 most	 notably,	
ICN1	 expression	 rescued	 this	 TLX1-driven	 phenotype	 and	 partially	 restored	 cell	
numbers	in	these	co-culture	experiments	(Figure	5).	
																								 	
Figure	 5:	Ex	 vivo	 TLX1-ICN1	 co-expression	 in	 human	 and	mouse	 T-cell	 progenitor	 cells.	 Averaged	
absolute	 total	 cell	 counts	 of	 CD34+	 progenitor	 T-cells	 cultured	 from	 three	 independent	 donors	 on	
OP9-DLL1	 for	 18	 or	 24	 days	 and	 transduced	with	 either	 control	 vectors,	 a	 TLX1	overexpression,	 an	
ICN1	overexpression	construct	or	TLX1	and	ICN1	together.	
	
A	tumor	suppressor	network	within	the	TLX1	regulome	in	T-ALL	
Previous	studies	have	shown	direct	binding	of	TLX1	in	the	promoter	region	of	well-	
established	T-ALL	tumor	suppressor	genes4,25,	including	BCL11B,	RUNX1	and	WT14,25.	
From	 this,	 a	 model	 emerged	 in	 which	 TLX1-mediated	 suppression	 of	 tumor	
suppressors	would	eventually	provide	genetic	pressure	towards	genomic	deletion	or	
mutation	of	these	factors	during	TLX1-driven	transformation4,25.	
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To	 further	expand	the	 tumor	suppressor	network	 regulated	by	TLX1,	we	evaluated	
the	TLX1	binding	pattern	near	currently	known	T-ALL	tumor	suppressor	genes.	This	
analysis	 revealed	 a	 broad	 network	 of	 tumor	 suppressors	 bound	 by	 TLX1	 including	
TET1,	EZH2,	FBXW7,	PTEN,	BCL11B,	FAT1,	RUNX1,	LEF1,	GATA3,	ETV6,	WT1,	PTPN2,	
CDKN1B,	RB1,	DNM2,	CNOT3,	RPL5,	RPL10	 and	 SH2B3	 (Figure	 6a,	 Supplementary	
Figure	 8	 and	 9).	 In	 line	with	 other	 results	 obtained	 from	 the	 genome-	wide	 TLX1	
binding	 profile,	 ChIP-seq	 peaks	 for	 ETS1,	 RUNX1	 and	 ICN1	 showed	 high	 positional	
overlap	with	TLX1	binding	sites	in	the	vicinity	of	these	T-ALL	tumor	suppressor	genes	
as	shown	for	BCL11B,	CNOT3,	ETV6	and	FAT1	(Figure	6a).	
Gene	expression	profiling	 confirmed	upregulation	 for	 the	majority	of	 these	 factors	
upon	TLX1	knockdown	in	ALL-SIL	(Figure	6b	and	6c)	and	was	confirmed	for	BCL11B	
by	RT-qPCR	analysis	 (Figure	 6c).	Although	the	majority	of	 these	 tumor	suppressors	
were	downregulated	upon	 JQ1	 treatment	 in	ALL-SIL	 (Figure	 6d),	 the	 strongest	and	
most	 significant	 effects	 were	 observed	 for	 FAT1,	WT1	 and	 ETV6	 (Figure	 6e),	 as	
confirmed	by	RT-qPCR	for	ETV6	(Figure	6e).	
	
Chapter	3:	Results	
	 	 	127	
	
Figure	6:	T-ALL	 tumor	suppressor	genes	 in	 the	TLX1	 regulatory	network.	 (a)	TLX1	ChIP-seq	binding	
profiles	at	the	known	T-ALL	tumor	suppressor	genes	BCL11B,	CNOT3,	ETV6	and	FAT1,	 (b)	Schematic	
overview	 with	 nodes	 of	 TLX1-bound	 tumor	 suppressor	 genes.	 Tumor	 suppressors	 that	 are	
upregulated	upon	TLX1	knockdown	in	ALL-SIL	are	shown	in	blue	and	the	size	of	the	node	corresponds	
to	 the	 respective	 fold	 change,	 (c)	 Scatter	 plot	 indicating	 the	 tumor	 suppressor	 genes	 significantly	
upregulated	upon	TLX1	knockdown	and	confirmation	of	BCL11B	upregulation	by	RT-qPCR,	(d)	Similar	
overview	as	(b).	Tumor	suppressors	that	are	downregulated	upon	JQ1	treatment	in	ALL-SIL	are	shown	
in	red	and	the	size	of	the	node	corresponds	to	the	respective	fold	change,	(e)	Scatter	plot	indicating	
significantly	differentially	expressed	tumor	suppressor	genes	in	ALL-SIL	upon	JQ1	exposure.	 	
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DISCUSSION	
TLX1	 is	 a	 driver	 oncogene	 in	 the	 pathogenesis	 of	 T-ALL	 that	 mediates	 T-cell	
transformation	 through	 transcriptional	 repression	 of	 its	 target	 genes.	 Our	 current	
understanding	of	the	oncogenic	properties	downstream	of	TLX1	includes	aneuploidy	
as	 a	 result	 of	 a	 deregulated	 mitotic	 checkpoint	 machinery4,	 T-cell	 differentiation	
arrest	caused	by	repression	of	TCRα	enhancer	activity25
	
and	simultaneous	inhibition	
of	 T-	ALL	 tumor	 suppressor	 genes4,25.	 These	 studies	provided	 important	 insights	 in	
the	mechanisms	that	mediate	T-cell	 transformation	downstream	of	TLX1,	but	were	
solely	focused	on	TLX1	binding	at	the	promoter	of	direct	target	genes.	Therefore,	the	
functional	 consequences	of	genome-wide	TLX1	binding	 in	 the	context	of	human	T-	
ALL	development	remained	to	be	established.	
Here,	 we	 report	 the	 genome-wide	 binding	 profile	 of	 TLX1	 in	 human	 T-ALL	 and	
confirm	 ETS1	 and	 RUNX17,25
	
as	 critical	 co-factors	 in	 TLX1	mediated	 transcriptional	
repression.	Moreover,	we	identified	clusters	of	high	intensity	TLX1	binding	peaks	at	
H3K27ac	 defined	 super-enhancers	 with	 broad	 binding	 of	 BRD49,	 which	 were	
localized	in	the	vicinity	of	genes	that	define	the	T-cell	 lineage	identity.	The	concept	
of	 TLX1	 driven	 repression	 of	 super-enhancers	 provides	 additional	 insights	 in	 the	
mechanisms	 that	 drive	 T-cell	 transformation	downstream	of	 TLX1,	 including	 global	
interference	 with	 T-cell	 differentiation	 and	 the	 V(D)J-recombination	machinery	 by	
targeting	enhancers	near	the	TCR	loci,	RAG1,	RAG2	and	BCL11B.	
ETS1	and	RUNX1	interact	with	NOTCH1	to	regulate	gene	expression	in	both	normal	
T-cell	 development	 as	 well	 as	 non-TLX1	 driven	 T-ALL	 and	 key	 components	 of	 the	
NOTCH1	 transcriptional	 program	 are	 driven	 by	 super-enhancer	 sequences9,10.	
Therefore,	 we	 subsequently	 explored	 the	 presumed	 cooperative	 relationship	
between	 TLX1	 and	 NOTCH1.	 Integration	 of	 TLX1,	 ICN1,	 ETS1	 and	 RUNX1	 binding	
patterns	 with	 transcriptional	 read-out	 in	 T-ALL	 revealed	 an	 unprecedented	
transcriptional	 antagonism	 between	 TLX1	 and	 NOTCH1,	 including	 TLX1	 driven	
repression	 of	 the	 canonical	 NOTCH1	 targets	NOTCH3,	 IGLL1,	WNK2,	 SHQ1,	 c-MYC	
and	 IL7R.	 Interestingly,	TLX1	mediated	repression	of	 the	 IL7R	gene	occurred	at	 the	
recently	described	distal	super-enhancer9
	
that	is	co-occupied	by	ICN1,	RUNX1,	ETS1	
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and	BRD4.	In	 line	with	this	notion,	ectopic	TLX1	expression	in	CD34+
	
human	thymic	
precursor	 T-cells	 caused	 significant	 down-regulation	 of	 NOTCH1	 target	 genes	
including	reduced	IL7R-alpha	(CD127)	surface	expression.	
Although	 transcriptional	 antagonism	 between	 cooperative	 T-ALL	 oncogenes	 seems	
counterintuitive,	it	provides	intriguing	new	insights	in	the	multi-step	pathogenesis	of	
TLX1	 driven	 human	 leukemia.	 The	 model	 that	 emerges	 from	 our	 results	 is	 that	
ectopic	expression	of	TLX1	would	hijack	ETS1	and	RUNX1	functionality	in	the	context	
of	 T-cell	 development.	 At	 a	 genome-wide	 level,	 this	 would	 trigger	 inhibition	 of	
enhancer	 activity,	 repression	 of	 key	 components	 of	 the	 NOTCH1	 transcriptional	
program	 and	 global	 interference	 with	 normal	 T-cell	 differentiation	 and	 the	 V(D)J-	
recombination	machinery.	These	oncogenic	properties	would	eventually	 result	 in	a	
pre-leukemic	 phenotype	 reminiscent	 of	 the	 thymic	 regression	 observed	 in	murine	
TLX1	 tumor	 models	 and	 drive	 T-cell	 maturation	 arrest.	 At	 the	 level	 of	 secondary	
genetic	 lesions	 required	 for	 full	 malignant	 transformation,	 this	 model	 implies	 a	
strong	genetic	pressure	for	acquiring	activating	NOTCH1	mutations	to	overcome	the	
initial	TLX1	mediated	suppression	of	NOTCH1	signaling,	which	is	in	line	with	the	high	
frequency	 of	 gain-of-function	 NOTCH1	 mutations	 in	 human14
	
and	 murine4,5
	
TLX1	
driven	 T-ALL.	 Moreover,	 broad	 TLX1	 mediated	 downregulation	 of	 an	 extensive	
network	 of	 T-ALL	 tumor	 suppressor	 genes	 provides	 additional	 genetic	 pressure	 to	
reinforce	 tumor	 suppressor	 gene	 inactivation	 by	 genomic	 deletions	 or	 mutations	
during	 tumor	 progression	 in	 TLX1	 positive	 leukemias.	 Notably,	 this	 model	 differs	
from	 the	 classical	 concept	 of	 the	 multistep	 pathogenesis	 of	 T-ALL	 in	 which	
cooperative	 oncogenes	 and	 tumor	 suppressors	 alter	 proliferation,	 differentiation	
and	 survival	 of	 thymic	 precursor	 cell	 and	 expand	 the	 oncogenic	 phenotype	 of	 the	
developing	 tumor	 cell	 in	 a	 stepwise	 fashion.	 Nevertheless,	 this	 particular	 model	
should	 be	 further	 confirmed	 beyond	 the	 use	 of	 T-ALL	 cell	 lines	 by	 analyzing	 the	
genome-wide	TLX1	binding	pattern	in	patient	derived	T-ALL	xenografts.	
All	together,	our	results	uncover	novel	mechanistic	insights	in	the	role	of	TLX1	during	
the	 earliest	 stages	 of	 T-cell	 transformation	 and	 illustrate	 the	 power	 of	 integrative	
genomic	analyses	 to	understand	the	multistep	pathogenesis	of	TLX1	driven	human	
leukemia.	 	
Chapter	3:	Results	
	 	 	130	
ACKNOWLEDGEMENTS	
The	authors	would	 like	 to	 thank	 following	 funding	agencies:	 the	Fund	 for	Scientific	
Research	 Flanders	 (‘FWO	 Vlaanderen’	 research	 projects	 G.0202.09,	 G.0869.10N,	
3G055013N,	 3G056413N	 to	 FS;	 3GA00113N,	 3G065614,	 G.0C47.13N	 to	 PVV	 and	
G0B2913N,	G037514N,	3G002711	to	TT;	doctoral	grant	 to	AW,	postdoctoral	grants	
to	IvdW,	TT,	PVV,	and	PR;	BP	is	a	senior	clinical	 investigator),	 IWT	Vlaanderen	(PhD	
grant	 to	KD);	Ghent	University	 (GOA	grant	01G01910	 to	 FS),	 the	Cancer	Plan	 from	
the	Federal	Public	Service	of	Health	 (FS),	 the	Children	Cancer	Fund	Ghent	 (FS)	and	
the	Belgian	Program	of	 Interuniversity	Poles	of	Attraction	 (IUAP	P7/03	and	P7/07).	
Additional	funding	was	provided	by	the	Cancéropole	IDF,	the	CIT	program	from	the	
Ligue	 Contre	 le	 Cancer,	 ERC	 St	 Grant	 Consolidator	 311660,	 and	 the	 ANR-10-IBHU-	
0002	 Saint-Louis	 Institute	 program	 (J.S).	 We	 also	 would	 like	 to	 thank	 Aline	
Eggermont	for	excellent	technical	assistance.	
	
AUTHORSHIP	
K.D.	 performed	 and	 analyzed	 experiments	 and	wrote	 the	 paper.	W.V.L.	 and	M.O.	
performed	bioinformatics	on	large-scale	data	sets.	J.V.d.M.,	I.V.d.W.,	P.R.,	A.W.	and	
C.E.d.B.,	performed	experiments.	J.C.,	J.S.,	B.P.,	N.V.R.,	T.T.	F.S.	and	P.V.V.	designed	
the	 experiments,	 directed	 research,	 analyzed	 data	 and	 wrote	 the	 paper.	 All	 the	
authors	read	and	edited	the	manuscript.	 	
Chapter	3:	Results	
	 	 	131	
REFERENCES	
1.	 Ferrando	 AA,	 Neuberg	 DS,	 Dodge	 RK,	 Paietta	 E,	 Larson	 RA,	 Wiernik	 PH,	 et	 al.	
Prognostic	 importance	 of	 TLX1	 (HOX11)	 oncogene	 expression	 in	 adults	 with	 T-cell	
acute	lymphoblastic	leukaemia.	Lancet	2004	Feb	14;	363(9408):	535-536.		
2.	Hawley	RG,	Fong	AZ,	Reis	MD,	Zhang	N,	Lu	M,	Hawley	TS.	Transforming	function	of	
the	HOX11/TCL3	homeobox	gene.	Cancer	research	1997	Jan	15;	57(2):	337-345.		
3.	Hawley	RG,	Fong	AZ,	Lu	M,	Hawley	TS.	The	HOX11	homeobox-containing	gene	of	
human	 leukemia	 immortalizes	 murine	 hematopoietic	 precursors.	 Oncogene	 1994	
Jan;	9(1):	1-12.		
4.	De	Keersmaecker	K,	Real	PJ,	Gatta	GD,	Palomero	T,	Sulis	ML,	Tosello	V,	et	al.	The	
TLX1	 oncogene	 drives	 aneuploidy	 in	 T	 cell	 transformation.	 Nature	 medicine	 2010	
Nov;	16(11):	1321-1327.		
5.	 Rakowski	 LA,	 Lehotzky	 EA,	 Chiang	 MY.	 Transient	 responses	 to	 NOTCH	 and	
TLX1/HOX11	 inhibition	 in	T-cell	 acute	 lymphoblastic	 leukemia/lymphoma.	PloS	one	
2011;	6(2):	e16761.		
6.	Owens	BM,	Hawley	TS,	 Spain	 LM,	Kerkel	KA,	Hawley	RG.	TLX1/HOX11-mediated	
disruption	 of	 primary	 thymocyte	 differentiation	 prior	 to	 the	 CD4+CD8+	 double-	
positive	stage.	British	journal	of	haematology	2006	Jan;	132(2):	216-229.		
7.	Dadi	S,	Le	Noir	S,	Payet-Bornet	D,	Lhermitte	L,	Zacarias-Cabeza	J,	Bergeron	J,	et	al.	
TLX	 homeodomain	 oncogenes	 mediate	 T	 cell	 maturation	 arrest	 in	 T-ALL	 via	
interaction	with	ETS1	and	suppression	of	TCRalpha	gene	expression.	Cancer	cell	2012	
Apr	17;	21(4):	563-576.		
8.	Weng	AP,	Ferrando	AA,	Lee	W,	Morris	JPt,	Silverman	LB,	Sanchez-Irizarry	C,	et	al.	
Activating	 mutations	 of	 NOTCH1	 in	 human	 T	 cell	 acute	 lymphoblastic	 leukemia.	
Science	2004	Oct	8;	306(5694):	269-271.		
9.	 Wang	 H,	 Zang	 C,	 Taing	 L,	 Arnett	 KL,	 Wong	 YJ,	 Pear	 WS,	 et	 al.	 NOTCH1-RBPJ	
complexes	 drive	 target	 gene	 expression	 through	 dynamic	 interactions	 with	
superenhancers.	 Proceedings	 of	 the	 National	 Academy	 of	 Sciences	 of	 the	 United	
States	of	America	2014	Jan	14;	111(2):	705-710.		
10.	Wang	H,	Zou	J,	Zhao	B,	Johannsen	E,	Ashworth	T,	Wong	H,	et	al.	Genome-wide	
analysis	reveals	conserved	and	divergent	features	of	Notch1/RBPJ	binding	in	human	
and	murine	T-lymphoblastic	leukemia	cells.	Proceedings	of	the	National	Academy	of	
Sciences	of	the	United	States	of	America	2011	Sep	6;	108(36):	14908-14913.		
	 	
Chapter	3:	Results	
	 	 	132	
11.	 Hnisz	 D,	 Abraham	 BJ,	 Lee	 TI,	 Lau	 A,	 Saint-Andre	 V,	 Sigova	 AA,	 et	 al.	 Super-
enhancers	 in	 the	control	of	cell	 identity	and	disease.	Cell	2013	Nov	7;	155(4):	934-
947.		
12.	Whyte	WA,	Orlando	DA,	Hnisz	D,	Abraham	BJ,	 Lin	CY,	Kagey	MH,	et	al.	Master	
transcription	 factors	 and	 mediator	 establish	 super-enhancers	 at	 key	 cell	 identity	
genes.	Cell	2013	Apr	11;	153(2):	307-319.		
13.	Loven	J,	Hoke	HA,	Lin	CY,	Lau	A,	Orlando	DA,	Vakoc	CR,	et	al.	Selective	inhibition	
of	tumor	oncogenes	by	disruption	of	super-enhancers.	Cell	2013	Apr	11;	153(2):	320-	
334.		
14.	 Asnafi	 V,	 Buzyn	 A,	 Le	 Noir	 S,	 Baleydier	 F,	 Simon	 A,	 Beldjord	 K,	 et	 al.	
NOTCH1/FBXW7	 mutation	 identifies	 a	 large	 subgroup	 with	 favorable	 outcome	 in	
adult	 T-cell	 acute	 lymphoblastic	 leukemia	 (T-ALL):	 a	 Group	 for	 Research	 on	 Adult	
Acute	Lymphoblastic	 Leukemia	 (GRAALL)	 study.	Blood	2009	Apr	23;	113(17):	3918-
3924.		
15.	 Clappier	 E,	 Gerby	 B,	 Sigaux	 F,	 Delord	 M,	 Touzri	 F,	 Hernandez	 L,	 et	 al.	 Clonal	
selection	 in	 xenografted	 human	 T	 cell	 acute	 lymphoblastic	 leukemia	 recapitulates	
gain	of	malignancy	 at	 relapse.	 The	 Journal	 of	 experimental	medicine	2011	Apr	11;	
208(4):	653-661.		
16.	Volders	PJ,	Helsens	K,	Wang	X,	Menten	B,	Martens	L,	Gevaert	K,	et	al.	LNCipedia:	
a	 database	 for	 annotated	 human	 lncRNA	 transcript	 sequences	 and	 structures.	
Nucleic	acids	research	2013	Jan;	41(Database	issue):	D246-251.		
17.	Lee	TI,	Johnstone	SE,	Young	RA.	Chromatin	immunoprecipitation	and	microarray-	
based	analysis	of	protein	location.	Nature	protocols	2006;	1(2):	729-748.		
18.	 Langmead	 B,	 Trapnell	 C,	 Pop	 M,	 Salzberg	 SL.	 Ultrafast	 and	 memory-efficient	
alignment	 of	 short	 DNA	 sequences	 to	 the	 human	 genome.	Genome	 biology	 2009;	
10(3):	R25.		
19.	Feng	J,	Liu	T,	Zhang	Y.	Using	MACS	to	identify	peaks	from	ChIP-Seq	data.	Current	
protocols	 in	bioinformatics	 /	editoral	board,	Andreas	D	Baxevanis	 [et	al]	2011	 Jun;	
Chapter	2:	Unit	2	14.		
20.	Quinlan	AR,	Hall	IM.	BEDTools:	a	flexible	suite	of	utilities	for	comparing	genomic	
features.	Bioinformatics	2010	Mar	15;	26(6):	841-842.		
21.	 Machanick	 P,	 Bailey	 TL.	 MEME-ChIP:	 motif	 analysis	 of	 large	 DNA	 datasets.	
Bioinformatics	2011	Jun	15;	27(12):	1696-1697.		 	
Chapter	3:	Results	
	 	 	133	
22.	 Heinz	 S,	 Benner	 C,	 Spann	 N,	 Bertolino	 E,	 Lin	 YC,	 Laslo	 P,	 et	 al.	 Simple	
combinations	 of	 lineage-determining	 transcription	 factors	 prime	 cis-regulatory	
elements	required	for	macrophage	and	B	cell	identities.	Molecular	cell	2010	May	28;	
38(4):	576-589.		
23.	Van	de	Walle	I,	Waegemans	E,	De	Medts	J,	De	Smet	G,	De	Smedt	M,	Snauwaert	S,	
et	 al.	 Specific	 Notch	 receptor-ligand	 interactions	 control	 human	 TCR-
alphabeta/gammadelta	development	by	 inducing	differential	Notch	signal	strength.	
The	Journal	of	experimental	medicine	2013	Apr	8;	210(4):	683-697.	
24.	 Van	 de	 Walle	 I,	 De	 Smet	 G,	 Gartner	 M,	 De	 Smedt	 M,	 Waegemans	 E,	
Vandekerckhove	 B,	 et	 al.	 Jagged2	 acts	 as	 a	 Delta-like	 Notch	 ligand	 during	 early	
hematopoietic	cell	fate	decisions.	Blood	2011	Apr	28;	117(17):	4449-4459.		
25.	 Della	 Gatta	 G,	 Palomero	 T,	 Perez-Garcia	 A,	 Ambesi-Impiombato	 A,	 Bansal	 M,	
Carpenter	ZW,	et	al.	Reverse	engineering	of	TLX	oncogenic	transcriptional	networks	
identifies	 RUNX1	 as	 tumor	 suppressor	 in	 T-ALL.	Nature	medicine	 2012	Mar;	 18(3):	
436-440.		
26.	 Allen	 TD,	 Zhu	 YX,	 Hawley	 TS,	 Hawley	 RG.	 TALE	 homeoproteins	 as	 HOX11-
interacting	 partners	 in	 T-cell	 leukemia.	 Leukemia	 &	 lymphoma	 2000	 Oct;	 39(3-4):	
241-256.		
27.	 Milech	 N,	 Gottardo	 NG,	 Ford	 J,	 D'Souza	 D,	 Greene	WK,	 Kees	 UR,	 et	 al.	 MEIS	
proteins	as	partners	of	the	TLX1/HOX11	oncoprotein.	Leukemia	research	2010	Mar;	
34(3):	358-363.		
28.	Filippakopoulos	P,	Qi	 J,	Picaud	S,	Shen	Y,	Smith	WB,	Fedorov	O,	et	al.	Selective	
inhibition	of	BET	bromodomains.	Nature	2010	Dec	23;	468(7327):	1067-1073.		
29.	Durinck	K,	Wallaert	A,	Van	de	Walle	I,	Van	Loocke	W,	Volders	PJ,	Vanhauwaert	S,	
et	al.	The	Notch	driven	long	non-coding	RNA	repertoire	in	T-cell	acute	lymphoblastic	
leukemia.	Haematologica	2014	Oct	24.		
30.	 Herranz	 D,	 Ambesi-Impiombato	 A,	 Palomero	 T,	 Schnell	 SA,	 Belver	 L,	Wendorff	
AA,	 et	 al.	 A	 NOTCH1-driven	 MYC	 enhancer	 promotes	 T	 cell	 development,	
transformation	and	acute	lymphoblastic	leukemia.	Nature	medicine	2014	Sep	7.		
 
 
 
  
Chapter	3:	Results	
	 	 	134	
SUPPLEMENTARY	FIGURES	
	
	
Supplementary	 Figure	 1:	 (a)	 Pie	 chart	 representation	 of	 the	 TLX1	 ChIP-seq	 peak	 distribution	
overlapping	with	specific	gene	features,	(b)	Boxplot	showing	that	binding	of	TLX1	correlates	to	higher	
average	 gene	 expression	 of	 the	 target	 gene,	 (c)	 ChIP-qPCR	 assays	 for	 BCL11B,	 BUB1,	 CHEK1	 and	
BRCA2	validating	TLX1	binding	as	shown	by	TLX1	ChIP-seq	and	previously	reported	by	ChIP-chip	data4.	 	
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Supplementary	 Figure	 2:	 (a-b)	 Validation	 of	 TLX1	 knockdown	 24h	 post-	 electroporation	 in	 ALL-SIL	
cells	 using	 2	 different	 siRNAs	 over	 3	 independent	 replicates	 (a)	 by	 RT-qPCR	 and	 (b)	 western	 blot	
analysis,	 (c)	 GSEA	 analysis	 (using	 the	 public	 gene	 set	 database	 MSigdb	 c2v3.1)	 shows	 significant	
enrichment	of	BCL11B	target	genes	within	the	set	of	genes	up-regulated	upon	TLX1	knockdown.	 (c)	
GSEA	analysis	shows	a	significant	enrichment	of	the	top-1000	scoring	(FDR<0.05)	TLX1	binding	sites	in	
proximity	(<=2kb)	of	the	TSS	amongst	the	TLX1	repressed	genes	in	ALL-SIL.	 	
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Supplementary	Figure	3:	GSEA	analysis	shows	a	significant	enrichment	of	genes	repressed	by	TLX1	in	
the	set	of	genes	up-regulated	upon	knockdown	of	RUNX1	(a)	or	ETS1	(b)	in	ALL-SIL	cells,	(c)	ChIP-qPCR	
assay	showing	significant	binding	of	RUNX1	to	validated	TLX1	target	genes	BCL11B,	CHEK1,	BRCA2	and	
BUB1,	 (d)	 ChIP-qPCR	 assay	 showing	 significant	 binding	 of	 RUNX1	 to	 validated	 TLX1	 target	 genes	
BCL11B,	CHEK1,	BRCA2	and	BUB1.	
	
																									 	
Supplementary	Figure	4:	ChIP-seq	heatmap	representation	is	shown	for	TLX1,	RUNX1	and	ETS1	ChIP-
seq	 binding	 profiles	 within	 10	 kb	 from	 the	 TSS	 of	 the	 top-500	 down-regulated	 genes	 upon	 TLX1	
knockdown	in	ALL-SIL	with	clustering	according	to	average	linkage.	 	
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Supplementary	Figure	5:	(a)	Hockey-stick	plot	representing	the	normalized	rank	and	cluster	signal	of	
clusters	of	H3K27ac	peaks	in	ALL-SIL,	(b-c)	Validation	of	c-	MYC	down-regulation	12h	post-treatment	
with	 JQ1	 of	 ALL-SIL	 cells	 by	 (b)	 RT-qPCR	 and	 (c)	 western	 blot	 analysis,	 (d)	 GSEA	 shows	 significant	
enrichment	of	 the	 top-500	scoring	H3K27ac	defined	super-enhancers	 (shown	 in	 in	panel	 (a))	within	
the	set	of	JQ1	downregulated	genes.	 	
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Supplementary	 Figure	 6:	 (a)	 Downregulation	 of	 DTX1	 and	 c-MYC	 expression	 upon	 GSI-treatment	
(48h)	 of	 ALL-SIL	 leukemic	 cells	 was	 validated	 by	 RT-qPCR,	 (b)	 western	 blot	 analysis	 shows	 down-
regulation	 of	 ICN1	 levels	 upon	 GSI	 treatment	 of	 ALL-SIL	 cells,	 (c)	 Scatterplot	 of	 significantly	
downregulated	genes	upon	GSI	 treatment	of	ALL-SIL	 cells,	 (d)	Heatmap	 representation	of	 the	ChIP-
seq	 overlap	 of	 TLX1-ICN1-ETS1-RUNX1	 sites	 across	 a	 score-based	 ranking	 of	 TLX1	 ChIP-seq	 signals	
(shown	for	top-1000	scoring	peaks).	
	
	
Supplementary	 Figure	 7:	 Flow	 cytometry	 profiles	 of	 CD34+	 progenitor	 T-cells	 12	 days	 post-
transduction	 (representative	 example	 shown	 for	 three	 replicates)	 showing	 a	 strong	 reduction	 in	
CD7+CD1a+
	
and	CD3+
	
TCRγδ-cells	of	thymocytes	ectopically	expressing	TLX1.	 	
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Supplementary	Figure	8:	ChIP-seq	profiles	of	ETS1,	RUNX1,	ICN1,	BRD4	and	TLX1	show	high	positional	
overlap	 at	 tumor	 suppressor	 genes	mutated	 and/or	 deleted	 in	 T-ALL	 (GATA3,	WT1,	PTPN2,	DNM2,	
RUNX1,	TET1,	FBXW7,	LEF1)	
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Supplementary	Figure	9:	ChIP-seq	profiles	of	ETS1,	RUNX1,	ICN1,	BRD4	and	TLX1	show	high	positional	
overlap	at	tumor	suppressor	genes	mutated	and/or	deleted	in	T-ALL	(EZH2,	PTEN,	CDKN1B,	RB1,	RPL5,	
RPL10,	SH2B3).	 	
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Abstract	 
Transcriptional	 control	 within	 the	 mammalian	 hematopoietic	 system	 involves	 a	
complex	wiring	of	genetic	and	epigenetic	 regulatory	networks.	 In	 the	past	decade,	
studies	have	shown	that	an	 intricate	crosstalk	between	 lineage-specific	 factors	and	
proteins	 controlling	 the	 chromatin	 architecture	 is	 essential	 in	 maintaining	
hematological	 homeostasis.	 Analysis	 of	 the	 mutational	 landscape	 of	 various	
hematological	 malignancies	 has	 shown	 that	 key	 regulators	 implicated	 in	 lineage	
commitment	 and	 differentiation	 are	 frequently	 implicated	 in	 leukemic	
transformation.	In	T-cell	acute	lymphoblastic	leukemia,	the	role	of	various	oncogenic	
and	tumor	suppressing	transcription	factors	has	been	extensively	investigated.	More	
recently,	an	exceptional	high	prevalence	of	mutations	affecting	epigenetic	modifiers	
in	 T-ALL	 has	 also	 been	 reported.	 In	 order	 to	 understand	 the	 exact	 contribution	 of	
such	 lesions	 on	 normal	 differentiation	 and	 oncogenic	 transformation,	 further	
functional	characterization	of	this	subclass	of	proteins	 is	warranted.	PHF6	 is	one	of	
these	 putative	 epigenetic	 players	 for	 which	 a	 high	 frequency	 of	 loss-of-function	
mutations	has	been	described	in	T-ALL.	Here,	we	demonstrate	a	key	regulatory	role	
for	PHF6	in	early	hematopoietic	differentiation	along	the	T-cell,	B-cell,	myeloid	and	
NK-cell	lineages.	In	addition,	we	show	that	PHF6	is	involved	in	the	maintenance	of	a	
NOTCH1	 gene	 signature	 during	 T-lineage	 differentiation.	 In	 conclusion,	 this	 study	
provides	novel	insights	into	the	complex	(epi-)genetic	control	of	haematopoiesis	and	
provides	a	basis	 for	 further	 research	 towards	understanding	 the	 specific	 impact	of	
PHF6	loss-of-function	in	T-cell	leukemogenesis.	
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Introduction	
Hematopoietic	cell	development	is	a	dynamic	and	hierarchically	structured	process,	
with	a	 functionally	diverse	set	of	blood	cell	 types	arising	 from	hematopoietic	 stem	
cells	 (HSC)	 residing	within	 the	 bone	marrow	niche.	 Two	major	 lineages	 arise	 from	
this	HSC	 pool,	 i.e.	 the	 lymphoid	 lineage	 differentiating	 towards	 T-cells,	 B-cells	 and	
NK-cells	and	the	myeloid	lineage	comprising	macrophages,	monocytes	and	platelets	
amongst	 others.	 The	 transcriptional	 programs	 required	 for	 establishment	 and	
maintenance	 of	 this	 complex	 biological	 system	 requires	 an	 interrelation	 between	
lineage-specific	 transcriptional	 regulators	 and	 more	 generally	 acting	 epigenetic	
modifiers	 in	a	time-	and	context-dependent	fashion.	For	example,	establishment	of	
the	T-cell	 lineage	 is	primarily	supported	by	the	action	of	BCL11B,	TCF7	and	GATA3,	
providing	 guidance	 for	 T-cell	 commitment	 and	 differentiation	 respectively1.	 At	 the	
epigenetic	 level,	 promoter	 methylation	 has	 an	 established	 role	 in	 cellular	
differentiation,	 including	 in	 the	 hematopoietic	 compartments.	 The	 presence	 and	
distribution	 of	 this	 epigenetic	 modification	 is	 regulated	 by	 a	 balanced	 interplay	
between	 DNA	 methyltransferases	 (DNMT)	 such	 as	 DNMT3	 and	 the	 ‘ten-eleven’	
translocation	 (TET)	protein	 family	of	demethylases.	 It	has	already	been	shown	that	
amongst	 others,	 TET2	 is	 a	 crucial	 enzyme	 in	 the	 hematopoietic	 system2-4	 and	 the	
finding	 of	 recurrent	 mutations	 of	 TET2	 in	 various	 hematological	 cancers	 further	
underscores	 its	 importance.	 Furthermore,	 enzymes	 involved	 in	 post-translational	
modification	 of	 histone	 proteins	 are	 also	 frequently	 deregulated	 by	 genomic	
alterations.	 Aberrant	 activity	 of	 these	 epigenetic	 modifiers	 leads	 to	 alterations	 in	
chromatin	 domain	 organization	 and	 function,	 contributing	 to	 a	 large	 extent	 to	
malignant	 transformation	 of	 hematopoietic	 progenitor	 cells5-7.	 Therefore,	 strict	
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regulation	 of	 the	 epigenetic	 states	 that	 govern	 critical	 checkpoints	 and	 lineage	
commitment	 is	 crucial	 to	 ensure	 normal	 hematopoiesis	 and	 avoid	 malignant	
transformation.		
Recent	studies	 indeed	 illustrated,	amongst	others,	 the	high	mutational	 frequencies	
in	 chromatin	 regulator	 encoding	 genes	 in	 T-ALL,	 an	 aggressive	 malignant	 blood	
disorder	that	arises	from	oncogenic	transformation	of	precursor	T-cells8.	In	addition	
to	the	plethora	of	activating	mutations	in	well-known	driver	genes	such	as	NOTCH19,	
an	 important	 role	 for	 epigenetic	 regulators	 has	 now	 also	 been	 established.	 This	
includes	amongst	others	‘Enhancer	of	Zeste	Homolog	2’	(EZH2),	catalytic	component	
of	the	'Polycomb	Repressor	Complex	2'	(PRC2)	and	frequently	affected	core	histone	
methyltransferase	 in	 many	 cancer	 types.	 EZH2	 serves	 as	 an	 important	 switch,	
balancing	 self-renewal	 capacity	 of	 hematopoietic	 stem	 cells	 (HSC)	 with	 their	
progression	to	specific	blood	cell	types10,11.	Loss-of-function	mutations	and	deletions	
affecting	 the	genes	encoding	EZH2	and	 its	 interaction	partner	 ‘Suppressor	of	Zeste	
Homolog	12’	(SUZ12)	occur	in	about	25%	of	T-ALL	patients.	Furthermore,	it	has	been	
shown	that	PRC2	mutations	could	further	potentiate	NOTCH1	driven	T-ALL6.		
Like	 EZH2,	 PHF6	 belongs	 to	 one	 of	 the	 top-15	 mutated	 epigenetic	 modifiers	 in	
pediatric	cancers,	albeit	exclusively	associated	with	leukemia.	PHF6	mutations	occur	
in	 16%	 of	 pediatric	 and	 38%	 of	 adult	 T-ALLs,	 thus	 representing	 one	 of	 the	 most	
prominent	 tumor	 suppressors	 in	 this	malignancy12.	 Interestingly,	 in	a	 recent	 study,	
PHF6	was	also	shown	to	act	as	an	oncogene	in	B-cell	malignancies13.	Based	on	these	
findings,	we	hypothesized	that	 like	EZH2,	PHF6	could	also	act	as	a	key	regulator	of	
normal	 hematopoietic	 differentiation	 and	 lineage	 commitment.	 The	 protein	
structure	of	PHF6	 is	composed	of	 four	nuclear	 localization	signals	 (NLS)	 that	 target	
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the	protein	to	the	nucleoplasm	and	nucleolar	compartments12,14	and	two	imperfect	
‘plant	 homeodomain’	 (PHD)	 zinc	 fingers.	 The	 latter	 are	 known	 as	 methyl	 lysine	
binding	pockets15	and	thus	suggest	a	role	for	PHF6	in	epigenetic	regulation	of	gene	
expression.	Since	no	catalytic	domains	are	present	 in	the	molecular	architecture	of	
PHF6,	the	protein	has	a	presumed	function	as	an	epigenetic	reader	recruiting	other	
chromatin	remodelers	and	modifier	enzymes	to	its	target	sites	to	mediate	epigenetic	
control	of	gene	transcription.	Recently,	this	hypothesis	has	been	supported	through	
the	 identification	 of	 protein-protein	 interactions	 between	 PHF6	 and	 the	 CHD4,	
RBBP4	 and	 HDAC1	 components	 of	 the	 ‘Nucleosome	 Remodeling	 and	 Deacetylase’	
complex	 (NurD)16,17.	 Interestingly,	 the	 NurD	 complex	 has	 an	 established	 role	 in	
maintenance	of	the	HSC	population	and	T-lymphopoiesis18.	Of	further	interest,	PHF6	
mutations	 were	 recently	 also	 identified	 in	 Coffin-Siris	 syndrome19,	 a	 mental	
retardation	syndrome	primarily	caused	by	de	novo	mutations	 in	multiple	members	
of	 the	 SWI-SNF	 complex.	 This	 SWI-SNF	 complex	 has,	 like	 the	 NurD	 complex,	 an	
established	function	in	hematopoiesis	thus	suggesting	that	PHF6	may	act	in	concert	
with	or	be	part	of	the	SWI-SNF	and/or	NurD	complexes	during	blood	formation.		
Here,	we	provide	 compelling	evidence	 for	 a	master	 regulator	 role	 for	PHF6	during	
early	 hematopoietic	 differentiation	 along	 the	 T-cell,	 B-cell,	 myeloid	 and	 NK-cell	
lineages.	 	 In	the	context	of	T-cell	differentiation	we	provide	evidence	for	a	positive	
regulation	 of	 PHF6	 on	NOTCH1	 driven	 gene	 expression	with	 additive	 effects	 on	 T-
lineage	differentiation.	 	
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Materials	and	methods	
Isolation	of	HPCs	
Cord	blood	(CB),	peripheral	blood	(PBL)	and	pediatric	thymus	samples	were	obtained	
and	 used	 according	 to	 the	 guidelines	 of	 the	Medical	 Ethical	 Commission	 of	Ghent	
University	 Hospital	 (Belgium).	 After	 lymphoprep	 density	 gradient	 of	 CB	 and	 PBL,	
mononuclear	 cells	 were	 isolated	 and	 used	 for	 further	 purifications.	 PBL-derived	
mononuclear	 cells	 were	 labelled	 with	 CD3-FITC	 and	 sorted	 on	 CD3+	 to	 isolate	 T-	
cells.	To	isolate	monocytes,	PBL	cell	populations	were	depleted	in	a	first	round	with	
CD3/CD19/glycophorin	 (unlabeled	 antibodies)	 and	 in	 a	 second	 round	 with	 Dynal	
beads,	followed	by	staining	of	the	depleted	fraction	with	CD3/CD56/CD19	(FITC)	and	
CD14-PE	to	sort	CD3-CD19-CD56-CD14+	monocytes.	For	isolation	of	B-	and	NK-cells,	
PBL	cells	were	first	depleted	for	CD3/CD14/glycophorin	and	after	depletion	labeled	
with	CD/CD14-FITC,	CD19-APC	and	CD56-PE	to	sort	for	CD3-CD14-CD19+	B-cells	and	
CD3-CD14-CD56+	 NK-cells.	 CB-derived	 CD34+	 cells	 were	 purified	 using	 magnetic	
activated	 cell	 sorting	 beads	 (MACS,	 Miltenyi	 Biotec).	 Subsequently,	 enriched	 cord	
blood	CD34+	 cells	were	 labeled	with	 CD34-PE,	 CD3-APC,	 CD14-APC,	 CD19-APC	 and	
CD56-APC	to	sort	CD34+Lin-	cells	with	a	FACSAriaII	 (BDIS).	Thymocyte	subsets	were	
purified	 as	 described22,23,25	 and	 purity	 of	 the	 sorted	 cells	 was	 checked	 on	 a	
FACSCalibur	or	LSRII	(BDIS)	and	was	always	>98%.	
	
Viral	constructs	and	transduction	of	HPCs	
pLKO.1-puroR	 (SHC002,	 control	 shRNA)	 and	 TRCN0000020122	 (SHC20122,	 PHF6	
shRNA)	 lentiviral	 vectors	 were	 purchased	 from	 Sigma	 in	 which	 the	 puromycin	
resistance	gene	was	replaced	with	a	PCR-amplified	EGFP	cDNA	using	BamHI	and	KpnI	
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restriction	sites.	Infectious	lentivirus	was	produced	by	jetPEI	(polyplus	transfection™)	
mediated	 transfection	 of	 the	 293FT	 cell	 line	 with	 either	 pLKO.1-SHC002-EGFP	 or	
pLK0.1-SHC20122-EGFP,	 in	 conjuction	 of	 the	 pCMV-VSV-G	 (envelope)	 and	 p8.91	
(packaging)	 constructs.	 The	 virus	 supernatant	 was	 harvested	 2	 and	 3	 days	 after	
transfection.	 Lentiviral	 transduction	of	HPCs	was	performed	on	sorted	CD34+lin-	CB	
cells	or	CD34+	thymocytes	previously	cultured	in	complete	IMDM	medium	containing	
10%	 FCS	 and	 supplemented	 with	 TPO	 (20ng/ml),	 SCF	 (100ng/ml)	 and	 FLT3-L	
(100ng/ml)	 or	 SCF	 (10ng/ml)	 and	 IL-7	 (10ng/ml),	 respectively,	 for	 two	 days	 (cord	
blood)	or	 one	day	 (thymocytes).	 48	hours	 after	 transduction,	 cells	were	harvested	
and	sorted	for	EGFP+	transduced	cells.			
	
OP9	co-cultures	and	flow	cytometry	
Transduced	 and	 sorted	 CD34+lin-EGFP+	 CB	 cells	 or	 CD34+EGFP+	 thymocytes	 were	
seeded	in	a	24-well	plate	containing	a	confluent	layer	of	either	control	OP9	stromal	
cells	 (OP9-GFP)	or	Delta-like	 ligand-1	expressing	OP9	 stromal	 cells	 	 (OP9-DLL1).	All	
co-cultures	were	performed	 in	α-MEM	media	 (Invitrogen)	 supplemented	with	20%	
heat-inactivated	FCS	plus	100	U/ml	penicillin,	100	µg/ml	streptomycin	and	2mM	L-
glutamin	 (all	 from	 Invitrogen).	 To	 induce	 and	 support	 T-	 and	B-cell	 differentiation,	
cultures	were	performed	in	the	presence	of	SCF,	IL-7	and	FLT3-L	(all	5	ng/ml)	on	OP9-
DLL1	 and	 OP9-GFP,	 respectively.	 For	 the	 generation	 of	 NK	 cells,	 co-cultures	 were	
supplemented	 with	 10	 ng/ml	 IL-15.	 For	 myeloid	 differentiation,	 co-cultures	 were	
executed	with	SCF,	TPO,	FLT3-L	(all	20	ng/ml)	and	G-CSF	and	GMCSF	both	10	ng/ml.	
Co-cultures	were	harvested	by	forceful	pipetting	at	indicated	time	points.	Obtained	
cell	 suspensions	were	blocked	with	anti-mouse	FcRγII/III	 (clone	2.4.G2)	and	human	
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IgG	(Fcblock,	Miltenyi)	 to	avoid	non-specific	binding	and	subsequently	stained	with	
combinations	 of	 anti-human	 monoclonal	 antibodies	 (BDIS,	 eBioscience,	 Biolegend	
and	Miltenyi).	Cells	were	examined	 for	 the	expression	of	cell	 surface	markers	on	a	
LSRII	(BDIS).		
	
Gene	expression	profiling	
RNA	samples	 from	control	and	PHF6	shRNA	transduced	CD34+	 thymocytes	of	OP9-
GFP	and	OP9-DLL1	co-cultures	were	harvested	72h	post-transduction	and	profiled	on	
a	 custom	 designed	 Agilent	 micro-array	 covering	 all	 protein	 coding	 genes	 (33,128	
mRNA	 probes,	 Human	 Sureprint	 G3	 8x60k	 micro-arrays	 (Agilent))	 and	 12,000	
lncRNAs	(23,042	unique	lncRNA	probes).	For	transduction	on	OP9-GFP	co-cultures,	3	
independent	 samples	 were	 profiled	 and	 for	 OP9-DLL1	 co-cultures	 4	 independent	
samples.	 Expression	 data	 were	 normalized	 using	 the	 VSN-package	 (Bioconductor	
release	2.12)	 in	R.	Differential	expression	analysis	was	performed	in	R	using	limma.	
Public	 datasets	 (GSE24759)	were	normalized	using	 the	Affy-package	 (Bioconductor	
release	2.12)	in	R.	
	
Gene	Set	Enrichment	Analysis	
Gene	 Set	 Enrichment	 Analysis	 (GSEA)20	 was	 used	 to	 score	 our	 genesets	 compiled	
from	the	publically	available	gene	expression	data21.	To	compile	the	genesets	used	in	
this	study,	the	p-value	(<0.05)	was	consistently	used	as	the	major	cut-off	to	define	a	
gene	signature.	 	
Chapter	3:	Results	
	 	 	151	
Results		
	
PHF6	is	an	essential	regulator	of	normal	thymopoiesis	through	reduction	of	Notch	
activity	during	human	T	cell	development.		
Given	the	high	incidence	of	PHF6	inactivating	mutations	in	T-ALL,	we	first	focused	on	
the	role	of	PHF6	during	normal	human	T-cell	development.	To	this	end,	PHF6	shRNA	
mediated	 knockdown	 in	 Jurkat	 T-ALL	 cells	was	 first	 optimized	 prior	 to	 subsequent	
further	 testing	 on	 the	 in	 vitro	OP9-DLL1	 co-culture	 system.	A	 knockdown	 level	 for	
PHF6	of	 >90%	at	 the	protein	 level	 could	be	obtained	 (Fig.	 1A).	 	Next,	we	 initiated	
OP9-DLL1	co-cultures	with	control	shRNA	or	PHF6	shRNA	transduced	human	CD34+	
thymocytes	 as	 these	 are	 the	 direct	 precursors	 of	 human	 T-cells.	 Remarkably,	
knockdown	of	PHF6	significantly	accelerated	differentiation	towards	the	CD4+/CD8+	
double	positive	(DP)	stage	(Fig.	1B	and	1C).	Most	notably,	a	similar	phenotypic	effect	
was	 previously	 observed	 upon	 reduction	 of	 Notch	 activation	 in	 the	 same	 cellular	
model	 system,	 suggesting	 that	 PHF6	 and	 NOTCH1	 might	 be	 functionally	
interconnected	in	the	context	of	early	T-cell	differentiation22,23.	To	further	elucidate	
this	functional	interplay,	we	used	'Gene	Set	Enrichment	Analysis'	(GSEA)	to	compare	
a	gene	signature	related	to	active	NOTCH1	signaling	in	CUTLL1	cells24	with	the	gene	
expression	 dataset	 obtained	 upon	 PHF6	 knockdown	 in	 Jurkat	 T-ALL	 cells.	 This	
analysis	revealed	a	significant	overlap	(NES:	1.533,	p-value<0.001)	between	NOTCH1-
induced	transcripts	and	genes	positively	regulated	by	PHF6	(Fig.	1D),	supporting	our	
phenotypic	readout	on	OP9-DLL1	co-cultures	and	in	line	with	recent	work	that	also	
described	a	putative	link	between	PHF6	and	transcriptional	regulation	of	NOTCH113.		
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To	 further	 explore	 the	 putative	 interaction	 between	 PHF6	 and	 NOTCH1,	 we	
modulated	 both	 factors	 in	 human	 CD34+	 thymic	 precursors	 using	 stable	 PHF6	
knockdown	 and	 pharmacological	 inhibition	 of	 NOTCH1	 using	 a	 gamma-secretase	
inhibitor	 (GSI,	DAPT)	 compound	and	 followed	T-cell	differentiation	using	OP9-DLL4	
co-cultures	 (closely	 resembles	DLL1	 function)25.	 In	 line	with	our	 initial	 results	using	
OP9-DLL1	 co-cultures,	 thymocytes	 with	 PHF6	 deficiency	 progressed	 significantly	
faster	 towards	 the	DP	 stage	 cells	 as	 compared	 to	 control	 cells,	 similar	 to	what	we	
observed	for	control	transduced	cells	that	are	exposed	to	GSI	(Fig.	1E	(6	days	of	co-
culture)	 and	 Fig.	 1G	 (18	 days	 of	 co-culture)).	 Interestingly,	 combined	 reduction	 of	
PHF6	 expression	 (shRNA)	 and	 Notch	 pathway	 activity	 (GSI)	 further	 increased	 this	
accelerated	differentiation	and	resulted	in	the	highest	frequency	of	DP	cells	as	well	
as	increased	absolute	numbers	of	DP	thymocytes	at	the	earliest	time	point	(Fig.	1F).	
At	 later	 timepoints,	 the	absolute	DP	 cell	 counts	between	 the	GSI	 fractions	with	or	
without	 loss	 of	 PHF6	 were	 comparable	 (Fig.	 1H),	 consistent	 with	 the	 absolute	
requirement	for	Notch	in	thymocyte	proliferation26,27.		
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Figure	 1:	 PHF6	 knockdown	 in	 cord	 blood	 CD34+	 progenitors	 leads	 to	 accelerated	 CD4+CD8+	
development	in	concert	with	NOTCH1.	(A)	Validation	of	stable	shRNA-mediated	knockdown	in	Jurkat	
T-ALL	 cells	 by	western	blot	 analysis,	 (B)	 PHF6	deficiency	 leads	 to	 accelerated	 (increased	 frequency)	
CD4+CD8+	(DP)	stage	development	of	CD34+	thymocyte	progenitor	cells	(also	in	absolute	counts	(C)),	
(D)	 Gene	 Set	 Enrichment	 Analysis	 reveals	 significant	 overlap	 between	 genes	 downregulated	 upon	
PHF6	 knockdown	 in	 Jurkat	 cells	 and	 genes	 downregulated	 upon	 pharmacological	 inhibition	 of	
NOTCH1	 signaling	 by	 gamma-secretase	 inhibitor	 (GSI,	 DAPT)	 treatment	 in	 CUTLL1	 T-ALL	 cells,	 (E-H)	
PHF6	 knockdown	 or	 GSI-treatment	 of	 cord	 blood	 CD34+	 progenitors	 induces	 a	 similar	 increased	
progression	 of	 CD34+	 precursor	 cells	 towards	 the	 DP	 (CD4+CD8+)	 T-cell	 stage,	 with	 combination	 of	
both	 showing	an	additive	effect	 in	absolute	counts	at	an	early	 timepoint	 (6	days)	during	co-culture	
analysis	(E,F)	but	no	longer	at	a	later	timepoint	of	co-culture	(18	days)	(G,H).	 	
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Consistent	with	the	DP	phenotype,	loss	of	PHF6	skewed	differentiation	of	human	T-
cell	precursors	towards	TCR-αβ	T	cells	(Fig.	2A	and	2B)	at	the	expense	of	TCR-γδ	T-	
cell	 lineage	 development	 (Fig.	 2C	 and	 2D).	 This	 differential	 PHF6	 dependency	
between	 both	 T-cell	 lineages	 is	 consistent	 with	 their	 Notch	 dependent	
development22,23,	further	supporting	a	functional	cooperation	between	NOTCH1	and	
PHF6	during	normal	T-cell	development.		
	
																								 																	
Figure	 2:	 PHF6	 knockdown	 in	 cord	 blood	 CD34+	 progenitors	 leads	 to	 skewed	 T-cell	 lineage	
development	towards	the	TCR-αβ	 lineage	at	expense	of	TCR-γδ	 lineage	development.	 	(A-B)	PHF6	
knockdown	 in	 cord	 blood	 CD34+	 progenitor	 cells	 leads	 to	 increased/skewed	 TCR-αβ	 lineage	
commitment,	 (C-D)	 at	 the	 expense	 of	 γδ	 T-cell	 lineage	 commitment	 with	 a	 functional	 cooperative	
effect	with	NOTCH1	inhibition.	 	
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To	 further	 explore	 the	 transcriptional	 changes	 that	 are	mediated	 by	 PHF6	 in	 both	
normal	 and	 malignant	 T-cell	 development	 we	 compared	 gene	 expression	 profiles	
associated	with	shRNA	mediated	knockdown	of	PHF6	in	Jurkat	T-ALL	cells	and	CD34+	
cultured	on	OP9-DLL1.	For	the	assembly	of	the	geneset	of	this	GSEA	analysis,	the	p-
value	 (<0.05)	 was	 used	 as	 a	 cut-off	 to	 identify	 the	 signature.	 The	 gene	 profiles	
induced	upon	PHF6	depletion	 in	both	 in	vitro	model	systems	appeared	very	robust	
and	showed	a	significant	overlap	as	visualized	by	GSEA,	further	confirming	that	PHF6	
controls	 overlapping	 gene	 regulatory	 programs	 in	 both	 T-ALL	 lymphoblasts	 and	
normal	 immature	T-cells	 	 (Fig.	 3A	and	3B).	Consistent	with	 its	 role	 in	TCR-γδ	T-cell	
development,	ETV5	was	identified	as	one	of	the	common	top-candidate	genes	that	
was	 downregulated	 upon	 PHF6	 knockdown	 (Fig.	 3A).	 In	 contrast,	 the	 αβ-lineage	
essential	 transcription	 factor	RORC	 is	upregulated	upon	PHF6	knockdown	(Fig.	 3B),	
indicating	 that	PHF6	affects	 the	expression	of	key	 regulators	of	TCR-αβ	and	–	γδ	T	
cell	development.		
Unexpectedly,	PHF6	knockdown	also	resulted	 in	upregulation	of	NOTCH3	and	 IL7R,	
two	 Notch	 target	 genes	 that	 are	 implicated	 in	 preferentially	 driving	 TCR-γδ	 T	 cell	
development23,28,29,	 in	 keeping	 with	 anti-correlation	 between	 PHF6	 and	 IL7R	
expression	during	 discrete	 stages	 of	 T-cell	 development	 and	 thus	 revealing	Notch-
independent	regulatory	roles	for	PHF6	(Fig.	3C).	Further	experiments	to	unravel	the	
broader	 gene	 regulatory	 control	 of	 PHF6	 during	 normal	 hematopoiesis	 and	 in	
particular	the	role	of	PHF6	regulation	of	IL7R	expression	are	currently	ongoing.		 	
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Figure	3:	 Identification	of	key	PHF6	downstream	target	genes	 in	thymocyte	progenitor	cells.	Gene	
Set	Enrichment	Analysis	 reveals	a	significant	overlap	between	genes	down-	 (A)	and	upregulated	 (B)	
upon	 PHF6	 knockdown	 in	 Jurkat	 and	 CD34+	 cord	 blood	 progenitor	 cells,	 (C)	 PHF6	 and	 IL7R	 mRNA	
expression	dynamics	are	anti-correlated	across	the	different	T-cell	subsets	that	can	be	discriminated	
during	normal	human	T-cell	development.	 	
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PHF6	is	implicated	in	control	of	multiple	hematopoietic	cell	lineage	gene	regulatory	
programs	
In	view	of	the	 literature	data	pointing	at	a	role	of	PHF6	 in	B-cell	oncogenesis13,	we	
hypothesized	that	PHF6	could	play	a	broader	role	in	hematopoietic	lineage	decisions.	
To	 investigate	this,	we	measured	PHF6	gene	expression	 levels	 in	subsets	of	various	
human	blood	cell	types	(Fig.	4).	Expression	was	observed	in	all	tested	samples	with	
prominently	 high	 expression	 levels	 in	 CD34+	 HPCs	 and	 CD19+	 B	 cells	 and	 lower	
expression	 in	CD3+	T	 cells.	CD56+	NK	cells	 and	CD14+	monocyte	 cells	displayed	 the	
lowest	PHF6	expression	levels.		
	
																				 	
Figure	 4:	 PHF6	 expression	 levels	 across	 different	 types	 of	 hematopoietic	 cell	 lineages.	 PHF6	
expression	levels	are	depicted	in	hematopoietic	progenitor	cells	(HPCs),	CD14+	monocytes,	CD19+	B-
cells,	CD56+	NK-cells	and	CD3+	T-cells.	
	
	
In	 a	 next	 step,	 PHF6	 knockdown	 was	 executed	 in	 CD34+lin-	 cord	 blood	 (CB)	
hematopoietic	progenitor	cells	(HPCs)	and	the	impact	of	PHF6	modulation	on	human	
B-cell,	 NK-cell	 and	 myeloid	 lineage	 development	 was	 evaluated	 using	 the	 well-
established	OP9	co-cultures25.		 	
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In	 OP9-GFP	 cultures	 conditions	 that	 permit	 B-cell	 development,	 we	 observed	 a	
significant	increase	in	both	the	frequency	and	absolute	number	of	CD19+HLA-DR+	B-	
cells	upon	PHF6	knockdown	compared	to	the	control	condition	(Fig.	5A	and	5B).		
To	study	the	role	of	PHF6	in	human	NK-cell	differentiation,	we	performed	OP9-GFP	
co-cultures	to	which	the	critical	NK-lineage	cytokine	IL-15	was	added,	in	addition	to	
SCF	 and	 FLT3-L.	 Knockdown	 of	 PHF6	 significantly	 decreased	 the	 generation	 of	
CD56+CD5-	NK-cells	from	CD34+	CB	HPCs	compared	to	control	transduced	cells	(Fig.	
5C	 and	 5D),	 indicating	 that	 PHF6	 expression	 is	 required	 for	 human	 NK-cell	
development.				
Finally,	to	study	the	requirement	for	PHF6	during	myeloid	lineage	differentiation,	we	
performed	 OP9-GFP	 stromal	 co-cultures	 with	 control	 or	 PHF6	 shRNA	 transduced	
CD34+	HPCs	in	the	presence	of	myeloid	growth	factors25,30.	Under	these	conditions,	
downregulation	 of	 PHF6	 induced	 a	 consistent	 increase	 in	 the	 frequency	 of	
CD14+CD4+	 monocytes	 (Fig.	 5E),	 but	 without	 increase	 in	 absolute	 monocyte	 cell	
numbers	 (Fig.	 5F).	 Rather,	 a	 small,	 but	 not	 significant	 reduction	 in	 the	 absolute	
number	 of	 monocytes	 was	 observed	 after	 two	 weeks	 of	 co-culture	 upon	 PHF6	
knockdown	 compared	 to	 the	 control	 co-cultures.	 Thus,	 in	 line	 with	 the	 rare	
occurrence	 of	 PHF6	 mutations	 in	 myeloid	 malignancies,	 only	 minor	 changes	 in	
myeloid	lineage	differentiation	were	observed	upon	PHF6	knockdown.	 	
To	 better	 understand	 these	 alterations	 in	 hematopoietic	 lineage	 differentiation,	
gene	 expression	 profiling	 was	 performed	 after	 short-term	 shRNA-mediated	
knockdown	 (72h)	 of	 PHF6	 in	 CD34+	 progenitor	 cells	 cultured	 on	 OP9-GFP.	 These	
expression	 signatures	 were	 subsequently	 compared	 to	 publically	 available	
transcriptional	profiles	of	sorted	populations	of	different	human	hematopoietic	cell	
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types21	 (GSE24759).	 Consistent	 with	 the	 preferential	 differentiation	 towards	 B-
lymphocytes,	B-cell	 lineage	genes	were	significant	enriched	upon	PHF6	knockdown	
when	 compared	 to	myeloid	 (Fig.	 5G)	 or	 NK-cell	 signatures	 (Fig.	 5H).	 Thus,	 loss	 of	
PHF6	 in	 human	 HPCs	 alters	 downstream	 gene	 expression	 and	 consequently,	
hematopoietic	lineage	differentiation.	
	
Chapter	3:	Results	
	 	 	160	
	
Figure	5:	PHF6	deficiency	strongly	impacts	on	the	development	of	different	hematopoietic	lineage	
types.	PHF6	knockdown	in	CD34+	cord	blood	progenitor	cells	cultured	on	an	OP9-GFP	stromal	feeder	
layer	significantly	enhances	in	comparison	to	control	cells	the	development	of	B-cells	(A-B),	reduces	
the	number	of	developing	NK-cells	(C-D),	without	significantly	altering	monocyte	development	(E-F),	
(G-H)	Gene	Set	Enrichment	Analysis	(GSEA)	shows	significant	enrichment	of	a	B-cell	signature	in	PHF6	
knockdown	 cells	 compared	 to	 controls	 at	 the	 expense	 of	 a	 monocyte	 (G)	 or	 NK-cell	 (H)	 gene	
signature.	 	
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Discussion	
This	study	 for	 the	 first	 time	provides	a	comprehensive	view	on	the	role	of	PHF6	 in	
control	of	multiple	hematopoietic	cell	 lineage	decisions.	While	our	data	 illustrate	a	
broad	involvement	across	various	hematopoietic	cell	types,	we	were	able	to	dissect	
in	more	detail	the	regulated	transcriptional	profile	and	underlying	mechanistic	basis	
of	PHF6	driven	 lineage	control	during	 thymopoiesis.	 Importantly,	 robust	 regulation	
of	two	key	transcription	factors	ETV5	and	RORC	was	demonstrated	in	addition	to	a	
crosstalk	 with	 Notch	 pathway	 activity,	 providing	 an	 explanation	 for	 the	 observed	
effects	 on	 perturbed	 T-cell	maturation	 upon	 PHF6	 knockdown.	 Interestingly,	 gene	
expression	profiling	also	revealed	PHF6	controlled	down	regulation	of	NOTCH3	and	
IL7R,	both	essential	factors	in	T-cell	development	that	are	associated	with	TCR-γδ	T-	
cell	 development.	 The	 exact	 importance	 of	 this	 observation	 in	 the	 context	 of	
thymopoiesis	 remains	 to	be	determined	and	 is	 currently	under	 investigation.	Since	
the	 increased	expression	of	both	genes	upon	PHF6	knockdown	 is	 inconsistent	with	
the	observed	loss	of	TCR-γδ	T	cell	development	and	accelerated	differentiation	into	
DP	 αβ-lineage	 cells,	 we	 are	 currently	 testing	 the	 hypothesis	 that	 signaling	
incompetent	 IL7Rα	 homodimers	 are	 formed	 that	 limit	 IL7	 levels	 within	 the	
cultures31,	thereby	causing	these	differentiation	effects	that	effectively	resemble	loss	
of	 IL7R	 signaling22.	 In	 addition,	 ChIP-sequencing	 to	 determine	 the	 genome-wide	
PHF6	binding	profile	and	chromatin	mark	distribution	at	PHF6	binding	sites	(as	well	
as	ATAC-sequencing)	should	shed	a	more	detailed	 light	onto	the	mode-of-action	of	
PHF6	as	an	epigenetic	modulator	of	gene	expression.	Also,	the	role	of	PHF6	in	T-ALL	
formation	 is	 largely	 unexplained.	 Interestingly,	 both	 ETV5	 and	 IL7R	 are	 known	
oncogenes	in	cancer	and	the	impact	of	altered	expression	levels	for	both	genes	upon	
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PHF6	 knockdown	 remains	 to	 be	 investigated.	Of	 particular	 interest,	 IL7R	 has	 been	
described	 as	 a	 bona	 fide	 oncogene	 in	 T-ALL	 and	 activating	 mutations	 driving	
JAK/STAT	 signaling	 have	 been	 recurrently	 described.	 Moreover,	 the	 particular	
enrichment	of	PHF6	mutations	in	TLX1	driven	T-ALLs	is	intriguing.	The	observation	of	
repression	of	IL7R	expression	by	both	TLX132	and	PHF6	(this	study)	possibly	provides	
a	strong	selective	pressure	towards	PHF6	 loss-of-function	mutations	 in	TLX1-driven	
leukemia	(see	also	paper	3,	Chapter	3,	Part	1).	
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ABSTRACT	
	
T-cell	 acute	 lymphoblastic	 leukemia	 (T-ALL)	 is	 a	 genetically	 heterogeneous	 disease	
with	 genetic	 subgroups	 being	marked	 by	 particular	 driver	 oncogenes.	 In	 addition,	
mutations	are	present	 in	various	classes	of	genes,	many	of	which	occur	across	 the	
defined	 genetic	 subsets	 such	 as	 NOTCH1.	 More	 recently,	 a	 remarkable	 high	
frequency	 of	 somatic	 mutations	 affecting	 epigenetic	 regulators	 was	 observed	
including	EZH2,	UTX,	JMJD3	and	PHF6.	The	latter,	a	presumed	epigenetic	reader,	was	
found	 mutated	 in	 16%	 of	 pediatric	 and	 38%	 of	 adult	 T-ALL	 patients	 with	 highest	
frequencies	observed	 in	the	TLX1/3	genetic	subgroup.	So	far,	the	functional	role	of	
PHF6	 in	 malignant	 T-cell	 transformation	 has	 not	 been	 resolved.	 To	 this	 end,	 we	
performed	a	functional	landscaping	of	the	transcriptional	regulatory	networks	under	
control	of	PHF6	in	T-ALL	lymphoblasts.	First,	we	provide	evidence	for	loss	of	PHF6	as	
a	crucial	cooperative	event	in	TLX1-driven	leukemia	with	opposing	roles	in	regulation	
of	expression	of	the	IL7R	receptor,	playing	an	essential	role	in	T-cell	maturation	and	
acting	 as	 a	 bona	 fide	 oncogene	 in	 T-ALL.	 Second,	 we	 provide	 data	 supporting	 a	
putative	functional	connection	between	PHF6	and	the	NurD	and	SWI-SNF	chromatin	
modifying	protein	complexes.	Our	study	paves	the	way	for	further	novel	therapeutic	
strategies	 targeting	 JAK-STAT	 signaling	 in	 PHF6	 mutated	 T-ALL	 and	 investigations	
unraveling	the	functional	interactions	with	NurD	and	SWI-SNF	protein	complexes	in	
epigenetic	control	of	gene	regulatory	networks	controlling	thymocyte	differentiation	
and	malignant	transformation.	 	
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INTRODUCTION	
	
T-cell	acute	lymphoblastic	leukemia	(T-ALL)	results	from	malignant	transformation	of	
immature	 thymocytes.	 T-ALL	 formation	 is	 characterized	 by	 the	 progressive	
accumulation	 of	 various	 genetic	 and	 epigenetic	 defects,	 therefore	 representing	 a	
paradigm	for	multistep	cancer	formation.	Recent	next-generation	sequencing	efforts	
have	 shown	 that	 genes	 encoding	 epigenetic	 regulatory	 proteins	 constitute	 a	
significant	portion	of	the	genes	mutated	in	various	cancer	types1.	Also	in	T-ALL,	there	
is	an	emerging	prominent	role	for	the	epigenome	and	its	regulators	to	participate	in	
malignant	 transformation2,	 as	 recently	 illustrated	 by	 the	 discovery	 of	 the	 PCR2	
complex	component	EZH2	as	a	novel	tumor	suppressor3.			
	
We	 previously	 identified	 inactivating	mutations	 and	 deletions	 in	 the	PHF6	 gene	 in	
16%	 of	 pediatric	 and	 38%	 of	 adult	 T-ALL	 cases4.	 Notably,	 PHF6	 mutations	 were	
enriched	 in	 TLX1	 and	 TLX3-driven	 T-ALL.	 In	 addition,	 PHF6	 mutations	 were	 also	
found,	 although	 at	 low	 frequency,	 in	 acute	myeloid	 leukemia5	 and	 hepatocellular	
carcinoma6,	 marking	 the	 broader	 role	 of	 PHF6	 in	 tumorigenesis.	 Constitutional	
mutations	 in	PHF6	 were	 previously	 described	 in	 patients	with	 Börjeson-Forssman-
Lehmann	syndrome	(BFLS),	an	X-linked	mental	retardation	disorder7.	Interestingly,	a	
case	study	by	Chao	and	co-workers8	reported	the	diagnosis	of	a	BFLS	patient	with	T-
ALL,	supporting	the	role	of	PHF6	as	T-ALL	specific	tumor	suppressor.	Moreover,	PHF6	
germline	 mutations	 were	 recently	 described	 in	 the	 Coffin-Siris	 and	 Nicolaides-
Baraitser	syndromes,	congenital	disorders	previously	characterized	by	mutations	 in	
various	members	of	the	SWI-SNF	protein	complex9.		
	
The	 protein	 structure	 of	 PHF6	 is	 characterized	 by	 the	 presence	 of	 four	 nuclear	
localization	signals	(NLS)	and	two	imperfect	plant	homeodomain	(PHD)	zinc	fingers.	
The	PHF6	protein	is	expressed	in	the	nucleus	with	specific	enriched	expression	in	the	
nucleoli7.	 These	 nuclear	 compartments	 are	 known	 to	 harbor	 tandemly	 repeated	
ribosomal	RNA	(rRNA)	gene	clusters	and	it	has	recently	been	put	forward	that	PHF6	
suppresses	rRNA	synthesis	through	its	interaction	with	the	Upstream	Binding	Factor	
(UBF)	 protein10.	 The	 family	 of	 PHD-finger	 proteins	 has	 already	 been	 extensively	
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described	 in	 literature	 to	 constitute	one	of	 the	 largest	 protein	 families	 involved	 in	
modifying	or	reading	the	epigenetic	code	and	this	domain	structure	thus	suggests	a	
role	 for	 PHF6	 as	 an	 epigenetic	 regulator	 of	 gene	 expression.	 This	 hypothesis	 is	
further	supported	by	the	observation	of	Todd	and	co-workers11	that	PHF6	interacts	
with	the	Nucleosome	Remodeling	and	Deacetylation	complex	(NurD-complex).		
	
In	 this	 study,	 we	 performed	 for	 the	 first	 time	 a	 dissection	 of	 the	 transcriptional	
landscape	under	control	of	PHF6	 in	T-ALL,	 revealing	the	potential	mechanisms	of	a	
functional	 crosstalk	with	other	 known	players	 in	T-ALL	oncogenesis	 and	epigenetic	
modifiers	such	as	the	NurD	and	SWI-SNF	chromatin	remodeling	complexes.	 	
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MATERIALS	AND	METHODS	
	
	
Cell	lines	
ALL-SIL	 cells	 were	 obtained	 from	 the	 DSMZ	 cell	 line	 repository.	 Cells	 were	
maintained	in	RPMI-1640	medium	(Life	Technologies)	supplemented	with	20%	fetal	
bovine	serum,	1%	of	L-glutamine	(Life	Technologies)	and	1%	penicillin/streptomycin	
(Life	Technologies,	15160-047).	MOHITO	murine	T-ALL	cells	were	a	kind	gift	from	the	
lab	 of	 prof.	 Jan	 Cools12	 (Center	 for	 the	 Biology	 of	 Disease,	 VIB,	 Leuven,	 Belgium).	
Cells	 were	 maintained	 in	 RPMI-1640	 medium	 (Life	 Technologies,	 catalog	 number	
52400-025)	 supplemented	 with	 20%	 fetal	 bovine	 serum,	 1%	 of	 L-glutamine	 (Life	
Technologies,	 15140-148),	 1%	 penicillin/streptomycin	 (Life	 Technologies),	 5	 ng/ml	
murine	IL-2	(PeproTech)	and	10	ng/ml	murine	IL-7	(PeproTech).	
	
siRNA	mediated	knockdown,	RNA-isolation,	cDNA	synthesis	and	RT-qPCR		
ALL-SIL	cells	were	electroporated	 (250	V,	1000	μF)	using	a	Genepulser	Xcell	device	
(Biorad)	with	400	nM	of	Silencer	Select	Negative	Control	1	siRNA	(Ambion)	or	siRNAs	
targeting	 PHF6	 (ON-TARGETplus	 SMARTpool;	 Dharmacon,	 Lafayette,	 CO,	 USA	 and	
Silencer	 Select,	 Ambion),	 SMARCA4	 (Silencer	 Select,	 Ambion)	 or	 CHD4	 (Silencer	
Select,	 Ambion).	 ALL-SIL	 cells	 were	 collected	 24h	 post-electroporation.	 Total	 RNA	
was	isolated	using	the	miRNeasy	mini	kit	(Qiagen)	with	DNA	digestion	on-column.	By	
means	of	spectrophotometry,	RNA	concentrations	were	measured	(Nanodrop	1000)	
and	 RNA	 integrity	 was	 evaluated	 (Experion,	 Bio-Rad).	 Next,	 cDNA	 synthesis	 was	
performed	using	the	iScript	cDNA	synthesis	Kit	(Bio-Rad)	followed	by	RT-qPCR	using	
the	LightCycler	480	(Roche).	Finally,	qPCR	data	was	analyzed	according	to	the	ΔΔCt-
method	using	the	qBasePLUS	software	(Biogazelle).		
	
CRISPR	mediated	knockout	of	Phf6	in	MOHITO	T-ALL	cells	
MSCV-Cas9-IRES-mCHERRY	and	pMX-U6_Phf6	guide	viral	vectors	were	produced	 in	
HEK293T	 cells	 using	 an	 EcoPack	 packaging	 plasmid	 and	 TurboFect	 transfection	
reagent	 (Fermentas).	 Supernatant	 containing	 virus	 was	 harvested	 48	 h	 after	
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transfection.	MOHITO	cells12		were	cultured	in	RPMI	1640	with	20%	FCS		and	IL-2	(25	
ng/mL;	 Peprotech),	 and	 IL7	 (50	 ng/mL;	 Peprotech).	 For	 retroviral	 transduction	 of	
MOHITO	cels,	 6-well	 plates	were	 coated	with	RetroNectin	 solution	overnight	 (final	
concentration	5	mg/cm2,	Takara	Bio	Inc.)	and	blocked	with	2%	FBS	in	PBS	for	30	min	
before	 use.	 Viral	 supernatant	 was	 pre-loaded	 onto	 RetroNectin	 coated	 plates	 by	
centrifugation	 (2000	 g,	 30	 min,	 30°C).	 After	 centrifugation,	 viral	 supernatant	 was	
discarded,	plates	were	washed	with	PBS	and	cells	were	added	at	a	density	of	0.5x106	
cells/mL.	 Retroviral	 transduction	 was	 achieved	 using	 standard	 spin-infection	
procedure	(2000	xg,	90	min,	30°C).	Cells	were	placed	in	an	incubator	for	24-48	h	to	
recover	prior	to	FACS	sorting	of	the	mCHERRY	and	GFP	double	positive	cells	(Bio-Rad	
S3	sorter).		
	
Viral	constructs	and	transduction	of	HPCs	
pLKO.1-puroR	 (control	 shRNA),	 TRCN0000015551	 (BRG1	 shRNA1)	 and	
TRCN0000015552	 (BRG1	 shRNA2)	 lentiviral	 vectors	were	 purchased	 from	 Sigma	 in	
which	the	puromycin	resistance	gene	was	replaced	with	a	PCR-amplified	EGFP	cDNA	
using	BamHI	and	KpnI	restriction	sites.	 Infectious	 lentivirus	was	produced	by	 jetPEI	
(polyplus	 transfection™)	 mediated	 transfection	 of	 the	 293FT	 cell	 line	 with	 either	
pLKO.1-SHC002-EGFP	 or	 pLK0.1-SHC20122-EGFP,	 in	 conjuction	 of	 the	 pCMV-VSV-G	
(envelope)	and	p8.91	(packaging)	constructs.	The	virus	supernatant	was	harvested	2	
and	 3	 days	 after	 transfection.	 Lentiviral	 transduction	 of	 HPCs	 was	 performed	 on	
sorted	CD34+lin-	CB	cells	or	CD34+	thymocytes	previously	cultured	in	complete	IMDM	
medium	containing	10%	FCS	and	supplemented	with	TPO	(20ng/ml),	SCF	(100ng/ml)	
and	 FLT3-L	 (100ng/ml)	 or	 SCF	 (10ng/ml)	 and	 IL-7	 (10ng/ml),	 respectively,	 for	 two	
days	 (cord	blood)	or	one	day	 (thymocytes).	48	hours	after	 transduction,	cells	were	
harvested	and	sorted	for	EGFP+	transduced	cells.			
	
OP9	co-cultures	and	flow	cytometry	
Transduced	 and	 sorted	 CD34+lin-EGFP+	 CB	 cells	 or	 CD34+EGFP+	 thymocytes	 were	
seeded	in	a	24-well	plate	containing	a	confluent	layer	of	either	control	OP9	stromal	
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cells	(OP9-GFP)	or	Delta-like-ligand1	expressing	OP9	stromal	cells		(OP9-DLL1).	All	co-
cultures	 were	 performed	 in	 α-MEM	 media	 (Invitrogen)	 supplemented	 with	 20%	
heat-inactivated	 FCS	 plus	 100U/ml	 penicillin,	 100	µg/ml	 streptomycin	 and	 2mM	L-
glutamin	 (all	 from	 Invitrogen).	 To	 induce	 and	 support	 T	 and	 B	 cell	 differentiation,	
cultures	were	performed	in	the	presence	of	SCF,	IL-7	and	FLT3-L	(all	5	ng/ml)	on	OP9-
DLL1	and	OP9-GFP,	respectively.	Co-cultures	were	harvested	by	forceful	pipetting	at	
indicated	 time	 points.	 Obtained	 cell	 suspensions	 were	 blocked	 with	 anti-mouse	
FcRγII/III	 (clone	 2.4.G2)	 and	 human	 IgG	 (Fcblock,	 Miltenyi)	 to	 avoid	 non-specific	
binding	 and	 subsequently	 stained	 with	 combinations	 of	 anti-human	 monoclonal	
antibodies	(BDIS,	eBioscience,	Biolegend	and	Miltenyi).	Cells	were	examined	for	the	
expression	of	cell	surface	markers	on	a	LSRII	(BDIS).		
	
RNA-sequencing	
In	 this	 study,	 RNA-sequencing	 by	 poly-A	 capture	 (unstranded,	 paired-end)	 was	
performed	 using	 100	 ng	 of	 RNA	 as	 input	 material	 (Biogazelle,	 Belgium).	 The	
sequencing	 read	 depth	 comprised	 for	 all	 samples	 +/-50	million	 reads,	which	were	
aligned	 to	 the	 reference	 genome	 hg38	 with	 STAR-2.4.2a	 and	 default	 settings.	
Differential	 expression	analysis	was	performed	with	DESeq2.	 Scrambled	 siRNA	was	
used	 as	 control	 and	 compared	 with	 2	 independent	 PHF6	 targeting	 siRNAs	 (3	
replicates).	A	multifactorial	design	was	used	to	control	for	batch	effects.		
	
Gene	expression	profiling	
RNA	samples	 from	ALL-SIL	cells	were	profiled	on	a	custom	designed	Agilent	micro-
array	covering	all	protein	coding	genes	(33,128	mRNA	probes,	Human	Sureprint	G3	
8x60k	micro-arrays	 (Agilent))	 and	 12,000	 lncRNAs	 (23,042	 unique	 lncRNA	 probes).	
Expression	data	were	normalized	using	the	VSN-package	(Bioconductor	release	2.12)	
in	R.	Differential	expression	analysis	was	performed	in	R	using	Limma.		
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Gene	ontology	analysis	using	the	GREAT	algorithm	
The	 'Genomic	 Regions	 Enrichment	 of	 Annotations'	 (GREAT)	 tool	
(http://bejerano.stanford.edu/great)	was	used	to	perform	gene	ontology	on	the	set	
of	 up-	 or	 downregulated	 set	 of	 genes	 upon	 PHF6	 knockdown.	 The	 'mouse	
phenotype'	 ontology	 comprises	 mouse	 genotype-phenotype	 associations,	 mainly	
obtained	by	curation	from	literature.,	that	are	mapped	to	human	genes.		
	 	
Chapter	3:	Results	
	 	 	175	
RESULTS		
	
PHF6	 modulation	 affects	 a	 broad	 gene	 regulatory	 landscape	 including	 multiple	
genes	implicated	in	thymocyte	maturation	and	T-ALL	oncogenesis		
	
We	previously	scrutinized	the	role	of	PHF6	in	normal	human	hematopoiesis	using	the	
in	vitro	model	system	OP9-DLL1	(paper	2	in	this	PhD	thesis).	In	brief,	we	showed	that	
PHF6	acts	as	a	novel	master	 regulator	 in	hematopoietic	 lineage	development,	with	
PHF6	 knockdown	 profoundly	 impacting	 on	 B-cell,	 T-cell	 and	 NK-cell	 lineages.	 A	
recent	 study	 by	 Meacham	 and	 colleagues	 suggested	 that	 PHF6	 could	 act	 as	 an	
oncogene	 in	 B-cell	malignancies13,	while	we	previously	 identified	PHF6	 as	 a	 tumor	
suppressor	in	T-ALL4	and	observed	a	significant	enrichment	of	PHF6	loss-of	function	
mutations	 in	 TLX1/TLX3	 positive	 T-ALL.	 In	 order	 to	 better	 understand	 the	 tumor	
suppressor	role	of	PHF6	in	T-ALL	lymphoblasts	and	its	functional	connection	to	TLX1	
in	T-ALL	blast	formation,	we	evaluated	the	transcriptional	effects	of	transient	PHF6	
knockdown	in	the	TLX1	positive	ALL-SIL	T-ALL	cell	line.	First,	significant	knockdown	of	
PHF6	levels	in	ALL-SIL	cells	using	two	independent	siRNAs	was	validated	by	RT-qPCR	
and	western	blot	analysis,	reaching	up	to	80%	knockdown	at	the	PHF6	protein	level	
(Fig.	 1a	 and	 1b).	 Subsequent	 RNA-sequencing	 of	 these	 samples	 revealed	 734	
significantly	 downregulated	 and	 216	 upregulated	 protein-coding	 genes	 upon	 PHF6	
knockdown.	Within	 the	set	of	downregulated	genes,	we	 found	by	 ‘Gene	Ontology’	
(GO)-analysis	 using	 the	 GREAT	 algorithm14	 amongst	 others	 enrichment	 for	 genes	
with	a	key	role	in	normal	T-cell	and	B-cell	differentiation		(CD7,	NOTCH1)	(Fig.	1c	and	
1d),	whereas	the	set	of	upregulated	genes	upon	PHF6	knockdown	was	enriched	not	
only	 in	 important	T-cell	marker	genes	(RAG1,	 IL7R,	MYB),	but	also	a	gene	signature	
related	 to	epigenetic	gene	expression	 regulation	 (Fig	 1c	 and	 1e).	Next,	 in	order	 to	
further	 identify	 potential	 co-regulators	 of	 the	 gene	 sets	 that	 we	 identified	 under	
control	 of	 PHF6,	 we	 performed	 iRegulon	 analysis15	 on	 the	 set	 of	 significantly	 (p-
value<0.05)	 down-	 and	 upregulated	 genes	 upon	 PHF6	 knockdown.	 For	 the	 set	 of	
PHF6	 activated	 genes	 we	 identified	 the	 transcriptional	 regulators	 TFAP2C	 (NES:	
5.348),	JAZF1	(NES:	4.657)	and	ZBTB7/MAZ	(NES:	4.584)	as	top-scoring	putative	PHF6	
co-factors.	Interestingly,	previously	published	work	from	Meacham	and	colleagues13	
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included	PHF6	ChIP-sequencing	in	Jurkat	T-ALL	cells.	We	performed,	by	means	of	the	
MEME	ChIP	tool16	motif	discovery	on	this	dataset	(data	not	shown)	and	one	of	the	
top-scoring	 motifs	 (E-value:	 3.2e-009)	 is	 the	 binding	 motif	 of	 the	 TFAP2C	
transcription	 factor.	 Notably,	 also	 TAL1	 (NES:	 4.099),	 ETS1	 (NES:	 4.038)	 and	 IKZF1	
(NES:	 3.990)	 were	 amongst	 the	 top-enriched	 co-factors.	 	 In	 a	 similar	 manner,	 we	
used	iRegulon	to	identify	putative	PHF6	co-regulators	for	the	set	of	PHF6	repressed	
genes.	For	this	set	of	genes,	we	found	enrichment	for	the	TBX	protein	family	(NES:	
4.078),	the	HOX	protein	family	(NES:	4.035)	and	PAX3/7	(NES:	4.00).		
	
							 	
Figure	1:	Scrutinizing	the	PHF6	downstream	regulatory	network	in	T-ALL	lymphoblasts.	Validation	of	
PHF6	 knockdown	 in	 ALL-SIL	 T-ALL	 cells	 by	 RT-qPCR	 (mRNA)	 (a)	 and	 western	 blot	 analysis	 (protein	
level)	 (b),	 diagonal	 plot	 showing	 some	 of	 the	 key	 targets	 that	 are	 downregulated	 (blue)	 or	
upregulated	(red)	upon	PHF6	knockdown	in	ALL-SIL	(c),	Gene	Ontology	analysis	(GREAT	algorithm)	on	
the	set	of	downregulated	(d)	and	upregulated	(e)	genes	upon	PHF6	knockdown	in	ALL-SIL.	 	
Chapter	3:	Results	
	 	 	177	
PHF6	loss-of-function	is	an	essential	functional	genetic	event	in	TLX1-positive	T-ALL	
To	 further	 elaborate	 on	 the	 potential	 functional	 interrelation	 with	 the	 ectopically	
expressed	oncogenic	factor	TLX1,	we	scored	the	gene	signatures	obtained	from	PHF6	
knockdown	in	ALL-SIL	cells	to	the	transcriptome	profile	obtained	upon	knockdown	of	
TLX1	 in	 the	 ALL-SIL	 cell	 line	 (Fig.	 2a	 and	 b)	 using	 ‘Gene	 Set	 Enrichment	 Analysis’	
(GSEA).	We	 could	 show	 that	 TLX1	 knockdown	 induces	 a	 largely	 overlapping	 gene	
signature	 to	 PHF6	 knockdown.	 Interestingly,	 as	 we	 have	 previously	 shown	 in	 our	
study	 on	 the	 role	 of	 PHF6	 in	 thymocyte	 progenitors	 (paper	 2),	 one	 of	 the	
predominant	upregulated	genes	upon	PHF6	knockdown	in	T-ALL	lymphoblasts	is	IL7R	
(Fig.	1d),	a	key	NOTCH1	target	gene	that	we	have	previously	found	to	be	repressed	
by	TLX117	(Fig.	2b).	We	hypothesize	that	the	PHF6-IL7R-TLX1	regulatory	axis	is	crucial	
to	explain	the	dependency	of	TLX1-positive	T-ALL	to	cooperative	PHF6	loss,	given	the	
essential	role	of	IL7R	for	survival	of	immature	T-cells	during	maturation.			
The	upregulated	expression	of	IL7R	in	ALL-SIL	cells	upon	PHF6	was	confirmed	by	RT-
qPCR	(Fig.	2c).	Notably,	comparing	the	IL7R	mRNA	expression	levels	between	a	panel	
of	PHF6	wild-type	and	mutant	T-ALL	cell	lines,	significantly	higher	expression	of	IL7R	
mRNA	levels	could	be	detected	in	PHF6	mutant	cells	(DND-41,	HPB-ALL	and	T-ALL1)	
in	 contrast	 to	PHF6	wild-type	 cells	 (Jurkat,	 ALL-SIL,	 LOUCY,	 KE-37,	MOLT-16,	 PEER,	
CCRF-CEM,	PF-382)	(Fig.	2d).	
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Figure	 2:	 Identification	 of	 a	 TLX1-IL7R-PHF6	 regulatory	 axis	 in	 T-ALL	 lymphoblasts.	 Gene	 Set	
Enrichment	 Analysis	 (GSEA)	 reveals	 a	 significant	 overlap	 between	 the	 downregulated	 (a)	 and	
upregulated	 (b)	 gene	 signatures	 associated	 with	 TLX1	 and	 PHF6	 knockdown	 in	 ALL-SIL	 cells,	 (c)	
Validation	of	IL7R	upregulation	upon	PHF6	knockdown	in	ALL-SIL	lymphoblasts	by	RT-qPCR,	(d)	Gene	
expression	 profiling	 from	 a	 T-ALL	 cell	 line	 panel	 indicates	 that	 IL7R	 mRNA	 levels	 are	 significantly	
higher	in	PHF6	mutant	T-ALL	cell	lines	compared	to	PHF6	wild-type	cell	lines.	
	
In	 order	 to	 further	 functionally	 evaluate	 the	 effects	 of	 PHF6	 knockdown	 on	 IL7R	
expression	and	the	downstream	JAK-STAT	signaling	cascade,	we	generated	a	stable	
Phf6	CRISPR	knock-out	model	in	the	murine	T-ALL	cell	line	MOHITO12,	given	that	this	
cell	line	is	IL7-sensitive.	Phf6	knockout	was	validated	on	protein	level	by	western	blot	
analysis	 (Fig.	 3a).	 Next,	 we	 compared	 IL7R	 (CD127)	 surface	 expression	 and	
intracellular	 pSTAT5	 levels	 by	 flow	 cytometry.	 The	MOHITO	 cells	 transduced	 only	
with	the	construct	encoding	the	Cas9	protein	were	used	as	a	negative	control.	As	a	
positive	 control	 for	 IL7R	 downstream	 JAK-STAT	 signaling	 induction	 by	 IL-7	
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administration,	we	used	MOHITO	cells	transduced	with	both	Cas9	and	JAK3	encoding	
vectors.	Using	 this	approach,	 robust	 induction	of	 IL7R-downstream	pSTAT5	protein	
in	JAK3	overexpressing	cells	was	observed.	Upon	co-transduction	of	MOHITO	T-ALL	
cells	with	a	Cas9	and	Phf6	gRNA	encoding	constructs,	we	observed	that	IL7R	(CD127)	
surface	 expression	 was	 strongly	 induced	 with	 a	 concomitant	 modest	 induction	 of	
downstream	pSTAT5	(Fig.	3b).This	is	in	line	with	our	previous	findings	(paper	2).	
	In	conclusion,	our	results	show	for	the	first	time	a	key	regulatory	effect	of	PHF6	on	
the	 IL7R-JAK-STAT	 pathway,	 indicating	 that	 PHF6	 mutated	 T-ALL	 patients	 could	
benefit	 from	 JAK-STAT	 cascade	 based	 molecular	 therapies,	 like	 ruxolitinib	 and	
tofacitinib	treatment.		
	
	
Figure	3:	MOHITO	cells	with	Phf6	CRISPR	knockout	 show	 increased	 levels	of	 IL7R	 (CD127)	 surface	
expression	and	downstream	pSTAT5	levels	as	compared	to	control	cells.	(a)	western	blot	analysis	of	
MOHITO	 murine	 T-ALL	 lymphoblasts	 confirms	 complete	 loss	 of	 Phf6	 protein	 expression	 using	 2	
independent	PHF6	targeting	gRNAs,	(b)	Flow	cytometry	analysis	shows	predominant	upregulation	of	
pSTAT5	 levels	 upon	 overexpression	 of	 JAK3	 (=	 positive	 control)	 in	 MOHITO	 cells,	 whereas	 Phf6	
knockout	mainly	leads	to	upregulation	of	IL7R	with	a	modest	increase	in	intracellular	pSTAT5	levels.	
	
	
	
PHF6	controls	super-enhancer	activity	in	T-ALL	lymphoblasts	
	
Given	 the	 known	 action	 of	 the	 SWI-SNF	 complex	 at	 enhancer	 regions18,	 we	
compared	 the	 gene	 signature	 obtained	 upon	 PHF6	 knockdown	 in	 ALL-SIL	
lymphoblasts	 to	 the	 transcriptional	 profile	 of	 ALL-SIL	 cells	 treated	 with	 the	 BET-
inhibitor	 JQ1,	 a	 compound	 that	 is	 known	 to	 selectively	 bind	 and	 inhibit	 the	
bromodomain	 protein	 BRD4,	 thereby	 broadly	 affecting	 genes	 in	 the	 vicinity	 of	
(super)-enhancer	 sites19.	 This	 analysis	 revealed	 a	 significant	 downregulation	 of	
enhancer-associated	 protein	 coding	 genes	 upon	 PHF6	 loss	 (Fig.	 4a).	 To	 further	
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specify	 this	analysis	 towards	super-enhancer	 loci	 in	ALL-SIL,	we	scored	the	top-500	
scoring	super-enhancers	 in	 the	vicinity	of	protein-coding	genes	and	evaluated	how	
these	were	affected	by	PHF6	knockdown	using	GSEA	(Fig.	4b).	By	means	of	a	super-
enhancer	 plot	 analysis,	 we	 identified	 that	 amongst	 others	 IGLL1,	 RUNX3	 and	
NOTCH1	 are	 significantly	 associated	 with	 super-enhancer	 sites	 in	 ALL-SIL	 that	 are	
under	control	of	PHF6	(Fig.	4c).		
	
														 	
Figure	 4:	 The	 putative	 epigenetic	 regulator	 PHF6	 controls	 (super)-enhancer	 activity	 in	 ALL-SIL	
lymphoblasts.	 (a)	 Gene	 Set	 Enrichment	 Analysis	 shows	 a	 significant	 enrichment	 of	 the	 top-500	
downregulated	genes	upon	PHF6	knockdown	in	ALL-SIL	within	th	set	of	genes	that	are	downregulated	
upon	JQ1	treatment	in	the	same	cellular	context,	(b)	Gene	Set	Enrichment	Analysis	shows	a	significant	
enrichment	of	 the	 top-500	 scoring	 super-enhancer	 sites	 in	 the	ALL-SIL	 genome	near	protein-coding	
genes	 within	 the	 gene	 signature	 downmodulated	 upon	 PHF6	 knockdown,	 (c)	 Hockey-stick	 plot	
representing	the	normalized	rank	and	cluster	signals	of	H3K27Ac	ChIP-seq	peaks	in	ALL-SIL,	with	red	
dots	 representing	 those	 super-enhancer	 associated	 protein	 coding	 genes	 that	 are	 significantly	
differentially	expressed	upon	PHF6	knockdown	in	ALL-SIL	as	determined	by	polyA	RNA-sequencing.	 	
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Functional	 crosstalk	 of	 PHF6	 as	 an	 epigenetic	 modifier	 with	 NurD	 and	 SWI-SNF	
chromatin	remodeler	complexes	
	
Recently,	Todd	and	co-workers11	described	the	identification	of	a	physical	interaction	
between	PHF6	and	the	core	components	of	the	NurD	protein	complex	CHD4,	RBBP4	
and	HDAC1.	So	far,	no	further	functional	evaluation	of	this	interaction	has	been	done	
in	 the	context	of	T-ALL.	Therefore,	we	performed	 transient	knockdown	of	CHD4,	a	
core	 catalytic	 component	 of	 NurD,	 in	 ALL-SIL	 cells.	 In	 total,	 we	 obtained	 403	
significantly	downregulated	and	526	upregulated	protein-coding	 genes	upon	CHD4	
knockdown.	Notably,		a	comparative	analysis	by	GSEA	between	the	gene	signatures	
obtained	upon	PHF6	and	CHD4	knockdown	 in	ALL-SIL	cells	 revealed	that	 the	set	of	
PHF6	activated	genes	 is	significantly	repressed	by	CHD4	(Fig.	5a)	while	a	small,	but	
significant	overlap	could	be	identified	between	genes	repressed	by	CHD4	and	PHF6	
(Fig.	 5b).	 This	 potential	 functional	 antagonism	 between	 PHF6	 and	 CHD4	 will	 be	
further	investigated	in	follow-up	of	this	PhD	mandate.	
Given	the	recent	identification	of	PHF6	mutations	in	Coffin-Siris	syndrome	cases,	we	
also	evaluated	the	potential	functional	relation	of	PHF6	to	the	SWI-SNF	complex.	To	
this	end,	we	performed	 transient	knockdown	of	 the	catalytic	 SWI-SNF	component,	
SMARCA4/BRG1,	 in	 ALL-SIL	 cells.	 In	 total,	 331	 protein-coding	 genes	 were	
downregulated	 and	 263	 protein-coding	 genes	 were	 upregulated	 upon	 transient	
SMARCA4/BRG1	 knockdown.	 The	 gene	 signature	 induced	 upon	 SMARCA4/BRG1	
knockdown	 significantly	 mimics	 the	 signature	 retrieved	 upon	 PHF6	 knockdown	 in	
ALL-SIL	cells	as	shown	by	GSEA	(Fig.	5c	and	5d).	The	role	of	SMARCA4/BRG1	in	T-ALL	
is	currently	unknown.	Further	studies	will	be	required	to	understand	the	role	of	the	
SWI-SNF	chromatin	remodeler	complex	in	T-ALL	pathogenesis.	
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Figure	 5:	 The	 putative	 epigenetic	 regulator	 PHF6	 controls	 overlapping	 gene	 signatures	 with	 the	
NurD	 and	 SWI-SNF	 chromatin	 remodeling	 complexes.	 (a)	 Gene	 Set	 Enrichment	 Analysis	 shows	 a	
significant	enrichment	of	PHF6	positively	 regulated	genes	 in	 the	set	of	CHD4	repressed	genes,	 (b)	a	
core	 set	 of	 genes	 significantly	 upregulated	 by	 PHF6	 overlaps	 with	 genes	 upregulated	 upon	 CHD4	
knockdown	 in	 ALL-SIL	 as	 shown	 by	 GSEA	 analysis,	 (c-d)	 Gene	 set	 Enrichment	 Analysis	 shows	 a	
significant	overlap	between	PHF6	and	SMARCA4	controlled	gene	signatures	in	ALL-SIL	lymphoblasts.	 	
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The	SWI-SNF	complex	core	component	SMARCA4/BRG1	plays	a	key	role	in	normal	
hematopoiesis	
	
A	 key	 role	 for	 SMARCA4/BRG1	 in	 murine	 thymocyte	 development	 has	 been	
previously	 described20.	 In	 order	 to	 better	 understand	 the	 potential	 functional	
interaction	between	SMARCA4/BRG1	and	PHF6	in	T-ALL	lymphoblasts,	we	evaluated	
potential	 converging	 effects	 on	 human	 hematopoiesis.	 In	 a	 first	 analysis,	 we	
performed	 stable	 knockdown	 of	 SMARCA4/BRG1	 in	 cord	 blood	 CD34+	 progenitor	
cells	 and	 plated	 them	 either	 on	 an	 OP9-GFP	 stromal	 feeder	 layer	 to	 evaluate	
phenotypic	effects	on	B-cell	development	or	on	an	OP9-DLL1	stromal	feeder	layer	to	
be	able	to	monitor	effects	on	T-cell	 lineage	differentiation.	We	observed	significant	
impact	of	SMARCA4/BRG1	knockdown	on	the	precursor	T-cell	populations	CD34+7+	
(Fig.	 6a),	CD7+CD5+	 (Fig.	 6b)	and	γδ	T-cell	 lineage	development	(Fig.	 6c),	with	both	
SMARCA4/BRG1	shRNAs	applied	 inducing	a	major	reduction	 in	the	aforementioned	
populations	both	in	frequencies	and	absolute	counts.	
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Figure	 6:	 BRG1	 deficiency	 leads	 to	 abberant	 T-cell	 lineage	 development.	 Stable	 knockdown	 of	
BRG1/SMARCA4	 (2	 independent	 shRNAs)	 in	CD34+	 cord	blood	progenitor	 cells	 cultured	on	an	OP9-
DLL1	stromal	feeder	layer	leads	to	(a)	significant	reduction	in	frequency	(left)	and	absolute	numbers	
of	CD34+CD7+	early	T-cell	populations	as	well	as	(b)	reduced	CD7+CD5+	mature	T-cell	formation	and	(c)	
significant	reduction	in	TCR-γδ	lineage	committed	cells.	
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With	respect	to	B-cell	development,	a	similar	drastic	reducing	effect	on	development	
of	precursor	B-cells	could	be	observed	upon	SMARCA4/BRG1	knockdown	(Fig.	7).		
	
	
Figure	 7:	 BRG1/SMARCA4	 knockdown	 in	 CD34+	 cord	 blood	 progenitors	 leads	 to	 a	 significant	
reduction	in	development	towards	CD19+HLA-DR+	B-cells.	
	
	
DISCUSSION	
	
In	this	study,	we	performed	a	first	landscaping	of	the	transcriptional	networks	in	T-
ALL	lymphoblasts,	complementing	our	study	focusing	on	the	role	of	PHF6	in	normal	
hematopoiesis	 (paper	 2).	 Our	 results	 indicate	 a	 functional	 cooperative	 interaction	
between	PHF6	loss	and	TLX1	ectopic	expression	for	malignant	T-cell	transformation	
through	a	converging	regulatory	role	on	IL7R	expression,	a	key	signaling	receptor	for	
survival	 and	 differentiation	 of	 thymocyte	 progenitor	 cells	 and	 a	 crucial	 T-ALL	
oncogene.	In	addition,	we	show	for	the	first	time	a	significant	overlap	between	the	
signature	 genes	 of	 the	 PHF6	 downstream	 transcriptional	 network	 and	 the	 genes	
under	 control	 of	 the	 NurD	 and	 SWI-SNF	 chromatin	 remodeler	 complexes.	 This	
observation	 further	 strengthens	 the	potential	 implication	of	PHF6	as	an	epigenetic	
regulator	of	gene	expression.		In	order	to	further	approach	the	PHF6	transcriptional	
network	from	an	epigenetic	perspective,	we	will	perform	ChIP-sequencing	for	PHF6	
and	 a	 series	 of	 key	 histone	 modifications	 (H3K27ac,	 H3K4me1,	 H3K4me3,	
H3K27me3)	under	default	conditions	and	upon	PHF6	perturbation	to	evaluate	how	
certain	histone	modification	profiles	are	affected	by	PHF6	knockdown.	Furthermore,	
we	are	currently	optimizing	the	protocol	for	ATAC-sequencing	in	the	lab,	which	will	
allow	 us	 to	 scrutinize	 the	 PHF6	 controlled	 epigenetic	 landscape	 (default	 and	 in	
combination	with	perturbation)	in	precursor	T-cells.	So	far,	the	role	of	the	SWI-SNF	
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complex	has	not	been	studied	in	the	context	of	T-ALL	development.	Interestingly,	a	
recent	 study	 by	 Mullighan	 and	 colleagues	 (online	 communication	 ASH	 meeting,	
2015)	reported	SMARCA4/BRG1	mutations	in	pediatric	T-ALL	patients.	Interestingly,	
our	 research	 team	 identified	 by	 arrayCGH	 analysis	 one	 T-ALL	 patient	 with	 a	
SMARCA4/BRG1	 deletion	 and	 one	 with	 an	 ARID1A	 deletion	 (unpublished	 data),	
suggestive	 that	 components	 of	 the	 SWI-SNF	 complex	 are	 involved	 in	 T-ALL	
pathogenesis.	 In	order	 to	better	understand	 the	underlying	molecular	mechanisms	
that	mediate	 the	observed	 significant	 effects	of	 SMARCA4/BRG1	knockdown	on	T-
cell	and	B-cell	differentiation,	we	anticipate	to	perform	gene	expression	profiles	of	
the	respective	co-cultures.		
The	 results	of	 this	 study	 give	 a	prelude	 to	 the	use	of	 IL7R-pathway	directed	drugs	
such	as	tofacitinib	and	ruxolitinib.	We	will	test	the	sensitivity	of	PHF6	deficient	cells	
to	 these	 drugs	 compared	 to	 wild-type	 cells.	 To	 this	 end,	 the	MOHITO	 cell	 model	
system	with	 stable	PHF6	CRISPR	 knockout	 is	 of	 great	 value.	One	would	predict	 no	
selective	pressure	for	activating	mutations	within	the	IL7R	signaling	pathway	if	PHF6	
inactivation	already	results	in	increased	expression	of	IL7R,	unless	this	is	associated	
with	reduced	downstream	signaling.	Such	a	reduction	in	IL7R	signaling	would	also	be	
consistent	 with	 inhibition	 of	 TCR-γδ	 T	 cell	 development	 and	 accelerated	
differentiation	 towards	 αβ-lineage	 DP	 cells	 previously	 observed	 (paper	 2).	 Using	
iRegulon,	 we	 identified	 that	 the	 PHF6	 repressed	 genes	 are	 significantly	 enriched	
within	 the	 set	 of	 known	 downstream	 target	 genes	 of	 the	 STAT	 family	 members	
(STAT3	and	STAT5A),	 indicating	that	downstream	target	genes	of	the	 IL7R	signaling	
pathway	 are	 not	 activated	 upon	 PHF6	 inactivation	 and	 thus	 suggesting	 that	 IL7R	
signaling	 is	 defective,	 despite	 increased	 IL7R	 expression	 (data	 not	 shown).	 This	 is	
currently	 further	 investigated	 by	 overexpression	 studies	 of	 the	 γc-chain	 (IL2RG)	 of	
the	 IL7R	 complex	 in	 Phf6	 MOHITO	 knockout	 cells,	 to	 see	 whether	 we	 then	 can	
significantly	induce/restore	IL7R	downstream	JAK-STAT	signaling.		
Given	 the	 frequent	 co-occurrence	 of	 mutations	 in	 T-ALL	 in	 both	 PHF6	 and	
components	 of	 the	 IL7R	 pathway21,	 we	 propose	 that	 PHF6	 functions	 as	 a	 tumor	
suppressor	 during	 human	 T	 cell	 development	 by	 limiting	 the	 amount	 of	 IL7R	
expression,	 thereby	 preventing	 selective	 pressure	 to	 induce	 activation	 mutations	
within	 this	 signaling	 pathway	 as	 a	 result	 of	 the	 decrease	 in	 signaling.
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The	 basic	 helix-loop-helix	 transcription	 factor	 TAL1	 is	 aberrantly	 expressed	 in	 a	
majority	 of	 T-cell	 acute	 lymphoblastic	 leukemia	 (T-ALL)	 cases	 characterized	 by	
arrested	 development	 in	 the	 thymic	 late	 cortical	 stage.1,2	Although	 TAL1	 is	 a	bona	
fide	 T-cell	 oncogene,3	 with	 known	 direct	 targets	 in	 T-ALL,4	 the	 aberrant	
transcriptional	 circuitry	 responsible	 for	 thymocyte	 transformation	 is	 not	 yet	 fully	
understood.	 MicroRNAs	 are	 small,	 non-coding	 RNAs	 that	 function	 as	 endogenous	
post-transcriptional	repressors	of	protein-coding	genes	by	binding	to	target	sites	 in	
the	 3’-UTR	 of	messenger	 RNAs.5	Aberrant	 expression	 of	 these	molecules	 has	 been	
reported	in	several	hematological	malignancies,	and	microRNA	expression	signatures	
delineate	 ALL	 subgroups6	and	 can	 be	 interpreted	 in	 light	 of	 their	 variation	 during	
hematopoiesis.7	Individual	microRNAs	and	networks	have	been	implicated	in	T-ALL,8	
but	the	mechanisms	responsible	for	altered	microRNA	expression	in	this	malignancy	
remain	 poorly	 explored.	 Here,	 we	 report	 the	 identification	 of	 novel,	 non-protein-
coding	TAL1	target	genes,	implicating	microRNA	genes	as	part	of	the	transcriptional	
network	 downstream	 of	 TAL1	 that	 may	 be	 putatively	 involved	 in	 its	 oncogenic	
properties.	
To	 identify	 a	 TAL1-dependent	 microRNA	 gene	 expression	 profile,	 we	 ectopically	
expressed	TAL1	in	the	TAL1-negative	T-ALL	cell	 line	P12	and	performed	low-density	
array	analysis	(see	Supplementary	Data	online	for	materials	and	methods).	From	204	
detected	 microRNAs	 (out	 of	 372	 analyzed),	 we	 identified	 eight	 whose	 expression	
changed	 significantly	 upon	 TAL1	 overexpression	 (Figure	 1a	 and	 Supplementary	
Tables	1	and	2).	Subsequent	validation	was	performed	by	quantitative	PCR	analysis	
of	each	microRNA	after	enforcing	or	silencing	the	expression	of	TAL1.	This	allowed	us	
to	confirm	the	expected	TAL1-mediated	regulation	for	five	microRNAs:	namely,	miR-
135a,	miR-223	and	miR-330-3p	as	being	upregulated	by	TAL1;	and	miR-146b-5p	and	
miR-545	 as	 being	 downregulated	 (Figures	 1b–f).	 The	 three	 remaining	 microRNAs	
were	 excluded	 from	 subsequent	 analyses,	 as	we	 stringently	 considered	only	 those	
genes	to	be	validated	whose	expression	was	regulated	in	the	predicted	manner	upon	
both	TAL1	overexpression	and	silencing	(data	not	shown).	
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Next,	we	evaluated	whether	the	validated	microRNAs	were	direct	targets	of	TAL1	in	
T-ALL	 cells.	 For	 this	 purpose,	 we	 scrutinized	 publicly	 available	 TAL1	 ChIP-seq	 data	
(GEO	accession	number	GSE29181)	for	two	T-ALL	cell	lines	(JURKAT	and	CCRF-CEM)	
and	two	primary	T-ALL	samples4	for	the	presence	of	TAL1-binding	peaks	up	to	10	kb	
upstream	of	 the	 transcription	start	 site	of	each	microRNA	gene.	We	 identified	one	
peak	 in	 a	 putative	promoter	 region	 for	miR-146b	 (Supplementary	 Figure	 1a),	 sug-	
gesting	 that	 this	 gene	may	 be	 a	 transcriptional	 target	 of	 TAL1.	 Furthermore,	 two	
peaks	 were	 observed	 upstream	 of	 the	 miR-223	 transcription	 start	 site	
(Supplementary	 Figure	 1b).	 To	 confirm	 these	 findings,	 we	 performed	 TAL1	 ChIP-
quantitative	 PCR	 in	 JURKAT	 and	 CCRF-CEM	 cells	 using	 primers	 designed	 for	 the	
genomic	areas	covered	by	 the	 two	peaks	 in	 the	miR-223	 locus.	We	confirmed	that	
there	is	more	than	two-fold	enrichment,	as	compared	with	a	mock	ChIP	performed	
against	 fibrillarin,	 in	 the	 amplified	 area	 within	 3.5	 kb	 upstream	 of	 the	 miR-223	
transcription	 start	 site	 (Figure	 1g).	 These	 results	 indicate	 that	miR-223	 is	 a	 direct	
target	of	TAL1	in	T-ALL.	Interestingly,	TAL1	appears	to	bind	to	a	previously	described	
region	containing	a	conserved	proximal	genomic	element	with	possible	binding	sites	
for	the	transcription	factor	C/EBP.9	We	did	not	find	evidence	from	the	available	TAL1	
ChIP-seq	 data	 for	 direct	 binding	 of	 TAL1	 to	 the	 remaining	 microRNA	 genes,	
suggesting	that	miR-135a,	miR-330-3p	and	miR-545	are	indirectly	regulated	by	TAL1,	
at	least	in	the	T-ALL	cells	analyzed.	
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Figure	1:	 Identification	of	TAL1-regulated	microRNA	genes.	 (a)	Heatmap	of	differentially	expressed	
microRNAs	 upon	 TAL1	 overexpression.	MicroRNAs	were	 hierarchically	 clustered	 (rows,	microRNAs;	
columns,	experiments).	See	Supplementary	Table	2	for	fold-difference	values.	Levels	greater	than	or	
less	 than	 the	mean	are	 shown	 in	 shades	of	 red	or	blue,	 respectively.	 (b–f)	Quantitative	PCR	 (qPCR)	
validation	of	microRNA	expression	modulation	by	TAL1.	Relative	expression	of	hsa-miR-135a	(b),	hsa-
miR-223	(c),	hsa-miR-330-3p	(d),	hsa-miR-146b-5p	(e),	and	hsa-miR-545	(f)	normalized	to	SNORD38B	
in	 T-ALL	 cell	 lines	with	 overexpression	 (left)	 or	 knockdown	 of	 TAL1	 (right).	 The	 bars	 represent	 the	
mean±s.d.	 of	 three	 independent	 replicates.	 siNT—non-targeting	 siRNA	 (g)	 TAL1	 ChIP-qPCR	 in	 T-ALL	
cell	 lines.	 The	 occupancy	 by	 TAL1	 of	 the	 genomic	 regions	 9.2	 and	 3.5	 kb	 upstream	of	 the	miR-223	
transcription	 start	 site	 was	 analyzed	 by	 ChIP-qPCR	 in	 JURKAT	 and	 CCRF-CEM	 cells.	 The	 promoter	
region	 of	 LCP2	was	 used	 as	 positive	 control	 for	 TAL1	 binding,	 and	 a	 random	 intergenic	 region	was	
used	as	negative	control.	TAL1	binding	 is	expressed	as	 the	 fold	enrichment	 relative	 to	a	mock	ChIP	
performed	 against	 fibrillarin.	 The	 error	 bars	 represent	 the	 95%	 CI	 of	 the	 fold	 enrichment.	 The	
horizontal	line	denotes	the	fold	enrichment	detection	for	the	negative	control.	 	
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Interestingly,	 analysis	 of	 microRNA	 gene	 expression	 profiles	 in	 different	 T-ALL	
subsets8	 revealed	 that	 TAL/LMO	 primary	 samples	 (integrating	 Sil-Tal1+	 and	 LMO+	
cases,	which	frequently	express	high	TAL1	levels)	display	higher	levels	of	miR-223	(P	
=0.035)	and	tend	to	express	lower	levels	of	miR-146b-5p	(P=0.092)	than	other	T-ALL	
cases	(Supplementary	Figure	2).	In	line	with	these	observations,	miR-223	appears	to	
follow	the	same	pattern	of	expression	along	normal	human	thymocyte	development	
as	 TAL1,10	with	 high	 levels	 in	 CD34+	 T-cell	 precursors	 and	 sharp	 downregulation	 in	
more	 differentiated	 subsets	 (Supplementary	 Figure	 3a).	 A	 similar	 pattern	 was	
observed	 for	miR-135a	 (Supplementary	 Figure	 3b),	 in	 agreement	with	 the	 notion	
that	 TAL1	 positively	 regulates	 both	 genes.	 In	 contrast,	 miR-146b-5p	 is	 clearly	
upregulated	 in	 the	double-positive	 to	 single-positive	 transition	 and	 is	 amongst	 the	
most	upregulated	microRNAs	 in	mature,	single-positive	thymocytes.11	The	fact	that	
miR-146b-5p	 levels	associate	with	thymocyte	maturation	(Supplementary	Figure	4)	
is	in	agreement	with	a	model	whereby	TAL1	overexpression	during	leukemogenesis	
inhibits	miR-146b-5p	and	promotes	T-cell	developmental	arrest.		
Data	 from	 the	 analysis	 of	 congruent	 putative	 interactions	 between	 known	 TAL1-
regulated	protein-coding	genes	and	 the	 validated	microRNA	genes	are	 in	 line	with	
the	 notion	 that	 the	 latter	 could	 be	 part	 of	 downstream	 networks	 collaborating	 in	
TAL1-mediated	 leukemogenesis	 (Figure	 2).	 Indeed,	 most	 TAL1	 upregulated	 genes	
that	have	3’-UTRs	predicted	as	targets	for	the	TAL1-downregulated	miR-146b-5p	and	
miR-545	 have	 a	 known	 or	 putative	 oncogenic	 function	 (Figure	 2a).	 For	 example,	
CD53	 was	 shown	 to	 protect	 JURKAT	 cells	 from	 apoptosis,	 PDE3B	 appears	 to	 be	
involved	in	glucocorticoid	resistance	in	CEM	cells	and	ETS-1	participates	in	the	T-cell	
maturation	arrest	mediated	by	TLX	genes	 in	T-ALL	 (see	Supplementary	 Table	3	 for	
details	 and	 references).	 Interestingly,	 the	 T-ALL	 associated	 oncogene	 MYB	 was	
recently	 shown	to	be	a	direct	TAL1	 target	 forming	a	 feed-forward	 loop	 involved	 in	
the	TAL1-dependent	leukemogenic	program.4	Our	bioinformatics	analyses	now	raise	
the	 possibility	 that	 TAL1	 may	 reinforce	 MYB	 upregulation	 by	 inhibiting	 the	
expression	of	miR-	545.	Also	of	note,	three	of	the	four	genes	(KRT1,	Rapgef5,	JAZF1)	
with	 predicted	 3’-UTR	 seed	 sequences	 for	 both	 miR-146b-5p	 and	 miR-545	 are	
associated	with	 protumoral	 functions	 (Supplementary	 Table	 3).	 In	 sharp	 contrast,	
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the	TAL1-downregulated	genes	that	are	predicted	targets	for	miR-135a,	miR-223	and	
miR-330-3p	 display	 a	 clear	 abundance	 in	 (putative)	 tumor	 suppressors	 or	 in	 genes	
whose	 functions	 are	 compatible	 with	 anti-tumoral	 effects	 (Figure	 2b	 and	
Supplementary	Table	4).	This	is	evident,	for	instance,	in	the	case	of	the	four	genes	
potentially	 regulated	 by	 two	microRNAs,	 in	which	 only	 one	 has	 an	 oncogenic	 role	
(IGF1R)	and	three	likely	have	tumor-suppressive	functions	(SRGAP3,	TOX,	LRP12).	
	
Figure	 2.	 Potential	 participation	 of	 the	 newly	 identified	 TAL1	 microRNA	 target	 genes	 in	 TAL1-
mediated	 leukemogenic	 pathways.	 Cross-examination	 of	 congruent	 TAL1-regulated	 protein-coding	
and	 miRNA	 genes	 was	 performed	 as	 described	 in	 Supplementary	 Methods.	 (a)	 Downregulated	
miRNAs	 and	 their	 predicted	 target	 genes	 previously	 shown	 to	 be	 upregulated	 by	 TAL1.	 (b)	
Upregulated	 miRNAs	 and	 their	 predicted	 target	 genes	 previously	 shown	 to	 be	 downregulated	 by	
TAL1.	Genes	are	color-coded	according	to	their	reported	function	in	the	context	of	cancer,	as	detailed	
in	Supplementary	Tables	3	and	4.	‘Tumor	suppressor-like’:	bona	fide	or	putative	tumor	suppressors	or	
genes	 that	 have	 pro-apoptotic,	 anti-proliferative	 or	 pro-differentiating	 roles;	 ‘Oncogene-like’:	 bona	
fide	or	putative	oncogenes	or	genes	 that	have	anti-apoptotic	or	proliferative	 roles.	 ‘Undetermined’:	
genes	with	undetermined	function	or	whose	role	in	cancer	remains	unknown.	 	
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Circumscription	of	our	analysis	to	validate	target	genes	of	each	microRNA,	followed	
by	 gene	 set	 enrichment	 analysis	 showed	 an	 enrichment	 in	 biological	 processes	
related	 to	 inflammation	 (e.g.	 NF-kB	 signaling	 pathway	 and	 IL1/IL1R	 signaling	
pathway)	and	cancer	(e.g.	pathways	in	cancer),	as	detailed	in	Supplementary	Table	5	
and	 Supplementary	 Table	 6.	 Interestingly,	 the	 validated	 targets	 for	 the	 TAL1-
downregulated	gene	of	miR-	146-5p	 include	 IRAK1,	TRAF6	and	NFKB1	 (all	of	which	
are	involved	in	chronic	inflammation),	as	well	as	the	oncogene	KIT	 (Supplementary	
Table	5	and	Supplementary	Figure	5).	In	contrast,	miR-330-3p,	upregulated	by	TAL1,	
reportedly	 targets	 E2F1	 and	 CDC42,	 both	 of	 which	 are	 described	 to	 promote	
apoptosis	in	different	cell	types	including	Jurkat	cells.	MiR-223	is	a	myeloid-	specific	
microRNA	 essential	 for	 normal	 neutrophil	 maturation,	 and	 responsible	 for	
granulocyte	 differentiation	 and	 negative	 regulation	 of	 progenitor	 proliferation	 via	
MEF2C	downregulation.12	In	agreement,	miR-223	functions	as	a	tumor	suppressor	in	
acute	myeloid	leukemia,13	and	appears	to	be	repressed	in	chronic	myeloid	leukemia,	
allowing	 for	 the	 expression	 of	 MEF2C.14	 In	 contrast,	 miR-223	 is	 frequently	
overexpressed	in	T-ALL,	cooperating	with	NOTCH1	to	accelerate	the	onset	of	disease	
in	a	Notch-induced	 leukemia	mouse	model.	This	effect	was	proposed	to	be	due,	at	
least	 in	 part,	 to	 inhibition	 of	 FBXW7,	 a	 negative	 regulator	 of	 Notch	 signaling.8	
However,	FBXW7	targets	the	degradation	of	other	oncogenic	proteins,	such	as	c-Myc	
and	mTOR,	and	the	expression	of	miR-223	is	significantly	elevated	in	TAL1-positive	T-
ALL	cases	(Supplementary	Figure	2),	suggesting	that	the	oncogenic	function	of	this	
microRNA	 may	 extend	 beyond	 mere	 collaboration	 in	 Notch-induced	 leukemia.	
Moreover,	the	pro-leukemic	role	of	mir-223	may	be	also	achieved	by	downregulating	
targets	 such	 as	E2F1,	FOXO1,	RHOB	 or	EPB41L3,	which	have	been	 associated	with	
induction	of	apoptosis	and/or	have	 tumor-suppressive	 roles	 (Supplementary	 Table	
5).	 Interestingly,	 the	 intriguing	 possibility	 that	 miR-223	 may	 potentially	 act	
downstream	 of	 TAL1	 to	 negatively	 regulate	 MEF2C,	 recently	 identified	 as	 an	
oncogene	 in	T-ALL,15	would	be	 in	 line	with	 the	observations	 that	TAL1	and	MEF2C	
tend	 to	 segregate,	 defining	 two	 discrete	 T-ALL	 subsets.15 In	 summary,	 our	 studies	
identify	and	validate	for	the	first	time	a	small	set	of	TAL1-regulated	microRNA	genes	
whose	 role	 may	 be	 important	 in	 the	 context	 of	 hematopoiesis	 and	 T-cell	
leukemogenesis.	 	
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SUPPLEMENTARY	METHODS	
Transduction	of	T-ALL	cells	for	TAL1	overexpression	
T-ALL	cell	lines	were	transduced	with	VSVG-pseudotyped	bicistronic	lentivirus	driving	
the	 concomitant	 expression	 of	 TAL1	 and	 GFP	 or	with	 the	 control	mock	 virus.	 The	
resulting	 cell	 lines	 expressing	 TAL1	 or	 the	 empty	 vector	 were	 sorted	 for	 an	
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equivalent	GFP	expression.	The	viral	production	and	transduction	was	performed	as	
previously	described1.		
	
Transfection	of	T-ALL	cells	for	TAL1	knockdown	
Nucleofection	 of	 JURKAT	 and	 PF-382	 cells	 was	 performed	 using	 the	 Amaxa	
Nucleofector	 II	 (Lonza,	 Switzerland)	 according	 to	 the	 manufacturer’s	 instructions.	
Cells	 (2x	 106)	 were	 washed	 in	 RPMI-10	 medium	 and	 resuspended	 in	 100	 μl	 of	
solution	V	with	2	μM	of	a	mock	pool	of	small	interfering	RNAs	(siRNAs)	or	a	pool	of	
siRNAs	 against	 TAL1	 (Dharmacon,	 Lafayette,	 USA).	 JURKAT	 and	 PF-382	 cells	 were	
nucleofected	 using	 the	 X-001and	 O-017	 programs,	 respectively.	 After	 the	
nucleofection	the	cells	were	cultured	for	48h	in	RPMI-10	medium.		
	
RNA	extraction	and	microRNA	expression	assessment	by	RT-qPCR	
Total	RNA	was	extracted	using	TRIZOL	reagent	(Life	Technologies	Corporation,	Califor	
nia,	 USA)	 followed	 by	 further	 purification	 with	 commercially	 available	 kits	 that	
preserve	 the	 low	 molecular	 weight	 RNA	 species	 (miRVANA,	 Life	 Technologies	
Corporation,	 California,	 USA),	 following	 manufacturer’s	 instructions.	 cDNA	 was	
produced	 with	miRCURY	 LNA™	 Universal	 RT	 kit	 (Exiqon,	 Denmark)	 using	 amounts	
that	 range	 from	 100-200ng	 of	 total	 RNA.	 Real	 time	 PCR	 was	 performed	 with	
commercial	 available	 LNA-based	 primers	 for	 mature	 microRNA	 detection	 in	
SybrGreen	 (Exiqon,	 Denmark)	 quantitative	 PCR	 assays	 on	 the	 7500	 Real	 Time	 PCR	
system	(Life	Technologies	Corporation,	California,	USA).	Relative	 	expression	of	 the	
microRNAs	was	normalized	to	SNORD38B	expression	using	the	ddCt	method.		
	
microRNA	expression	analysis	
Gene	 expression	 analysis	 for	 372	 human	 miRNA	 genes	 was	 performed	 in	 3	
independent	 samples	 of	 P12	 mock	 transduced	 and	 P12	 transduced	 with	 a	 vector	
driving	the	expression	of	TAL1,	using	a	qRT-PCR	based	array	(microRNA	Ready-to-Use	
PCR,	 Human	 Panel	 I,	 V2.M,	 Exiqon).	 Total	 RNA	 was	 extracted,	 in	 3	 independent		
occasions,	from	P12-Empty	and	P12-TAL1	sorted	cells.	The	RNA	quality	was	assessed		
with	an	Agilent	2100	Bioanalyzer	(Agilent	Technologies,	California,	USA),	assuring	the		
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presence	 of	 low	molecular	 weight	 RNA	 species	 and	 RNA	 integrity.	 A	 cut-off	 cycle	
threshold	value	of	35	was	assigned	and	mean	expression	value	normalization2	used	
as	normalization	method.	The	p-value	was	calculated	using	a	two-tailed	Student's	t-
Test.	Fold	changes	relative	to	mock	transduced	cells	and	p-values	were	determined	
by	the	Comparative	Marker	Selection	suite3.	Cut-offs	for	statistical	significance	were	
a	p-value<0.05	and	a	fold	change>1.5.	
	
Heat	Map	Illustration	
Heat	 map	 illustration	 of	 differentially	 expressed	 microRNAs	 upon	 TAL1	
overexpression	 was	 generated	 with	 the	 GENE-E	 software	
(http://www.broadinstitute.org/cancer/software/GENE-E/).	 MicroRNAs	 were	
hierarchically	 clustered	 (rows,	miRNAs;	 columns,	 experiments).	 Relative	 expression	
levels	were	normalized	across	the	samples	as	described;	 levels	greater	than	or	 less	
than	 the	mean	 are	 shown	 in	 shades	 of	 red	 or	 blue,	 respectively.	 Confirmation	 of	
ChIP-seq	 enrichment	 by	 qPCR.	 Public	 available	 ChIP-seq	 (GEO	 accession	 number	
GSE29181)	 was	 analyzed	 with	 the	 Integrative	 Genomics	 Viewer	 (IGV)	 tool.	 To	
confirm	the	ChIP-seq	data	we	performed	ChIP	of	TAL1	in	JURKAT	and	CCRF-CEM	cells	
followed	 by	 qPCR	 for	 the	 selected	 genomic	 regions.	 ChIP	 was	 performed	 as		
described4,	using	the	following	antibodies:	TAL1	(Abcam),	10μg;	Fibrillarin	(Abcam),	
10μg	 (Abcam).	 The	 occupancy	 by	 TAL1	 of	 the	 genomic	 regions	 9.2kb	 and	 3.5kb	
upstream	miR-223	 TSS	 was	 analyzedby	 ChIP-qPCR	 in	 the	 cell	 lines.	 The	 promoter	
region	 of	 LCP25	 was	 used	 as	 a	 positive	 control	 for	 TAL1	 binding	 and	 a	 random	
intergenic	region	was	used	as	negative	control.	TAL1	binding	was	calculated	as	the	
fold	enrichment	relative	to	a	mock	ChIP	performed	against	Fibrillarin.		
	
Primers	used:	
LCP2-ChIP	Fwd:	AAGGCTGCTTTGGATCTTGAAA;		
LCP2-ChIP	Rev:	CCTCCAGCCTGGCTGCTA;		
chip223peak-3FWD:CCTGTTGAAGACACCAAGGGC;		
chip223	peak-3REV:TTCCCCAGTGCTGAGCCAAC;		
chip223peak-9FWD:	GCAGTGGCTATTCACAGGTGACC;		
chip223peak-9REV:	CACTCCCACTATTCACATCACACCTG;	
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Intergenic	region	ChIP-Fwd:	GGCTAATCCTCTATGGGAGTCTGTC;		
Intergenic	region	ChIP	Rev-CCAGGTGCTCAAGGTCAACATC	
	
miRNA	target	prediction	and	gene	set	enrichment	analysis		
Prediction	of	microRNA	putative	targets	was	performed	by	MirDIP	data	 integration	
portal6,	 with	 a	 minimum	 threshold	 of	 4	 different	 applications.	 MicroRNAs		
experimentally	 validated	 human	 targets	 were	 obtained	 from	 mirTARbase	 3.5,	
miRrecords	and	TarBase	6.0.	Target	genes	without	matching	Entrez	gene	identifiers	
in	NCBI	were	discarded.	Graphical	 representation	 and	analysis	 of	miRNA	and	 their	
cognate	 targets	 was	 done	 with	 Navigator	 software7.	 We	 compiled	 a	 list	 of	 high	
confidence	 TAL1	 positively	 or	 negatively	 regulated	 genes	 from	 publicly	 available	
data5,	 8.	 For	 cross-examination	 of	 congruent	 TAL1	 regulated	 protein-coding	 and	
miRNA	 genes,	 we	 intersected	 the	 predicted	 targets	 of	 TAL1	 downregulated	
microRNAs	 with	 the	 protein-coding	 gene	 targets	 previously	 demonstrated	 to	 be	
positively	regulated	by	TAL1,	and	vice	versa,	and	searched	for	common	hits	in	both	
lists.	For	biological	function	and	pathway	analysis	we	collected	T-lymphocyte	and	T-
ALL	 related	 gene	 sets	 from	 Ingenuity	 Pathway	 Analysis	 (IPA),	 and	 from	 the	
literature5,	 8,	 9.	 Additional	 gene	 sets	 were	 downloaded	 from	 version	 3.1	 of	 the	
Molecular	 Signature	 Database	 (MSigDB)	 at	 the	 Broad	 Institute	
(http://www.broad.mit.edu/gsea/msigdb);	 we	 used	 three	 categories	 of	 gene	 sets	
from	MSigDB:	(C2)	all	curated	gene	sets,	(C5)	GO	biological	processes	and	molecular	
functions,	and	(C6)	all	oncogenic	signatures	gene	sets.	Gene	set	enrichment	analysis	
was	 performed	 using	 Genomica	 software	 	 (http://genomica.weizmann.ac.il/).	 P-
values	were	determined	by	a	hypergeometric	test,	followed	by	a	false	discovery	rate	
correction	to	account	for	multiple	hypotheses	(FDR	<	0.05).		 	
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SUPPLEMENTARY	FIGURES	
	
Supplementary	Figure	1:	Evidence	for	direct	binding	of	TAL1	to	miR-146b	and	miR-223	loci	
Analysis	 of	 publicly	 available	 ChIP-seq	 data	 for	 JURKAT,	 CCRF-CEM	 and	 two	 primary	 T-ALL	 samples	
(GEO	 accession	 number	 GSE29181).	 Representative	 Integrative	 Genomics	 Viewer	 (IGV)	 gene	 tracks	
show	TAL1	binding	peaks	detected	in	the	genomic	area	upstream	of	the	miR-146b	(a)	and	miR-223	(b)	
TSS,	 whose	 direction	 of	 transcription	 is	 indicated	 by	 an	 arrow.	 	 The	 arrow	 heads	 indicate	 regions	
bound	by	TAL1.	The	top	horizontal	bars	indicate	the	scale	in	kilobases	(kb).	The	black	double	arrows	
indicate	the	genomic	areas	to	which	primers	were	designed	to	validate	TAL1	binding	by	ChIP-qPCR.	 	
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Supplementary	 Figure	 2.	 Analysis	 of	microRNA	 gene	 expression	 levels	 in	 different	 T-ALL	 subsets.	
TAL/LMO	primary	samples	 (integrating	Sil-Tal1+	and	LMO+)	display	higher	 levels	of	miR-223	 (a)	and	
lower	 levels	 of	miR-146b-5p	 (b)	 than	 other	 T-ALL	 cases.	 Data	 was	 collected	 from8.	 P-values	 were	
calculated	using	a	two-tailed	Student's	t-Test.	
	
	
	
							 	
	
Supplementary	Figure	3.	Analysis	of	microRNA	gene	expression	levels	in	normal	human	thymocyte	
subsets.	miR-223	(a)	and	miR-135a	(b)	are	expressed	in	immature	CD34+	cells	and	their	expression	is	
dramatically	downregulated	in	more	mature	CD4+CD8+	thymocytes.	Data	was	collected	from8.	 	
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Supplementary	 Figure	 4.	 Analysis	 of	 miR-146b-5p	 gene	 expression	 levels	 in	 normal	 human	
thymocyte	 subsets.	 miR-146b-5p	 expression	 is	 clearly	 upregulated	 in	 mature	 SP	 (CD4+	 or	 CD8+)	
thymocytes.	Data	was	collected	from8.	
													 	
Supplementary	 Figure	 5.	 Association	 of	 miR-146b-5p	 target	 genes	 with	 cancer	 pathways.	
Highlighted	 are	 experimentally	 validated	 target	 genes	 of	miR-146b-5p	 (see	 Supplementary	 Table	 5)	
within	a	zoomed	representation	of	KEGG	Pathways	in	Cancer.	 	
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SUPPLEMENTARY	TABLES	
Detector	Name	
Ct	
Empty	
1	
Ct	
Empty	
2	
Ct	
Empty	
3	
Ct	
Tal1	
1	
Ct	
Tal1	
2	
Ct	
Tal1	
3	
ddCT	 FC	 p-value	
hsa-miR-135a	 3.82	 3.45	 4.09	 0.20	 0.26	 -0.16	 -3.69	 12.90	 0.000082	
hsa-miR-223	 -6.62	 -6.54	 -6.54	 -7.33	 -7.26	 -7.04	 -0.64	 1.56	 0.002056	
hsa-miR-146b-5p	 3.26	 3.64	 3.45	 4.62	 4.43	 4.11	 0.94	 0.52	 0.007100	
hsa-miR-503	 -0.51	 -0.66	 -0.67	 -1.18	 -0.99	 -0.93	 -0.42	 1.34	 0.010567	
hsa-miR-652	 -2.30	 -2.51	 -2.45	 -2.78	 -2.74	 -3.01	 -0.42	 1.34	 0.016594	
hsa-miR-545	 3.65	 3.97	 4.11	 4.52	 4.37	 4.67	 0.61	 0.66	 0.019659	
hsa-miR-148a	 -3.36	 -3.42	 -3.37	 -3.21	 -3.03	 -2.89	 0.34	 0.79	 0.021373	
hsa-miR-20b	 -2.59	 -2.67	 -2.62	 -2.78	 -2.94	 -2.78	 -0.21	 1.15	 0.021580	
hsa-miR-574-3p	 6.25	 6.75	 7.19	 5.75	 5.87	 5.24	 -1.11	 2.16	 0.028828	
hsa-miR-20a	 -8.16	 -8.27	 -8.09	 -8.02	 -7.82	 -7.90	 0.26	 0.84	 0.029180	
hsa-miR-491-5p	 2.63	 2.33	 2.82	 3.16	 3.53	 3.03	 0.64	 0.64	 0.034590	
hsa-miR-375	 3.09	 3.34	 3.25	 5.56	 3.94	 6.06	 1.96	 0.26	 0.038284	
hsa-miR-150	 -2.63	 -2.48	 -2.64	 -3.14	 -2.94	 -2.76	 -0.37	 1.29	 0.038396	
hsa-miR-330-3p	 2.69	 3.11	 2.41	 1.97	 2.20	 2.12	 -0.64	 1.55	 0.040909	
hsa-miR-181a	 -7.31	 -7.02	 -7.38	 -7.71	 -7.58	 -7.52	 -0.37	 1.29	 0.042010	
hsa-miR-146a	 -1.19	 -0.90	 -1.12	 -1.62	 -1.30	 -1.44	 -0.38	 1.30	 0.042392	
hsa-miR-501-5p	 1.52	 1.40	 1.49	 1.61	 1.91	 1.69	 0.27	 0.83	 0.049712	
hsa-miR-29b-2*	 0.13	 0.51	 0.18	 -0.28	 0.04	 -0.18	 -0.41	 1.33	 0.054029	
hsa-miR-153	 -4.17	 -4.06	 -4.08	 -4.25	 -4.20	 -4.18	 -0.11	 1.08	 0.055977	
hsa-miR-219-5p	 0.16	 0.02	 -0.29	 0.20	 0.54	 0.43	 0.43	 0.74	 0.061502	
hsa-miR-30d	 -1.17	 -0.85	 -1.09	 -0.33	 -0.79	 0.09	 0.70	 0.62	 0.062895	
hsa-miR-193b	 -0.59	 0.48	 0.62	 1.14	 1.03	 1.78	 1.14	 0.45	 0.063713	
hsa-miR-107	 -5.49	 -5.41	 -5.38	 -5.31	 -5.06	 -5.27	 0.21	 0.86	 0.063745	
hsa-miR-425	 -2.99	 -3.28	 -2.81	 -3.51	 -3.64	 -3.27	 -0.45	 1.36	 0.064679	
hsa-miR-130b	 -1.28	 -0.99	 -1.34	 -0.98	 -0.67	 -0.89	 0.35	 0.78	 0.065254	
hsa-miR-27b	 -1.65	 -1.46	 -1.73	 -1.37	 -1.47	 -1.30	 0.23	 0.85	 0.066819	
hsa-miR-484	 -3.67	 -3.51	 -3.66	 -3.53	 -3.28	 -3.39	 0.22	 0.86	 0.067794	
hsa-miR-514	 6.25	 6.21	 6.11	 7.27	 6.42	 6.75	 0.62	 0.65	 0.069056	
hsa-miR-590-5p	 -2.13	 -2.26	 -1.92	 -1.92	 -1.81	 -1.81	 0.26	 0.84	 0.069945	
hsa-miR-500	 1.50	 2.02	 1.30	 0.77	 1.19	 1.04	 -0.61	 1.52	 0.070630	
hsa-miR-425*	 -0.82	 -0.53	 -0.69	 -0.43	 -0.35	 -0.54	 0.24	 0.85	 0.073797	
hsa-miR-766	 -2.47	 -2.41	 -2.43	 -2.25	 -2.16	 -2.40	 0.17	 0.89	 0.074513	
hsa-miR-151-5p	 0.19	 -0.07	 0.33	 -0.70	 -0.18	 -0.16	 -0.50	 1.41	 0.078148	
hsa-miR-509-3p	 5.82	 7.44	 7.01	 4.58	 5.39	 5.94	 -1.45	 2.73	 0.081093	
hsa-miR-362-5p	 4.26	 3.81	 4.09	 3.74	 3.67	 3.80	 -0.32	 1.25	 0.082577	
hsa-miR-142-3p	 -9.38	 -9.53	 -9.58	 -9.64	 10.09	 -9.75	 -0.33	 1.26	 0.087948	
hsa-miR-92b	 -1.62	 -1.93	 -1.75	 -0.91	 -1.50	 -1.50	 0.46	 0.73	 0.103038	
hsa-miR-328	 0.66	 1.11	 0.96	 0.51	 0.58	 0.73	 -0.30	 1.23	 0.111700	
hsa-miR-450a	 -0.33	 0.06	 0.01	 -0.24	 -0.39	 -0.50	 -0.29	 1.22	 0.113072	
hsa-miR-589	 2.75	 3.00	 3.17	 2.83	 2.69	 2.46	 -0.32	 1.24	 0.125328	
hsa-miR-101	 -2.58	 -2.42	 -2.54	 -2.31	 -2.49	 -2.34	 0.14	 0.91	 0.129458	
hsa-miR-423-5p	 -2.29	 -2.33	 -2.52	 -2.25	 -1.88	 -2.22	 0.26	 0.83	 0.129647	
hsa-miR-199b-5p	 3.94	 3.17	 3.69	 3.28	 2.82	 3.21	 -0.49	 1.41	 0.139039	
hsa-miR-760	 4.42	 4.29	 3.95	 5.25	 6.46	 4.38	 1.14	 0.45	 0.139471	
hsa-miR-22*	 3.54	 3.25	 3.39	 3.58	 3.68	 3.48	 0.19	 0.88	 0.139646	
hsa-miR-26a-2*	 5.99	 5.13	 5.39	 6.26	 6.54	 5.69	 0.66	 0.63	 0.139965	
hsa-miR-361-5p	 5.62	 5.89	 6.11	 6.04	 6.99	 6.31	 0.57	 0.67	 0.142388	
hsa-miR-424	 -4.27	 -4.34	 -4.08	 -4.51	 -4.32	 -4.38	 -0.17	 1.13	 0.149796	
hsa-miR-194	 2.48	 2.27	 2.54	 1.27	 1.71	 2.44	 -0.63	 1.54	 0.150582	
hsa-miR-98	 6.45	 7.21	 6.60	 5.71	 6.56	 6.24	 -0.59	 1.50	 0.158025	
hsa-miR-18b	 -4.71	 -5.05	 -4.97	 -4.56	 -4.73	 -4.81	 0.21	 0.86	 0.170112	
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hsa-miR-188-5p	 3.81	 3.39	 3.52	 3.83	 3.87	 4.98	 0.66	 0.63	 0.171733	
hsa-let-7g	 -2.45	 -2.09	 -2.04	 -2.01	 -1.93	 -1.99	 0.21	 0.86	 0.176532	
hsa-miR-151-3p	 1.10	 1.11	 2.07	 1.67	 2.79	 2.07	 0.75	 0.59	 0.177609	
hsa-miR-196b	 0.22	 0.40	 0.24	 0.30	 0.48	 0.68	 0.20	 0.87	 0.179888	
hsa-miR-140-3p	 -1.74	 -1.58	 -1.96	 -2.27	 -2.04	 -1.81	 -0.28	 1.21	 0.180941	
hsa-miR-15b	 -5.79	 -6.03	 -6.01	 -6.05	 -6.58	 -6.09	 -0.30	 1.23	 0.184828	
hsa-miR-128	 -4.52	 -4.51	 -4.24	 -4.28	 -4.14	 -4.34	 0.17	 0.89	 0.185386	
hsa-miR-374b*	 5.79	 5.30	 4.54	 5.65	 7.51	 5.79	 1.11	 0.46	 0.187952	
hsa-miR-642	 4.77	 4.58	 5.33	 5.16	 5.17	 5.58	 0.41	 0.75	 0.193765	
hsa-miR-365	 -0.16	 0.07	 0.16	 0.20	 0.10	 0.80	 0.34	 0.79	 0.221041	
hsa-miR-502-5p	 -1.78	 -2.12	 -2.26	 -2.40	 -2.06	 -3.03	 -0.45	 1.36	 0.232702	
hsa-miR-181d	 1.65	 1.26	 1.23	 1.56	 1.50	 1.75	 0.22	 0.86	 0.233556	
hsa-miR-570	 3.36	 2.13	 2.38	 2.27	 2.00	 1.99	 -0.54	 1.45	 0.235832	
hsa-miR-196a	 0.31	 0.43	 0.42	 0.20	 0.42	 0.20	 -0.11	 1.08	 0.256236	
hsa-miR-20b*	 0.34	 0.63	 0.47	 0.47	 0.82	 0.66	 0.17	 0.89	 0.267089	
hsa-miR-103	 -6.97	 -6.79	 -6.91	 -7.03	 -6.90	 -7.02	 -0.09	 1.06	 0.268748	
hsa-miR-30c	 -5.00	 -4.78	 -5.32	 -5.23	 -5.31	 -5.18	 -0.21	 1.15	 0.268926	
hsa-miR-200c	 3.54	 3.08	 3.57	 3.34	 3.96	 3.86	 0.32	 0.80	 0.270059	
hsa-miR-23a	 -0.85	 -0.72	 -0.43	 -1.16	 -1.04	 -0.60	 -0.27	 1.20	 0.271755	
hsa-miR-199a-3p	 4.39	 3.74	 3.47	 4.54	 4.02	 4.22	 0.39	 0.76	 0.277362	
hsa-miR-126	 1.40	 1.56	 1.37	 1.05	 1.43	 1.36	 -0.16	 1.12	 0.277853	
hsa-miR-9	 0.27	 0.89	 0.94	 -0.10	 0.80	 0.10	 -0.44	 1.35	 0.278480	
hsa-miR-141	 5.00	 5.06	 4.50	 4.82	 4.47	 4.47	 -0.27	 1.20	 0.279235	
hsa-miR-30c-2*	 4.03	 2.62	 2.59	 4.83	 3.53	 3.35	 0.82	 0.57	 0.283335	
hsa-miR-222	 -0.48	 -1.39	 -1.35	 -1.58	 -1.35	 -1.42	 -0.38	 1.30	 0.284723	
hsa-miR-181b	 -4.43	 -4.91	 -5.07	 -4.99	 -4.92	 -5.31	 -0.27	 1.21	 0.296664	
hsa-miR-193a-5p	 6.31	 5.78	 6.32	 6.31	 6.62	 6.22	 0.25	 0.84	 0.308875	
hsa-miR-340	 1.61	 1.80	 1.26	 1.03	 1.14	 1.66	 -0.28	 1.21	 0.326468	
hsa-miR-138	 3.09	 2.33	 2.81	 3.01	 3.66	 2.71	 0.39	 0.76	 0.338066	
hsa-let-7f	 -2.25	 -2.25	 -1.96	 -2.16	 -1.83	 -2.05	 0.14	 0.91	 0.352603	
hsa-miR-193a-3p	 5.85	 7.30	 7.10	 6.92	 5.71	 5.71	 -0.63	 1.55	 0.354666	
hsa-miR-18a	 -3.85	 -4.01	 -4.15	 -3.81	 -3.76	 -4.05	 0.13	 0.91	 0.355906	
hsa-miR-629	 1.05	 1.06	 0.62	 0.39	 0.58	 1.02	 -0.25	 1.19	 0.359113	
hsa-miR-296-5p	 6.17	 4.98	 7.32	 6.35	 4.62	 4.81	 -0.90	 1.86	 0.359666	
hsa-miR-132	 0.13	 0.19	 0.32	 0.18	 0.28	 0.76	 0.19	 0.88	 0.360467	
hsa-miR-182	 -2.53	 -2.32	 -2.34	 -2.63	 -2.48	 -2.37	 -0.10	 1.07	 0.370423	
hsa-miR-602	 4.03	 5.35	 4.03	 3.70	 3.51	 4.57	 -0.54	 1.46	 0.377500	
hsa-miR-96	 -2.17	 -2.02	 -2.19	 -2.16	 -1.92	 -2.04	 0.09	 0.94	 0.387327	
hsa-miR-215	 1.65	 1.48	 1.88	 1.65	 1.39	 1.56	 -0.14	 1.10	 0.389938	
hsa-miR-23b	 -0.83	 -0.58	 -0.58	 -0.73	 -0.33	 -0.52	 0.13	 0.91	 0.391212	
hsa-miR-625*	 0.18	 -0.33	 -0.17	 -0.42	 0.69	 0.47	 0.35	 0.78	 0.398829	
hsa-miR-374a	 0.29	 0.26	 -0.30	 0.32	 0.39	 0.11	 0.19	 0.88	 0.416088	
hsa-miR-26a	 -4.99	 -4.63	 -4.66	 -4.67	 -4.83	 -4.15	 0.21	 0.86	 0.417115	
hsa-miR-19a	 -3.73	 -3.91	 -3.89	 -3.94	 -4.43	 -3.73	 -0.19	 1.14	 0.418386	
hsa-miR-361-3p	 1.07	 0.97	 0.92	 1.01	 0.83	 0.94	 -0.06	 1.04	 0.418523	
hsa-miR-622	 6.03	 4.99	 5.29	 6.78	 6.14	 5.00	 0.53	 0.69	 0.429399	
hsa-miR-550	 3.09	 3.40	 3.58	 3.09	 2.66	 3.56	 -0.26	 1.19	 0.434541	
hsa-miR-31	 2.54	 1.31	 2.01	 2.66	 2.17	 2.06	 0.35	 0.79	 0.438209	
hsa-miR-572	 -0.17	 0.01	 -0.23	 0.05	 -0.39	 0.99	 0.35	 0.78	 0.445683	
hsa-miR-532-5p	 1.28	 0.50	 0.02	 0.25	 0.54	 -0.01	 -0.34	 1.26	 0.448130	
hsa-miR-324-3p	 -2.27	 -2.22	 -2.16	 -2.33	 -2.30	 -2.17	 -0.05	 1.04	 0.450359	
hsa-miR-30e	 -1.97	 -1.35	 -1.32	 -1.74	 -1.16	 -0.95	 0.26	 0.83	 0.452450	
hsa-miR-106a	 -7.88	 -7.87	 -7.88	 -7.93	 -7.84	 -7.93	 -0.03	 1.02	 0.453527	
hsa-let-7e	 5.03	 5.35	 5.14	 5.14	 5.28	 5.40	 0.10	 0.93	 0.464845	
hsa-miR-663	 2.74	 1.94	 1.73	 2.67	 2.10	 2.47	 0.28	 0.83	 0.469921	
hsa-miR-671-5p	 1.33	 1.28	 0.88	 1.27	 1.55	 1.11	 0.15	 0.90	 0.470775	
hsa-miR-221	 -2.52	 -2.48	 -1.95	 -2.71	 -2.37	 -2.38	 -0.17	 1.13	 0.475720	
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hsa-miR-139-5p	 4.08	 4.42	 4.49	 5.13	 4.18	 4.40	 0.24	 0.84	 0.481149	
hsa-miR-93	 -7.09	 -6.78	 -6.95	 -7.14	 -6.93	 -7.01	 -0.08	 1.06	 0.481216	
hsa-miR-665	 2.37	 1.71	 1.02	 2.25	 0.26	 0.96	 -0.54	 1.46	 0.483505	
hsa-let-7d	 3.47	 5.99	 4.19	 3.85	 4.01	 4.07	 -0.57	 1.49	 0.487519	
hsa-miR-200a	 5.96	 7.12	 5.21	 6.12	 6.66	 6.84	 0.45	 0.73	 0.497809	
hsa-let-7a	 -0.89	 -2.12	 -2.08	 -2.04	 -1.84	 -2.14	 -0.31	 1.24	 0.500801	
hsa-miR-30e*	 -0.62	 -1.31	 -0.78	 -0.78	 -0.56	 -0.86	 0.17	 0.89	 0.502214	
hsa-miR-301b	 -1.14	 -0.56	 -0.68	 -1.31	 -1.07	 -0.60	 -0.20	 1.15	 0.505207	
hsa-let-7d*	 1.33	 1.28	 1.09	 1.30	 1.15	 1.03	 -0.08	 1.05	 0.513348	
hsa-miR-345	 1.17	 0.89	 1.86	 0.96	 1.17	 1.16	 -0.21	 1.16	 0.520043	
hsa-miR-197	 -2.46	 -2.37	 -2.53	 -2.67	 -2.45	 -2.43	 -0.06	 1.05	 0.525333	
hsa-miR-195	 2.83	 2.97	 5.29	 3.29	 3.17	 3.00	 -0.54	 1.46	 0.535421	
hsa-miR-301a	 -3.82	 -3.86	 -3.88	 -4.03	 -3.65	 -3.62	 0.09	 0.94	 0.542762	
hsa-miR-28-5p	 -0.65	 -0.02	 -0.06	 -0.44	 0.15	 0.12	 0.19	 0.88	 0.544032	
hsa-miR-660	 1.28	 1.21	 0.89	 2.56	 1.14	 0.78	 0.37	 0.78	 0.546601	
hsa-miR-145	 2.45	 2.64	 2.35	 2.55	 2.41	 2.74	 0.08	 0.94	 0.550921	
hsa-miR-16	 -6.98	 -6.93	 -6.87	 -6.18	 -6.94	 -7.11	 0.18	 0.88	 0.556475	
hsa-miR-363*	 3.61	 4.63	 4.68	 4.46	 3.92	 3.76	 -0.26	 1.20	 0.557152	
hsa-miR-30b*	 1.88	 1.31	 1.83	 2.07	 1.18	 1.09	 -0.23	 1.17	 0.564083	
hsa-miR-548b-3p	 6.17	 5.93	 5.12	 6.23	 5.30	 6.66	 0.32	 0.80	 0.566582	
hsa-miR-615-3p	 3.87	 4.56	 3.85	 4.25	 3.89	 4.79	 0.21	 0.86	 0.573312	
hsa-miR-21*	 2.80	 2.45	 2.86	 2.81	 2.50	 2.52	 -0.09	 1.07	 0.590173	
hsa-miR-106b	 -3.21	 -3.50	 -3.44	 -2.82	 -3.49	 -3.46	 0.13	 0.91	 0.609844	
hsa-miR-34c-3p	 2.27	 2.89	 2.61	 2.12	 3.17	 1.69	 -0.26	 1.20	 0.612025	
hsa-miR-29a	 -0.79	 -1.21	 -1.40	 -1.36	 -1.08	 -1.29	 -0.11	 1.08	 0.612360	
hsa-miR-190	 3.18	 3.05	 3.27	 4.06	 2.92	 3.11	 0.19	 0.88	 0.620201	
hsa-miR-505	 0.46	 0.32	 -0.03	 0.44	 0.44	 0.15	 0.09	 0.94	 0.621448	
hsa-miR-181c	 0.68	 0.61	 1.18	 0.79	 1.06	 0.92	 0.10	 0.93	 0.622658	
hsa-miR-155	 -2.32	 -1.99	 -2.10	 -2.24	 -2.00	 -1.96	 0.07	 0.95	 0.623293	
hsa-miR-216b	 5.39	 5.15	 5.09	 5.38	 5.46	 4.08	 -0.24	 1.18	 0.629242	
hsa-miR-346	 3.84	 3.32	 4.04	 3.56	 3.72	 4.47	 0.18	 0.88	 0.637894	
hsa-miR-7	 0.51	 0.05	 -0.41	 -0.01	 0.59	 0.07	 0.17	 0.89	 0.639984	
hsa-miR-27a	 -1.85	 -1.81	 -1.67	 -1.77	 -1.86	 -1.78	 -0.03	 1.02	 0.644751	
hsa-miR-148b	 -3.14	 -2.85	 -2.83	 -2.93	 -3.12	 -2.95	 -0.06	 1.04	 0.649274	
hsa-miR-22	 1.51	 1.72	 1.38	 1.72	 1.95	 1.26	 0.11	 0.93	 0.657996	
hsa-miR-95	 1.43	 1.92	 1.19	 1.44	 2.73	 1.13	 0.25	 0.84	 0.662929	
hsa-miR-191	 -3.90	 -4.07	 -4.12	 -4.14	 -3.91	 -4.20	 -0.05	 1.04	 0.672211	
hsa-miR-140-5p	 -0.77	 -1.01	 -0.92	 -1.16	 -0.84	 -0.87	 -0.06	 1.04	 0.675227	
hsa-miR-181a*	 -0.41	 -0.45	 -0.50	 -0.03	 -0.64	 -1.08	 -0.13	 1.09	 0.692030	
hsa-miR-185	 -2.27	 -2.44	 -2.56	 -2.48	 -2.35	 -2.31	 0.04	 0.97	 0.693710	
hsa-miR-720	 -5.57	 -5.08	 -5.08	 -5.76	 -5.27	 -5.03	 -0.11	 1.08	 0.700137	
hsa-miR-33a	 -3.96	 -3.47	 -3.62	 -4.05	 -3.94	 -3.37	 -0.10	 1.07	 0.705818	
hsa-miR-210	 -5.12	 -4.52	 -4.56	 -4.87	 -4.99	 -3.87	 0.15	 0.90	 0.723296	
hsa-miR-454	 -0.47	 -0.44	 -0.74	 -0.65	 -0.63	 -0.50	 -0.04	 1.03	 0.725827	
hsa-miR-26b	 -2.50	 -2.58	 -2.55	 -2.47	 -2.64	 -2.45	 0.02	 0.98	 0.726570	
hsa-miR-576-3p	 4.66	 4.10	 4.34	 5.64	 3.39	 4.84	 0.25	 0.84	 0.727678	
hsa-let-7i	 2.96	 2.92	 2.80	 2.54	 3.28	 2.60	 -0.09	 1.06	 0.728789	
hsa-miR-192	 0.38	 0.78	 0.32	 0.25	 0.51	 0.54	 -0.06	 1.04	 0.742232	
hsa-miR-32	 -4.25	 -4.22	 -4.08	 -4.26	 -4.15	 -4.07	 0.03	 0.98	 0.742343	
hsa-miR-25	 -4.37	 -4.59	 -4.63	 -4.69	 -4.39	 -4.37	 0.05	 0.97	 0.743510	
hsa-let-7c	 2.30	 3.07	 3.35	 2.69	 4.12	 2.53	 0.21	 0.87	 0.747065	
hsa-miR-18a*	 -1.20	 -1.54	 -1.64	 -1.46	 -1.46	 -1.60	 -0.05	 1.03	 0.753884	
hsa-miR-338-3p	 4.82	 3.71	 5.09	 4.45	 4.45	 5.18	 0.15	 0.90	 0.766918	
hsa-miR-627	 3.40	 3.98	 4.07	 4.11	 3.43	 4.19	 0.10	 0.93	 0.775678	
hsa-miR-17	 -3.63	 -4.22	 -4.11	 -3.49	 -4.33	 -3.86	 0.09	 0.94	 0.778927	
hsa-miR-199a-5p	 6.86	 6.48	 6.27	 6.85	 5.21	 7.02	 -0.18	 1.13	 0.782708	
hsa-miR-744	 1.37	 1.01	 0.67	 1.36	 0.91	 0.97	 0.07	 0.95	 0.800982	
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hsa-miR-542-5p	 1.42	 1.43	 2.02	 1.58	 1.68	 1.45	 -0.05	 1.04	 0.819452	
hsa-miR-421	 0.45	 -0.26	 0.11	 -0.03	 0.17	 0.00	 -0.05	 1.04	 0.820257	
hsa-miR-92a	 -7.53	 -7.22	 -7.70	 -7.45	 -7.60	 -7.50	 -0.03	 1.02	 0.827535	
hsa-miR-934	 5.67	 5.48	 5.09	 5.34	 5.28	 5.77	 0.05	 0.96	 0.833448	
hsa-miR-149	 3.81	 4.58	 3.85	 4.08	 4.44	 3.92	 0.06	 0.96	 0.836850	
hsa-miR-33b	 0.79	 0.65	 2.13	 1.97	 1.11	 0.87	 0.13	 0.92	 0.836993	
hsa-miR-9*	 4.15	 3.26	 4.43	 3.64	 4.24	 4.21	 0.09	 0.94	 0.840513	
hsa-miR-940	 -0.47	 -0.53	 -0.64	 0.10	 -0.94	 -0.60	 0.07	 0.95	 0.841596	
hsa-miR-373*	 5.31	 4.42	 3.84	 5.13	 4.13	 3.96	 -0.11	 1.08	 0.848090	
hsa-miR-877	 1.52	 0.67	 0.70	 0.96	 0.86	 0.91	 -0.06	 1.04	 0.852306	
hsa-miR-142-5p	 -5.19	 -5.34	 -4.52	 -5.05	 -4.96	 -5.19	 -0.05	 1.04	 0.858633	
hsa-miR-1979	 -7.68	 -8.70	 -8.31	 -7.81	 -8.13	 -9.02	 -0.09	 1.06	 0.859521	
hsa-miR-21	 -5.53	 -4.41	 -4.82	 -5.43	 -4.11	 -4.96	 0.09	 0.94	 0.870639	
hsa-miR-885-5p	 4.40	 4.01	 3.89	 3.57	 4.62	 3.93	 -0.06	 1.04	 0.873436	
hsa-miR-431	 4.51	 3.70	 3.97	 4.50	 4.35	 3.52	 0.06	 0.96	 0.880718	
hsa-let-7b	 0.30	 0.52	 0.06	 0.15	 0.67	 -0.04	 -0.04	 1.03	 0.886549	
hsa-miR-339-5p	 0.70	 0.55	 0.68	 0.61	 0.58	 0.71	 -0.01	 1.01	 0.890510	
hsa-miR-326	 2.80	 2.21	 3.45	 3.32	 2.50	 2.46	 -0.06	 1.04	 0.903217	
hsa-miR-374b	 -1.66	 -1.59	 -2.34	 -1.81	 -1.91	 -1.96	 -0.03	 1.02	 0.909933	
hsa-miR-331-3p	 -2.90	 -2.89	 -3.02	 -3.01	 -2.98	 -2.84	 -0.01	 1.01	 0.910861	
hsa-miR-320a	 -5.47	 -5.41	 -5.42	 -5.52	 -5.59	 -5.14	 0.02	 0.99	 0.911347	
hsa-miR-324-5p	 -2.77	 -2.58	 -2.56	 -2.82	 -2.55	 -2.50	 0.01	 0.99	 0.919008	
hsa-miR-92a-1*	 -0.63	 -0.48	 -0.48	 -0.77	 -0.56	 -0.30	 -0.01	 1.01	 0.929499	
hsa-miR-143	 1.57	 2.51	 2.31	 1.87	 1.96	 2.66	 0.04	 0.98	 0.930560	
hsa-miR-183	 -0.41	 0.50	 0.40	 0.79	 -0.41	 0.00	 -0.04	 1.03	 0.938704	
hsa-miR-363	 -2.80	 -2.69	 -3.64	 -2.51	 -3.44	 -3.29	 -0.03	 1.02	 0.940303	
hsa-miR-31*	 3.76	 4.15	 5.13	 4.48	 4.65	 3.80	 -0.04	 1.02	 0.945267	
hsa-miR-29c	 -4.66	 -4.69	 -3.97	 -4.34	 -4.50	 -4.53	 -0.02	 1.01	 0.952637	
hsa-miR-126*	 3.84	 5.48	 4.67	 4.53	 4.18	 5.19	 -0.03	 1.02	 0.955280	
hsa-miR-342-3p	 -3.58	 -3.66	 -3.58	 -3.93	 -3.33	 -3.59	 -0.01	 1.01	 0.956477	
hsa-miR-378	 -1.75	 -2.44	 -2.57	 -2.31	 -2.06	 -2.43	 -0.01	 1.01	 0.963598	
hsa-miR-30b	 -5.05	 -4.74	 -4.84	 -5.05	 -4.80	 -4.80	 -0.01	 1.00	 0.963711	
hsa-miR-15a	 -7.02	 -7.21	 -7.13	 -7.16	 -7.07	 -7.14	 0.00	 1.00	 0.971982	
hsa-miR-497	 3.47	 3.54	 3.21	 3.31	 3.15	 3.77	 0.00	 1.00	 0.984350	
hsa-miR-29b	 -3.24	 -2.97	 -2.94	 -2.96	 -3.01	 -3.18	 0.00	 1.00	 0.984619	
hsa-miR-19b	 -8.39	 -8.29	 -8.41	 -8.49	 -8.39	 -8.21	 0.00	 1.00	 0.991189	
hsa-miR-24	 -1.72	 -1.59	 -1.34	 -1.87	 -1.37	 -1.42	 0.00	 1.00	 0.992020	
hsa-miR-423-3p	 -4.54	 -4.40	 -4.31	 -4.51	 -4.48	 -4.26	 0.00	 1.00	 0.992399	
hsa-miR-130a	 -0.31	 -0.39	 -0.19	 -0.22	 -0.37	 -0.31	 0.00	 1.00	 0.994561	
	
Supplementary	Table	1:	microRNA	gene	expression	analysis.	Columns	B-G	present	the	normalized	CT	
values	 for	 each	 detected	microRNA	 in	 the	 samples	 screened.	Normalization	was	 performed	 by	 the	
mean	expression	value	normalization	method.	P-values	were	calculated	using	two-tailed	Student's	t-
Test.	 	
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Rank	 Up	in	 Feature	 score	 P-value	 fold	change	
Empty	
Mean	
Empty	
Std	
TAL1	
Mean	
TAL1	
Std	
1	 TAL1	 hsa-mir-135a	 -5.147	 0.009	 12.796	 0.074	 0.016	 0.941	 0.152	
2	 TAL1	 hsa-mir-223	 -2.974	 0.022	 1.565	 94.941	 3.038	 148.59	 14.999	
9	 TAL1	 hsa-mir-330-3p	 -1.475	 0.042	 1.528	 0.153	 0.036	 0.234	 0.019	
13	 TAL1	 hsa-mir-574-3p	 -1.34	 0.041	 2.121	 0.01	 0.003	 0.021	 0.005	
15	 Empty	 hsa-mir-491-5p	 1.282	 0.046	 1.561	 0.167	 0.029	 0.107	 0.018	
10	 Empty	 hsa-mir-545	 1.475	 0.054	 1.533	 0.067	 0.001	 0.044	 0.005	
4	 Empty	 hsa-mir-375	 1.993	 0.032	 3.17	 0.107	 0.009	 0.034	 0.027	
3	 Empty	 hsa-mir-146b-5p	 2.11	 0.009	 1.906	 0.092	 0.012	 0.048	 0.009	
	
	
Supplementary	 Table	 2.	 MicroRNAs	 differentially	 expressed	 upon	 TAL1	 overexpression	 	 as	
determined	by	the	Comparative	Marker	Selection	suite.	Cutoffs	for	statistical	significance	were:	1)	p-
value	<	0.05,	and	2)	fold	change	>	1.5.	
	
	
	
	
Chapter	3:	Results	
	 	 	212	
	
	
	
Chapter	3:	Results	
	 	 	213	
	
	
	
Chapter	3:	Results	
	 	 	214	
	
	
	
Chapter	3:	Results	
	 	 	215	
	
	
	
Supplementary	Table	3:	List	of	known	TAL1	upregulated	genes	that	are	potentially	targeted	by	TAL1	
downregulated	 microRNAs,	 as	 in	 Figure	 2a.	 Described	 function(s),	 putative	 role	 in	 cancer	 and	
corresponding	 relevant	 references	 are	 presented	 for	 each	 gene.	 For	 gene	 assessment	 details	 see	
supplemental	methods.	 	
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Supplementary	Table	4:	List	of	known	TAL1	downregulated	genes	that	are	potentially	targeted	by	
TAL1	 upregulated	 microRNAs,	 as	 in	 Figure	 2b.	 Described	 function(s),	 putative	 role	 in	 cancer	 and	
corresponding	 relevant	 references	 are	 presented	 for	 each	 gene.	 For	 gene	 assessment	 details	 see	
supplemental	methods.	
	
	
	
microRNA Modulation by TAL1 
Validated 
Target Genes 
Top Enriched 
Gene Sets 
(Selection) 
hsa-miR-135a UP APC, JAK2, NR3C2, FLAP ___ 
hsa-miR-223 UP 
RHOB, NFIX, 
E2F1, MEF2C, 
NFIA,LMO2, 
STMN1, Arid4b, 
Il6, Lpin2, CHUK, 
FBXW7, IGF1R, 
S100B, LIF, SP3, 
EPB41L3, 
SLC2A4, IRS1 
Genes down-
regulated in MEF 
cells upon TGFB1 
stimulation 
hsa-mir-330-3p UP 
VEGFA, E2F1, 
NTRK3, CDC42, 
CD44 
Pathways in cancer 
hsa-miR-545 DOWN LRP1 ___ 
hsa-miR-146b- 
5p DOWN 
NFKB1, 
CDKN1A, 
MMP16, KIT, 
Card10, Scube2, 
TRAF6, IRAK1 
NF-kB Signaling 
Pathway 
IL1/IL1R Signaling 
Pathway  
Pathways in cancer 
		
Supplementary	table	5:	Validated	microRNAs	regulated	by	TAL1	and	their	experimentally	validated	
human	 targets.	These	where	obtained	from	mirTARbase	3.5,	miRrecords	and	TarBase	6.0.	Gene	set	
enrichment	analysis	was	performed	as	described	in	supplemental	methods.	 	
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Supplementary	Table	6:	Gene	 set	enrichment	analysis	 for	 the	experimentally	 validated	 targets	of	
TAL1	 regulated	 microRNAs.	 Analysis	 was	 performed	 using	 Genomica	 software	
(http://genomica.weizmann.ac.il/).	P-values	were	determined	by	a	hypergeometric	test,	followed	by	a	
false	discovery	rate	correction	to	account	for	multiple	hypotheses	(FDR	<	0.05).	
	
	 	
Chapter	3:	Results	
	 	 	219	
The	Notch	driven	long	non-coding	RNA	repertoire	in	T-cell	acute	
lymphoblastic	leukemia		
Kaat	 Durinck1*,	 Annelynn	 Wallaert1*,	 Inge	 Van	 de	 Walle2,	 Wouter	 Van	 Loocke1,	
Pieter-Jan	 Volders1,	 Suzanne	 Vanhauwaert1,	 Ellen	Geerdens3,	 Yves	 Benoit1,	 Nadine	
Van	 Roy1,	 Bruce	 Poppe1,	 Jean	 Soulier4,	 Jan	 Cools3,	 Pieter	 Mestdagh1,	 	Jo	
Vandesompele1,	Pieter	Rondou1,	Pieter	Van	Vlierberghe1,	Tom	Taghon2**
	
and	Frank	
Speleman1** 
1Center	for	Medical	Genetics,	Ghent	University,	Ghent,	Belgium	
2Department	of	Clinical	Chemistry,	Microbiology	and	Immunology,	Ghent	University,	
Ghent,	Belgium; 
3Laboratory	 for	 the	Molecular	Biology	of	Leukemia,	Center	 for	Human	Genetics,	KU	
Leuven	and	Center	for	the	Biology	of	Disease,	VIB,	Leuven,	Belgium		
4Genome	 Rearrangements	 and	 Cancer	 Laboratory,	 U944	 INSERM,	 University Paris	
Diderot	and	Hematology	Laboratory,	Saint-Louis	Hospital,	Paris,	France	
*shared	first	authorship 
	
Haematologica.	2014	Dec;99(12):1808-16	 	
Chapter	3:	Results	
	 	 	220	
ABSTRACT	
Genetic	studies	in	T-cell	acute	lymphoblastic	leukemia	have	uncovered	a	remarkable	
complexity	 of	 oncogenic	 and	 loss-of-function	mutations.	 Amongst	 this	 plethora	 of	
genetic	 changes,	 NOTCH1	 activating	 mutations	 stand	 out	 as	 the	 most	 frequently	
occurring	genetic	defect,	 identified	 in	more	than	50%	of	T-cell	acute	 lymphoblastic	
leukemias,	 supporting	 a	 role	 as	 an	 essential	 driver	 for	 this	 gene	 in	 T-cell	 acute	
lymphoblastic	 leukemia	 oncogenesis.	 In	 this	 study,	 we	 aimed	 to	 establish	 a	
comprehensive	 compendium	 of	 the	 long	 non-coding	 RNA	 transcriptome	 under	
control	 of	 Notch	 signaling.	 For	 this	 purpose,	 we	 measured	 the	 transcriptional	
response	 of	 all	 protein	 coding	 genes	 and	 long	 non-coding	 RNAs	 upon	
pharmacological	Notch	inhibition	in	the	human	T-cell	acute	lymphoblastic	 leukemia	
cell	 line	 CUTLL1	 using	 RNA-sequencing.	 Similar	 Notch	 dependent	 profiles	 were	
established	 for	 normal	 human	 CD34+	 thymic	 T-cell	 progenitors	 exposed	 to	 Notch	
signaling	activity	in	vivo.	In	addition,	we	generated	long	non-coding	RNA	expression	
profiles	 (array	 data)	 from	 ex	 vivo	 isolated	 Notch	 active	 CD34+	 and	 Notch	 inactive	
CD4+CD8+	 thymocytes	 and	 from	 a	 primary	 cohort	 of	 15	 T-cell	 acute	 lymphoblastic	
leukemia	 patients	 with	 known	 NOTCH1	 mutation	 status.	 Integration	 of	 these	
expression	datasets	with	publicly	available	Notch1	ChIP-sequencing	data	resulted	in	
the	 identification	 of	 long	 non-coding	 RNAs	 directly	 regulated	 by	 Notch	 activity	 in	
normal	 and	 malignant	 T	 cells.	 Given	 the	 central	 role	 of	 Notch	 in	 T-cell	 acute	
lymphoblastic	leukemia	oncogenesis,	these	data	pave	the	way	for	the	development	
of	novel	therapeutic	strategies	that	target	hyperactive	Notch	signaling	 in	human	T-
cell	acute	lymphoblastic	leukemia.	 	
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INTRODUCTION	
The	Notch	pathway	comprises	a	highly	conserved	signaling	pathway	 that	 regulates	
various	 cellular	 processes	 in	 all	 metazoans,	 including	 stem	 cell	 maintenance,	
regulation	of	cell	fate	decisions,	cellular	proliferation,	differentiation,	cell	death	and	
adult	 tissue	 homeostasis.1	 As	 such,	 Notch	 signaling	 is	 critically	 involved	 in	 many	
different	tissues	including	epithelial,	neuronal,	blood,	bone,	muscle	and	endothelial	
cells.2	 Precise	 regulation	 and	 duration	 of	 Notch	 signaling	 activity	 is	 of	 critical	
importance	to	ensure	appropriate	execution	of	the	various	developmental	cues	and	
cellular	 processes.	 Consequently,	 constitutive	 or	 acquired	 perturbation	 of	 Notch	
signaling	frequently	leads	to	human	disease	and	cancer.1-4	
Notch	 signaling	 plays	 multiple	 roles	 in	 hematopoiesis	 and	 is	 essential	 for	 the	
establishment	of	definitive	hematopoiesis	through	the	generation	of	hematopoietic	
stem	cells,5	as	well	as	for	their	subsequent	differentiation	in	an	expanding	number	of	
blood	 cell	 types.6-9	 	 The	 role	 of	 Notch	 signaling	 has	 been	 particularly	 well	
documented	 in	 T-cell	 development	 where	 Notch1/Dll4	 interactions	 are	 crucial	 to	
induce	T-lineage	differentiation	at	the	expense	of	other	hematopoietic	lineages.10-14	
Subsequently,	 Notch	 signaling	 is	 implemented	 in	 TCR-rearrangements,15,16	
modulation	 of	 TCR-αb	 versus-γδ	 development,17-21	 and	 in	 the	 support	 of	
proliferation	during	β-selection.22-24		Sustained	activation	of	Notch1	signaling	beyond	
this	developmental	checkpoint	has	been	shown	to	cause	T-cell	acute	 lymphoblastic	
leukemia	(T-ALL)	and	NOTCH1	activating	mutations	are	amongst	the	most	frequently	
observed	 genetic	 alterations	 in	 T-ALL.25,26	 Importantly,	 γ-secretase	 inhibitors	 (GSIs)	
that	 block	 S3	 cleavage	 of	 the	 Notch1	 receptor	 and	 subsequent	 release	 of	 the	
intracellular	signaling	domain	(ICN)	are	the	subject	of	intensive	investigation	as	novel	
drugs	to	combat	T-ALL.	However,	single	compound	therapies	almost	invariably	lead	
to	 resistance.	 Therefore,	 a	 deeper	 understanding	 of	 Notch	 signaling	 in	 normal	
thymocyte	maturation27	 and	 in	 Notch1	 activated	 T-ALLs	 could	 yield	 novel	 insights	
that	could	make	treatment	more	effective.		
Activation	of	Notch1	converts	the	intracellular	domain	(ICN1)	of	the	Notch1	receptor	
into	a	 transcriptional	 activator	and	 ICN1	 subsequently	 acts	 as	a	direct	 regulator	of	
multiple	 target	 genes.28	 However,	 despite	 intensive	 investigation,	 the	 nature	 of	
these	genes,	as	well	as	their	context-dependent	activation,	remains	 largely	elusive.	
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In	 general,	 oncogenic	 Notch	 signaling	 promotes	 leukemic	 T-cell	 growth	 through	
direct	 transcriptional	upregulation	of	multiple	anabolic	genes	 involved	 in	 ribosome	
biosynthesis,	 protein	 translation,	 and	 nucleotide	 and	 amino	 acid	 metabolism.	
Furthermore,	Notch1	positively	regulates	G1/S	cell	cycle	progression	in	T-ALL29-31	and	
upregulates	several	cyclins	and	CDKs,30		in	addition	to	the	recurrent	oncogene	MYC.	
Furthermore,	 Notch	 signaling	 regulates	 cell	 size,	 glucose	 uptake	 and	 PI3K-AKT	
activated	 glycolysis	 through	 HES1-mediated	 PTEN	 repression.	 Besides	 direct	
regulation	of	HES1,	Notch1	 is	also	 implicated	 in	the	control	of	essential	early	T-cell	
genes	 such	 as	 pre-TCRα	 (PTCRA)	 and	 IL7R.32-34	 Taken	 together,	 these	 genes	 and	
pathways,	 as	 well	 as	 a	 further	 expanding	 list	 controlled	 by	 Notch1	 in	 T-ALL	 and	
normal	 T-cell	 development,	 illustrate	 the	 complexity	 and	 vastness	 of	 the	 Notch1	
controlled	regulatory	program.  
 
Recent	 transcriptome-wide	 profiling	 efforts	 have	 uncovered	 an	 unanticipated	
pervasiveness	of	transcription	of	the	human	genome,	most	of	which	is	not	translated	
into	 protein.35-38	 Evidence	 is	 now	 emerging	 that	 more	 than	 60%	 of	 the	 entire	
genome	 is	 transcribed.39	 In	 addition	 to	 previously	 well-characterized	 untranslated	
RNA	molecules	such	as	tRNAs,	snoRNAs	and	microRNAs	(miRNAs),	thousands	of	so-
called	 long	 non-coding	 RNAs	 (lncRNAs)	 have	 been	 annotated	 to	 the	 human	
genome.40,	 41	 Although	 functional	 studies	 still	 need	 to	 be	 carried	 out	 on	 the	 vast	
majority	of	 these	 lncRNA	sequences,	 important	 cellular	 functions	are	 rapidly	being	
attributed	to	some	of	them,	including	roles	in	disease	processes	such	as	cancer.42	In	
contrast	to	microRNAs,	a	picture	is	emerging	in	which	lncRNAs	can	exhibit	a	myriad	
of	 different	 functions.	 These	 include	 various	 regulatory	 mechanisms	 of	 gene	
transcription,	 splicing,	 post-transcriptional	 control,	 protein	 activity	 and	 nuclear	
architecture.43-45	Despite	this	initial	progress,	mechanisms	of	upstream	regulation	of	
lncRNAs	have	so	far	remained	largely	unexplored.		
	
In	this	study,	we	investigate	the	role	of	Notch	in	the	control	of	lncRNA	transcription	
in	 the	 context	 of	 normal	 T-cell	 development	 and	 T-ALL.	 To	 this	 end,	 lncRNA	
expression	was	measured	following	modulation	of	Notch	signaling	 in	 the	T-ALL	cell	
line	CUTLL1	as	well	as	in	normal	human	thymocytes,	and	the	recently	published	data	
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on	 genome-wide	 Notch1	 binding	 sites	 was	 used	 to	 reveal	 the	 potential	 for	 direct	
regulation.34	Using	this	approach,	we	identified	a	total	of	40	Notch-driven	lncRNAs,	
thereby	 revealing	 a	 novel	 layer	 in	 the	 molecular	 machinery	 that	 mediates	 Notch	
signaling.	
	
	
METHODS	
	
GSI	treatment	of	T-ALL	cell	lines	
HPB-ALL,	TALL-1,	ALL-SIL	and	CUTLL1	cells	(see	also	Online	Supplementary	Methods)	
were	seeded	at	a	density	of	1x106	cells/mL	and	treated	with	either	DMSO	or	1	μM	of	
Compound	E	(Enzo	Life	Sciences).	Cells	were	harvested	12	and	48	h	after	treatment.	
	
Human	thymocytes	and	OP9-DLL1	co-cultures	
Pediatric	thymus	samples	were	obtained	and	used	according	to	the	guidelines	of	the	
Medical	 Ethical	 Commission	 of	 the	 Ghent	 University	 Hospital,	 Belgium.	 CD34+	
thymocytes	 were	 purified	 using	 magnetic	 activated	 cell	 sorting	 (MACS,	 Miltenyi	
Biotec)	 to	a	purity	of	more	 than	98%	and	seeded	onto	confluent	OP9-GFP	or	OP9-
DLL1	plates	 for	48h	 in	α-MEM	media	supplemented	with	20%	heat-inactivated	FCS	
plus	 100	 U/mL	 penicillin,	 100	 μg/mL	 streptomycin,	 2	 mM	 L-glutamine	 and	 the	 T-
lineage	supporting	cytokines	SCF,	Flt3-L	and	IL-7	at	5	ng/mL	each.20	Following	48	h	of	
OP9	co-culture,	cells	were	harvested	by	forceful	pipetting	and	stained	with	CD45-PE	
(Miltenyi)	 to	 purify	 CD45+	 human	 thymocytes	 through	 sorting	 to	 remove	
contaminating	 OP9	 stromal	 cells.	 For	 validation	 of	 selected	 lncRNAs,	 CD34	 MACS	
purified	 thymocytes	were	 labeled	with	CD34,	CD1	and	CD4	to	sort	CD34+CD1–CD4–	
uncommitted	 and	 CD34+CD1+CD4–	 committed	 early	 thymocytes,	 while	
CD4+CD8+CD3–	and	CD4+CD8+CD3+	double	positive	thymocytes	were	sorted	following	
CD4,	CD8	and	CD3	labeling	of	a	total	thymus	suspension20.	Sorted	cells	were	lysed	in	
700	μl	QIAzol	(Qiagen)	and	stored	at	-70°C	prior	to	RNA	isolation.	
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Clinical	samples	
Diagnostic	blood	samples	of	15	individuals	with	T-ALL	were	acquired	after	informed	
consent	 from	 the	 Department	 of	 Pediatric	 Hemato-Oncology	 at	 Ghent	 University	
Hospital,	 Belgium.	 This	 cohort	 includes	 8	 wild-type	 NOTCH1	 cases	 and	 7	 mutant	
NOTCH1	 cases	 (all	 FBXW7	 wild	 type).	 Sequencing	 was	 performed	 as	 described	 by	
Mavrakis	et	al.46	Correlation	analysis	was	performed	on	bone	marrow	 lymphoblast	
samples	 from	 64	 T-ALL	 patients	 (unknown	NOTCH1	 mutation	 status),	 which	 were	
collected	after	informed	consent	according	to	the	Declaration	of	Helsinki	from	Saint-
Louis	 Hospital,	 Paris,	 France.	 The	 study	was	 approved	 by	 the	 Institut	Universitaire	
d’Hématologie	 Institutional	 Review	 Board.	 This	 primary	 T-ALL	 cohort	 had	 been	
previously	 investigated47	 and	 the	 high-quality	 RNA	 samples	 from	 this	 cohort	were	
used	for	lncRNA	micro-array	based	expression	profiling.		
	
RNA	sequencing	
RNA	 samples	 from	 the	 CUTLL1	 cells	 treated	with	 GSI	 and	 thymocytes	 cultured	 on	
OP9-GFP/DLL1	 were	 prepared	 (see	 also	 Supplementary	 Methods).	 RNA-seq	 was	
performed	after	unstranded	poly-A	library	prep	with	an	average	coverage	of	130x106	
paired-end	reads.	Reads	were	mapped	to	the	hg19	reference	genome	using	Tophat	
and	 transcript	 assembly	 was	 performed	 with	 Cufflinks.	 Differential	 expression	
analysis	was	carried	out	with	DESeq2	in	R.	The	design	formula	was	adjusted	to	take	
into	account	the	paired	nature	of	the	data.	
	
Micro-array	based	gene	expression	profiling	
RNA	samples	(see	also	Supplementary	Methods)	were	profiled	on	a	custom	designed	
Agilent	micro-array	 covering	 all	 protein	 coding	 genes	 and	 12,000	 lncRNAs	 (23,042	
unique	 lncRNA	probes)	as	described	by	Volders	et	al.48	The	data-analysis	workflow	
can	be	found	in	the	Supplementary	Methods.	The	data	discussed	in	this	publication	
have	 been	 deposited	 in	 the	 NCBI	 Gene	 Expression	 Omnibus49	 and	 are	 accessible	
through	GEO	Series	accession	number	GSE62006.	Complete	details	of	study	methods	
can	be	found	in	the	Online	Supplementary	Appendix.	 	
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RESULTS	
Pharmacological	 Notch	 inhibition	 followed	 by	 RNA-sequencing	 reveals	 a	 set	 of	
Notch	regulated	lncRNAs	in	T-ALL.		
To	identify	lncRNAs	that	are	regulated	through	Notch	signaling	activity	in	the	context	
of	T-ALL,	we	used	the	γ-secretase	(GSI)	inhibitor	responsive	T-ALL	cell	line	CUTLL1	as	
a	model	 system,	 since	 genome-wide	 information	 on	 this	 cell	 line	 is	 available	with	
respect	to	Notch1	binding34	and	the	Notch	dependent	expression	of	coding	genes.50	
CUTLL1	T-ALL	cells	were	treated	with	GSI	for	12h	and	48h	in	triplicate.	Genome-wide	
transcriptional	changes	determined	by	performing	differential	expression	analysis	on	
the	RNA-seq	data	(see	alignment	summary	in	Supplementary	Table	S1)	with	DESeq2	
using	Ensembl	(release	75)	as	a	reference,	showed	robust	downregulation	of	several	
of	 the	 canonical	 Notch1	 protein	 coding	 target	 genes	 (e.g.	DTX1,	NRARP,	NOTCH3)	
upon	 GSI	 treatment	 (Figure	 1A).	 A	 decrease	 in	 ICN1	 protein	 levels	 was	 shown	 by	
western	blot	analysis	and	downregulation	of	the	canonical	Notch1	target	gene	DTX1	
upon	GSI	 treatment	was	 further	 validated	by	RT-qPCR	 (Supplementary	 Figure	 S1).	
Amongst	 previously	 annotated	 lncRNAs48	 we	 could	 detect	 significant	 differential	
expression	(adjusted	P-value	<0.05)	for	83	lncRNAs,	using	a	basemean	cut	off	of	100	
(Figure	 1B).	 In	 total,	 50	 out	 of	 the	 83	 differentially	 expressed	 lncRNAs	 were	
downregulated	after	GSI	treatment.		
Besides	 previously	 annotated	 lncRNAs,	we	 also	 detected	 differential	 expression	 of	
non-coding	transcripts	that	had	not	been	previously	annotated	in	other	databases	
(Gencode,	 lncRNAdb,	 Broad	 Institute	 and	 Ensembl	 release	 64).48	 Differentially	
expressed	lncRNA	loci	with	a	basemean	higher	than	100	and	identified	as	“unknown,	
intergenic	 transcript”	 or	 “transfrag	 falling	 entirely	 within	 a	 reference	 intron”	 by	
Cuffcompare	were	retained	for	further	analysis.	This	led	to	a	selection	of	134	lncRNA	
loci	of	which	74	were	downregulated	upon	GSI	treatment.		 	
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Figure	 1:	 Pharmacological	Notch	 inhibition	 followed	 by	 RNA-sequencing	 identifies	 a	 set	 of	Notch	
regulated	 lncRNAs	 in	T-ALL.	 (A)	Volcano	(left)	and	MA	plot	 (right)	representation	of	the	differential	
expression	 of	 protein	 coding	 genes	 in	 CUTLL1	 cells	 upon	 GSI	 treatment.	 Red	 dots	 represent	 the	
significant	 differentially	 expressed	 genes	 (adjusted	 P-value	 <0.05).	 (B)	 Volcano	 (left)	 and	 MA	 plot	
(right)	representation	of	the	differential	expression	of	previously	annotated	 lncRNAs	 in	CUTLL1	cells	
upon	 GSI	 treatment.	 Red	 dots	 represent	 the	 significant	 differentially	 expressed	 genes	 (adjusted	 P-
value<0.05;	n=2).	LncRNAs	names	depicted	in	the	plots	are	the	top	differentially	regulated	lncRNAs.	
	
	
Transcriptional	regulation	of	Notch	regulated	lncRNAs	in	immature	normal	human	
thymocytes	
Physiological	levels	of	Notch	signaling	are	essential	during	the	earliest	stages	of	T-cell	
development,	but	no	information	is	available	on	the	Notch	dependent	expression	of	
lncRNAs	 in	these	cells.27	Therefore,	and	 in	order	to	have	an	 independent	screening	
method	in	addition	to	the	CUTLL1	cell	line	to	identify	Notch	dependent	lncRNAs,	we	
used	 the	 in	 vitro	 OP9-DLL1	 co-culture	 system	 (Figure	 2A).	 Here,	 ex	 vivo	 purified	
CD34+	thymocytes	from	healthy	human	donors	(n=2)	were	cultured	on	a	feeder	layer	
of	 stromal	 OP9	 cells	 either	 expressing	 GFP	 (as	 a	 negative	 control)	 or	 the	 Notch1	
ligand	DLL1	 to	 trigger	Notch	 signaling.	 CD34+	 progenitor	 cells	were	 collected	 after	
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48h	of	co-culture	and	deep	RNA-sequencing	was	performed	(see	alignment	summary	
in	Supplementary	Table	S2).	The	set	of	differentially	expressed	protein	coding	genes	
and	 lncRNAs	was	defined	as	above	 for	 the	CUTLL1	cells.	Detection	of	differentially	
expressed	protein	 coding	genes	known	 to	be	 regulated	by	Notch	 signaling	 in	early	
human	 thymocytes,20,27	 also	 validated	 our	 approach	 in	 this	 model	 system	 (Figure	
2B).	Differential	expression	analysis	 for	previously	annotated	 lncRNAs	revealed	131	
significantly	upregulated	lncRNAs	as	a	consequence	of	Notch	activation	(Figure	2C).	
From	 these	 131	 lncRNAs,	 27	 overlapped	 with	 the	 set	 of	 downregulated	 lncRNAs	
upon	GSI	treatment	of	the	CUTLL1	cell	line	(Figure	2D	and	Supplementary	Table	S3).	
Furthermore,	we	identified	156	unannotated	lncRNA	loci	(base	mean	>100;	adjusted	
P-value	<0.05)	in	CD34+	thymocytes	that	were	upregulated	by	the	Notch	ligand	DLL1.	
In	 total,	 13	 unique	 unannotated	 lncRNA	 loci	 were	 identified	 to	 be	 positively	
regulated	by	Notch	in	both	normal	and	malignant	T-cell	development	(Figure	2E	and	
Supplementary	Table	S4).	Amongst	the	set	of	13	overlapping	Notch	lncRNA	loci,	the	
recently	 described	 LUNAR151	 was	 present,	 thus	 supporting	 the	 validity	 of	 our	
approach.	 In	 addition,	we	 also	 identified	 33	 annotated	 lncRNAs	 to	 be	upregulated	
upon	GSI	treatment	of	CUTLL1	cells	by	RNA-seq,	18	of	them	overlapping	with	the	set	
of	 lncRNAs	 downregulated	 in	 CD34+	 T-cell	 progenitors	 upon	 DLL1	 exposure	 in	 the	
OP9	in	vitro	culture	system	(366	in	total)	(Supplementary	Table	S5	and	Figure	S2A).	
In	a	similar	manner,	7	of	57	previously	unannotated	lncRNAs	upregulated	upon	GSI	
treatment	 of	 CUTLL1	 cells	 overlapped	 with	 the	 set	 of	 320	 unannotated	 lncRNAs	
downregulated	 in	CD34+	 thymocytes	with	DLL1	exposure	(Supplementary	Table	S6	
and	 Figure	 S2B).	 Furthermore,	we	hypothesize	 that	 the	Notch	dependent	 lncRNAs	
(both	annotated	and	unannotated)	that	are	not	shared	between	CUTLL1	T-ALL	cells	
and	 normal	 human	 thymocytes	 can	 be	 assumed	 to	 have	 very	 context-specific	
functions	and	should	be	regarded	as	potentially	interesting	for	further	exploration	in	
future	 studies.	 For	 example,	 lncRNAs	 expressed	 exclusively	 in	 T-ALL	 cells	 could	 be	
restrictively	 connected	 to	 a	 malignant	 context.	 To	 evaluate	 the	 putative	 protein	
coding	potential	of	all	unannotated	 lncRNA	loci	 identified	by	RNA-seq	 in	CUTLL1	T-	
ALL	 cells	 and	 CD34+	 T-cell	 progenitors	 cultured	 on	OP9	 stromal	 cells,	 Phylogenetic	
Codon	Substitution	Frequency	(PhyloCSF)	scores	for	all	 loci	were	calculated	and	we	
could	 confirm	 that	more	 than	90%	of	 all	unannotated	 lncRNA	 loci	 determined	are	
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truly	 ‘non-coding’	 (Supplementary	 Figure	 S3).	 Putative	 unannotated	 lncRNA	 loci	
with	 a	 PhyloCSF	 score	 higher	 than	 the	 determined	 threshold	 score	 are	 listed	 and	
thus	 predicted	 to	 be	 ‘coding’	 (Supplementary	 Tables	 S7	 and	 S8)	 (see	 also	
Supplementary	Methods).	 	
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Figure	 2:	 Transcriptional	 regulation	 of	 Notch	 regulated	 lncRNAs	 in	 immature	 normal	 human	
thymocytes.	 (A)	 Schematic	 overview	 of	 the	 OP9-control	 and	 OP9-DLL1	 co-culture	 system	 used	 to	
manipulate	Notch	signaling	in	healthy	human	immature	CD34+	thymocytes.	(B)	Volcano	(left)	and	MA	
plot	(right)	representation	of	the	differential	expression	of	protein	coding	genes	in	CD34+	cells	upon	
Notch	 signaling	 induction	 by	 an	 OP9-DLL1	 feeder	 layer.	 Red	 dots	 represent	 the	 significant	
differentially	 expressed	 genes	 (adjusted	 P-value	 <0.05;	 n=2).	 (C)	 Volcano	 (left)	 and	MA	 plot	 (right)	
representation	 of	 the	 differential	 expression	 of	 previously	 annotated	 lncRNAs	 in	 CD34+	 cells	 upon	
Notch	 activation	 by	 an	 OP9-DLL1	 feeder	 layer.	 LncRNA	 names	 depicted	 in	 the	 figure	 are	 the	 top	
differentially	 regulated	 lncRNAs.	 (D)	 Venn	 diagram	 depicting	 the	 overlap	 between	 previously	
annotated	 lncRNAs	 that	 are	 downregulated	 upon	 GSI	 treatment	 of	 the	 CUTLL1	 cell	 line	 and	 up-
regulated	 upon	 co-culturing	 of	 CD34+	 thymocytes	 on	 the	OP9-DLL1	 feeder	 layer.	 (E)	 Venn	 diagram	
depicting	 the	 overlap	 between	 previously	 unannotated	 lncRNAs	 that	 are	 downregulated	 upon	 GSI	
treatment	of	 the	CUTLL1	 cell	 line	and	upregulated	upon	co-culturing	of	CD34+	 thymocytes	on	OP9-
DLL1	stromal	cells.	 	
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Validation	 of	 Notch	 regulated	 lncRNAs	 in	 an	 extended	 panel	 of	 T-ALL	 cell	 lines,	
normal	T-cell	subsets	and	primary	T-ALLs	
To	 further	 validate	 our	 data,	 we	 used	 a	 custom	 designed	 Agilent	 micro-array48	
developed	 in	 house	 that	 contains	 probes	 for	 15	 of	 the	 27	 previously	 annotated	
lncRNAs	 and	 the	 recently	 identified	 LUNAR1	 lncRNA	 that	 were	 shown	 to	 be	
regulated	by	Notch	in	the	above	described	RNA-seq	data	from	the	T-ALL	and	normal	
thymocyte	models.	First,	we	treated	the	T-ALL	cell	lines	ALL-SIL,	TALL-1,	HPB-ALL	and	
DND-41	with	GSI	(Supplementary	Figure	S4A	and	B)	and	carried	out	gene	expression	
profiling	after	12	hand	48	h.	Inclusion	of	the	GSI-treated	CUTLL1	cell	line	samples	and	
the	 samples	 of	 4	 donors	 of	 CD34+	 thymocytes	 cultured	 on	 OP9	 stromal	 cells,	
revealed	that	there	was	a	significant	overlap	between	the	RNA-sequencing	data	and	
the	 micro-array	 data	 as	 validated	 by	 overlapping	 the	 protein-coding	 signatures	
derived	from	both	datasets	by	Gene	Set	Enrichment	Analysis	(GSEA)		(Supplementary	
Figure	 S4C	 and	D).	 Nevertheless,	 few	 lncRNAs	were	 significantly	Notch	 dependent	
over	all	samples	of	the	extended	panel	of	T-ALL	cell	lines	(ALL-SIL,	HPB-ALL,	DND-41	
and	TALL-1),	 probably	 related	 to	 the	difference	 in	 the	T-ALL	 genetic	 subgroup	and	
concomitant	 differences	 in	 maturation	 arrest	 of	 the	 different	 cell	 lines	 evaluated	
(Figure	 3A).	 From	 our	 selection,	 only	 lnc-PLEKHB2-1	 and	 lnc-UBXN4-1	 were	
differentially	 expressed	 at	 a	 significant	 level,	 while	 lnc-GSDMC-2	 and	 lnc-CA7-2	
narrowly	 failed	 to	 reach	 significance.	 As	 we	 were	 able	 to	 detect	 the	 previously	
unannotated	 and	 recently	 described	 lncRNA	 LUNAR151	 on	 our	 custom	 designed	
micro-array	 platform,	 this	 lncRNA	 was	 one	 of	 the	 strongest	 overlapping	 and	
significantly	differentially	expressed	lncRNAs	amongst	the	four	GSI-treated	T-ALL	cell	
lines	screened.	Secondly,	we	validated	the	Notch	dependency	of	selected	lncRNAs	in	
normal	 thymocytes	 by	 analyzing	 their	 expression	 in	 the	 most	 immature	 Notch	
dependent	CD34+	stages	in	comparison	to	the	Notch	independent	CD4+CD8+	double	
positive	stages	of	human	T-cell	development.	As	 is	evident	from	the	profiles	of	the	
Notch	 target	 gene	 DTX1,	 we	 could	 show	 that	 in	 these	 two	 T-cell	 subpopulations	
LUNAR1	 follows	 the	 expression	 pattern	 of	 this	 canonical	Notch	 target	 (Figure	 3B).	
Remarkably,	 9	 out	 of	 15	 lncRNAs	 (and	 LUNAR1)	 from	 this	 selection	 significantly	
correlated	 with	 DTX1	 expression	 (Spearman	 rho	 correlation),	 supporting	 their	
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regulation	by	Notch	during	early	stages	of	normal	T-cell	development	(Figure	3C	and	
Supplementary	Table	S9).	
Moreover,	 we	 also	 had	 access	 to	 15	 primary	 T-ALL	 samples	 of	 which	 7	 harbored	
activating	NOTCH1	mutations	while	8	were	wild	type	(all	cases	are	FBXW7	wild	type).	
There	was	 a	 significant	 difference	 in	 expression	 of	 LUNAR1	and	 lnc-FAM120AOS-1	
between	NOTCH1	wildtype	and	mutant	cases	(Figure	3D	and	Supplementary	Tables	
S10	and	S11).	By	implying	an	additional	dataset	of	64	primary	T-ALL	patient	samples,	
we	 could	 correlate	 the	expression	of	 lncRNAs	 lnc-PGBD5-2,	 lnc-FAM120AOS-1,	 lnc-
c2orf55-1	 and	 LUNAR1	 with	 the	 Notch1	 positively	 regulated	 gene	 set	
Vilimas_NOTCH1_targets_up52	 by	 GSEA	 (Figure	 3E).	 Overall,	 these	 independent	
experiments	 confirm	 the	 Notch	 dependent	 regulation	 of	 the	 selected	 lncRNAs,	
thereby	validating	the	RNA-seq	data	from	the	GSI	treated	CUTLL1	T-ALL	cell	line	and	
the	Notch	perturbed	normal	human	thymocytes.	
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Figure	3:	Screening	expression	of	Notch	regulated	lncRNAs	in	an	extended	panel	of	T-ALL	cell	lines,	
normal	 T-cells	 subsets	 and	 primary	 T-ALLs.	 (A)	 Volcano	 plot	 representation	 of	 the	 differential	
expression	 of	 lncRNAs	upon	GSI	 treatment	 of	 ALL-SIL,	 TALL-1,	HPB-ALL	 and	DND-41	 cells.	Red	dots	
represent	 the	 significant	 differentially	 expressed	 genes	 (adjusted	 P-value	 <0.05).	 LUNAR1	 was	
amongst	the	top-differentially	expressed	lncRNAs	across	the	panel	of	GSI-treated	T-ALL	cell	lines.	The	
other	 lncRNA	names	depicted	 in	 the	 figure	are	 some	of	 the	 selected	 lncRNAs	 from	 the	CUTLL1	GSI	
treatment	 and	 the	OP9-DLL1	 co-culture	 system.	 (B)	 Plot	 representing	 the	 expression	 of	 lncRNAs	 in	
selected	Notch-dependent	 and	 -independent	 stages	 of	 normal	 T-cell	 development	 for	 one	 healthy	
donor.	 LUNAR1	 expression	 is	 significantly	 correlated	 with	 the	 expression	 of	 DTX1	 (see	 also		
Supplementary	 Table	 S6)	 and	 the	 data	 are	 representative	 for	 4	 independent	 donors.	 (C)	 Similar	
analysis	as	 in	(B)	for	the	other	 lncRNAs	that	are	significantly	correlated	with	the	expression	of	DTX1	
(see	also	Supplementary	Table	S6);	data	are	representative	for	4	independent	donors.	(D)	Expression	
of	 LUNAR1,	 lnc-FAM120AOS-1	 and	 lnc-UBXN4-1	 in	NOTCH1	wildtype	 (WT)	 versus	NOTCH1	 mutant	
(MUT)	 primary	 T-ALL	 samples.	 (E)	 Gene	 set	 enrichment	 analysis	 (GSEA)	 using	 the	 public	 gene	 set	
‘VILIMAS_NOTCH1_TARGETS_UP’52	and	the	Spearman	correlations	between	all	protein	coding	genes	
and	 the	 set	 of	 15	 selected	 annotated	 candidate	 Notch	 lncRNAs	 was	 performed.	 This	 NOTCH1	
signature	was	significantly	enriched	within	the	set	of	protein	coding	genes	positively	correlated	to	the	
expression	of	 lnc-PGBD5-2,	 lnc-FAM120AOS-1	and	 lnc-c2orf55-1.	This	enrichment	was	also	found	for	
lncRNA	LUNAR1.	
 
Genome-wide	analysis	reveals	direct	Notch1	binding	to	selected	lncRNAs	
To	 further	 validate	 the	 direct	 regulation	 of	 selected	 lncRNAs	 by	 Notch,	 publically	
available	ChIP	 sequencing	 (ChIP-seq)	data	 from	the	CUTLL1	cell	 line	were	analyzed	
for	Notch1	binding	at	specific	loci.34	From	the	Notch-driven	annotated	lncRNAs	that	
overlapped	between	normal	and	malignant	thymocytes	(Figure	2D),	13	out	of	the	27	
lncRNAs	 were	 bound	 by	 ICN1	 (Supplementary	 Table	 S12)	 as	 illustrated	 for	 lnc-
UBXN4-1	and	lnc-PLEKHB2-1	(Figure	4).	Remarkably,	12	out	of	the	13	lncRNAs	with	a	
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Notch1	binding	peak	also	show	Brd4	and	Med1	binding.	Notably,	from	the	putative	
Notch	regulated	lncRNAs	that	showed	correlated	expression	with	DTX1	in	CD34+	and	
CD4+CD8+	normal	 thymocytes,	 6	out	of	 9	 (Figure	 4	 and	 Supplementary	 Figure	 S5)	
showed	binding	of	ICN1,	suggesting	that	the	majority	is	a	direct	Notch	target.	
	
 
Figure	 4:	 Notch1	 ChIP-seq	 reveals	 direct	 binding	 of	 Notch1	 to	 a	 subset	 of	 regulated	 lncRNAs.	
Representation	of	ChIP-sequencing	tracks34	for	Notch1,	Brd4,	Med1	and	H3K27ac	and	representative	
RNA-sequencing	tracks	for	CUTLL1	DMSO/GSI	treatment	and	OP9-GFP/DLL1	of	 lnc-UBXN4-1	and	 lnc-
PLEKHB2-1.	
 
In	 addition,	 we	 evaluated	 the	 presence	 of	 H3K27	 acetylation	 (H3K27ac)	 ChIP-seq	
signal	at	these	lncRNA	loci,	a	histone	mark	indicative	for	putative	enhancer	regions.	
For	18	out	of	the	27	selected	lncRNAs,	H3K27ac	ChIP-seq	signal	was	present	in	close	
proximity	 of	 the	 promoter	 region	 (Supplementary	 Table	 S12),	 suggesting	 the	
presence	of	enhancer	sequences.	Moreover,	 this	public	ChIP-seq	data	also	showed	
LUNAR1	to	be	directly	bound	by	ICN1,	Brd4,	Med1	and	H3K27ac	(Figure	5).	We	also	
evaluated	ICN1	binding	at	annotated	lncRNA	loci	up-regulated	upon	GSI	treatment	of	
CUTLL1	 T-ALL	 cells	 and	 downregulated	 in	 CD34+	 T-cell	 progenitors	 upon	 DLL1	
exposure	 in	 the	 OP9	 in	 vitro	 co-culture	 system.	 Only	 4	 out	 of	 the	 18	 overlapping	
annotated	 lncRNAs	 that	 are	 negatively	 regulated	 by	 Notch	 (Supplementary	 Figure	
S2A)	showed	direct	binding	by	ICN1.	The	same	analysis	was	performed	on	the	set	of	
7	unannotated	 lncRNAs	repressed	by	Notch1	signaling	 (Supplementary	Figure	S2B).	
Only	 3	 out	 of	 these	 7	 lncRNA	 loci	 showed	 ICN1	 binding	 in	 the	 proximity	 of	 its	
promoter	 region.	 Given	 the	 established	 predominant	 role	 of	 Notch1	 as	 a	
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transcriptional	 activator,	 lncRNAs	 that	 are	 negatively	 affected	 by	 Notch1	 signaling	
may	actually	be	indirect	targets.	
	
 
 
Figure	5:	Notch1	ChIP-seq	reveals	direct	binding	of	Notch1	to	LUNAR1.		
LUNAR151	 (lnc-IGF1R-1)	was	 identified	amongst	 the	 top	differentially	 expressed	novel,	 unannotated	
lncRNAs	 in	 both	 GSI-treated	 CUTLL1	 cells	 and	 CD34+	 thymic	 progenitor	 cells	 exposed	 to	 DLL1-
triggered	Notch	signaling.	Publically	available	ChIP-seq	tracks34	for	ICN1	BRD4,	MED1	and	H3K27ac	as	
well	 as	 representative	 in	 house	 generated	RNA-seq	data	 tracks	 for	 CUTLL1	DMSO/GSI	 treated	 cells	
and	OP9-GFP/DLL1	are	shown	at	the	LUNAR1	locus.	
	
	
Attributing	 functional	 annotation	 to	 Notch	 regulated	 lncRNAs	 through	 guilt-by-
association	analysis	
As	 described	 above,	 we	 defined	 a	 core	 set	 of	 27	 Notch	 driven	 and	 previously	
annotated	lncRNAs	by	considering	only	those	differentially	expressed	and	positively	
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regulated	by	Notch	signaling	in	the	GSI	perturbation	model	in	CUTLL1	cells	and	the	in	
vitro	 OP9-DLL1	 co-culture	 system.	 As	 a	 next	 step,	 we	 aimed	 to	 assign	 potential	
functionalities	 to	 each	 of	 these	 candidates.	 To	 this	 end,	 we	 used	 the	 ‘guilt-by-
association’	 approach	 (see	 Supplementary	Methods).	 As	 previously	 mentioned,	 15	
out	of	these	27	lncRNAs	(together	with	LUNAR1)	were	detectable	by	a	probe	on	our	
custom	designed	micro-array	platform.	 In	a	 first	 step,	we	calculated	 the	Spearman	
correlation	 coefficients	 between	 the	 lncRNAs-of-interest	 and	 all	 protein-coding	
genes	using	the	expression	data	of	a	primary	T-ALL	cohort	of	64	patients	from	which	
we	profiled	all	 samples	on	 the	custom	designed	Agilent	array.48	These	correlations	
were	subsequently	used	as	an	input	for	a	GSEA	pre-ranked	analysis.	Next,	the	output	
of	 this	GSEA	 analysis	was	 further	 refined	 into	 functional	 clusters	 of	 enriched	 gene	
sets	using	the	Cytoscape	plug-in	enrichment	mapping.	This	analysis	yielded	markedly	
different	 functional	 clustering	 patterns	 for	 each	 of	 the	 16	 lncRNAs	 analyzed	
(including	LUNAR1).	 Important	putative	functionalities	were	represented	 in	each	of	
the	networks	as	exemplified	by	TCR-signaling	and	phospholipid	metabolism	for	 lnc-
PLEKHB2-1,	 DNA	 replication	 and	 DNA	 repair	 for	 lnc-UBXN4-1	 and	 splicing	 and	 cell	
cycle	regulation	for	LUNAR1	(Figure	6A-C	and	Supplementary	Figure	S6A-M).	
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Figure	 6:	 Attributing	 functional	 annotation	 to	 selected,	 annotated	 lncRNAs	 through	 guilt-by-
association	analysis.		
Enrichment	maps	of	gene	sets	correlated	with	the	expression	of	(A)	 lnc-PLEKHB2-1,	 (B)	 lnc-UBXN4-1	
and	 (C)	LUNAR1.	Red	nodes	represent	 the	positively	correlated	gene	sets	 to	the	 lncRNA	of	 interest,	
blue	nodes	the	negatively	correlated	gene	sets.	The	size	of	the	nodes	depicts	the	size	of	the	gene	sets.	
Nodes	that	are	clustered	represent	gene	sets	with	the	same	or	similar	functional	indication.	 	
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DISCUSSION	
Non-coding	 RNAs	 are	 emerging	 as	 important	 players	 in	 normal	 development	 and	
disease,	including	cancer.	In	previous	studies,	we	investigated	the	role	of	miRNAs	in	
T-cell	 acute	 lymphoblastic	 leukemia	 (T-ALL),	 thereby	 identifying	 a	 small	 set	 of	
miRNAs	 that	 is	 responsible	 for	 the	 cooperative	 suppression	 of	 several	 tumor	
suppressor	genes.46		
These	miRNAs	produced	overlapping	and	co-operative	effects	with	several	bona	fide	
T-ALL	 tumor	 suppressor	 genes	 including	 IKZF1,	PTEN,	BIM,	PHF6,	NF1	 and	FBXW7,	
and	 more	 recently	 this	 network	 was	 expanded	 further	 with	 PHF6.53	 In	 order	 to	
provide	some	insight	 into	the	genetic	components	driving	 long	non-coding	RNAs	 in	
T-ALL	formation,	we	performed	an	integrated	analysis	of	 lncRNA	profiling	data	sets	
from	 GSI	 inhibited	 Notch-driven	 T-ALL	 cell	 lines	 and	 Notch-stimulated	 immature	
normal	human	thymocytes	using	the	OP9	co-culture	system,	together	with	publically	
available	 genome-wide	 data	 on	 Notch1	 binding	 and	 specific	 chromatin	 marks.	 In	
addition,	we	correlated	the	expression	of	Notch-dependent	lncRNAs	with	the	Notch-
dependent	 stages	 of	 normal	 thymocytes	 during	 T-cell	 differentiation.	 Overall,	 our	
work	 establishes	 a	 novel	 lncRNA	 network	 that	 acts	 downstream	 of	 Notch	 during	
normal	and	malignant	thymocyte	development.	
Our	 study	 provides	 a	 number	 of	 fundamental	 new	 insights	 into	 Notch-dependent	
regulation	 of	 lncRNAs	 in	 T-ALL	 and	 normal	 developing	 thymocytes.	 First,	 we	
unambiguously	 demonstrate	 that	 a	 significant	 number	 of	 lncRNAs	 are	 directly	
regulated	 by	 Notch	 signaling	 activity.	 Through	 RNA-sequencing,	 we	 identified	 40	
lncRNAs	 that	 are	 positively	 regulated	 by	 Notch	 in	 both	 normal	 and	 malignant	 T-	
lymphocytes	(annotated	as	well	as	previously	unannotated	lncRNAs),	supporting	an	
important	 role	 for	 these	 lncRNAs	 in	 Notch-regulated	 T-cell	 biology.	 This	 could	 be	
related	to	various	functions	of	Notch	signaling,	 including	T-cell	 lineage	specification	
and	 commitment,	 proliferation	 and	 differentiation.	 Importantly,	 the	 recently	
identified	lncRNA	LUNAR151	was	present	amongst	the	most	robustly	Notch	regulated	
long	 non-coding	 RNAs	 in	 our	 data	 sets.	 LUNAR1	 was	 shown	 to	 be	 required	 for	
efficient	 T-ALL	 growth	 as	 a	 consequence	 of	 its	 role	 in	 enhancing	 IGF1R	 mRNA	
expression	 to	 sustain	 IGF1	 signaling.51	 As	 a	 prelude	 to	 assigning	 functional	
annotation	to	the	newly	assigned	Notch-regulated	lncRNAs	in	this	study,	we	applied	
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the	so-called	‘guilt-by-association’	approach	in	which	functions	are	predicted	based	
upon	 correlation	 with	 known	 protein-coding	 genes	 and	 subsequent	 gene	 set	
enrichment	 analysis.	 For	 the	 selected	 lncRNAs,	 various	 functions	 were	 predicted,	
several	 of	 which	 are	 linked	 to	 T-cell	 biology	 or	 processes	 that	 are	 perturbed	 in	
cancer.	This	marks	 these	 lncRNAs	as	prime	 targets	 for	 further	 functional	 studies	 in	
order	to	unravel	their	mode	of	action	and	assess	to	what	extent	they	might	serve	as	
future	therapeutic	targets	for	treatment	of	T-ALL.	
Not	all	of	the	40	overlapping	lncRNAs	displayed	ICN1	binding,	as	is	evident	from	the	
publically	 available	 ChIP-seq	 data.34	 This	 may	 relate	 to	 the	 complexity	 of	 the	
chromosomal	3D-structures	 that	are	generated	when	 lncRNAs	act	as	cis-regulatory	
elements,	as	well	as	 to	 the	sensitivity	of	 the	Notch1	ChIP	procedure.	However,	 for	
the	previously	annotated	lncRNAs	directly	bound	by	ICN1,	all	but	one	displayed	Brd4	
and	Med1	binding.	Those	lncRNAs	that	are	characterized	by	Brd4	and	Med1	ChIP-seq	
signal	 are	 also	 characterized	 by	 the	 presence	 of	 H3K27ac	 ChIP-seq	 signal,	 which	
could	be	indicative	of	an	enhancer	activity	of	these	loci.	
A	 second	 aspect	 of	 our	 study	 involved	 the	 identification	 of	 novel,	 previously	
unannotated	lncRNAs.	 Indeed,	previous	studies	have	shown	that	 lncRNAs	are	often	
shown	to	be	very	restricted,	but	with	biologically	high	relevant	expression.40-45	This	
includes	 expression	 during	 very	 specific	 time	 points	 during	 development	 and/or	
differentiation,	 as	 well	 as	 restriction	 to	 very	 specific	 cell	 subsets.	 Typically,	 these	
lncRNAs	are	expressed	at	significant	levels	in	these	cells	whereas	in	other	cell	types	
their	 expression	 is	 very	 low	 or	 absent.	 Here,	 we	 identified	 novel	 lncRNAs	 in	 the	
CUTLL1	 cell	 line	 and	 in	 the	OP9-DLL1	 co-culture	 system.	 Interestingly,	 61	 of	 these	
lncRNAs	were	 present	 in	 T-ALL	 cells	 only,	 suggesting	 that	 their	 ectopic	 expression	
could	 be	 restricted	 to	 the	 malignant	 context.	 Likewise,	 lncRNAs	 only	 present	 in	
thymocytes	may	be	implicated	in	differentiation	of	normal	T-cells	which	is	disrupted	
in	T-ALL	cells,	or	may	reflect	differential	Notch3	activity	as	the	DLL1	ligand,	to	which	
CD34+	progenitor	T	cells	are	exposed	in	the	OP9-DLL1	co-culture	system,	can	activate	
both	Notch1	and	Notch3	(Waegemans	E,	Van	de	Walle	I	and	Taghon	T,	unpublished	
data	on	preferential	Notch	receptor-ligand	 interactions	 in	human,	2011)	while	both	
receptors	are	implicated	in	modulating	human	T-cell	development.21	Both	subsets	of	
lncRNAs	may,	therefore,	serve	as	novel	therapeutic	targets	for	T-ALL	treatment.	It	is	
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evident	 that	 our	 work,	 as	 well	 as	 the	 recent	 paper	 by	 Aifantis	 and	 colleagues,51	
strongly	 favors	an	 important	 role	 for	 lncRNAs	 in	normal	T-cell	development	and	T-
ALL	 oncogenesis.	Moreover,	we	 show	 that	 the	Notch1	 transcription	 factor	 directly	
controls	 the	 transcription	 of	many	 of	 these	 long	 non-coding	RNAs.	 Therefore,	 one	
can	predict	 that	other	oncogenic	 transcription	 factors	and	drivers	 in	T-ALL,	such	as	
TAL1,	 TLX1/TLX3,	 LMO1/2	 and	 HOXA	 genes,	 as	 well	 as	 other	 transcriptional	
regulators	 of	 normal	 T-cell	 development,	 will	 also	 perform	 similar	 transcriptional	
control.	 Therefore,	 specific	 T-ALL	 subgroups	 and	 more	 distinct	 subsets	 of	 normal	
immature	 developing	 T	 cells	 need	 to	 be	 analyzed	 in	 human	 for	 detection	 of	 all	
lncRNAs.	We	predict	that	this	will	further	dramatically	expand	the	lncRNA	landscape	
for	 T-ALL	 and	 thymocyte	 maturation,	 and	 thus	 provide	 an	 important	 regulatory	
framework	for	understanding	some	of	the	unique	features	that	control	human	T-cell	
biology.27	Finally,	given	the	central	role	of	oncogenic	Notch1	activation	in	most	if	not	
all	T-ALLs,	and	the	current	limitations	of	targeted	therapy,	further	exploration	of	the	
new	 therapeutic	 opportunities	 offered	 by	 these	 lncRNAs	 in	 the	 context	 of	 their	
specific	functionality	is	strongly	recommended.	
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SUPPLEMENTARY	METHODS	
Cell	lines	and	compound	treatment	
HPB-ALL,	TALL-1	and	ALL-SIL	cells	were	obtained	from	the	DSMZ	cell	line	repository,	
CUTLL1	 cells	 were	 a	 kind	 gift	 of	 H.G.	 Wendel	 (Memorial	 Sloan	 Kettering	 Cancer	
Center,	 New	 York,	 USA).	 Cells	 were	 maintained	 in	 RPMI-.-1640	 medium	 (Life	
Technologies,	 52400-025),	 supplemented	 with	 10%	 or	 20	 %	 (ALL-SIL	 and	 CUTLL1)	
fetal	bovine	serum	(Biochrom	AG,	S0615),	1	%	L-glutamin	(Life	Technologies)	and	1%	
penicillin/streptomycin	 (Life	 Technologies).	 CUTLL1,	 HPB-ALL,	 TALL-1	 and	 ALL-SIL	
cells	were	seeded	at	a	density	of	1*106	cells/ml	and	treated	with	either	DMSO	or	1	
μM	of	Compound	E	(Enzo	Life	Sciences).	Cells	were	harvested	12	and	48	hours	after	
treatment.	
	
RNA-isolation,	cDNA	synthesis	and	RT-qPCR	
Total	RNA	was	harvested	with	the	miRNeasy	minikit	(Qiagen)	with	DNase	treatment	
on-column.	 RNA-concentrations	 were	 measured	 by	 means	 of	 spectrophotometry	
(Nanodrop).	 cDNA	 was	 synthesized	 using	 the	 iScript	 cDNA	 synthesis	 kit	 (Biorad)	
according	to	the	manufacturers’	protocol,	starting	with	500ng	of	RNA,		followed	by	
RT-qPCR	using	 the	 Light	Cycler	480	 (Roche).	 Finally,	 qPCR	data	was	analyzed	using	
the	qBasePLUS	software	(Biogazelle)	according	to	the	ΔΔCt-method.	
	
Target	 Forward	primer	 Reverse	primer	
c-MYC	 GCCACGTCTCCACACATCAG	 TGGTGCATTTTCGGTTGTTG	
HES1	 TGTCAACACGACACCGGATAAA	 CCATAATAGGCTTTGATGACTTTCTG	
DTX1	 ACGAGAAAGGCCGGAAGGT	 GGTGTTGGACGTGCCGATAG	
HPRT	 TGACACTGGCAAAACAATGCA	 GGTCCTTTTCACCAGCAAGCT	
HMBS	 GGCAATGCGGCTGCAA	 GGGTACCCACGCGAATCAC	
TBP	 CACGAACCACGGCACTGATT	 TTTTCTTGCTGCCAGTCTGGAC	
B2M	 TGCTGTCTCCATGTTTGATGTATCT	 TCTCTGCTCCCCACCTCTAAGT	
	
	
	 	
Reaction	conditions	for	RT-qPCR	
	
Components	 Amount	
sSo	Advanced	2x	mastermix	 2,5	µl	
Forward	Primer	(5	µM)	 0,25	µl	
Reverse	Primer	(5	µM)	 0,25	µl	
cDNA	(2,5	ng/µl)	 2	µl	
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Thermocycling	parameters	
	
Step	 Temperature	 Time	 Cycles	
Enzyme	activation	 95	°C	 2	min	 1	
Amplification	 95	°C	
60	°C	
72	°C	
5	sec	
30	sec	
1	sec	
44	
Melting	cyclus	 95	°C	
60	°C	
95	°C	
5	sec	
1	min	
continuous	
1	
Cooling	 37	°C	 3	min	 1	
	
	
Western	blotting	
Total	 protein	 isolation	 was	 performed	 with	 RIPA-lysis	 buffer,	 supplemented	 with	
protease	 inhibitors	and	SDS-PAGE	was	performed	according	 to	 standard	protocols.	
For	 immunoblotting,	 the	 rabbit	 polyclonal	 antibody	 to	 cleaved	 NOTCH1	 (Cell	
signaling)	was	used	in	a	1:500	dilution	in	BSA.	
	
Protein	coding	potential	calculation	
We	 used	 PhyloCSF	 to	 identify	 putative	 protein	 coding	 	 transcripts	 in	 the	
unannotated,	 novel	 putative	 lncRNA	 loci	 obtained	 by	 RNA-seq.	 This	 algorithm	
employs	codon	substitution	frequencies	 in	whole-genome	multi-species	alignments	
to	distinguish	between	coding	and	non-coding	loci.	Whole-genome	alignments	of	46	
species	are	obtained	from	the	UCSC	website	and	processed	using	the	PHAST	package	
(version	1.3)	to	obtain	the	required	input	format	for	PhyloCSF.		
	
To	validate	our	workflow,	we	benchmarked	PhyloCSF	with	transcripts	annotated	 in	
Ensembl	 (version	 75).	 Transcripts	 with	 biotype	 ‘lincRNA’	 or	 ‘antisense’	 (20,320	
transcripts)	 serve	 as	 a	 negative	 set	while	 transcripts	with	 biotype	 ‘protein	 coding’	
and	an	annotated	coding	sequence	(36,959	transcripts)	serve	as	a	positive	set.	Using	
these	 sets,	 we	 have	 determined	 41.2019	 as	 an	 optimal	 treshold	 for	 the	 PhyloCSF	
score	(precision	of	95%	and	sensitivity	of	91%).	
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Micro-array	based	gene	expression	profiling	
RNA	samples	 from	T-ALL	 cells	 treated	with	GSI,	CD34+	 thymocytes	 cultured	on	 the	
OP9-GFP/DLL1	system,	sorted	T-cell	subsets	(CD34+	and	CD4+CD8+)	and	two	primary	
T-ALL	patient	 cohorts	 of	which	one	 cohort	 including	 samples	with	 known	NOTCH1	
mutation	 status	 (n=15)	 (all	 FBXW7	 wild	 type)	 and	 a	 larger	 cohort	 (n=64)	 were	
profiled	on	a	custom	designed	Agilent	micro-array	covering	all	protein	coding	genes	
and	12,000	lncRNAs	(23,042	unique	lncRNA	probes)	as	described	by	Volders	et	al.46	
Profiling	 was	 performed	 according	 to	 the	 manufacturers	 protocol	 (One-color	
Microarray-Based	Gene	Expression	Analysis,	Low	Input	Quick	Amp	Labeling,	Agilent	
Technologies),	with	100	ng	RNA	as	input.	Normalization	of	the	expression	data	was	
performed	with	the	VSN-package	(BioConductor	release	2.12)	in	R.	Expression	values	
were	 further	 subjected	 to	 background	 subtraction	 by	 selecting	 those	 probes	
detecting	 a	 10%	 higher	 expression	 than	 the	 negative	 control	 probes	 of	 the	 array	
design	in	at	least	one	treatment.	Differential	expression	analysis	was	performed	in	R	
using	Limma.	A	multifactorial	design	was	used	to	control	for	batch	effects.	
	
Correlation	analysis	for	functional	annotation	of	selected	lncRNAs	
Normalized	 micro-array	 based	 gene	 expression	 profiles	 were	 generated	 for	 all	
samples	 of	 the	 primary	 T-ALL	 patient	 cohort	 (n=64).	 Spearman’s	 rho	 values	 were	
calculated	between	15	out	of	 the	set	of	27	overlapping	annotated	 lncRNAs	 (Figure	
2E)	 (and	 also	 for	 LUNAR1	 (lnc-IGF1R-1))	 for	 which	 a	 probe	 on	 the	 custom	micro-
array46	was	available.	This	output	was	used	to	generate	a	ranked	(.rnk)	file	and	used	
as	 an	 input	 for	 a	 GSEA	 pre-ranked	 analysis	 using	 the	 c2v3.1	MsigDB	 collection	 as	
geneset	 database.	 The	 output	 files	 were	 subsequently	 loaded	 into	 Cytoscape.	 By	
means	 of	 the	 Cytoscape	 plug-in	 ‘enrichment	 mapping’	 (Isserling	 et	 al.,	
F1000Research,	2014),	enrichment	maps	were	built	representing	functional	gene	set	
clusters	that	were	significantly	correlated	(red	nodes)	or	anti-correlated	(blue	nodes)	
with	the	lncRNA-of-interest.			
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SUPPLEMENTARY	TABLES	
	
Supplementary	Table	1:	RNA-seq	alignment	summary	for	CUTLL1	samples	
Sample	
name	
Paired-end	
reads	
Aligned	
Pairs	
Aligned	
Pairs	
(%)	
Multimapping	
pairs	
Multimapping	
pairs	(%)	
Concordant	
aligned	
pairs	(%)	
DMSO	12h	repl1	 146323593	 131275766	 89.7	 3216065	 2.4	 88.8	
DMSO	48h	repl1	 131215273	 117807914	 89.8	 2895717	 2.5	 88.9	
GSI	12h	repl1	 159416630	 143627829	 90.1	 3462073	 2.4	 89.3	
GSI	48h	repl1	 95100288	 85514736	 89.9	 2019348	 2.4	 89.1	
DMSO	12h	repl2	 135554412	 122299013	 90.2	 2828382	 2.3	 89.5	
DMSO	48h	repl2	 100687539	 90796028	 90.2	 2110770	 2.3	 89.4	
GSI	12h	repl2	 199650982	 180374457	 90.3	 4257865	 2.4	 89.6	
GSI	48h	repl2	 169001713	 152387296	 90.2	 3637367	 2.4	 89.3	
DMSO	12h	repl3	 153193248	 138567335	 90.5	 3389716	 2.4	 89.6	
DMSO	48h	repl3	 98349936	 88513219	 90.0	 2165418	 2.5	 89.1	
GSI	12h	repl3	 117967005	 106283685	 90.1	 2499311	 2.4	 89.2	
GSI	48h	repl3	 95918114	 86593969	 90.3	 2058472	 2.4	 89.4	
	
Chapter	3:	Results	
	 	 	249	
Supplementary	Table	2:	RNA-seq	alignment	summary	for	OP9	samples	
Sample	
Name	
Paired-end	
reads	
Aligned	
Pairs	
Aligned	
Pairs	
(%)	
Multimapping	
pairs	
Multimapping	
pairs	(%)	
Concordant	
aligned	
pairs	(%)	
OP9-GFP	donor	1	 175557925	 157523775	 89.7	 3998129	 2.5	 88.9	
OP9-DLL1	donor	1	 121468805	 110981627	 91.4	 2682569	 2.4	 90.4	
OP9-GFP	donor	2	 133723750	 119466289	 89.3	 3172892	 2.5	 88.4	
OP9-DLL1	donor	2	 194441409	 177560274	 91.3	 4350749	 2.5	 90.5	
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Supplementary	Table	3:	Overview	of	27	differentially	expressed	(baseMean	>	100)	
and	annotated	Notch	positively	 regulated	 lncRNAs	shared	between	CUTLL1	T-ALL	
cells	and	CD34+	T-cells	on	OP9	
Chr	 start	 stop	 													Ensembl	ID	 lncipedia	
chr1	 113499037	 113544813	 ENSG00000226419	 lnc-LRIG2-4	
chr1	 173833038	 173838020	 ENSG00000234741	 lnc-SERPINC1-1	
chr1	 230394440	 230404229	 ENSG00000227006	 lnc-PGBD5-2	
chr1	 239866684	 239893765	 ENSG00000233355	 lnc-GREM2-6	
chr2	 87754887	 87906324	 ENSG00000222041	 lnc-PLGLB2-1	
chr2	 99378401	 99388543	 ENSG00000226791	 lnc-c2orf55-1	
chr2	 111965353	 112252677	 ENSG00000172965	 lnc-AC108463.1-3	
chr2	 132160474	 132166622	 ENSG00000223631	 lnc-PLEKHB2-1	
chr2	 136577761	 136580657	 ENSG00000226806	 lnc-UBXN4-1	
chr5	 987295	 997423	 ENSG00000215246	 lnc-SLC12A7-4	
chr5	 111496223	 111499973	 ENSG00000224032	 lnc-APC-6	
chr6	 86370710	 86388451	 ENSG00000203875	 lnc-SYNCRIP-2	
chr7	 22893875	 22901021	 ENSG00000228649	 lnc-IL6-2	
chr8	 130228728	 130253496	 ENSG00000250400	 lnc-GSDMC-2	
chr9	 96197614	 96199403	 ENSG00000227603	 lnc-FAM120AOS-1	
chr9	 139440664	 139444345	 ENSG00000237886	 lnc-c9orf163-2	
chr16	 2204798	 2205359	 ENSG00000260260	 lnc-PKD1-1	
chr16	 66921918	 66922834	 ENSG00000261705	 lnc-CA7-1	
chr16	 66923072	 66924996	 ENSG00000261088	 lnc-CA7-2	
chr16	 81416874	 81424489	 ENSG00000261609	 lnc-GAN-1	
chr17	 13932609	 13972775	 ENSG00000223385	 lnc-CDRT15-2	
chr17	 14113805	 14121239	 ENSG00000231595	 lnc-COX10-1	
chr17	 14207171	 14208822	 ENSG00000266709	 lnc-COX10-3	
chr17	 16342136	 16381992	 ENSG00000175061	 lnc-TRPV2-1	
chr21	 47013568	 47017005	 ENSG00000233922	 lnc-PCBP3-1	
chr22	 23804273	 23829167	 ENSG00000178248	 lnc-IGLL1-2	
chrX	 130836678	 130964671	 ENSG00000213468	 lnc-FRMD7-1	
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Supplementary	Table	4:	Overview	of	13	differentially	expressed	(baseMean	>	100)	
and	 unannotated	Notch	 positively	 regulated	 lncRNAs	 shared	 between	 CUTLL1	 T-
ALL	cells	and	CD34+	T-cells	on	OP9	
Chr	 CUTLL1_Start	 CUTLL1_End	 CUTLL1_Name	 OP9_Start	 OP9_End	 OP9_Name	
chr3	 72762617	 72774075	 XLOC_032451	 72767224	 72773948	 XLOC_032318	
chr3	 73027441	 73028329	 XLOC_032454	 73027514	 73028331	 XLOC_032320	
chr3	 138253033	 138254792	 XLOC_032825	 138252949	 138255180	 XLOC_032820	
chr5	 81616893	 81636923	 XLOC_036711	 81616441	 81629071	 XLOC_036960	
chr5	 81667707	 81678632	 XLOC_036719	 81672215	 81678702	 XLOC_036966	
chr12	 113652353	 113654532	 XLOC_010851	 113649939	 113654123	 XLOC_010919	
chr14	 72878457	 72906694	 XLOC_012963	 72875211	 72906687	 XLOC_012750	
chr15	 99557714	 99589675	 XLOC_014517	 99557739	 99586083	 XLOC_014390	
chr17	 3577525	 3578999	 XLOC_019018	 3578539	 3578908	 XLOC_018585	
chr17	 3599783	 3616722	 XLOC_018313	 3600043	 3602985	 XLOC_018591	
chr20	 13350996	 13368579	 XLOC_028304	 13350988	 13366426	 XLOC_027976	
chr21	 46975354	 46985114	 XLOC_029412	 46975468	 46978095	 XLOC_029330	
chr22	 23874749	 23889951	 XLOC_029562	 23878831	 23890363	 XLOC_029452	
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Supplementary	Table	5:	Overview	of	18	differentially	expressed	(baseMean	>	100)	
and	annotated	Notch	negatively	regulated	lncRNAs	shared	between	CUTLL1	T-ALL	
cells	and	CD34+	T-cells	on	OP9	
Chr	 start	 stop	 Ensembl	ID	 lncipedia	
chr1	 111196182	 111216076	 ENSG00000259834	 lnc-KCNA3-1	
chr4	 153021906	 153025872	 ENSG00000245954	 lnc-FAM160A1-6	
chr4	 174243357	 174250845	 ENSG00000248774	 lnc-HMGB2-1	
chr6	 114290865	 114792869	 ENSG00000228624	 lnc-MARCKS-5	
chr6	 71961061	 72037787	 ENSG00000232295	 lnc-B3GAT2-2	
chr7	 141404138	 141438146	 ENSG00000228775	 lnc-KIAA1147-2	
chr8	 60031599	 60034363	 ENSG00000167912	 lnc-SDCBP-2	
chr12	 47599681	 47610239	 ENSG00000247774	 lnc-AMIGO2-1	
chr13	 30914407	 30951327	 ENSG00000238121	 lnc-KATNAL1-3	
chr14	 98602411	 98628990	 ENSG00000258511	 lnc-C14orf177-3	
chr15	 58879706	 58883875	 ENSG00000259250	 lnc-LIPC-1	
chr15	 38794807	 38797182	 ENSG00000259326	 lnc-FAM98B-1	
chr16	 66441932	 66447150	 ENSG00000246898	 lnc-CDH5-1	
chr16	 89179583	 89181687	 ENSG00000261546	 lnc-CBFA2T3-2	
chr17	 67547499	 67550002	 ENSG00000267194	 lnc-MAP2K6-5	
chr19	 35302493	 35305249	 ENSG00000261754	 lnc-ZNF599-1	
chr19	 35279486	 35323773	 ENSG00000267767	 lnc-ZNF599-2	
chr19	 54862991	 54864894	 ENSG00000268802	 lnc-LAIR1-1	
	
	
Supplementary	 Table	 6:	 Overview	 of	 7	 differentially	 expressed	 (baseMean>100)	
and	 unannotated	Notch	 positively	 regulated	 lncRNAs	 shared	 between	 CUTLL1	 T-
ALL	cells	and	CD34+	T-cells	on	OP9	
	
Chr	 CUTLL1_Start	 CUTLL1_End	 CUTLL1_Name	 OP9_Start	 OP9_End	 OP9_Name	
chr2	 191439671	 191455565	 XLOC_026974	 191439699	 191456830	 XLOC_027082	
chr3	 141515902	 141519763	 XLOC_032844	 141515791	 141519759	 XLOC_030962	
chr5	 80698801	 80702028	 XLOC_036686	 80699345	 80701960	 XLOC_036927	
chr14	 53020359	 53032577	 XLOC_013366	 53020411	 53032938	 XLOC_013224	
chr15	 58731929	 58747956	 XLOC_015245	 58737362	 58747955	 XLOC_015119	
chr15	 60824624	 60829179	 XLOC_015269	 60824529	 60829869	 XLOC_015183	
chr22	 22609022	 22620320	 XLOC_030158	 22615017	 22620331	 XLOC_029961	
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Supplementary	Table	7:	Unannotated	putative	lncRNA	loci	identified	in	CUTLL1	by	
RNA-seq	and	predicted	as	‘coding’	by	PhyloCSF	analysis	(precision:	95%;	sensitivity:	
90%)	
	
ID	 Score	 Chr	 Start	 End	
TCONS_00056766	 52.15	 chr1	 2246753	 2251281	
TCONS_00086798	 43.68	 chr1	 51628045	 51630685	
TCONS_00081942	 44.76	 chr1	 111333342	 111342403	
TCONS_00056764	 52.15	 chr1	 117354279	 117370293	
TCONS_00051781	 54.1	 chr2	 102007909	 102010517	
TCONS_00048597	 60.08	 chr2	 235384613	 235389131	
TCONS_00056543	 49.11	 chr2	 240516862	 240526394	
TCONS_00059899	 41.56	 chr2	 241126710	 241128149	
TCONS_00080921	 72.2	 chr4	 187952855	 187953853	
TCONS_00086799	 43.68	 chr5	 39099174	 39103319	
TCONS_00086796	 43.68	 chr5	 82223281	 82226577	
TCONS_00056765	 52.15	 chr6	 14444424	 14450217	
TCONS_00081943	 44.76	 chr6	 14451309	 14514496	
TCONS_00080012	 48.79	 chr6	 33548126	 33551228	
TCONS_00048598	 60.08	 chr6	 85587066	 85588203	
TCONS_00056767	 52.15	 chr7	 44122439	 44135578	
TCONS_00076833	 65.01	 chr7	 64940991	 64949641	
TCONS_00088333	 466.21	 chr8	 53673358	 53694399	
TCONS_00086792	 43.68	 chr8	 53675310	 53676444	
TCONS_00081938	 44.76	 chr8	 144272996	 144280254	
TCONS_00040364	 48.99	 chr9	 46278172	 46282364	
TCONS_00055762	 113.61	 chr9	 139472437	 139475056	
TCONS_00090830	 60.61	 chr10	 8393180	 8395114	
TCONS_00055763	 112.45	 chr10	 89871096	 89872775	
TCONS_00077100	 103.42	 chr10	 125757085	 125759130	
TCONS_00081941	 44.76	 chr11	 134570645	 134576828	
TCONS_00048600	 60.08	 chr12	 10472892	 10473695	
TCONS_00086793	 43.68	 chr13	 87409766	 87431966	
TCONS_00086794	 43.68	 chr13	 87441562	 87444206	
TCONS_00051777	 86.28	 chr13	 105817944	 105838505	
TCONS_00086795	 43.68	 chr13	 110359240	 110360897	
TCONS_00088327	 117.61	 chr14	 97646784	 97665870	
TCONS_00077099	 103.42	 chr14	 106837417	 106838015	
TCONS_00022415	 43.96	 chr14	 106856726	 106857157	
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TCONS_00056483	 65.43	 chr14	 107161628	 107161912	
TCONS_00087227	 86.57	 chr14	 107164554	 107166077	
TCONS_00062955	 46.92	 chr15	 46675349	 46676557	
TCONS_00083990	 45.3	 chr16	 13337081	 13337749	
TCONS_00040365	 48.35	 chr17	 3599782	 3616722	
TCONS_00088325	 117.61	 chr17	 63491521	 63501505	
TCONS_00088330	 117.61	 chr17	 72486556	 72487602	
TCONS_00081939	 44.76	 chr18	 10298402	 10305837	
TCONS_00056542	 61.16	 chr18	 10319095	 10322466	
TCONS_00086797	 43.68	 chr18	 76390627	 76397128	
TCONS_00091468	 158.24	 chr18	 76393073	 76397128	
TCONS_00086800	 43.68	 chr18	 76393688	 76397128	
TCONS_00038764	 42.54	 chr18	 76423717	 76444074	
TCONS_00080917	 46.34	 chr18	 76525660	 76529323	
TCONS_00091467	 158.49	 chr20	 24688672	 24707491	
TCONS_00088326	 466.21	 chr20	 39373455	 39385194	
TCONS_00088328	 50	 chr20	 39373455	 39383151	
TCONS_00088332	 117.61	 chr20	 56293787	 56304682	
TCONS_00081940	 44.76	 chr20	 56293787	 56304682	
TCONS_00058284	 85.71	 chr20	 56414001	 56415852	
TCONS_00021977	 58.74	 chr21	 47037435	 47038182	
TCONS_00059898	 41.56	 chr21	 47045984	 47059169	
TCONS_00022416	 43.96	 chr21	 47372575	 47376597	
TCONS_00021976	 85.3	 chr22	 23874748	 23889951	
TCONS_00088331	 117.61	 chr22	 46544029	 46545743	
TCONS_00088329	 466.21	 chrX	 18902412	 18903831	
TCONS_00087753	 186.24	 chrX	 63985367	 64002448	
TCONS_00056486	 95.4	 chrX	 78606175	 7861790	
TCONS_00087636	 70.65	 chrX	 130828109	 130829871	
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Supplementary	 Table	 8:	 Unannotated	 putative	 lncRNA	 loci	 identified	 in	 CD34+	
thymocytes	cultured	on	an	OP9	stromal	feeder	layer	by	RNA-seq	and	predicted	as	
‘coding’	by	PhyloCSF	analysis	(precision:	95%;	sensitivity:	90%)	
ID	 Score	 Chr	 Start	 End	
TCONS_00072393	 44.47	 chr1	 59763517	 59766075	
TCONS_00000024	 71.81	 chr1	 94482764	 94483785	
TCONS_00049576	 119.44	 chr1	 184071088	 184080918	
TCONS_00018092	 49.19	 chr1	 201492686	 201496026	
TCONS_00013282	 57.67	 chr1	 204579092	 204583098	
TCONS_00005447	 74.64	 chr1	 206266987	 206269412	
TCONS_00028199	 47.43	 chr2	 8578376	 8582043	
TCONS_00056874	 57.99	 chr2	 47765920	 47769139	
TCONS_00052880	 192.83	 chr2	 75488665	 75490774	
TCONS_00008149	 71.82	 chr2	 75944631	 75947096	
TCONS_00006489	 53.11	 chr2	 89074227	 89074933	
TCONS_00059446	 73.91	 chr2	 102979438	 102980995	
TCONS_00036912	 58.06	 chr2	 128352279	 128353933	
TCONS_00037996	 44.64	 chr2	 129448171	 129449912	
TCONS_00007201	 51.59	 chr2	 173364320	 173364905	
TCONS_00025943	 65.72	 chr2	 197044762	 197046167	
TCONS_00061061	 99.23	 chr3	 16005716	 16014366	
TCONS_00006917	 203.31	 chr3	 18572889	 18574386	
TCONS_00046453	 72.11	 chr3	 45844195	 45846999	
TCONS_00009952	 43.38	 chr3	 45854323	 45856659	
TCONS_00029725	 42.29	 chr3	 72767223	 72773948	
TCONS_00050097	 130.58	 chr3	 107844588	 107860198	
TCONS_00041198	 54.4	 chr3	 129325763	 129327842	
TCONS_00009908	 98.04	 chr3	 167462678	 167466894	
TCONS_00071913	 41.51	 chr3	 185543397	 185547711	
TCONS_00024054	 385.19	 chr3	 194355573	 194360483	
TCONS_00050052	 113.61	 chr3	 194356984	 194360483	
TCONS_00023792	 46.54	 chr4	 25171054	 25176183	
TCONS_00062252	 43.52	 chr4	 25213770	 25219660	
TCONS_00019745	 42.84	 chr4	 40187190	 40191932	
TCONS_00071014	 138.77	 chr4	 123200409	 123200928	
TCONS_00064666	 45.23	 chr5	 345191	 345528	
TCONS_00029210	 73.7	 chr5	 5315687	 5317724	
TCONS_00062251	 43.52	 chr5	 65386257	 65389744	
TCONS_00024695	 55.93	 chr5	 86362230	 86371165	
TCONS_00007271	 57.61	 chr5	 89774583	 89776807	
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TCONS_00011164	 49.19	 chr5	 133376357	 133393098	
TCONS_00062270	 49.32	 chr5	 150606606	 150631743	
TCONS_00057599	 66.44	 chr5	 179890063	 179891602	
TCONS_00052572	 57.74	 chr6	 2403148	 2406370	
TCONS_00050701	 47.74	 chr6	 3304830	 3310274	
TCONS_00026406	 90.5	 chr6	 5072922	 5073683	
TCONS_00064968	 68.85	 chr6	 6702961	 6704251	
TCONS_00047535	 48.93	 chr6	 14398440	 14401713	
TCONS_00064969	 68.85	 chr6	 14452366	 14452809	
TCONS_00064967	 68.85	 chr6	 14511669	 14512993	
TCONS_00013283	 57.67	 chr6	 14661252	 14662655	
TCONS_00013983	 87.82	 chr6	 15744959	 15749318	
TCONS_00045206	 66.38	 chr6	 29850640	 29852333	
TCONS_00006709	 61.13	 chr6	 37009596	 37012118	
TCONS_00029415	 50.56	 chr6	 106277928	 106340820	
TCONS_00052342	 50.46	 chr6	 130516350	 130518701	
TCONS_00066073	 79.81	 chr6	 130519728	 130521019	
TCONS_00045196	 49.01	 chr6	 130538723	 130540284	
TCONS_00068680	 78.18	 chr6	 149453055	 149454182	
TCONS_00028198	 52.78	 chr6	 150206104	 150207553	
TCONS_00066074	 79.81	 chr6	 156149206	 156204567	
TCONS_00007518	 47.02	 chr6	 157795798	 157802109	
TCONS_00068988	 94.15	 chr6	 161585933	 161586608	
TCONS_00049704	 82.1	 chr7	 1549453	 1560923	
TCONS_00057036	 51.44	 chr7	 23562289	 23569431	
TCONS_00052257	 66.33	 chr7	 99822288	 99824735	
TCONS_00023996	 48.35	 chr10	 88159462	 88162084	
TCONS_00013280	 57.67	 chr10	 98774668	 98775476	
TCONS_00039798	 49.01	 chr11	 36618167	 36618905	
TCONS_00029745	 61.14	 chr11	 64098670	 64099428	
TCONS_00023407	 51.88	 chr11	 127920833	 128057011	
TCONS_00029266	 125.21	 chr11	 127921365	 127931679	
TCONS_00019744	 42.84	 chr12	 2853698	 2858699	
TCONS_00029267	 125.21	 chr12	 2862395	 2865432	
TCONS_00050031	 69.4	 chr12	 9756644	 9758808	
TCONS_00029209	 73.7	 chr12	 12881631	 12883860	
TCONS_00018582	 172.63	 chr12	 92032126	 92039218	
TCONS_00056635	 46.92	 chr12	 113649938	 113654123	
TCONS_00064971	 43.71	 chr12	 113671963	 113673219	
TCONS_00050079	 72.43	 chr12	 117254966	 117257189	
TCONS_00059445	 73.91	 chr13	 49105331	 49107037	
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TCONS_00028236	 57.24	 chr13	 100065629	 100070089	
TCONS_00064970	 49.99	 chr14	 23437727	 23438969	
TCONS_00013979	 180.78	 chr14	 53068696	 53069630	
TCONS_00007335	 42.33	 chr14	 65420816	 65423040	
TCONS_00067832	 284.96	 chr14	 72893256	 72906687	
TCONS_00062629	 47.14	 chr14	 72893256	 72906552	
TCONS_00036913	 58.06	 chr14	 72900554	 72900967	
TCONS_00049502	 51.09	 chr14	 72991218	 72992231	
TCONS_00034745	 42.14	 chr14	 73032380	 73033337	
TCONS_00029813	 69.45	 chr14	 100528647	 100529255	
TCONS_00009953	 43.98	 chr14	 106969092	 106969523	
TCONS_00024694	 55.93	 chr15	 40338297	 40342680	
TCONS_00036185	 49.23	 chr15	 56939054	 56939702	
TCONS_00063288	 47.57	 chr15	 56942051	 56942536	
TCONS_00013977	 46.88	 chr15	 66761087	 66770639	
TCONS_00050927	 52.15	 chr15	 69117878	 69120611	
TCONS_00057832	 48.94	 chr15	 70551056	 70553387	
TCONS_00050925	 52.15	 chr15	 90597897	 90599313	
TCONS_00059609	 215.5	 chr15	 99557738	 99574337	
TCONS_00034744	 42.54	 chr15	 99569810	 99574337	
TCONS_00063770	 88.29	 chr16	 2469884	 2470738	
TCONS_00063304	 49.76	 chr16	 49672974	 49674445	
TCONS_00048613	 42.52	 chr16	 67602034	 67603724	
TCONS_00059447	 73.91	 chr16	 68428413	 68430973	
TCONS_00052256	 41.29	 chr16	 72260597	 72265505	
TCONS_00047337	 74.83	 chr16	 83976427	 83979066	
TCONS_00029774	 63.28	 chr16	 85495679	 85496270	
TCONS_00071013	 138.77	 chr16	 87931351	 87934262	
TCONS_00033907	 63.44	 chr17	 26218043	 26218928	
TCONS_00067628	 142.98	 chr17	 29042829	 29051874	
TCONS_00024062	 248.12	 chr17	 37314134	 37315360	
TCONS_00072724	 53.63	 chr17	 43277314	 43281145	
TCONS_00029705	 64.89	 chr17	 45023736	 45030864	
TCONS_00018205	 59.56	 chr17	 62396691	 62407826	
TCONS_00050080	 53.87	 chr17	 66361368	 66363633	
TCONS_00059448	 73.91	 chr17	 75842425	 75847375	
TCONS_00008150	 71.82	 chr18	 3696263	 3697848	
TCONS_00014925	 41.49	 chr19	 16259690	 16259996	
TCONS_00067730	 47.41	 chr19	 21714994	 21717673	
TCONS_00063275	 119.25	 chr19	 54878348	 54879779	
TCONS_00057833	 45.18	 chr20	 4185348	 4187974	
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TCONS_00026403	 42.58	 chr20	 13770520	 13773490	
TCONS_00063302	 44.62	 chr21	 45614432	 45619053	
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Supplementary	 Table	 9:	 Correlation	 of	 selected	 annotated	 lncRNAs	 with	 DTX1	
expression	in	T-cell	subsets	of	4	healthy	donors	
Spearman	 correlation	
lncRNA	with	DTX1	
r	 p	(two-tailed)	 p-value	summary	
LUNAR1	 0.9386	 0,0165	 *	
lnc-SYNCRIP-2	 0.2912	 0.3344	 ns	
lnc-SLC12A7-4	 0.7308	 0,0045	 **	
lnc-PLEKHB2-1	 0.8022	 0,0010	 ***	
lnc-c2orf55-1	 0.7033	 0,0073	 **	
lnc-UBXN4-1	 0.6154	 0,0252	 *	
lnc-PGBD5-2	 0.3681	 0,2159	 ns	
lnc-FAM120AOS-1	 -0.06593	 0,8305	 ns	
lnc-COX10-1	 -0.2692	 0,3737	 ns	
lnc-SERPINC1-1	 0.7857	 0,0015	 **	
lnc-c9orf163-2	 0.01099	 0,9716	 ns	
lnc-GSDMC-2	 0.7582	 0,0027	 **	
lnc-PKD1-1	 0.7527	 0,0030	 **	
lnc-CA7-2	 0.7967	 0,0011	 **	
lnc-GAN-1	 0.3242	 0,2799	 ns	
lnc-CA7-1	 0.7198	 0,0055	 **	
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Supplementary	Table	10:	NOTCH1	mutation	status	of	primary	T-ALL	samples	
	 NOTCH1	
WT	
NOTCH1	MUT	
PEST	
NOTCH1	MUT	
HD	
NOTCH1	MUT	
PEST+HD	
n	 8	 3	 2	 2	
	
Supplementary	Table	11:	Differential	expression	and	significance	level	of	selected	
annotated	lncRNAs	in	primary	T-ALL	samples	of	8	NOTCH1	WT	and	7	NOTCH1	MUT	
cases		
lncRNA	 logFC	 P	
LUNAR1	 2.376	 0.0290	
lnc-SYNCRIP-2	 0.3544	 0.4765	
lnc-SLC12A7-4	 -0.0466	 0.9400	
lnc-PLEKHB2-1	 0.3689	 0.5840	
lnc-c2orf55-1	 0.3275	 0.6443	
lnc-UBXN4-1	 1.3274	 0.0600	
lnc-PGBD5-2	 0.2793	 0.3982	
lnc-FAM120AOS-1	 0.9387	 0.0072	
lnc-COX10-1	 0.3860	 0.5047	
lnc-SERPINC1-1	 0.2643	 0.4333	
lnc-c9orf163-2	 0.5812	 0.0982	
lnc-GSDMC-2	 2.2868	 0.1052	
lnc-PKD1-1	 0.2334	 0.6461	
lnc-CA7-2	 0.1776	 0.6448	
lnc-GAN-1	 0.3355	 0.4639	
lnc-CA7-1	 0.0539	 0.8577	
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Supplementary	Table	12:	Notch1,	Brd4,	Med1	and	H3K27ac	ChIP-sequencing	peaks	
for	the	selected	annotated	lncRNAs	
lncRNA	 Notch1	 Brd4	 Med1	 H3K27ac	
lnc-SYNCRIP-2	 X	 X	 X	 X	
lnc-SLC12A7-4	 -	 X	 X	 X	
lnc-PLEKHB2-1	 X	 X	 -	 X	
lnc-c2orf55-1	 X	 X	 X	 X	
lnc-UBXN4-1	 X	 X	 X	 X	
lnc-PGBD5-2	 -	 X	 -	 X	
lnc-FAM120AOS-1	 -	 -	 -	 -	
lnc-COX10-1	 -	 -	 -	 -	
lnc-SERPINC1-1	 X	 X	 X	 X	
lnc-c9orf163-2	 X	 X	 X	 X	
lnc-GSDMC-2	 X	 X	 X	 X	
lnc-PKD1-1	 X	 X	 X	 X	
lnc-CA7-2	 -	 -	 -	 -	
lnc-GAN-1	 -	 -	 -	 -	
lnc-CA7-1	 -	 -	 -	 -	
lnc-AC108463.1-3	 -	 -	 -	 -	
lnc-TRPV2-1	 X	 X	 X	 X	
lnc-IGLL1-2	 -	 X	 X	 X	
lnc-FRMD7-1	 -	 -	 -	 -	
lnc-PLGLB2-1	 -	 -	 -	 -	
lnc-CDRT15-2	 -	 X	 X	 X	
lnc-APC-6	 X	 X	 X	 X	
lnc-LRIG2-4	 X	 X	 X	 X	
lnc-IL6-2	 X	 X	 X	 X	
lnc-GREM2-6	 X	 X	 X	 X	
lnc-PCBP3-1	 -	 X	 -	 X	
lnc-COX10-3	 -	 -	 -	 -	
	
X:	presence	of	a	ChIP-sequencing	peak,	-:	absence	of	a	ChIP-sequencing	peak	
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SUPPLEMENTARY	FIGURES	
	
	
Supplementary	Figure	1:	Validation	of	the	pharmacological	Notch	inhibition	model	in	CUTLL1.	
(A)	 Down-regulation	 of	 ICN1	 protein	 levels	 upon	 GSI	 treatment	 for	 12h	 and	 48h	 in	 CUTLL1	 was	
validated	 by	western	 blot	 analysis.	 (B)	 RT-qPCR	 could	 confirm	 down-regulation	 of	DTX1	 expression	
upon	GS	Itreatment	of	CUTLL1	T-ALL	cells.	
	
	
	
Supplementary	 Figure	 2:	 Overlap	 between	 lncRNAs	 that	 are	 negatively	 correlated	 with	 Notch	
signaling	in	GSI	treatment	of	CUTLL1	cells	and	co-culturing	of	CD34+	thymocytes	on	the	OP9-DLL1	
feeder	layer.	
(A)	Venn	diagram	depicting	the	overlap	between	previously	annotated	lncRNAs	that	are	upregulated	
upon	 GSI	 treatment	 of	 the	 CUTLL1	 cell	 line	 and	 down-regulated	 upon	 co-culturing	 of	 CD34+	
thymocytes	 on	 the	 OP9-DLL1	 feeder	 layer.	 (B)	 Venn	 diagram	 depicting	 the	 overlap	 between	
previously	unannotated	lncRNAs	that	are	upregulated	upon	GSI	treatment	of	the	CUTLL1	cell	line	and	
downregulated	upon	co-culturing	of	CD34+	thymocytes	on	the	OP9-DLL1	feeder	layer.	
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Supplementary	 Figure	3:	PhyloCSF	density	plot	 to	evaluate	 the	protein-coding	potential	of	novel,	
unannotated	lncRNA	loci	by	RNA-seq.	
The	putative	protein	coding	potential	of	unannotated	lncRNA	loci	in	CUTLL1	T-ALL	cells	and	CD34+	T-
cell	progenitors	cultured	on	an	OP9	stromal	feeder	layer	was	calculated	using	the	PhyloCSF	algorithm.	
The	optimal	treshold	for	the	PhyloCSF	score	was	determined	as	41.2019	to	obtain	a	precision	of	95%	
and	sensitivity	of	90%.	 	
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Supplementary	Figure	4:	Validation	of	Notch	regulated	lncRNAs	in	other	model	systems.	
(A)	Western	 blot	 analysis	 confirms	 down-regulation	 of	 ICN1	 in	 HPB-ALL	 and	 ALL-SIL	 cells	 upon	GSI	
treatment	for	12	h	and	48	h.	(B)	RT-qPCR	shows	DTX1	downregulation	upon	GSI	treatment	of	HPB-ALL	
and	 ALL-SIL	 T-ALL	 cells.	 GSEA	 shows	 significant	 overlap	 for	 differentially	 expressed	 protein-coding	
genes	 found	by	 RNA-seq	 and	micro-array	 data	 of	 (C)	GSI-treated	 CUTLL1	 cells	 and	 (D)	 CD34+	 T-cell	
progenitor	on	OP9-DLL1/GFP	co-cultures.	 	
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Supplementary	Figure	5:	Validation	of	direct	regulation	of	selected	lncRNAs	by	Notch1.	
ChIP-seq	tracks	in	CUTLL1	cells	of	Notch1,	Brd4,	Med1	and	H3K27ac	are	depicted	for	the	selection	of	
annotated	 lncRNAs	 that	were	 identified	 as	 overlapping	Notch1	 driven	 lncRNAs	 in	 CUTLL1	 cells	 and	
CD34+	progenitor	 cells	 cultured	on	OP9	 stromal	 cells.	Representative	RNA-seq	 tracks	are	 shown	 for	
both	in	vitro	model	systems.	
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Supplementary	Figure	6:	Functional	annotation	of	candidate	Notch	driven	lncRNAs	in	CUTLL1	T-ALL	
cells	and	CD34+	thymic	progenitor	T-cells	through	enrichment	mapping.	
(A-M)	 Pairwise	 Spearman’s	 rho	 correlations	 were	 calculated	 between	 the	 selected	 Notch	 driven	
lncRNAs	 (with	 probes	 on	 the	 custom	 array)	 and	 all	 protein-coding	 genes	 and	 used	 for	 functional	
annotation	of	each	of	the	candidate	lncRNAs	by	GSEA.	Followingly,	enrichment	maps	were	generated	
in	Cytoscape	for	all	selected	Notch	driven	 lncRNAs	and	 indicates	potential	clusters	of	 functionalities	
linked	to	each	of	the	candidate	lncRNAs	such	as	involvement	in	the	TCA-cycle,	meiosis,	TCR-signaling,	
....	
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ABSTRACT	
For	a	long	time,	proteins	were	considered	to	be	the	sole	hubs	that	could	support	a	
regulatory	 network.	 Technological	 advances	 have	 recently	 contributed	 to	 the	
recognition	and	understanding	of	the	central	role	of	RNA	species	in	homeostasis	and	
malignant	 transformation.	 More	 in	 particular,	 lncRNAs	 have	 now	 proven	 to	 be	
versatile	 and	 key	 players	 in	 transcriptional	 control,	 mainly	 acting	 in	 concert	 with	
epigenetic	modifier	proteins.	TLX1	is	a	transcription	factor	that	is	critically	involved	in	
the	 multi-step	 pathogenesis	 of	 T-cell	 acute	 lymphoblastic	 leukemia	 (T-ALL),	 an	
aggressive	 blood	 cancer	 mainly	 diagnosed	 in	 children.	 Although	 the	 oncogenic	
transcriptional	program	downstream	of	TLX1	has	been	extensively	characterized	at	
the	 level	 of	 protein	 coding	 genes,	 a	 comprehensive	 overview	 of	 lncRNAs	 that	 are	
regulated	by	this	transcription	factor	oncogene	remains	to	be	established.	Here,	we	
identified	and	functionally	dissected	the	role	of	lncRNAs	downstream	of	TLX1	in	the	
context	 of	 malignant	 T-cell	 transformation.	 These	 include	 amongst	 others,	 lnc-
THADA-1	 as	 the	 top-scoring	 super-enhancer	 associated	 lncRNA	 located	 in	 cis	 to	
ZFP36L2,	 a	 recently	 identified	 novel	 T-ALL	 tumor	 suppressor	 gene	 and	 lnc-DAD1-2	
residing	within	 the	 TCRα	 locus	 and	putatively	 involved	 in	 the	 interference	of	 TLX1	
with	 TCRα	 function.	 Locked	 nucleic	 acid	 (LNA)-mediated	 lnc-DAD1-2	 knockdown	
revealed	 a	 core	 set	 of	 commonly	 regulated	 genes	 as	 compared	 to	 TLX1,	 including		
important	genes	in	differentiation	and	cell	proliferation	such	as	RAG1	and	TERT.	This	
study	thus	provides	the	first	in	depth	landscaping	of	the	TLX1	lncRNAome	providing	
novel	 insights	 for	 further	 exploration	 of	 lncRNAs	 involved	 in	 T-cell	 transformation	
and	 normal	 thymocyte	 maturation	 and	 also	 offers	 novel	 targets	 for	 therapeutic	
intervention.		
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INTRODUCTION	
T-cell	 acute	 lymphoblastic	 leukemia	 (T-ALL)	 is	 an	 aggressive	 hematological	
malignancy arising	 from	uncontrolled	proliferation	 (clonal	 expansion)	 and	 arrested	
differentiation	of	immature	precursor	T-cells.	Genetic	and	epigenetic	studies	in	T-ALL	
have	 uncovered	 a	 remarkable	 complexity	 of	 oncogenic	 and	 loss-of-function	
mutations	 over	 the	 past	 decade.	 Distinct	molecular-cytogenetic	 subgroups	 can	 be	
defined	and	are	associated	with	a	 specific	gene	expression	signature.	So	 far,	 these	
profiles	have	only	been	defined	at	the	level	of	protein	coding	genes.	Considering	that	
the	proportion	of	the	whole	genome	with	protein	coding	potential	only	constitutes	
about	 2%,	 while	 up	 to	 70-90%	 is	 transcribed,	 the	 complexity	 of	 regulatory	
mechanisms	 involved	 in	 normal	 development	 and	 disease	 can	 only	 be	 fully	
understood	when	also	considering	the	non-coding	part	of	the	genome1.		
For	 acute	 T-cell	 leukemia,	we	 previously	 identified	 a	 set	 of	microRNAs	 acting	 in	 a	
cooperative	manner	 to	 regulate	 key	 transcription	 factors	with	 a	 tumor	 suppressor	
role	 in	T-ALL2.	Long	non-coding	RNAs	 (lncRNAs)	are	now	a	newly	emerging	class	of	
non-coding	RNAs.	These	transcripts	are	more	than	200	nucleotides	in	length	and	are	
rather	poorly	evolutionary	conserved	in	contrast	to	other	types	of	non-coding	RNAs3.	
The	mechanisms	by	which	they	regulate	gene	expression	or	cellular	functions	more	
broadly	 are	 not	 yet	 fully	 understood,	 but	 a	 significant	 portion	 of	 lncRNAs	 is	
considered	 to	 act	 in	 concert	with	 chromatin	modifier	 enzymes.	 In	 this	 way,	 three	
main	modes-of-action	 can	 be	 defined:	 they	 can	 act	 as	 ‘guides’	 (eg	 recruitment	 of	
epigenetic	 regulatory	 protein	 complexes),	 ‘decoys’	 (eg	 titrate	 proteins	 away	 from	
their	 DNA	 binding	 site)	 or	 ‘scaffolds’	 (eg	 assist	 in	 the	 formation	 of	 multi-
ribonucleoprotein	 complexes).	 The	 level	 of	 lncRNA-mediated	 gene	 regulation	 can	
also	 differ,	 acting	 either	 locally	 on	 the	 same	 chromosome	 from	which	 the	 lncRNA	
itself	is	transcribed	(in	cis)	or	affecting	multiple	genes	located	at	other	chromosomes	
(in	 trans).	The	role	 for	 lncRNAs	as	crucial	 transcriptional	 regulators	 in	many	cancer	
types	 including	 malignant	 hematopoiesis	 is	 now	 emerging.	 LncRNAs	 are	 also	
considered	to	be	essential	components	of	normal	development	as	has	been	shown	
amongst	 other	 for	 normal	 haematopoiesis4,5.	 Thusfar,	 the	 role	 and	 expression	
patterns	of	lncRNAs	in	T-ALL	and	the	regulatory	networks	in	which	they	take	part	are	
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still	poorly	defined.	In	a	recent	effort,	we	and	others	identified	a	subset	of	lncRNAs	
that	act	in	concert	with	NOTCH1	in	both	normal	T-cell	development	and	malignant	T-
cell	 transformation6,7.	 Besides	 NOTCH1,	 another	 key	 driver	 in	 T-ALL	 is	 the	 ‘T-cell	
leukemia	homeobox	1’	(TLX1,	HOX11)	transcription	factor.			
TLX1	is	involved	in	spleen	organogenesis	and	is	normally	not	expressed	in	developing	
thymocytes.	In	T-ALL,	TLX1	is	ectopically	expressed	in	5-10%	of	pediatric	patients	and	
30%	 of	 adult	 cases	 due	 to	 either	 of	 two	 chromosomal	 translocations,	 t(7;10)	 or	
t(10;14),	involving	the	TCR-δ	or	TCR-β	regulatory	regions	respectively.	The	molecular	
subgroup	 defined	 by	 TLX1	 overexpression	 shows	 a	 gene	 expression	 profile	 that	 is	
indicative	for	a	leukemic	arrest	at	the	early	cortical	stage	of	T	cell	development	and	
TLX1-positive	 T-ALL	 cases	 are	 generally	 associated	 with	 a	 favorable	 prognostic	
outcome8,9.	 The	 TLX1	 regulatory	 network	 in	 terms	 of	 co-factors	 and	 downstream	
protein-coding	gene	targets	has	been	extensively	studied10.	Recently,	we	proposed	
that	 the	 long	 latency	 in	TLX1-driven	 leukemia	can	at	 least	be	partly	explained	by	a	
transcriptional	antagonism	between	TLX1	and	NOTCH1	during	pre-leukemic	stages,	
establishing	a	large	dependency	for	these	T-ALL	blasts	to	acquire	activating	NOTCH1	
mutations	 as	 a	 prerequisite	 to	 further	 evolve	 towards	 full	 malignant	
transformation11.	 Here,	 we	 implemented	 an	 integrative	 genomics	 approach	 to	
identify	 and	 functionally	 characterize	 TLX1	 regulated	 lncRNAs	 in	 the	 context	 of	
human	T-ALL	and	identify	several	TLX1	driven	lncRNAs	with	a	putative	role	in	normal	
T-cell	development	and	T-cell	oncogenesis.		
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METHODS	
	
Cell	lines	
ALL-SIL	 cells	 were	 obtained	 from	 the	 DSMZ	 cell	 line	 repository.	 Cells	 were	
maintained	in	RPMI-1640	medium	(Life	Technologies)	supplemented	with	20%	fetal	
bovine	serum,	1%	of	L-glutamine	(Life	Technologies)	and	1%	penicillin/streptomycin	
(Life	Technologies).		
	
Clinical	samples	
Bone	 marrow	 lymphoblast	 samples	 from	 64	 T-ALL	 patients	 (15	 immature,	 25	
TAL/LMO,	 17	 TLX1/TLX3	 and	 7	 HOXA)	 were	 collected	 with	 informed	 consent	
according	to	the	declaration	of	Helsinki	from	Saint-Louis	Hospital	(Paris,	France)	and	
the	 study	 was	 approved	 by	 the	 Institut	 Universitaire	 d’Hématologie	 Institutional	
Review	Board.		
	
siRNA-mediated	knockdown	TLX1,	RNA-isolation,	cDNA	synthesis	and	RT-qPCR		
ALL-SIL	cells	were	electroporated	 (250	V,	1000	μF)	using	a	Genepulser	Xcell	device	
(Biorad)	with	400	nM	of	Silencer	Select	Negative	Control	1	siRNA	(Ambion)	or	siRNAs	
targeting	TLX1	 (Silencer	 Select,	Ambion,	 #4392420,	 s6746	and	 s6747).	ALL-SIL	 cells	
were	collected	24h	post-electroporation.	Total	RNA	was	isolated	using	the	miRNeasy	
mini	 kit	 (Qiagen)	with	DNA	digestion	 on-column.	 By	means	 of	 spectrophotometry,	
RNA	 concentrations	 were	 measured	 (Nanodrop	 1000)	 and	 RNA	 integrity	 was	
evaluated	(Experion,	Bio-Rad).	Next,	cDNA	synthesis	was	performed	using	the	iScript	
cDNA	synthesis	Kit	(Bio-Rad)	followed	by	RT-qPCR	using	the	LightCycler	480	(Roche).	
Finally,	qPCR	data	was	analyzed	according	to	the	ΔΔCt-method	using	the	qBasePLUS	
software	(Biogazelle).		
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LNA-mediated	knockdown	lnc-DAD1-2		
ALL-SIL	 cells	 were	 electroporated	 (300	 V,	 1	 mF)	 using	 a	 Genepulser	 Xcell	 device	
(Biorad)	 with	 400	 nM	 of	 negative	 control	 LNA	 (Exiqon,	 antisense	 LNA	 GapmeR,	
Premium,	300611-00,	sequence:	AACACGTCTATACGC)	or	LNAs	targeting	 lnc-DAD1-2	
(custom	 designed	 LNAs,	 Exiqon,	 LNA1	 (sequence:	 ATAGAATCAAGATCAC	 en	 LNA2	
(sequence:	 GTAATTCAGTGTAAGT)),	 ALL-SIL	 cells	 were	 collected	 48h	 post-
electroporation.	 RNA-isolation,	 cDNA	 synthesis	 and	 qPCR	 were	 performed	 as	
described	above.	
	
	
Cell	fractionation	assay	
This	 cell	 fractionation	protocol	has	been	adapted	 from	previous	 studies12.	 In	brief,	
10*10e6	 ALL-SIL	 cells	 were	 collected,	 resuspended	 in	 lysis	 buffer	 (0.5%	NP-40,	 60	
mM	KCl,	15	mM	NaCl,	0.15	mM	spermine,	0.5	mM	spermidine,	15	mM	2-mercapto-
ethanol,	 15	mM	Tris-HCl	 (pH	 7.4))	 and	 centrifugated	 (3000	 rpm,	 5	min.,	 4°C).	 The	
resulting	 supernatant	 is	 the	cytoplasmic	 fraction	and	was	kept	aside.	The	 resulting	
pellet	was	resuspended	 in	1	ml	 lysis	buffer,	with	 incubation	on	 ice	 for	30	min.	The	
resulting	lysate	was	centrifugated	(3000	rpm,	10	min.)	and	through	a	350	ul	cushion	
of	20%	sucrose	(W/W)	 in	 lysis	buffer.	The	resulting	supernatant	was	discarded	and	
the	resulting	pellet	was	respuspended	in	1	ml	lysis	buffer.	 	The	resulting	lysate	was	
centrifugated	 (3000	 rpm,	 10	 min.)	 and	 through	 a	 350	 ul	 cushion	 of	 30%	 sucrose	
(W/W)	 in	 lysis	 buffer.	 The	 resulting	 pellet	was	 resuspended	 in	 500	 ul	 lysis	 buffer.	
RNA-isolation	from	the	cytoplasmic	fraction	was	performed	using	the	Qiagen	RNeasy	
mini	 protocol	 for	 isolation	 of	 cytoplasmic	 RNA	 from	 animal	 cells	 (Qiagen).	 RNA-
isolation	from	the	nuclear	fraction	was	performed	using	the	Qiagen	miRNeasy	mini	
kit.	 cDNA	 synthesis	 was	 performed	 using	 the	 iScript	 cDNA	 synthesis	 Kit	 (Bio-Rad)	
followed	by	RT-qPCR	using	the	LightCycler	480	(Roche).		
	
Gene	expression	profiling	and	Gene	Set	Enrichment	Analysis	
RNA	samples	 from	ALL-SIL	cells	were	profiled	on	a	custom	designed	Agilent	micro-
array	covering	all	protein	coding	genes	(33,128	mRNA	probes,	Human	Sureprint	G3	
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8x60k	micro-arrays	 (Agilent))	 and	 12,000	 lncRNAs	 (23,042	 unique	 lncRNA	 probes).	
Expression	data	were	normalized	using	the	VSN-package	(Bioconductor	release	2.12)	
in	 R.	 Differential	 expression	 analysis	 was	 performed	 in	 R	 using	 Limma.	 Gene	
expression	profiling	data	from	TLX1	siRNA	mediated	knockdown	and	JQ1	treatment	
in	 ALL-SIL	 cells	 were	 previously	 published	 and	 deposited	 in	 the	 GEO	 database	
(GSE62144).	 Gene	 Set	 Enrichment	 analysis	 was	 performed	 against	 the	 c2	MSigDB	
collections	(curated	gene	sets).		
	
polyA	RNA-sequencing	
In	this	study,	RNA-sequencing	by	poly-A	capture	(unstranded)	was	performed	using	
100	ng	of	RNA	as	 input	material	 (Biogazelle,	Belgium).	 The	 sequencing	 read	depth	
comprised	 for	 all	 samples	 100	million	 reads,	which	were	 aligned	 to	 the	 reference	
genome	hg38	with	STAR-2.4.2a	and	default	settings.	Differential	expression	analysis	
was	performed	with	DESeq2.	 Scrambled	 siRNA	was	used	as	 control	 and	 compared	
with	2	independent	TLX1	targeting	siRNAs	(3	replicates).	A	multifactorial	design	was	
used	to	control	for	batch	effects.	
	
Motif	enrichment	
TLX1	ChIP-seq	reads	were	aligned	with	bowtie2	and	peak	calling	was	performed	with	
MACS1.4	using	input	DNA	as	control.	BEDTools	was	used	to	make	a	fasta	file	500bp	
centered	 to	 the	 TLX1	 peak	 summits.	 MEME-ChIP	 was	 used	 to	 perform	 motif	
enrichment	analysis	on	this	file.		
	
Super-enhancer	analysis	
ROSE	software	 (Young	Lab)	was	used	 to	 identify	 superenhancers.	BEDtools	overlap	
was	used	to	assign	genes	to	enhancers.	
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RESULTS	and	DISCUSSION	
	
TLX1	regulated	lncRNAs	are	 located	within	the	vicinity	of	T-ALL	tumor	suppressor	
genes	
	
To	elucidate	the	lncRNA	repertoire	under	control	of	the	TLX1	transcription	factor,	we	
perfomed	 RNA-sequencing	 by	 polyA-capture	 from	 ALL-SIL	 cells	 with	 transient	
knockdown	of	TLX1	using	two	independent	siRNAs	(Fig.	1A).	In	total,	119	long	non-
coding	 RNAs	 of	 the	 biotype	 ‘lincRNA’	 or	 ‘antisense’	were	 significantly	 (adjusted	 p-
value<0.05)	 downregulated	 versus	 77	 upregulated	 upon	 TLX1	 knockdown	 (Fig.	 1A	
and	1B).	Notably,	the	ratio	of	significantly	up-	and	downregulated	lncRNA	transcripts	
is	opposite	as	compared	to	 the	effect	of	TLX1	knockdown	on	protein-coding	genes	
(881	 downregulated	 and	 1294	 upregulated	 upon	 TLX1	 knockdown)	 (Fig.	 1C).	
Interestingly,	some	of	the	identified	TLX1	regulated	lncRNAs	are	in	cis	to	a	known	T-
ALL	tumor	suppressor	gene,	as	exemplified	by	lnc-PTPN2	(Fig.	1D	and	1E),	suggesting	
that	 certain	 TLX1-driven	 lncRNAs	 might	 be	 involved	 in	 the	 regulation	 of	 TLX1	
repressed	tumor	suppressor	genes.	Our	results	thus	indicate	that	TLX1	can	act	both	
as	an	activator	or	 repressor	of	 lncRNA	expression.	 To	understand	which	 co-factors	
might	 potentially	 be	 involved	 in	 lncRNA	 expression	 regulation	 together	with	 TLX1,	
we	performed	de	novo	motif	analysis	on	the	set	of	differentially	regulated	lncRNAs	
upon	 TLX1	 knockdown	 and	 found	 significant	 enrichment	 for	 ETS	 family	 and	 RUNX	
family	transcription	factor	motifs	(Fig.	1F),	similar	as	to	what	we	previously	found	for	
TLX1	regulated	protein-coding	genes	as	identified	by	ChIP-sequencing11.	
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Figure	1:	 Identification	of	TLX1	regulated	long	non-coding	RNAs	using	an	 in	vitro	TLX1	knockdown	
model	 system	 in	 ALL-SIL	 lymphoblasts.	 (A)	 Diagonal	 plot	 showing	 significantly	 (p-adjusted<0.05)	
downregulated	(blue)	and	upregulated	(red)	lncRNAs	upon	TLX1	knockdown	in	ALL-SIL	as	determined	
by	polyA	RNA-seq,	(B)	Bar	plot	indicating	the	numbers	of	differentially	expressed	lncRNAs	per	biotype,	
(C)	Bar	plot	showing	the	numbers	of	significantly	differentially	expressed	protein-coding	genes	(left)	
and	 lncRNAs	 (biotype:	 lincRNA	 or	 antisense)	 upon	 TLX1	 knockdown	 in	 ALL-SIL	 (right),	 (D)	 Box	 plot	
showing	 the	 average	 log2-expression	 of	 lnc-PTPN2	 across	 triplicate	 samples	 of	 ALL-SIL	 cells	
electroporated	with	either	scrambled	siRNA	(pink	box),	TLX1	targeting	siRNA	1	(green	box)	and	TLX1	
targeting	siRNA	2	(blue),	 (E)	 IGV	screenshot	of	the	 lnc-PTPN2	 locus	with	the	corresponding	RNA-seq	
profiles	of	representative	samples	of	scrambled	or	TLX1	targeting	siRNA	electroporated	ALL-SIL	cells		
(purple	tracks),	H3K27ac	(blue)	 	and	TLX1	(green)	ChIP-seq	profiles	at	the	 lnc-PTPN2	 locus,	(F)	Motif	
enrichment	 analysis	 on	 the	 set	 of	 TLX1	 regulated	 lncRNAs	 using	 the	 MEME-ChIP	 suite	 identifies	
significant	enrichment	of	the	DNA	binding	motifs	of	the	ETS	and	RUNX	family	of	transcription	factors.	
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Next	to	the	screening	in	ALL-SIL	T-ALL	cells	in	vitro,	we	also	aimed	to	retrieve	TLX1/3	
driven	lncRNAs	from	a	primary	T-ALL	patient	cohort,	including	5	TLX1+	and	12	TLX3+	
cases	(Fig.	2A,	2B	and	2C).	Notably	and	similar	to	what	we	observed	in	our	 in	vitro	
TLX1	 knockdown	model,	more	protein-coding	genes	were	 significantly	upregulated	
upon	 TLX1	 knockdown,	 whereas	 the	 opposite	 was	 true	 for	 lncRNAs	 (Fig.	 2C).	 In	
addition,	 we	 could	 identify	 199	 lncRNAs	 that	 are	 higher	 expressed	 in	 the	 TLX1/3	
genetic	 subgroup	 in	 comparison	 to	 the	 other	 T-ALL	 subtypes	 represented	 in	 the	
cohort	of	study	(TAL1+,	immature,	HOXA+),	amongst	others	also	lnc-PTPN2	(Fig.	2D).	
	
														 	
Figure	 2:	 Identification	 of	 TLX1/3	 regulated	 lncRNAs	 in	 a	 primary	 T-ALL	 cohort.	 (A)	Diagonal	 plot	
based	on	the	RNA-seq	dataset	from	a	primary	cohort	of	T-ALL	patients	(see	method	section)	showing	
lncRNAs	that	are	significantly	(p-adjusted	value<0.05)	higher	(red)	or	lower	(blue)	expressed	in	TLX1/3	
subgroup	 T-ALLs	 compared	 to	 T-ALL	 patients	 belonging	 to	 other	 T-ALL	 subtypes	 (TAL1+,	 immature,	
HOXA),	 (B)	Bar	plot	 indicating	 the	numbers	of	differentially	 expressed	 lncRNAs	per	biotype,	 (C)	Bar	
plot	 showing	 the	 numbers	 of	 significantly	 differentially	 expressed	 protein-coding	 genes	 (left)	 and	
lncRNAs	(biotype:	lincRNA	or	antisense)	(right)	between	the	TLX1/3	genetic	subgroup	and	the	other	T-
-ALL	 subtypes	 of	 the	 studied	 primary	 patient	 cohort,	 (D)	 Boxplots	 showing	 lncRNAs	 that	 are	
significantly	higher	expressed	in	the	TLX1/3	genetic	subtypes	compared	to	the	other	T-ALL	subtypes.	
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A	 fascinating	 question	 arising	 from	 the	 current	 data	 is	 how	 TLX1	 controlled	
repression	of	protein	coding	tumor	suppressor	genes	is	linked	to	the	nearby	located	
TLX1	putative	 cis-regulatory	 lncRNAs.	At	 least	 part	 of	 these	 TLX1	 lncRNA	 loci	 have	
features	of	enhancers	(so-called	eRNAs)	and	are	enriched	for	H3K4me1	and	H3K27ac	
enhancer	 marks.	 To	 study	 this	 interrelationship	 in	 more	 detail,	 chromatin	
conformation	 studies	 are	 ongoing	 while	 further	 functional	 dissection	 e.g.	 using	
CRIPSR-Cas9	 technology	 is	 mandatory.	 An	 exciting	 therapeutic	 perspective	 from	
these	novel	findings	is	the	possibility	to	reveal	TLX1	controlled	repression	of	multiple	
tumor	 suppressor	 genes	 through	 modulation	 of	 their	 functionally	 connected	
enhancer	RNAs.		
	
Super-enhancer	associated	long	non-coding	RNAs	under	control	of	TLX1	
We	have	previously	 shown	 that	 TLX1	 significantly	 associates	with	 super-enhancers	
near	 protein-coding	 genes	 with	 a	 key	 role	 in	 normal	 and	 malignant	 T-cell	
development11.	 In	 this	 study,	 we	 aimed	 to	 identify	 (super)-enhancer	 associated	
lncRNAs	 that	 could	 be	 regulated	 by	 TLX1.	 To	 this	 end,	 we	 treated	 ALL-SIL	
lymphoblast	 cells	 with	 the	 small	 molecule	 inhibitor	 JQ1,	 interfering	 with	 BRD4	
activity	and	thereby	known	to	affect	major	context-specific	enhancer	sites	(Fig.	3A).	
This	set	of	differentially	expressed	lncRNAs	upon	JQ1	treatment	of	ALL-SIL	was	then	
compared	to	overlap	with	the	 lncRNA	expression	signatures	obtained	upon	TLX1	in	
the	 same	cellular	 context	 (Fig.	 3B).	 In	 total,	 20	 lncRNAs	downregulated	upon	TLX1	
knockdown	 and	 21	 lncRNAs	 upregulated	 upon	 TLX1	 knockdown	were	 overlapping	
with	 those	 lncRNAs	 downregulated	 upon	 JQ1	 exposure.	 To	 identify	 in	more	 detail	
super-enhancer	 associated	 lncRNAs	 from	 this	 set,	 we	 integrated	 previously	
generated	H3K27ac	ChIP-seq	data	 from	ALL-SIL	 cells11	 and	ordered	 TLX1	 regulated	
lncRNAs	 according	 to	 their	 overlapping	 signal	 and	 rank	 of	 H3K27ac	 ChIP-seq	 peak	
clusters	 (Fig.	 3C).	 From	 this	 analysis,	we	 identified	 lnc-THADA-1	 as	 the	 top-scoring	
super-enhancer	associated	lncRNA	under	control	of	TLX1	(Fig.	3D).	Interestingly,	this	
lncRNA	resides	in	cis	to	ZFP36L2,	a	recently	identified	novel	T-ALL	tumor	suppressor	
gene14.	 By	 means	 of	 cellular	 fractionation12,	 we	 could	 show	 that	 lnc-THADA-1	 is	
enriched	four	times	more	in	the	nuclear	fraction	than	in	the	cytoplasmic	fraction,	to	
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the	 same	 extent	 as	 the	 positive	 control	 for	 the	 nuclear	 fraction	 lncRNA	MALAT1	
(GADPH	as	a	positive	control	for	the	cytoplasmic	fraction)	(Fig.	3E).	
												 	
Figure	3:	 Identification	of	 super-enhancer	associated	 lncRNAs	under	 control	of	 TLX1.	 (A)	Diagonal	
plot	 showing	 significantly	 (p-adjusted<0.05)	 down-	 (blue)	 or	 upregulated	 lncRNAs	 (red)	 upon	 JQ1	
treatment	 of	 ALL-SIL	 cells,	 (B)	 Diagrams	 showing	 overlapping	 lncRNAs	 significantly	 downregulated	
upon	 JQ1	 treatment	 of	 ALL-SIL	 	 cells	 with	 lncRNAs	 significantly	 downregulated	 (upper	 diagram)	 or	
upregulated	 (lower	 diagram)	 upon	 TLX1	 knockdown,	 (C)	 Hockey-stick	 plot	 representing	 the	
normalized	 rank	 and	 cluster	 signal	 of	 clusters	 of	 H3K27ac	 peaks	 at	 lncRNA	 transcripts	 that	 are	
significantly	differentially	expressed	upon	TLX1	knockdown	in	ALL-SIL	cells	(red	dots),	(D)	Screenshot	
of	the	lnc-THADA-1	locus	in	ALL-SIL	cells		as	the	top-scoring	super-enhancer	associated	lcnRNAs	that	is	
differentially	 expressed	 upon	 TLX1	 knockdown	 in	 the	 same	model	 system,	 (E)	 Cell	 fractionation	 of	
ALL-SIL	 cells	 followed	 by	 RT-qPCR	 analysis	 shows	 that	 lnc-THADA-1	 is	 a	 putative	 nuclear	 expressed	
lncRNA,	with	 a	 similar	 enrichment	 as	 the	 positive	 control	 lncRNA	MALAT1	 for	 the	 nuclear	 fraction,	
while	GAPDH	was	used	as	a	positive	control	for	the	cytoplasmic	fraction.	 	
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Functional	landscaping	of	lnc-DAD1-2,	a	TCRα-locus	associated	lncRNA	
	
Previous	 studies	 on	 the	 transcriptional	 regulatory	 networks	 of	 TLX1	 showed	 that	
ectopic	expression	of	TLX1	in	developing	thymocytes	causes	a	developmental	arrest	
at	 the	 early	 cortical	 T-cell	 differentiation	 stage	 by	 binding	 with	 ETS1,	 with	 the	
formation	of	 a	 repressor	 complex	 at	 the	 TCRα	enhanceosome15.	 From	our	 in	 vitro	
TLX1	 knockdown	model	 system,	we	 identified	 lnc-DAD1-2	 as	 one	of	 the	 repressed	
lncRNAs	by	TLX1	(Fig.	1A	and	4A).	Notably,	this	lncRNA	resides	within	the	TCRα	locus	
and	might	 thus	be	 involved	 in	 the	 interference	of	TLX1	with	TCRα	 function.	 In	 this	
study,	 we	 further	 scrutinized	 the	 potential	 function	 of	 lnc-DAD1-2	 by	 transient	
knockdown	 applying	 ‘locked	 nucleic	 acids’	 (LNAs)	 targeting	 this	 lncRNA.	 We	
identified	 two	 very	 potent	 LNAs,	 resulting	 in	 up	 to	 90%	 reduction	 of	 lnc-DAD1-2	
expression,	as	verified	by	RT-qPCR	(Fig.	4B).	We	performed	knockdown	of	lnc-DAD1-
2	 in	 triplicate	 using	 both	 LNAs	 in	 ALL-SIL	 lymphoblasts,	 followed	 by	 micro-array	
based	 gene	 expression	 profiling.	 Using	 ‘Gene	 Set	 Enrichment	 Analysis’	 (GSEA),	 we	
identified	various	 significantly	enriched	gene	 sets	 from	 the	C2	Molecular	 signature	
database	(MSigDB)	(Fig.	4C).	Amongst	others,	a	signature	of	genes	high	in	immature	
stages	 of	 T-cell	 development	 (LEE_EARLY_THYMOCYTES_UP)	 compared	 to	 later	
stages	 is	 significantly	 upregulated	 upon	 knockdown	 of	 lnc-DAD1-2.	 Furthermore,	
genes	downregulated	 in	 the	 immature	B-cell	 stages	 are	 also	upregulated	with	 lnc-
DAD1-2	depletion.	 Interestingly,	we	also	 found	a	set	of	EZH2	target	genes	 that	are	
significantly	 upregulated	 upon	 lnc-DAD1-2	 knockdown,	 suggesting	 a	 potential	
functional	 interaction	between	 lnc-DAD1-2	and	the	PRC2	complex,	given	that	many	
recent	studies	show	interaction	between	EZH2	and	a	variety	of	lncRNAs16.		
In	order	to	verify	a	putative	overlap	of	downstream	target	genes	between	TLX1	and	
lncRNA	lnc-DAD1-2,	we	compared	the	gene	signatures	related	to	TLX1	and	lnc-DAD1-
2	knockdown	by	GSEA.	Notably,	we	found	that	a	core	set	of	genes	is	shared	amongst	
both,	 including	 amongst	 others	 RAG1	 and	 TERT.	 We	 hypothesize	 that	 lnc-DAD1-2	
might	 be	 a	 key	 lncRNA	 involved	 in	 TCR-rearrangements.	 In	 order	 to	 further	
landscape	 the	 functional	 role	of	 this	 lncRNA	 in	normal	 T-cell	 development,	we	are	
currently	 setting	 up	 functional	 studies	 using	 the	 in	 vitro	 model	 system	 OP9-DLL1.	
From	 the	 first	 LNA	 ‘passive	 uptake’	 experiments,	 we	 could	 reach	 about	 80%	
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knockdown	 of	 lnc-DAD1-2	 in	 CD34+	 cord	 blood	 progenitor	 cells	 (data	 not	 shown).	
This	will	allow	us	to	 further	evaluate	the	phenotypic	 implications	of	 lnc-DAD1-2	on	
normal	hematopoietic	 lineage	development	and	by	directed	PCR-assays	 to	the	TCR	
loci,	we	will	be	able	to	further	monitor	the	functional	implications	of	 lnc-DAD1-2	 in	
TCR-rearrangements.	
	
	
Figure	 4:	 Identification	 of	 lnc-DAD1-2,	 a	 TLX1	 regulated	 lncRNA	 within	 the	 TCRα	 locus.	 (A)	
Screenshot	of	 the	 lnc-DAD1-2	 locus	 in	ALL-SIL	 lymphoblast,	 (B)	RT-qPCR	validation	of	LNA-mediated	
downregulation	of	lnc-DAD1-2	in	ALL-SIL	using	2	independent	LNAs,	(C)	Gene	Set	Enrichment	Analysis	
showing	 significantly	 enriched	 gene	 sets	 of	 the	 C2	 MSigDB	 database	 within	 the	 gene	 signature	
upregulated	 upon	 lnc-DAD1-2	 knockdown	 in	 ALL-SIL	 cells,	 (D)	 Gene	 Set	 Enrichment	 Analysis	 shows	
significant	overlap	between	genes	differentially	expressed	upon	TLX1	knockdown	and	its	downstream	
lncRNA	lnc-DAD1-2	in	ALL-SIL	lymphoblasts.	
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TLX1	regulates	multiple	previously	unannotated	lncRNAs	
	
In	the	last	part	of	this	study,	we	searched	for	previously	unnanotated	lncRNAs	in	the	
ALL-SIL	genome	and	evaluated	which	of	those	are	directly	under	control	of	TLX1.	In	
total,	we	 identified	35	TLX1	activated	and	20	TLX1	repressed	unannotated	 lncRNAs	
(basemean>100),	 p-adjusted<0.05)(Fig.	 5A),	 with	 XLOC_023952	 as	 an	 example	 of	
one	of	the	top-downregulated	unannotated	lncRNA	upon	TLX1	knockdown	(Fig.	5B).		
Secondly,	we	evaluated	whether	a	set	of	these	unannoted	lncRNA	transcripts	could	
act	as	potential	enhancer	RNAs.	To	this	end,	we	again	matched	the	H3K27ac	ChIP-
seq	data11	to	the	respective	lncRNA	loci	and	scored	them	based	on	their	rank-signal	
ratio	for	H327ac	ChIP-seq	peaks	(Fig.	5C).	We	identified	XLOC_1477	to	be	associated	
with	 the	 strongest	 super-enhancer	 site	 of	 all	 identified	 unannotated	 lncRNAs	 that	
are	 significantly	 differentially	 expressed	 upon	 TLX1	 knockdown	 (Fig.	 5D).	 Further	
studies	will	 include	the	analysis	of	 these	novel	 lncRNA	during	the	various	stages	of	
thymocyte	 maturation	 and	 in	 other	 genetic	 subsets	 of	 T-ALL.	 Ultimately,	 further	
selected	 lncRNAs	 will	 be	 functionally	 analysed	 in	 order	 to	 unravel	 their	 normal	
function	and	role	in	transformation.		
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Figure	5:	Scrutinizing	the	set	of	unannoted	lcnRNAs	under	control	of	TLX1	regulation.	(A)	Screenshot	
of	the	RNA-seq	tracks	(purple)	and	ChIP-seq	tracks	(blue	and	green)	for	XLOC_023952	locus	as	one	of	
the	 top-downregulated	 unannotated	 lncRNAs	 upon	 TLX1	 knockdown	 in	 ALL-SIL	 lymphoblasts,	 (B)	
Hockey-stick	plot	representing	the	normalized	rank	and	cluster	signal	of	clusters	of	H3K27ac	peaks	at	
the	 set	 of	 unannotated	 lncRNA	 transcripts	 that	 are	 significantly	 differentially	 expressed	 upon	 TLX1	
knockdown	in	ALL-SIL	cells	(red	dots),	(C)	Screenshot	of	the	RNA-seq	(purple)	and	ChIP-seq	data	tracks	
for	H3K27ac	 (blue)	and	TLX1	 (green)	 for	 the	XLOC_01477	 locus	 identified	as	one	of	 the	 top-scoring	
super-enhancer	associated	unannotated	lncRNAs	upon	TLX1	knockdown	in	ALL-SIL	lymphoblasts	 	
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Discussion	and	future	perspectives	
	
In	 the	 field	 of	 T-ALL	 research,	 the	 aim	 for	 a	 comprehensive	 and	 in	 depth	
understanding	of	the	genetic	landscape	that	underlies	the	oncogenic	rewiring	of	the	
transcriptional	 circuitries	 that	 govern	 normal	 thymopoiesis	 has	 already	 made	 a	
significant	 leap	 forward	 over	 the	 past	 decade,	 mainly	 driven	 by	 technological	
advances	 in	 the	 field	of	next-generation	 sequencing,	but	 is	 still	 very	much	work	 in	
progress.	 One	 of	 the	 major	 challenges	 that	 we	 still	 face	 today	 is	 a	 profound	
understanding	 of	 the	 mechanism-of-action	 for	 many	 of	 these	 known	 and	 novel	
drivers	 in	 T-ALL	 and	 how	 they	 work	 in	 concert	 to	 establish	 malignant	 T-cell	
transformation.		
	
To	this	end,	I	aimed	during	my	PhD	mandate	to	perform	a	comprehensive	functional	
analysis	 for	 some	 of	 the	 key	 transcriptional	 regulators	 (TLX1,	 NOTCH1,	 PHF6)	
implicated	 in	 normal	 T-cell	 development	 and	 T-ALL	 and	 landscape	 their	
interconnection	at	the	level	of	gene	expression	networks.	In	summary,	this	work	has	
amongst	others	resulted	in	intruiging	novel	insights	on	the	molecular	mechanism	of	
oncogene	 cooperativity	 between	 two	 important	 T-ALL	 drivers	 NOTCH1	 and	 TLX1.	
More	specifically,	I	could	demonstrate	a	crucial	cooperative	role	for	PHF6	as	a	novel	
and	important	epigenetic	regulator	in	the	genetic	crosstalk	with	NOTCH1	and	TLX1.	
In	 addition,	 my	 work	 uncovers	 a	 key	 regulatory	 role	 for	 PHF6	 in	 normal	
hematopoiesis.	The	TLX1	and	NOTCH1	cellular	model	systems	developed	during	this	
investigation	also	opened	initially	unanticipated	possibilities	to	study	the	impact	on	
lncRNAomes	in	their	respective	transcriptional	networks.	In	this	part	of	the	thesis,	I	
will	 elaborate	 on	 the	 novel	 insights	 that	 were	 retrieved	 in	 this	 PhD	 thesis	 with	
respect	to	the	functional	evaluation	of	the	transcriptional	networks	that	underlie	T-
ALL	 formation,	 evaluate	 the	 therapeutic	 potential	 of	 our	 findings	 and	 discuss	 how	
these	results	can	be	exploited	as	novel	entry	points	for	further	studies,	both	in	the	
context	of	T-ALL	and	other	cancer	entities.	
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1.	Dissection	of	interconnected	transcriptional	networks	in	T-ALL	pathogenesis	
	
Throughout	 the	 past	 decades,	 a	 key	 set	 of	 transcriptional	 regulators	 has	 been	
identified	 that	 act	 as	 individual	 hubs	 in	 the	 context	 of	 a	 larger	 transcriptional	
network	underlying	normal	hematopoietic	lineage	development.	This	knowledge	has	
broadened	our	understanding	how	their	individual	mechanism-of-action	and	the	set	
of	 dowstream	 target	 genes	 they	 regulate	 is	 driving	 lineage	 commitment	 and	
differentiation	 in	 a	 hierarchical	 biological	 system.	 Nevertheless,	 we	 are	 now	 only	
taking	 the	 first	 leap	 forward	 in	 our	 understanding	 and	 insights	 in	 the	 global	
architecture	 in	 which	 these	 individually	 studied	 factors	 are	 embedded	 and	 how	
these	organisational	maps	 contribute	 to	 the	 complexity	 of	 gene	 regulation.	 In	 this	
PhD	 thesis,	 I	 anticipated	 to	 address	 the	 question	 how	 TLX1,	 as	 an	 ectopically	
expressed	 transcription	 factor	 in	 developing	 thymocytes,	 can	 rewire	 individual	
regulatory	 subnetworks	 of	 the	 T-cell	 developmental	 path	 and	 how	 these	 events	
collectively	contribute	to	leukemic	transformation.		I	have	learned	that	TLX1	hijacks	
the	 intrinsic	 regulatory	 machinery,	 that	 normally	 drives	 thymocytes	 into	 a	 T-cell	
differentiation	 path,	 in	 a	 genome-wide	 manner	 and	 that	 a	 large	 part	 of	 this	
deregulation	 can	 be	 atributed	 by	 its	 interfere	 with	 super-enhancer	 sites	 that	 are	
associated	with	critical	nodes	in	normal	T-cell	programming.	In	this	study,	we	could	
also	 show	 for	 the	 first	 time	 that	 this	 ectopically	 expressed	 factor	 is	 partially	
hampering	 full-blown	 leukemia	 formation	 through	 its	 repression	 of	 the	 NOTCH1	
driven	 transcriptional	 program,	 explaining	 why	 NOTCH1	 activating	 mutations	 are	
significantly	 enriched	 in	 the	 TLX1	 subtype	 of	 T-ALL	 patients.	 However,	 in	 order	 to	
fully	grasp	the	complete	transcriptional	map	that	underlies	the	transforming	capacity	
of	 ectopically	 induced	 TLX1	 in	 thymocytes,	we	 also	 needed	 to	 further	 functionally	
characterize	other	genetic	events	that	co-occur	with	a	TLX1	translocation.	One	of	the	
most	 obvious	 candidate	 genes	 for	 a	 follow-up	 study	 was	 PHF6,	 as	 PHF6	 loss-of-
function	mutations	 are	 predominantly	 enriched	 in	 the	 TLX1-driven	 T-ALL	 subtype.	
We	studied	the	functionalities	of	PHF6	in	several	in	vitro	model	systems.	Evaluation	
of	 the	 gene	 signatures	 under	 control	 of	 PHF6	 in	 these	 different	 model	 systems	
revealed	some	interesting	but	nevertheless	complex	insights	that	we	now	only	start	
to	 understand	 and	 which	 will	 require	 further	 investigation.	 First,	 the	 overlap	
Chapter	4:	Discussion	and	Future	Perspectives	
	 	 	297	
between	 the	 gene	 signatures	 obtained	 in	 Jurkat	 T-ALL	 lymphoblasts	 and	 CD34+	
thymocyte	 progenitors	 was	 significant.	 This	 implies	 that	 with	 respect	 to	 the	
transcriptional	network	connected	to	PHF6	in	these	cellular	contexts,	not	much	has	
changed.	 In	 both	 systems	 we	 could	 find	 a	 functional	 connection	 to	 the	 NOTCH1	
driven	program.		In	contrast,	when	comparing	the	transcriptional	profiles	upon	PHF6	
knockdown	between	Jurkat	and	ALL-SIL	lymphoblast	as	well	as	in	the	comparison	of	
CD34+	T-cell	progenitors	and	ALL-SIL	cells	with	PHF6	perturbation	(not	shown	in	this	
thesis),	 we	 could	 hardly	 find	 any	 overlap	 between	 the	 PHF6	 imposed	 gene	
signatures.	 We	 propose	 that	 this	 is	 attributed	 to	 an	 intricate	 connectivity	 of	 the	
transcriptional	networks	governed	by	TLX1	and	PHF6.	As	long	as	TLX1	is	not	present	
(like	in	Jurkat	and	CD34+)	progenitors,	it	will	drive	part	of	the	NOTCH1	transcriptional	
program.	 Notably,	 we	 could	 not	 find	 a	 significant	 enrichment	 of	 the	 NOTCH1	
signature	 in	 the	 PHF6	 expression	 dataset	 with	 PHF6	 knockdown	 in	 ALL-SIL	 cells,	
probably	because	TLX1	is	there	to	intervene	with	NOTCH1	signature	genes.	Instead,	
if	 PHF6	 resides	 in	 a	 cellular	 context	 where	 TLX1	 is	 active,	 the	 PHF6	 downstream	
network	will	probably	get	rewired.	An	interesting	and	remarkable	shared	target	gene	
between	PHF6	en	TLX1	is	IL7R.	We	propose	that	TLX1-driven	T-ALLs	will	impose	loss	
of	PHF6	expression	as	a	way	to	upregulate	IL7R	coupled	JAK-STAT	signaling	(see	also	
point	2	of	this	discussion	section).		
	
In	the	second	part	of	this	thesis,	I	elaborated	on	the	functional	implications	of	non-
coding	 RNAs	 embedded	 as	 an	 additional	 and	 key	 layer	 of	 the	 multidimensional	
networks	 in	 hematopoietic	 development	 and	 malignant	 leukemic	 transformation.	
We	have	identified	NOTCH1	and	TLX1	regulated	lncRNAs.	Notably,	there	is	a	core	set	
of	lncRNAs	that	are	positively	regulated	by	NOTCH1	and	repressed	by	TLX1,	in	line	to	
what	we	 found	at	 the	 level	of	protein-coding	genes.	We	thus	propose	 that	 further	
study	 is	 required	 to	 evaluate	 the	 potential	 involvement	 of	 these	 novel	 identified	
lncRNAs	in	the	functional	antagonism	between	TLX1	and	NOTCH1.		
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2..	The	IL7R	signaling	pathway	as	a	therapeutic	entry	point	in	PHF6	mutated	T-ALL	
	
Our	 findings	 indicate	 the	 IL7R-JAK-STAT	 signaling	 cascade	 as	 a	 crucial	 node	 at	 the	
crossroads	of	the	NOTCH1-TLX1-PHF6	regulatory	axis	in	T-ALL.	Interleukin-7	(IL-7)	is	
an	 important	 trophic	 factor	 in	 the	 hematopoietic	 system,	 especially	 for	 the	 T-cell	
lineage.	A	functional	IL-7	receptor	(IL7R)	is	composed	as	a	heterodimer	of	the	IL7Rα	
and	 the	 common	 γ-chain	 (γc)	 and	 surface	 expression	 is	 tightly	 regulated	 and	
coordinated	with	T-cell	maturation1.	Receptor	heterodimerization	is	triggered	by	IL-7	
ligand	 binding,	 with	 subsequent	 downstream	 activation	 of	 the	 JAK-STAT	 pathway.	
Under	normal	physiological	conditions,	the	JAK	kinase	family	(JAK1,	JAK2,	JAK3	and	
TYK2)	is	activated	following	receptor	phosphorylation	(eg	IL7R)	upon	ligand	binding2.	
Although	IL7R	was	already	for	a	long	time	recognized	as	a	key	NOTCH1	target	in	both	
normal	 and	 malignant	 T-cell	 development,	 its	 inherent	 driver	 role	 in	 T-ALL	 blast	
formation	was	 only	 rather	 recently	 underscored	 by	 the	 identification	 of	 activating	
IL7R	 mutations	 in	 about	 10%	 of	 all	 T-ALL	 cases3.	 Intriguingly,	 we	 could	 show	 that	
TLX1-driven	 T-ALL	 blasts	 are	 hampered	 for	 full	 leukemic	 transformation	 through	
aberrant	suppression	of	the	NOTCH1	gene	signature,	most	notably	IL7R	expression,	
by	ectopic	TLX1	at	pre-leukemic	T-ALL	stages	(paper	1).	First,	 this	provided	us	with	
an	essential	 lead	to	understand	why,	amongst	all	T-ALL	subgroups,	especially	TLX1-
positive	T-ALL	cases	are	significantly	enriched	for	NOTCH1	activating	mutations	(90%	
of	 all	 cases).	 Secondly,	 during	 this	 PhD	mandate,	we	 identified	 IL7R	 as	 one	 of	 the	
most	robust	PHF6	negatively	regulated	downstream	targets	in	both	developing	T-cell	
precursors	 and	 T-ALL	 blasts	 (paper	 2	 and	 3).	 Given	 that	 PHF6	 mutations	 are	
significantly	associated	with	ectopic	TLX1/3	expression,	this	discovery	puts	functional	
loss	 of	 PHF6	 forward	 a	 second	mechanism	 to	 upregulate	 IL7R	 expression	 and	 the	
downstream	 JAK-STAT	 signaling	 cascade	 in	 this	 leukemia	 subtype.	 Oncogenic	
mutations	 in	 the	 JAK-STAT	 pathway	 occur	 in	 both	 various	 hematological	
malignancies	 and	 solid	 cancer	 types	 such	 as	 breast	 and	 lung	 cancer	 (Figure	 1)4.	
Interestingly,	a	recent	study	conducted	by	Vicente	and	co-workers5	revealed	not	only	
a	significant	burden	(27%)	in	T-ALL	of	oncogenic	aberrations	in	IL7R,	JAK1,	JAK3	and	
STAT5,	 but	 also	 an	 unrecognized	 association	 between	 IL7R-JAK	 and	 epigenetic	
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regulator	 gene	mutations,	most	 notably	 in	 35%	of	 all	 cases	with	PHF6	 inactivating	
mutations,	further	underscoring	the	relevance	of	our	findings.	
	
																						 	
Figure	1:	Overview	of	the	JAK-STAT	pathway	mutational	repertoire	 in	various	hematological	cancers	
often	 indicative	 for	a	poor	prognosis.	Novel	 	 small	molecule	compounds	and	combination	therapies	
are	 readily	 evaluated	 to	 improve	 therapeutic	 efficacy	 of	 targeting	 this	 pathway	 frequently	
overactivated	in	many	hematological	cancers	(adapted	from	Springuel	et	al.,	Haematologica,	2015)4.		
	
Current	treatment	regiments	in	T-ALL	reach	survival	rates	of	50-60%	in	adults	and	up	
to	 80%	 in	 pediatric	 patients6,7.	 Nevertheless,	 this	 success	 rate	 is	 currently	 still	
hampered	due	to	therapy	resistance	in	25%	of	pediatric	and	50%	of	adult	cases8-10.	
The	 JAK-STAT	 pathway	 is	 in	 T-ALL	 amongst	 the	 potent	 pathways	 for	 targeted	
therapy,	 together	 with	 the	 Wnt-signaling,	 MAPK	 and	 NOTCH1	 pathway	 amongst	
other11.	Taken	together,	our	results	further	warrant	the	therapeutic	relevance	of	JAK	
inhibitors,	 such	 as	 tofacitinib	 and	 ruxolitinib,	 in	 treatment	of	PHF6	mutated	T-ALL.	
Ruxolitinib	has	already	been	approved	for	treatment	of	myelofibrosis	patients	and	is	
currently	 being	 tested	 for	 many	 hematological	 cancers2.	 For	 instance,	 ruxolitinib	
treatment	 has	 already	 been	 shown	 efficacious	 for	 immature	 T-ALL	 in	 pre-clinical	
studies12.	To	further	test	the	role	of	PHF6	 loss	in	counteracting	TLX1	mediated	IL7R	
repression	 in	vivo,	we	performed	Phf6	 gene	 inactivation	by	 injection	of	gRNAs	and	
Cas9	 protein	 into	 one-cell	 stage	 zebrafish	 embryos	 yielding	 varying	 out-of-frame	
in/dels	(unpublished	data).	Next,	we	will	investigate	the	genetic	interaction	between	
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TLX1	 and	 PHF6	 either	 by	 crossing	 PHF6	 deficient	 and	 Rag2-TLX1	 overexpressing	
stable	lines	or	injection	of	Rag2-TLX1	constructs	into	PHF6	deficient	embryos.		
	
	
	
3.	Deciphering	the	role	of	PHF6	as	an	epigenetic	regulator	in	neuroblastoma	
	
In	 this	 PhD	 thesis,	 we	 have	 revealed	 PHF6	 as	 a	 novel	master	 regulator	 of	 human	
hematopoietic	 lineage	development	using	the	OP9-DLL1	 in	vitro	model	system.	 	To	
validate	 these	 observations	 in	 a	 relevant	 in	 vivo	 context,	 we	 are	 currently	
investigating	 the	 phenotypic	 and	 molecular	 consequences	 of	 Phf6	
knockdown/knock-out	 during	 zebrafish	 hematopoiesis.	 Preliminary	 results	
demonstrate	marked	increased	expression	of	LMO2,	a	marker	for	erythropoiesis	and	
primitive	 hematopoiesis	 by	 in	 situ	 hybridization	 upon	morpholino-mediated	 knock	
down	of	Phf6	and	CRISPR-mediated	Phf6	knockout	(unpublished	data).	Interestingly,	
a	 significant	 increase	 in	 thymus	 development	 and	 size	 could	 be	 observed	 in	 Phf6	
deficient	Rag2:GFP	zebrafish,	in	line	with	the	in	vitro	observed	accelerated	CD4+CD8+	
T-cell	 stage	 progression	 of	 human	 CD34+	 thymocytes	 cultured	 on	 an	 OP9	 stromal	
feeder	layer	(paper	2).		
The	identification	of	PHF6	as	an	important	lineage	switch	in	the	blood	system	could	
serve	as	a	prelude	to	trigger	further	functional	analysis	of	the	role	of	PHF6	in	other	
tissue	 types.	 Notably,	 besides	 its	 expression	 in	 the	 hematopoietic	 system,	 PHF6	 is	
also	 abundantly	 expressed	 in	 neuronal	 tissue.	 In	 neuronal	 cells,	 PHF6	 has	 already	
been	shown	to	functionally	act	in	concert	with	the	PAF1	complex	to	regulate	neuron	
migration13	 and	 with	 miR-128	 to	 control	 neuronal	 morphology14.	 Many	 well-
established	 tumor	 suppressor	 genes	were	 formerly	 identified	 from	 familial	 cancer	
syndromes,	 suggestive	 for	 their	 role	 in	malignant	 transformation	 in	 specific	 tissue	
types.	 Notably,	 PHF6	 germline	 mutations	 were	 previously	 linked	 to	 the	 Börjeson-
Forssman-Lehman15,	 Coffin-Siris	 and	 Nicolaides-Baraitser	 syndromes16,	 in	 which	
patients	 suffer	 amongst	 others	 from	 intellectual	 disability.	 Given	 the	 prominent	
somatic	 mutation	 rate	 of	 PHF6	 in	 T-ALL17	 and	 to	 a	 minor	 extent	 also	 in	 AML,	
hepatocellular	 carcinoma,	 CML	 in	 blast	 crisis	 and	 bladder	 cancer18,19,	 it	 could	 be	
speculated	 that	 PHF6	 loss	 could	 also	 play	 a	 critical	 role	 in	 neuronal	 cancer	 types.	
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Given	 the	 significant	 track	 record	 of	 our	 research	 team	 in	 the	 study	 of	
neuroblastoma,	a	rare	childhood	neuroendocrine	tumor	arising	from	neuroblasts	of	
the	 sympatho-adrenal	 lineage,	 I	 will	 study	 the	 functional	 role	 of	 PHF6	 in	 this	
malignancy	as	a	follow-up	of	this	PhD	mandate.	In	the	‘Cancer	cell	line	Encyclopedia’	
(CCLE),	 neuroblastoma	 is	 one	 of	 the	 top-ranked	 tumor	 entities	 with	 high	 PHF6	
expression	 besides	 T-ALL.	 In	 addition,	 preliminary	 data	 from	 our	 research	 team	
indicate	 that	 stable	 overexpression	 of	 PHF6	 in	 neuroblastoma	 cell	 lines	 leads	 to	 a	
significant	 induction	 of	 anchorage	 independent	 growth	 in	 a	 soft	 agar	 assay	
(unpublished	data),	hinting	towards	an	oncogenic	 role	 for	PHF6	 in	 this	malignancy.	
Recent	 work	 by	Meacham	 and	 co-workers	 already	 proposed	 a	 role	 for	 PHF6	 as	 a	
potential	B-ALL	oncogene20.	The	dual	and	 lineage-specific	 role	 for	PHF6	as	either	a	
tumor	 suppressor	 or	 oncogene	 depending	 on	 the	 type	 of	 cancer	 is	 an	 intruiging	
aspect	that	I	will	further	investigate.	
	
	
4.	The	SWI/SNF	complex	regulatory	network	in	T-ALL	and	neuroblastoma	
	
The	 mammalian	 SWI/SNF	 remodeling	 complex	 has	 12	 possible	 subunits,	 with	 the	
constellation	 of	 the	 complex	 changing	 depending	 on	 the	 specialized	 function	
required	 in	 a	 specific	 context21.	 	 This	 complex	 binds	 to	 DNA	 in	 a	 sequence-
independent	manner,	but	likely	associates	with	its	target	sites	upon	recruitment	by	
other	tissue-specific	 transcriptional	regulators22.	This	 is	nicely	 illustrated	by	a	study	
of	 Bakshi	 and	 co-workers	 showing	 that	 the	 ATPase	 subunit	 BRG1	 associates	 with	
RUNX1	to	control	gene	expression	 in	 the	hematopoietic	system23.	Most	notably,	 in	
murine	 model	 systems	 the	 role	 of	 Brg1	 as	 a	 critical	 regulator	 of	 the	 T-cell	
compartment	 is	 already	 established24.	 Following	 this	 PhD	 mandate,	 I	 will	 further	
elaborate	on	the	functional	implications	of	several	of	the	SWI-SNF	complex	members	
in	human	normal	 and	malignant	T-cell	 development.	 To	 this	 end,	we	have	already	
established	stable	knockdown	of	BRG1	in	human	CD34+	progenitors	cultured	on	an	
OP9	stromal	 feeder	 layer.	Preliminary	data	 indicate	massive	 induction	of	apoptosis	
and	 a	 differentiation	 block	 at	 early	 T-cell	 stages	 for	 BRG1	 deficient	 thymocytes	 in	
comparison	to	controls	(paper	3).	Moreover,	we	have	performed	initial	experiments	
evaluating	 the	 transcriptional	 program	 of	 BRG1	 in	 human	 T-ALL	 blasts,	 hinting	
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towards	overlap	with	a	PHF6/TLX1	gene	signature	(paper	3).	Interestingly,	mutations	
in	PHF6	 have	been	 recently	 identified	 in	Coffin-Siris	 syndrome	 cases	 that	normally	
typically	harbor	germline	mutations	 in	 genes	encoding	SWI-SNF	 complex	members	
(BRG1,	ARID1A/1B,	SMARCB1	 and	SMARCE1).	 	 First,	 this	 observation	 could	 further	
underscore	 a	 functional	 link	 between	 PHF6	 and	 BRG1	 in	 T-ALL.	 Notably,	 using	
arrayCGH	analysis,	we	very	recently	identified	in	our	T-ALL	cohort	one	patient	with	a	
focal	ARID1A	deletion	and	one	with	a	SMARCA4	(BRG1)	deletion	(unpublished	data),	
strongly	 suggesting	 the	 potential	 implication	 of	 the	 SWI-SNF	 complex	 as	 a	 novel	
tumor	supppressor	in	T-ALL,	in	contrast	to	its	known	oncogenic	role	in	AML22.	Most	
recently,	 Mullighan	 and	 colleagues	 identified	 SMARCA4	 mutations	 in	 3%	 of	 a	
pediatric	 T-ALL	 cohort	 (online	 communication	 abstracts	 ASH	 meeting	 2015).	 This	
finding	further	triggers	our	interest	to	explore	the	role	of	SMARCA4	and	other	SWI-
SNF	components	in	T-ALL.	
	
Similar	 to	PHF6,	also	BRG1	has	proven	a	key	role	 in	neuronal	differentiation25.	The	
mutational	 association	 between	 SOX11	 and	 the	 SWI-SNF	 complex	 in	 Coffin-Siris	
syndrome	could	also	in	that	respect	be	of	broader	relevance,	given	that	our	research	
team	 has	 identified	 SOX11	 as	 a	 novel	 oncogene	 in	 neuroblastoma	 (unpublished	
data).	 From	 the	 CCLE-database,	 T-ALL	 and	 neuroblastoma	 cell	 lines	 show	 amongst	
other	entities	 the	highest	 levels	of	BRG1	expression.	Moreover,	 it	has	been	shown	
that	 in	 AML	 cells	 BRG1	 occupies	 a	 distal	 c-MYC	 enhancer	 region,	 regulating	 its	
interaction	with	other	transcriptional	regulators	and	chromatin	looping	towards	the	
c-MYC	promoter22.	Both	MYC	and	MYCN	have	a	central	role	in	neuroblastoma	tumor	
biology	 and	 it	 could	 thus	 be	 speculated	 that	 functional	 interaction	 of	 BRG1	 with	
MYC/MYCN/MAX	in	the	context	of	neuroblastoma	could	be	relevant	 in	the	context	
of	transcriptional	deregulation	(Figure	2)26.	To	this	end,	we	will	further	evaluate	the	
transcriptional	networks	of	BRG1	both	 in	T-ALL	and	neuroblastoma	context	using	a	
genome-wide	 approach	 combining	 RNA-sequencing	 and	 ChIP-sequencing	 amongst	
others.	
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Figure	2:	Schematic	overview	of	possible	interactions	between	BRG1,	MYC	and	its	co-factor	MAX.	The	
physical	 interaction	between	MYC	and	BRG1	 (SWI-SNF)	 is	 required	 for	 regulating	 the	 expression	of	
MYC	and	MYC	target	genes	and	antagonizes	MYC	activity	to	induce	cell	differentiation	in	the	context	
of	malignant	 transformation,	 thereby	 acting	 as	 a	 tumor	 suppressor	 gene	 (upper	 panel).	 In	 case	 of	
BRG1	mutations,	this	regulatory	loop	is	distorted	and	will	lead	to	a	switch	from	differentation	towards	
cell	 growth	 (proliferation)	 (middle	 pannel).	 In	 case	 of	MYC	 amplification	 (mutually	 exclusive	 with	
BRG1	mutations)	MYC	will	 repress	pro-differentiation	genes	and	 induce	a	proliferative	 state	 (lower	
panel)	(adapted	from	Romero	et	al.,	Cancer	Discovery,	2014)26	
	
Chromatin	modifier	enzymes	have	been	proven	 to	be	 the	main	 interactors	of	 long	
non-coding	 RNAs	 both	 in	 development	 and	 in	 the	 process	 of	 malignant	
transformation,	 as	 exemplified	 by	 their	 recognized	 role	 in	 both	 normal	
hematopoiesis	and	leukemia27,28	(Figure	3).	The	ENCODE	consortium	now	estimates	
that	 the	human	genome	encodes	 approximately	 28,000	distinct	 lncRNAs29.	 A	well-
known	 example	 is	 the	 lncRNA	 ANRIL,	 exerting	 its	 function	 by	 guiding	 the	 PRC2	
complex	to	silence	the	expression	of	the	tumor	suppressor	genes	p15	 (INK4A),	p14	
(ARF)	and	p16	(INK4B),	eventually	contributing	to	uncontrolled	tumor	growth	(Figure	
3,	 right)27.	 In	 the	 meantime,	 many	 cancer	 types	 have	 been	 identified	 with	 ANRIL	
overexpression	 such	 as	 breast,	 lung	 and	 ovarian	 cancer.	 The	 PRC2	 complex	 is	
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currently	the	prototype	chromatin	modifier	complex	that	is	known	for	its	interaction	
with	various	 lncRNAs	such	as	XIST	 to	mediate	X-chromosome	 inactivation	 for	gene	
dosage	 compensation.	 Interestingly,	 a	 recent	 study	 by	 Yildirim	 and	 co-workers	
identified	XIST	as	a	novel	tumor	suppressor	 in	hematological	cancer,	affecting	both	
the	myeloid	and	the	lymphoid	blood	lineages30.		
Recent	studies	now	show	that	also	other	chromatin	remodeling	complexes,	including	
the	 SWI-SNF	 complex	 interacts	 with	 lncRNAs	 to	 exert	 is	 function.	 In	many	 cancer	
types,	the	function	of	the	SWI-SNF	complex	is	directly	affected	in	one	or	more	of	its	
core	components.	In	prostate	cancer	however,	it	seems	that	SWI-SNF	mutations	are	
much	 less	 frequent.	 Nevertheless,	 SWI-SNF	 complex	 function	 is	 deregulated	 in	
prostate	cancer	cases	due	to	the	overexpression	of	the	lncRNA	SChLAP1,	binding	to	
the	SNF5	component	of	the	complex	and	thereby	interfering	with	association	to	its	
target	genes31.	Also	in	the	context	of	plant	development	(Arabidopsis	Thaliana),	the	
SWI-SNF	 complex	 was	 recently	 shown	 to	 take	 part	 in	 complex	 formation	 with	
lncRNAs	 in	 concert	 with	 other	 lncRNA	 binding	 proteins	 and	 in	 that	 way	 facilitate	
lncRNA	mediated	gene	silencing32.	In	follow-up	of	this	PhD	mandate,	I	will	evaluate	
whether	 also	 in	 the	 context	 of	 normal	 and	 malignant	 T-cell	 development	 either	
association	 between	 the	 SWI-SNF	 complex	 and	 lncRNAs	 or	 direct	 regulation	 of	
lncRNA	expression	by	BRG1	amongst	other	takes	place.		
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Figure	 3:	 Schematic	 overview	 of	 lncRNAs	 known	 so	 far	 to	 be	 involved	 in	 normal	 and	 malignant	
hematopoiesis.	 This	 set	 of	 lncRNAs	 will	 actively	 participate	 in	 the	 gene	 regulatory	 networks	 that	
govern	 normal	 hematopoietic	 development	 or	 malignant	 leukemic	 transformation	 either	 through	
their	 interaction	 with	 chromatin	 remodeler	 complexes	 or	 guidance/sequestration	 of	 key	 master	
regulators	that	are	involved	in	hematopoietic	lineage	commitment	and	differentiation		(adapted	from	
Han	and	Chen,	Science	Signaling,	2013)27.		
	
1.4	Non-coding	RNAs	as	novel	therapeutic	targets	in	T-ALL	
	
Our	 research	 team	 has	 previously,	 in	 collaboration	 with	 the	 team	 of	 Hans-Guido	
Wendel	(Memorial	Sloan	Kettering,	New	York,	USA),	identified	five	novel	oncogenic	
miRNA	 (miR-19b,	miR-20a,	miR-26a,	miR-92	 and	miR-223),	 that	 were	 capable	 of	
inducing	 T-ALL	 in	 a	 NOTCH1-induced	 mouse	 model,	 linked	 to	 their	 cooperative	
suppression	 of	 several	 known	 T-ALL	 tumor	 suppressor	 genes	 (PHF6,	 BIM,	 IKZF1,	
FBXW7,	PTEN	and	NF1)33.	Later,	Gusscott	and	co-workers	showed	that	NOTCH1	itself	
is	 capable	of	 regulating	miRNA-expression	 in	T-ALL	blasts.	More	 specifically,	 it	was	
shown	that	NOTCH1	represses	the	expression	of	miR-223	to	counteract	the	negative	
regulation	 of	 IGF1R	 signaling	 by	miR-22334.	 	 During	 this	 PhD	 mandate,	 we	 have	
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identified,	 in	 parallel	with	 the	 study	of	 Trimarchi	 and	 colleagues35,	 LUNAR1	 as	 the	
most	robustly	regulated	NOTCH1	lncRNA,	both	 in	thymocyte	progenitors	and	T-ALL	
blasts	 (paper	 6).	 The	 contribution	 of	 LUNAR1	 to	 malignant	 transformation	 was	
shown	to	be	linked	to	its	direct	induction	of	IGF1R	expression	and	signaling.	We	have	
also	 extended	 the	 TLX1	 regulome	 towards	 long	 non-coding	 RNAs,	 landscaping	 the	
implication	of	these	non-coding	RNAs	in	this	T-ALL	subtype	(paper	5).	In	addition,	we	
scrutinized	the	set	of	miRNAs	implicated	in	the	TAL1	downstream	network	in	T-ALL	
(paper	4).	Altogether,	these	findings	indicate	that	the	pool	of	non-coding	RNAs,	both	
miRNAs	 and	 lncRNAs,	 are	 a	 novel	 class	 of	 targets	 in	 the	 future	 for	 innovative	
therapeutic	strategies	in	T-ALL	treatment.		
MiRNA-directed	therapeutic	strategies	offer	the	advantage	of	the	ability	to	affect	the	
expression	 of	multiple	 genes	 at	 a	 time,	 but	 this	may	 also	 cause	 at	 the	 same	 time	
potential	off-target	effects36.	Effective	targeting	of	oncogenic	miRNAs	such	as	those	
identified	 in	T-ALL	by	Mavrakis	and	colleagues33	can	be	reached	by	the	use	of	anti-
miRs	or	modified	versions	such	as	‘locked	nucleic	acids’	(LNAs),	which	are	currently	
evaluated	 for	 clinical	application37,	but	also	by	using	miRNA	sponges,	 that	harbour	
binding	 sites	 for	 the	 miRNA	 to	 be	 targeted	 through	 complementarity	 with	 the	
heptamer	sequence	of	its	seed	site38.	
	
Although	the	function	of	many	lncRNAs	is	still	poorly	characterized	so	far,	a	plethora	
of	recent	studies	underscore	their	key	role	in	malignant	transformation	such	as	in	T-
ALL	and	various	aspects	make	them	attractive	for	targeted	therapeutic	applications.	
Some	 lncRNAs	 are	 involved	 in	 many	 cancer	 types,	 such	 as	 MALAT1,	 which	 is	
overexpressed	 in	 lung	 cancer,	 gastric	 cancer	and	colorectal	 cancer	amongst	others	
and	 this	 is	 associated	with	overall	 poor	 survival39.	However,	many	 lncRNAs	display	
tissue-specific	 expression	 patterns,	 making	 them	 attractive	 for	 biomarker	
development	 and	 targeted	 treatment	 (Table	 1)40,41.	 A	 prototypical	 example	 is	 the	
lncRNA	PCA3	which	is	specifically	overexpressed	in	prostate	cancer42.	The	detection	
of	PCA3	in	urine	is	currently	used	as	a	diagnostic	tool	for	prostate	cancer	and	turned	
out	to	be	more	specific	than	the	previously	used	‘prostate-specific	antigen’	(PSA)41,43.	
Various	 strategies	 can	 be	 applied	 to	 downregulate	 oncogenic	 lncRNAs	 such	 as	 by	
antisense	 oligonucleotides	 (ASOs),	 small	 interfering	 RNAs	 (siRNAs)	 or	 short-hairpin	
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RNAs	 (shRNAs)	 as	 well	 as	 genome-editing	 tools	 like	 CRISPR-Cas9	 and	 these	 have	
been	successfully	applied	in	various	in	vitro	models.	The	challenge	remains	however	
to	perform	lncRNA	targeting	in	vivo.	Another	interesting	aspect	of	lncRNAs	that	can	
be	exploited	to	target	them	is	that	many	lncRNAs	exert	their	function	by	interactions	
with	 various	 chromatin-remodeling	 complexes.	 Small	 molecule	 compounds,	
designed	to	disrupt	these	interactions	could	be	very	potent44.		
	
										 	
											 	
Table	1:	Long	non-coding	RNAs	as	biomarkers	for	different	cancer	types41	
	
Nevertheless,	 advances	 in	 the	 field	 of	 lncRNA	 directed	 therapy	 development	 are	
currently	hampered	amongst	others	by	the	lack	of	knowledge	on	the	in	vivo	function	
for	many	of	the	identified	lncRNAs44.	Profound	functional	and	structural	analysis	of	
lncRNAs	will	be	required	to	drive	the	therapeutic	potential	of	this	novel	pool	of	non-
coding	RNAs	towards	clinical	application45.	 	
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Summary	
T-cell	acute	lymphoblastic	leukemia	(T-ALL)	is	a	highly	aggressive	malignant	disorder.	
While	 originally	 associated	 with	 poor	 prognosis,	 more	 recent	 intensified	 T-ALL	
therapy	 has	 led	 to	 remarkable	 improvements	 in	 survival	 of	 these	 patients.	
Unfortunately,	 these	 therapeutic	 schemes	 are	 associated	 with	 severe	 acute	 and	
long-term	 toxicities,	 thus	 demanding	 for	 further	 research	 in	 order	 to	 design	more	
precision	medicine	oriented	treatment.	Importantly,	for	T-ALL	patients	with	relapsed	
and	 refractory	 T-ALL,	 outcome	 remains	 extremely	 poor,	 thus	 urging	 further	
investigations	 to	 design	 therapies	 with	 further	 reduced	 relapse	 risk	 and/or	 novel	
treatment	 to	 cure	 relapsed	 cases.	 To	 shift	 towards	 this	 personalized	 medicine	
approach,	 a	 more	 profound	 understanding	 of	 the	 molecular	 basis	 of	 T-ALL	
progression	is	required.	Several	decades	of	genetic	studies	in	T-ALL	have	uncovered	
a	 remarkable	 heterogeneous	 and	 complex	 landscape	 of	 combined	 oncogenic	 and	
loss-of-function	mutations	 that	 contribute	 to	malignant	 thymocyte	 transformation.	
One	of	the	major	challenges	in	T-ALL	research	is	to	unravel	in	detail	how	the	diverse	
complement	of	oncogenes	 and	 tumor	 suppressors	 functionally	 contribute	 to	 T-ALL	
pathogenesis	 and	 response	 to	 therapy.	 To	 this	 end,	 I	 have	 studied	 the	 functional	
properties	 and	 cooperation	 of	 several	 key	 players	 that	 participate	 in	 normal	 and	
malignant	T-cell	development	at	the	level	of	transcriptional	regulatory	networks.			
TLX1	 is	 a	 major	 driver	 oncogene	 causing	 transformation	 of	 immature	 thymocytes	
towards	 T-ALL.	 Previous	 pioneering	 work	 partly	 uncovered	 its	 mode	 of	 action	 in	
relation	 to	 T-ALL	 formation,	 showing	 that	 ectopic	 overexpression	 of	 TLX1	 in	
immature	thymocytes	causes	repression	of	multiple	T-ALL	tumor	suppressor	genes.	
The	 study	 performed	 during	 this	 doctoral	 mandate,	 led	 to	 the	 observation	 of	 an	
unexpected	antagonism	between	the	TLX1	and	NOTCH1	oncogenes,	with	activated	
TLX1	suppressing	NOTCH1	and	key	NOTCH1	target	genes.	Based	on	this	finding,	we	
hypothesized	that	this	unique	interaction	between	both	oncogenes	could	explain	the	
presence	 of	 NOTCH1	 mutations	 in	 most	 TLX1	 driven	 T-ALL.	 Furthermore,	 the	
required	 cooperativity	 of	NOTCH1	 (pathway)	 activating	mutations	 can	 also	 explain	
the	very	long	latency	of	T-ALL	development	in	a	TLX1	driven	leukemia	mouse	model	
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(paper	 1).	 In	 addition	 to	 NOTCH1	 mutations,	 PHF6	 loss-of-function	mutations	 are	
also	frequently	observed,	pointing	at	a	further	putative	required	cooperative	genetic	
lesion	for	full-blown	TLX1	driven	T-ALL	formation.		Given	the	lack	of	insight	into	the	
normal	cellular	function	of	the	epigenetic	reader	protein	PHF6,	I	investigated	its	role	
during	 normal	 hematopoiesis	 and	 observed	 a	 profound	 effect	 of	 PHF6	 loss	 on	
hematopoietic	 lineage	 development	 (paper	 2).	 Moreover,	 in	 the	 context	 of	 TLX1	
driven	 T-ALL	 formation,	 I	 identified	 the	 tyrosine	 kinase	 ‘interleukine-7	 receptor’	
(IL7R)	as	a	robustly	upregulated	gene	upon	PHF6	knockdown.	Given	the	role	of	IL7R	
signaling	 in	 survival	 of	 maturing	 thymocytes,	 this	 observation	 opens	 an	 exciting	
perspective	 that	 PHF6	 loss	 is	 required	 as	 an	 essential	 cooperative	 event	 in	 TLX1	
driven	 T-ALL	 pathogenesis	 by	 re-installment	 of	 TLX1	 repressed	 IL7R	 expression.	
Importantly,	 in	 addition	 to	 paving	 the	 way	 for	 further	 animal	 modeling	 and	
mechanistic	 studies,	 this	 finding	 is	 also	 highly	 relevant	 in	 the	 context	 of	 design	 of	
novel	therapies	targeting	IL7R	downstream	JAK-STAT	signaling	(paper	3).	
Until	recently,	transcriptional	regulatory	networks	were	mainly	studied	from	a	‘gene-
protein	 coding’	 genomic	 viewpoint.	 Several	 studies	 have	 challenged	 this	 central	
dogma	based	on	 the	proven	 role	of	non-coding	RNAs	 in	 control	 of	normal	 cellular	
behavior.	 Given	 this	 exciting	 new	 perspective	 on	 further	 expanding	 complexity	 of	
gene	 regulation	 during	 normal	 development	 and	 malignant	 transformation,	 I	
decided	 to	study	 the	 role	of	 such	micro-RNAs	 (miRNAs)	and	 long	non-coding	RNAs	
(lncRNAs)	 in	 T-ALL	 perturbed	 transcriptional	 networks.	More	 specifically,	 I	 studied	
the	 role	 of	 miRNAs	 under	 control	 of	 TAL1	 (paper	 4),	 unraveled	 the	 landscape	 of	
lncRNAs	 implicated	 in	the	NOTCH1	signaling	pathway	(paper	5)	and	performed	the	
first	landscaping	of	the	TLX1	lncRNAome	(paper	6).	
In	 conclusion,	 my	 work	 has	 contributed	 to	 novel	 insights	 into	 transcriptional	
networks	in	normal	and	malignant	T-cell	development,	revealing	several	novel	nodes	
for	therapeutic	intervention	in	the	pursuit	of	personalized	medicine	development	in	
the	field	of	T-ALL	research.	
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T-cel	 acute	 lymfoblastische	 leukemie	 (T-ALL)	 is	 een	 uiterst	 agressieve,	 maligne	
aandoening.	Hoewel	 dit	 type	 kanker	 voorheen	 gekenmerkt	werd	 door	 een	 slechte	
prognose,	 heeft	 de	 evolutie	 naar	 geïntensifieerde	 therapie	 geleid	 tot	 een	 enorme	
verbetering	 in	 de	 huidige	 overlevingskansen	 van	 T-ALL	 patiënten.	 Deze	
behandelingsstrategieën	 zijn	 echter	 geassocieerd	 met	 heel	 wat	 toxische	
neveneffecten,	zowel	op	korte	als	lange	termijn.	Verder	onderzoek	is	daarom	vereist	
om	de	overgang	naar	gepersonaliseerde	en	gerichte	behandeling	mogelijk	te	maken.	
Voornamelijk	 voor	 T-ALL	 patiënten	 die	 hervallen	 of	 resistent	 zijn	 voor	 de	 huidige	
behandelingsprotocollen,	 blijft	 de	 kans	 op	 genezing	 enorm	 gering,	 wat	 de	 sterke	
nood	aan	behandelingsmethodes	waarbij	 geen	herval	 kan	optreden	of	die	 in	 staat	
zijn	patiënten	met	herval	van	ziekte	te	genezen	verder	onderstreept.	Om	de	transitie	
naar	dergelijke	gepersonaliseerde	behandeling	mogelijk	te	maken	is	een	grondigere	
kennis	 van	 de	 moleculaire	 basis	 van	 T-ALL	 progressie	 van	 uitermate	 belang.	
Verscheidene	decennia	van	genetische	studies	omtrent	T-ALL	hebben	geleid	 tot	de	
ontrafeling	 van	 een	 onwaarschijnlijk	 heterogene	 en	 complexe	 constellatie	 van	
oncogene	en	verlies-van-functie	mutaties	die	bijdragen	tot	de	maligne	transformatie	
van	voorloper	T-cellen.	Eén	van	de	huidige	uitdagingen	in	het	onderzoek	naar	T-ALL,	
omvat	het	ontrafelen	van	de	manier	waarop	het	geheel	aan	oncogenen	en	 tumor-	
suppressor	 genen	 functioneel	 bijdragen	 tot	 T-ALL	 pathogenese	 en	 de	 respons	 op	
therapie.	 In	 dit	 opzicht	 heb	 ik	 de	 functionele	 eigenschappen	 en	 de	 samenwerking	
tussen	verschillende	belangrijke	 factoren	 in	normale	en	maligne	T-cel	ontwikkeling	
bestudeerd	op	het	niveau	van	transcriptionele	netwerken.	
	
De	transcriptiefactor	TLX1	is	één	van	de	voornaamste	‘driver’	oncogenen	die	maligne	
transformatie	 van	 ontwikkelende	 T-cellen	 naar	 T-ALL	 lymfoblasten	 veroorzaakt.	
Baanbrekend	werk	heeft	reeds	eerder	aangetoond	dat	de	ectopische	expressie	van	
TLX1	van	belang	 is	 in	T-ALL	vorming	door	de	werking	als	 repressor	eiwit	 voor	heel	
wat	gekende	T-ALL	tumor	suppressor	genen	in	voorloper	T-cellen.	Het	onderzoek	in	
dit	 doctoraatsproefschrift	 heeft	 aangetoond	 dat	 een	 functioneel	 antagonisme	 zich	
voordoet	 tussen	 de	 oncogenen	 TLX1	 en	 NOTCH1	 in	 pre-leukemische	 T-ALL	 stadia,	
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waarbij	 TLX1	 de	 expressie	 van	 NOTCH1	 en	 een	 aantal	 van	 zijn	 belangrijke	
doelwitgenen	 onderdrukt.	 Op	 basis	 van	 deze	 bevinding	 stellen	 we	 als	 hypothese	
voorop	dat	deze	unieke	antagonistische	interactie	tussen	twee	oncogenen	de	uiterst	
hoge	 frequentie	 van	 activerende	 NOTCH1	 mutaties	 in	 TLX1-gedreven	 T-ALL	 kan	
verklaren.	 Daarnaast	 vormen	 de	 vereiste	 activerende	 mutaties	 in	 de	 NOTCH1	
signaalcascade	een	mogelijke	verklaring	voor	de	uiterst	lange	latentieperiode	van	T-
ALL	 ontwikkeling	 in	 het	 eerder	 beschreven	 TLX1	 gedreven	 T-ALL	 muismodel	
(manuscript	 1).	 Naast	 mutaties	 in	 NOTCH1,	 komen	 ook	 vaak	 verlies-van-functie	
mutaties	voor	 in	het	PHF6	gen	 in	TLX1-positieve	T-ALL	patiënten,	wat	aangeeft	dat	
bijkomende	coöperatieve	genetische	veranderingen	nodig	zijn	om	te	evolueren	naar	
een	 mature,	 TLX1-gedreven	 T-ALL	 vorming.	 De	 normale	 cellulaire	 functie	 van	 de	
epigenetische	regulator	PHF6	 is	tot	op	heden	ongekend.	 In	mijn	proefschrift	heb	 ik	
de	 rol	 van	 PHF6	 in	 normale	 humane	 hematopöese	 bestudeerd.	 Dit	 heeft	 tot	 het	
inzicht	geleid	dat	verlies	van	PHF6	expressie	de	vorming	van	de	verschillende	types	
hematopoiëtische	 cellen	 sterk	 verstoort	 (manuscript	 2).	 Daarnaast	 heeft	 dit	
onderzoek	geleid	 tot	de	 identificatie	 van	de	 ‘interleukine	7	 receptor’	 (IL7R)	 als	 één	
van	de	sterkst	opgereguleerde	genen	bij	PHF6	neerregulatie	in	de	context	van	TLX1-
gedreven	 T-ALL.	 IL7R-signalisatie	 is	 van	 uiterst	 belang	 in	 de	 overleving	 van	
ontwikkelende	 T-cellen.	 Deze	 observatie	 postuleert	 dus	 dat	 verlies	 van	 PHF6	 een	
cruciale	coöperatieve	genetische	wijziging	is	in	TLX1-gedreven	T-ALL	vorming,	om	zo	
de	onderdrukking	van	IL7R	expressie	door	TLX1	te	kunnen	herstellen	(manuscript	3).		
	
Transcriptionele	 regulatorische	 netwerken	 werden	 tot	 recent	 nog	 voornamelijk	
vanuit	het	‘gen-eiwit’	genetisch	perspectief	benaderd.	Verschillende	studies	hebben	
dit	centrale	dogma	nu	in	vraag	gesteld	op	basis	van	de	huidig	aangetoonde	cruciale	
rol	 van	 niet-coderende	 RNA	 species	 in	 de	 regulatie	 van	 normale	 cellulaire	
ontwikkeling.	 In	 het	 kader	 van	 deze	 nieuwe,	 evoluerende	 inzichten	 in	 de	
complexiteit	 van	 genregulatie	 tijdens	 normale	 ontwikkeling	 en	 maligne	
transformatie,	bestudeerde	ik	tijdens	dit	doctoraatsmandaat	de	rol	van	micro-RNAs	
en	lange	niet-coderende	RNAs	in	de	verstoorde	transcriptionele	netwerken	die	T-ALL	
vorming	 onderbouwen.	 In	 het	 bijzonder	 hebben	 deze	 studies	 geleid	 tot	 de	
identificatie	van	micro-RNAs	die	gereguleerd	worden	door	de	transcriptiefactor	TAL1	
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(manuscript	4),	de	ontdekking	van	lange	niet-coderende	RNAs	die	deel	uitmaken	van	
de	 NOTCH1	 signaalcascade	 (manuscript	 5)	 en	 de	 ontrafeling	 van	 het	 complement	
van	lange	niet-coderende	RNAs	onder	controle	van	TLX1	(manuscript	6).	
	
Samenvattend	 heeft	 het	 onderzoek	 uitgevoerd	 in	 het	 kader	 van	 dit	
doctoraatsproefschrift	 bijgedragen	 tot	 nieuwe	 inzichten	 in	 de	 transcriptionele	
netwerken	 van	 belang	 in	 normale	 en	 maligne	 T-cel	 ontwikkeling,	 waarbij	
verschillende	 nieuwe	 aanknopingspunten	 voor	 de	 ontwikkeling	 van	 nieuwe	
therapeutische	 strategieën	werden	blootgelegd,	 in	 het	 kader	 van	het	 streven	naar	
gepersonaliseerde	en	doelgerichte	behandeling	in	het	T-ALL	onderzoeksgebied.	
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Dankwoord	
Ik	 herinner	 me	 nog	 goed	 de	 eerste	 gesprekken	 met	 mijn	 promotor	 prof.	 Frank	
Speleman	voor	de	aanvang	van	dit	doctoraat:	'Denk	er	nog	eens	goed	over	na	of	je	
dit	zeker	wil	doen,	4	jaar	is	een	lange	tijd'.	Voor	mij	was	er	geen	twijfel,	de	kans	om	
me	als	wetenschapper	te	vormen	in	een	sterk	en	gemotiveerd	onderzoeksteam	wou	
ik	zo	graag	grijpen.	De	tijd	is	voorbij	gevlogen,	we	zijn	ondertussen	vijf	jaar	verder	en	
ik	kan	terugkijken	op	een	fantastische	periode.	De	stimulerende	en	warme	groep	van	
collega's	 waarin	 ik	 heb	 mogen	 vertoeven	 is	 uitzonderlijk	 en	 daar	 ben	 ik	 enorm	
dankbaar	 voor.	 De	 boeiende	 en	 uitdagende	 projecten	 waar	 ik	 mocht	 aan	
meewerken,	 de	 talrijke	 binnen-	 en	 buitenlandse	 meetings	 waaraan	 ik	 heb	
deelgenomen,	 de	 samenwerkingen	 met	 binnen-	 en	 buitenlandse	
onderzoeksgroepen,	 …	 zijn	 allen	 een	 enorme	 leerschool	 geweest	 tijdens	 dit	
doctoraatstraject,	niet	alleen	als	onderzoeker	maar	ook	als	persoon.		
	
In	de	eerste	plaats	wil	ik	in	dit	dankwoord	dan	ook	voor	dit	alles	mijn	promotor	prof.	
Frank	 Speleman	 bedanken.	 Je	 eindeloze	 enthousiasme	 en	 passie	 voor	
wetenschappelijk	 onderzoek	 zijn	 zo	 aanstekelijk,	 dat	 ik	 onder	 jouw	begeleiding	 de	
spirit	 vond	 om	 te	 blijven	 doorgaan,	 ook	 al	waren	 sommige	 projecten	 een	 enorme	
uitdaging.	 Frank,	 je	 was	mijn	 supervisor,	mentor,	 coach	 in	 schrijf-	 en	 presentatie-
skills,	mental	coach,	…	in	al	deze	aspecten	als	promotor	was	je	uitmuntend	en	heb	je	
een	 sfeer	 en	 omgeving	 gecreëerd	 waarin	 ik	 me	 als	 wetenschapper	 ten	 volle	 heb	
kunnen	ontplooien	en	daar	ben	ik	 je	enorm	dankbaar	voor.	 Ik	kijk	dan	ook	met	vol	
enthousiasme	uit	naar	onze	verdere	samenwerking.	
	
Verder	 wil	 ik	 ook	 mijn	 co-promotoren	 prof.	 Pieter	 van	 Vlierberghe	 en	 prof.	 Tom	
Taghon	 heel	 erg	 bedanken.	 Pieter,	 onze	 samenwerking	 heeft	 een	 vliegende	 start	
genomen	 nadat	 je	 terug	 was	 uit	 New	 York	 en	 is	 gegroeid	 tot	 een	 belangrijke	
leerschool	 voor	 mij	 tijdens	 dit	 doctoraat.	 Brainstormen	 over	 talrijke	 projecten,	
samen	 werken	 om	 een	manuscript	 te	 vormen	 en	 te	 schrijven	 tot	 het	 goed	 zit,	 …	
samen	met	Frank	was	je	steeds	paraat	om	me	te	helpen	en	ondersteuning	te	bieden	
waar	nodig,	enorm	bedankt	daarvoor.	Tom,	de	samenwerking	met	jouw	lab	gaf	me	
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de	 opportuniteit	 om	 mee	 te	 proeven	 van	 onderzoek	 in	 de	 context	 van	 normale	
hematopoëse	en	ervaar	 ik	dan	ook	als	een	enorme	meerwaarde	van	dit	doctoraat.	
Samen	met	 Inge	zijn	we	verschillende	uitdagingen	tijdens	dit	doctoraat	aangegaan,	
waarbij	ik	van	jullie	beide	veel	heb	geleerd	en	de	samenwerking	met	jullie	heeft	ook	
een	erg	motiverende	invloed	gehad	tijdens	deze	volledige	periode.		
	
Daarnaast	wil	ik	ook	graag	dr.	Pieter	Rondou	bedanken	voor	de	leerrijke	begeleiding	
en	ondersteuning.	Van	bij	 de	 start	 van	mijn	master	 thesis	 tot	op	heden	 zijn	we	er	
samen	voor	gegaan	om	de	rol	van	PHF6	in	normale	en	maligne	T-cel	ontwikkeling	te	
bestuderen.	Je	stond	altijd	paraat	om	me	te	helpen,	bedankt	daarvoor!	
	
Een	speciaal	woordje	van	dank	wil	ik	heel	graag	richten	tot	Aline.	Van	bij	de	start	van	
mijn	master	thesis	hebben	we	elkaar	leren	kennen	en	dit	is	echt	kunnen	uitgroeien	
tijdens	 deze	 doctoraatsperiode	 tot	 een	 duo-samenwerking	 die	 draait	 als	 een	
tandem.	 Ik	bewonder	 je	 inzet	en	enthousiasme	waarmee	 je	elke	dag	er	weer	voor	
gaat,	 ook	 al	 moesten	 we	 soms	 moeilijke	 en	 uitdagende	 experimenten	 tegemoet,	
merci	Aline!	
	
Tijdens	 de	 periode	 van	 deze	 PhD	 thesis,	 heb	 ik	 ook	 met	 heel	 wat	 andere	
onderzoekers	 mogen	 kennis	 maken	 en	 samenwerken,	 een	 zeer	 verrijkende	 en	
boeiende	ervaring.	Ik	had	dit	PhD	traject	dan	ook	nooit	kunnen	vervolledigen	zonder	
de	hulp	van	heel	wat	mensen	buiten	het	 lab	en	 ik	wil	hier	dan	ook	een	aantal	van	
hen	in	de	aandacht	brengen.	Van	bij	de	aanvang		van	dit	doctoraat	tot	het	einde	heb	
in	het	L3	lab	van	prof.	Bruno	Verhasselt	de	kans	gekregen	om	me	te	ontplooien	in	de	
wondere	wereld	van	 'virusproductie	en	 transductie',	bedankt	aan	het	volledige	L3-
team.	 In	 samenwerking	met	 het	 lab	 onder	 leiding	 van	prof.	 Jan	Cools,	 kreeg	 ik	 de	
kans	om	onderzoek	te	verrichten	onder	andere	samen	met	dr.	Charles	de	Bock,	van	
wie	ik	de	eerste	mouse	handling	skills	heb	aangeleerd	gekregen	en	die	steeds	paraat	
stond	tijdens	onze	samenwerkingen,	bedankt	Charley!		
	
Daarnaast	 wil	 ik	 ook	 een	 grote	 'dankjewel'	 richten	 naar	mijn	 vroegere	 en	 huidige	
bureaugenootjes	waar	ik	altijd	heb	op	kunnen	rekenen	en	vele	leuke	momenten	heb	
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mogen	 beleven	 (ik	 hoop	 dat	 ik	 hier	 niemand	 vergeet):	 Nadine,	 Pieter	 R,	 Sofie,	
Evelien,	 Joni,	 Suzanne,	 Hetty,	 Fary,	 Aline,	 Jolien,	 Annelynn,	 Bruce,	 Karen,	 Frank.	
Superbedankt	voor	de	grappige	(en	soms	hilarische)	momenten,	de	sappige	roddels	
en	de	leuke	sfeer!	Verder	wil	 ik	uiteraard	ook	een	heel	dikke	merci	richten	aan	alle	
andere	collega's,	iedereen	staat	steeds	paraat	om	elkaar	te	helpen	en	dankzij	jullie	is	
er	steeds	een	'warme'	wersksfeer	in	het	lab.	
	
Een	speciaal	dankwoord	ook	aan	mijn	familie	en	vrienden.	Mijn	ouders,	broer	en	zus	
hebben	 in	 dit	 volledige	 traject	 een	 warm	 nest	 van	 onuitputtelijke	 steun	 en	
aanmoediging	 betekend,	 what	 a	 family!	 Ook	 de	 schoonfamilie	 verdient	 hiervoor	
zeker	ook	een	hartelijke	merci.	Daarnaast	wil	 ik	de	sGKC,	de	dames	van	het	 'thesis	
hokje'	en	andere	vriendenkringen	enorm	bedanken	voor	de	vele	 leuke	en	gezellige	
momenten	samen.	Last	but	not	least	wil	ik	mijn	liefste,	Sven,	bedanken	om	er	altijd	
te	zijn	voor	mij	en	de	zalige	momenten	samen.	
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Nationality:	Belgian	
	
	
Experience	
	
9	months	Faculty	grant	of	the	Faculty	of	Medicine	and	Health	Sciences	
	
• Period:	January	1st,	2016	to	September	30th,	2016	
	
	
1	year	PhD	grant	of	VLK	Emmanuel	van	der	Schueren	sholarship	
	
• Period:	2014	–	2015	
Institute:	Ghent	University,	Center	for	Medical	Genetics,	Ghent,	Belgium	
Thesis:	Unraveling	the	role	of	PHF6	 in	normal	T-cell	development	and	T-cell	
acute	lymphoblastic	leukemia	
Promotor:	 Prof.	dr.	 Frank	Speleman	&	co-promotors	 prof.	dr.	 ir.	 Pieter	 van	
Vlierberghe	and	prof.	dr.	Tom	Taghon	
	
	
Doctoral	research	Assistant,	4	years	PhD	grant	of	IWT,	Flanders	
	
• Period:	2011	–	2014	
Institute:	Ghent	University,	Center	for	Medical	Genetics,	Ghent,	Belgium	
Thesis:	Unraveling	the	role	of	PHF6	 in	normal	T-cell	development	and	T-cell	
acute	lymphoblastic	leukemia	
Promotor:	 Prof.	dr.	 Frank	Speleman	&	co-promotors	prof.	dr.	 ir.	 Pieter	 van	
Vlierberghe	and	prof.	dr.	Tom	Taghon	
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Education 
 
Master	of	Science	in	Biochemistry	and	Biotechnology	
	
	
• Period:	2005-2010	
Institute:	Ghent	University	
Thesis:	 Ontrafelen	 van	 de	 rol	 van	 PHF6	 in	 normale	 T-cel	 ontwikkeling	 en	
acute	T-cel	leukemie	
Promotor:	Prof.	dr.	Frank	Speleman	&	co-promotor	dr.	Pieter	Rondou	
	
	
Scientific	Achievements	
 
Publications,	oral	presentations,	posters,	conferences	and	supervision	of	students	
	
Publications:	
	
1.	Durinck	K,	Goossens	S,	Peirs	S,	Wallaert	A,	Van	Loocke	W,	Matthijssens	F,	Pieters	
T,	Milani	G,	Lammens	T,	Rondou	P,	Van	Roy	N,	De	Moerloose	B,	Benoit	Y,	Haigh	 J,	
Speleman	 F,	 Poppe	 B,	 Van	 Vlierberghe	 P.	Novel	 biological	 insights	 in	 T-cell	 acute	
lymphoblastic	 leukemia.	 Exp	Hematol.	 2015	 Aug;43(8):625-39.	 (IF:	 2.746,	 ranking:	
Q3)	
	
2.	Durinck	K,	Loocke	WV,	Van	der	Meulen	J,	Van	de	Walle	I,	Ongenaert	M,	Rondou	P,	
Wallaert	A,	de	Bock	CE,	Van	Roy	N,	Poppe	B,	Cools	J,	Soulier	J,	Taghon	T,	Speleman	F,	
Van	Vlierberghe	P.	Characterization of	the	genome-wide	TLX1	binding	profile	 in	T-
cell	acute	 lymphoblastic	 leukemia.	Leukemia.	2015	Dec;29(12):2317-27	(IF:	10.431,	
ranking:	Q1)	
	
3.	Goossens	S,	Radaelli	E,	Blanchet	O,	Durinck	K,	Van	der	Meulen	J,	Peirs	S,	Taghon	T,	
Tremblay	CS,	Costa	M,	Farhang	Ghahremani	M,	De	Medts	J,	Bartunkova	S,	Haigh	K,	
Schwab	C,	Farla	N,	Pieters	T,	Matthijssens	F,	Van	Roy	N,	Best	JA,	Deswarte	K,	Bogaert	
P,	 Carmichael	 C,	 Rickard	 A,	 Suryani	 S,	 Bracken	 LS,	 Alserihi	 R,	 Canté-Barrett	 K,	
Haenebalcke	 L,	 Clappier	 E,	 Rondou	 P,	 Slowicka	 K,	 Huylebroeck	 D,	 Goldrath	 AW,	
Janzen	 V,	 McCormack	 MP,	 Lock	 RB,	 Curtis	 DJ,	 Harrison	 C,	 Berx	 G,	 Speleman	 F,	
Meijerink	 JP,	 Soulier	 J,	 Van	 Vlierberghe	 P,	 Haigh	 JJ.	 ZEB2	 drives	 immature	 T-cell	
lymphoblastic	 leukaemia	 development	 via	 enhanced	 tumour-initiating	 potential	
and	IL-7	receptor	signalling.	Nat	Commun.	2015	Jan	7;6:5794.	(IF:	11.47,	ranking	Q1)	
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4.	Durinck	K*,	Wallaert	A*,	Van	de	Walle	I,	Van	Loocke	W,	Volders	PJ,	Vanhauwaert	
S,	 Geerdens	 E,	 Benoit	 Y,	 Van	 Roy	 N,	 Poppe	 B,	 Soulier	 J,	 Cools	 J,	 Mestdagh	 P,	
Vandesompele	 J,	 Rondou	 P,	 Van	 Vlierberghe	 P,	 Taghon	 T,	 Speleman	 F.	 The	Notch	
driven	 long	 non-coding	 RNA	 repertoire	 in	 T-cell	 acute	 lymphoblastic	 leukemia.	
Haematologica.	2014	Dec;99(12):1808-16.	(IF:	5.814,	ranking:	Q1)	
	
5.	 Bethuyne	 J,	 De	 Gieter	 S,	 Zwaenepoel	 O,	 Garcia-Pino	 A,	 Durinck	 K,	 Verhelle	 A,	
Hassanzadeh-Ghassabeh	 G,	 Speleman	 F,	 Loris	 R,	 Gettemans	 J.	 A	 nanobody	
modulates	 the	 p53	 transcriptional	 program	 without	 perturbing	 its	 functional	
architecture.	Nucleic	acids	research.	2014;42(20):12928-38	(IF:	8.867,	ranking:	Q1)	
	
6.	 Van	 der	 Meulen	 J,	 Sanghvi	 V,	 Mavrakis	 K,	 Durinck	 K,	 Fang	 F,	 Matthijssens	 F,	
Rondou	 P,	 Rosen	 M,	 Pieters	 T,	 Vandenberghe	 P,	 Delabesse	 E,	 Lammens	 T,	 De	
Moerloose	 B,	 Menten	 B,	 Van	 Roy	 N,	 Verhasselt	 B,	 Poppe	 B,	 Benoit	 Y,	 Taghon	 T,	
Melnick	 AM,	 Speleman	 F,	 Wendel	 HG,	 Van	 Vlierberghe	 P.	 The	 H3K27me3	
demethylase	 UTX	 is	 a	 gender-specific	 tumor	 suppressor	 in	 T-cell	 acute	
lymphoblastic	leukemia.	Blood.	2015;125(1):13-21	(IF:	10.452,	ranking:	Q1)	
	
7.	Atak	ZK,	Gianfelici	V,	Hulselmans	G,	De	Keersmaecker	K,	Devasia	AG,	Geerdens	E,	
Mentens	 N,	 Chiaretti	 S,	 Durinck	 K,	 Uyttebroeck	 A,	 Vandenberghe	 P,	 Wlodarska	 I,	
Cloos	 J,	 Foà	 R,	 Speleman	 F,	 Cools	 J,	 Aerts	 S.	 Comprehensive	 analysis	 of	
transcriptome	 variation	 uncovers	 known	 and	 novel	 driver	 events	 in	 T-cell	 acute	
lymphoblastic	leukemia.	PLoS	genetics.	2013;9(12):e1003997	(IF:	8.167,ranking:	Q1)	
	
8.	Bustin	SA,	Benes	V,	Garson	J,	Hellemans	J,	Huggett	J,	Kubista	M,	Mueller	R,	Nolan	
T,	 Pfaffl	 MW,	 Shipley	 G,	 Wittwer	 CT,	 Schjerling	 P,	 Day	 PJ,	 Abreu	 M,	 Aguado	 B,	
Beaulieu	 JF,	 Beckers	 A,	 Bogaert	 S,	 Browne	 JA,	 Carrasco-Ramiro	 F,	 Ceelen	 L,	
Ciborowski	 K,	 Cornillie	 P,	 Coulon	 S,	 Cuypers	 A,	 De	 Brouwer	 S,	 De	 Ceuninck	 L,	 De	
Craene	 J,	 De	 Naeyer	 H,	 De	 Spiegelaere	 W,	 Deckers	 K,	 Dheedene	 A,	 Durinck	 K,	
Ferreira-Teixeira	M,	Fieuw	A,	Gallup	JM,	Gonzalo-Flores	S,	Goossens	K,	Heindryckx	F,	
Herring	E,	Hoenicka	H,	Icardi	L,	Jaggi	R,	Javad	F,	Karampelias	M,	Kibenge	F,	Kibenge	
M,	 Kumps	 C,	 Lambertz	 I,	 Lammens	 T,	 Markey	 A,	 Messiaen	 P,	 Mets	 E,	 Morais	 S,	
Mudarra-Rubio	A,	Nakiwala	J,	Nelis	H,	Olsvik	PA,	Pérez-Novo	C,	Plusquin	M,	Remans	
T,	Rihani	A,	Rodrigues-Santos	P,	Rondou	P,	Sanders	R,	Schmidt-Bleek	K,	Skovgaard	K,	
Smeets	K,	Tabera	L,	Toegel	S,	Van	Acker	T,	Van	den	Broeck	W,	Van	der	Meulen	J,	Van	
Gele	M,	 Van	 Peer	 G,	 Van	 Poucke	M,	 Van	 Roy	N,	 Vergult	 S,	Wauman	 J,	 Tshuikina-
Wiklander	 M,	 Willems	 E,	 Zaccara	 S,	 Zeka	 F,	 Vandesompele	 J.	 The	 need	 for	
transparency	 and	 good	 practices	 in	 the	 qPCR	 literature.	 Nature	 methods.	
2013;10(11):1063-7	(IF:	25.953,	ranking:	Q1)	
	
9.	Correia	NC,	Durinck	K,	Leite	AP,	Ongenaert	M,	Rondou	P,	Speleman	F,	Enguita	FJ,	
Barata	JT.	Novel	TAL1	targets	beyond	protein-coding	genes:	identification	of	TAL1-
regulated	 microRNAs	 in	 T-cell	 acute	 lymphoblastic	 leukemia.	 Leukemia.	 2013	
Jul;27(7):1603-6.	(IF:	10.431,	ranking:	Q1)	
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Oral	presentations:	
 
• Unraveling	 a	 NOTCH1-lncRNA-miRNA	 regulatory	 network	 in	 acute	 T-cell	
lymphoblastic	 leukemia	 and	 normal	 T-cell	 development.	 Durinck	 K,	
Mestdagh	P,	Taghon	T,	Van	der	Meulen	J,	Van	de	Walle	I,	Volders	PJ,	Pattyn	F,	
Van	Roy	N,	Benoit	Y,	Poppe	B,	Van	Vlierberghe	P,	Menten	B,	Vandesompele	J,	
Rondou	P,	Speleman	F.	12th	BeSHG	meeting,	March	2nd,	2012,	Liège,	Belgium	
	
• Functional	interplay	of	NOTCH1	and	PHF6:	balancing	between	normal	T-cell	
development	and	T-	ALL.	Durinck	K,	Van	der	Meulen	J,	Pattyn	F,	Ongenaert	
M,	Verhasselt	B,	Taghon	T,	Van	Roy	N,	Poppe	B,	Van	Vlierberghe	P,	Rondou	P,	
Speleman	F.	1st	Oncopoint	meeting,	May	23th,	2012,	Ghent,	Belgium	
	
• Unraveling	 a	 NOTCH1-lncRNA-miRNA	 regulatory	 network	 in	 acute	 T-cell	
lymphoblastic	 leukemia	 and	 normal	 T-cell	 development.	 Durinck	 K,	
Mestdagh	P,	Taghon	T,	Van	der	Meulen	J,	Van	de	Walle	I,	Volders	PJ,	Pattyn	F,	
Van	Roy	N,	Benoit	Y,	Poppe	B,	Van	Vlierberghe	P,	Menten	B,	Vandesompele	J,	
Rondou	 P,	 Speleman	 F.	 17th	 Congress	 of	 the	 European	 Hematology	
Association,	June	14-17th,	2012,	Amsterdam,	The	Netherlands	
	
• Expanding	 the	 TLX1-regulome	 in	 T-cell	 acute	 lymphoblastic	 leukemia	
towards	 long	non-coding	RNAs.	Durinck	K,	Van	der	Meulen	J,	Ongenaert	M,	
Volders	 PJ,	 Wallaert	 A,	 Van	 Roy	 N,	 Benoit	 Y,	 Poppe	 B,	 Mestdagh	 P,	
Vandesompele	 J,	 Rondou	 P,	 Soulier	 J,	 Van	Vlierberghe	 P,	 Speleman	 F.	 55th	
ASH	Annual	Meeting	and	Exposition,	December	5-10th,	2013,	New	 	Orleans,	
USA	
	
• Expanding	 the	 TLX1-regulome	 in	 T-cell	 acute	 lymphoblastic	 leukemia	
towards	 long	non-coding	RNAs.	Durinck	K,	Van	der	Meulen	J,	Ongenaert	M,	
Volders	 PJ,	 Wallaert	 A,	 Van	 Roy	 N,	 Benoit	 Y,	 Poppe	 B,	 Mestdagh	 P,	
Vandesompele	 J,	 Rondou	 P,	 Soulier	 J,	 Van	 Vlierberghe	 P,	 Speleman	 F.	 2nd	
Oncopoint	meeting,	February	6th,	2014,	Ghent,	Belgium	
	
• PHF6	 loss	 causes	 IL7R	 upregulation	 and	 sensitization	 to	 JAK	 inhibitors.	
Durinck	 K,	 Van	 de	Walle	 I*,	 De	 Bock	 C*,	 Rondou	 P*,	 Van	 Roy	 N,	 Benoit	 Y,	
Poppe	B,	Soulier	J,	Taghon	T,Cools	J,	Van	Vlierberghe	P	and	Speleman	F.	Pre-
EHA	workshop,	June	10-11th,	2014,	Amsterdam,	The	Netherlands	
	
• Expanding	 the	 TLX1	 regulome	 towards	 long	 non-coding	 RNAs.	 Durinck	 K,	
Van	der	Meulen	J,	Ongenaert	M,	Volders	PJ,	Wallaert	A,	Van	Roy	N,	Benoit	Y,	
Poppe	B,	Mestdagh	P,	Vandesompele	J,	Rondou	P,	Soulier	J,	Van	Vlierberghe	
P,	 Speleman	 F.	 Non-coding	 RNA	 meeting,	 June	 22nd-25th,	 Heidelberg,	
Germany	
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• Functional	 genomic	 dissection	 of	 the	 PHF6-TLX1	 regulatory	 axis	 in	 T-ALL.	
Durinck	 K,	 Van	 de	Walle	 I*,	 De	 Bock	 C*,	 Rondou	 P*,	 Van	 Roy	 N,	 Benoit	 Y,	
Poppe	B,	Soulier	 J,	Taghon	T,Cools	 J,	Van	Vlierberghe	P	and	Speleman	F.	 re-
EHA	workshop,	June	9-10th,	2014,	Rotterdam,	The	Netherlands	
	
	
Posters:		
 
• Unraveling	 a	 NOTCH1-lncRNA-miRNA	 regulatory	 network	 in	 acute	 T-cell	
lymphoblastic	 leukemia	 and	 normal	 T-cell	 development.	 Durinck	 K,	
Mestdagh	P,	Taghon	T,	Van	der	Meulen	J,	Van	de	Walle	I,	Volders	PJ,	Pattyn	F,	
Van	Roy	N,	Benoit	Y,	Poppe	B,	Van	Vlierberghe	P,	Menten	B,	Vandesompele	J,	
Rondou	 P,	 Speleman	 F.	 Keystone	 Symposia:	 non-coding	 RNAs,	 March	 31st-
April	5th,	2012,	Utah,	USA	
	
• Unraveling	 a	 NOTCH1-lncRNA-miRNA	 regulatory	 network	 in	 acute	 T-cell	
lymphoblastic	 leukemia	 and	 normal	 T-cell	 development.	 Durinck	 K,	
Mestdagh	P,	Taghon	T,	Van	der	Meulen	J,	Van	de	Walle	I,	Volders	PJ,	Pattyn	F,	
Van	Roy	N,	Benoit	Y,	Poppe	B,	Van	Vlierberghe	P,	Menten	B,	Vandesompele	J,	
Rondou	 P,	 Speleman	 F.	 Cell	 Symposia:	 Angiogenesis,	 Metabolic	 Regulation	
and	Cancer	Biology	in	association	with	VIB,	July	6-8th,	2012,	Leuven,	Belgium	
	
• Integrative	 analysis	 of	 the	 NOTCH1	 regulatory	 network	 identifies	 key	
downstream	lncRNAs	in	acute	T-cell	lymphoblastic	leukemia	and	normal	T-
cell	development.	Durinck	K,	Mestdagh	P,	Volders	PJ,	Taghon	T,	Van	de	Walle	
I,	Ongenaert	M,	Van	der	Meulen	J,	Vanhauwaert	S,	Wallaert	A,	Soulier	J,	Van	
Roy	 N,	 Benoit	 Y,	 Poppe	 B,	Menten	 B,	 Vandesompele	 J,	 Van	 Vlierberghe	 P,	
Rondou	P,	Speleman	F.	Keystone	Symposia:	noncoding	RNAs	in	Development	
and	Cancer,	January	20th-25th,	2013,	Vancouver,	Canada	
	
• NOTCH1	 driven	 miRNAs	 implicated	 in	 normal	 and	 malignant	 T-cell	
development.	 Durinck	 K,	 Van	 der	 Meulen	 J,	 Van	 de	 Walle	 I,	 Pipelers	 P,	
Mestdagh	P,	Ongenaert	M,	Van	Roy	N,	Benoit	Y,	Poppe	B,	Vandesompele	 J,	
De	 Preter	 K,	 Thas	O,	 Van	 Vlierberghe	 P,	 Rondou	 P,	 Soulier	 J,	 Speleman	 F*,	
Taghon	T*.	EHA-ESH:	Second	Scientific	Workshop:	T-cell	acute	lymphoblastic	
leukemia,	March	22nd-24th,	2013,	Lisbon,	Portugal	
	
• NOTCH1	signaling	induces	global	transcriptional	changes	in	long	non-coding	
RNA	 expression	 in	 T-cell	 acute	 lymphoblastic	 leukemia	 and	 normal	 T-cell	
development.	Durinck	K,	Mestdagh	P,	Volders	PJ,	Taghon	T,	Van	de	Walle	I,	
Ongenaert	M,	Van	der	Meulen	 J,	Vanhauwaert	S,	Wallaert	A,	 Soulier	 J,	Van	
Roy	 N,	 Benoit	 Y,	 Poppe	 B,	Menten	 B,	 Vandesompele	 J,	 Van	 Vlierberghe	 P,	
Rondou	 P,	 Speleman	 F.	 EHA-ESH:	 Second	 Scientific	 Workshop:	 T-cell	 acute	
lymphoblastic	leukemia,	March	22nd-24th,	2013,	Lisbon,	Portugal	
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• Phf6	 deficiency	 causes	 defective	 primitive	 and	 definitive	 hematopoiesis	
during	 zebrafish	 development.	 Vanhauwaert	 S,	 Janssens	 E,	 Willaert	 A,	
Durinck	 K,	 De	 Paepe	 A,	 Vandesompele	 J,	 Van	 Vlierberghe	 P,	 Rondou	 P,	
Speleman	 F.	 8th	 European	 Zebrafish	 Meeting,	 July	 9-13th,	 2013,	 Barcelona,	
Spain	
	
• The	plant	homeodomain	 (PHD)-like	 finger	protein	PHF6	chromatin	binding	
pattern	 and	 transcriptional	 regulation	 indicates	 a	 functional	 link	 with	
NOTCH1	in	T-cell	acute	lymphoblastic	 leukemia.	Durinck	K,	Van	der	Meulen	
J,	Ongenaert	M,	Verhasselt	B,	Taghon	T,	Van	de	Walle	I,	Van	Roy	N,	Poppe	B,	
Benoit	Y,	Gevaert	K,	Van	Vlierberghe	P,	Rondou	P,	Speleman	F.	Cell	symposia:	
Cancer	Epigenomics,	October	6-8th,	2013,	Sitges,	Spain	
	
• Characterization	of	the	NOTCH1	driven	miRNA	network	that	controls	normal	
human	T-	cell		
	development.	Van	der	Meulen	J,	Durinck	K,	Van	de	Walle	I,	Mestdagh	P,	De	
Preter	K,	Van	Peer	G,	Van		
	Roy	N,	Poppe	B,	Ongenaert	M,	Vandesompele	J,		Rondou	P,	Van	Vlierberghe	
P,	Speleman	F,	Taghon		
	T.	2nd	Oncopoint	Meeting,	February	6th,	2014,	Ghent,	Belgium	
	
• Phf6	plays	a	role	in	hematopoiesis	and	thymopoiesis	 in	zebrafish.	Janssens	
E.,	Vanhauwaert	S,	Willaert	A,	Durinck	K,	De	Paepe	A,	Vandesompele	J,	Van	
Vlierberghe	P,	Rondou	P,	Speleman	F.	2nd	Oncopoint	Meeting,	February	6th,	
2014,	Ghent,	Belgium	
	
• Expanding	 the	 TLX1-regulome	 in	 T-cell	 acute	 lymphoblastic	 leukemia	
towards	 long	non-coding	RNAs.	Durinck	K,	Van	der	Meulen	J,	Ongenaert	M,	
Volders	 PJ,	 Wallaert	 A,	 Van	 Roy	 N,	 Benoit	 Y,	 Poppe	 B,	 Mestdagh	 P,	
Vandesompele	 J,	 Rondou	 P,	 Soulier	 J,	 Van	 Vlierberghe	 P,	 Speleman	 F.	 14th	
BeSHG	meeting,	February	7th,	2014,	Antwerp,	Belgium	
	
• Unique	 lncRNA	 signatures	 mark	 the	 major	 T-ALL	 genetic	 subgroups.	
Wallaert	A,	Durinck	K,	Vanloocke	W,	Volders	PJ,	Benoit	Y,	Poppe	B,	Mestdagh	
P,	Vandesompele	J,	Soulier	J,	Cools	J,	Van	Vlierberghe	P,	Rondou	P,	Speleman	
F.	14th	BeSHG	meeting,	February	7th,	2014,	Antwerp,	Belgium	
	
• PHF6	 loss	drives	 IL7R	oncogene	addiction	 in	T-ALL.	Durinck	K,	Rondou	P*,	
Van	de	Walle	I*,	De	Bock	C,	Van	Roy	N,	Benoit	Y,	Poppe	B,	Taghon	T,	Soulier	J,	
Cools	J,	Van	Vlierberghe	P	and	Speleman	F.	19th	congress	of	EHA,	June	12-
15th,	Milan,	Italy	
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• Transcriptional	 antagonism	 between	 the	 cooperative	 oncogenes	NOTCH1	
and	TLX1	in	T-cell	acute	lymphoblastic	leukemia.	Durinck	K,	Van	Loocke	W,	
Van	 der	Meulen	J,	 Van	 de	Walle	I,	 Rondou	P,	 de	 Bock	CE,	 Poppe	B,	 Cools	J,	
Soulier	 J,	 Taghon	 T,	 Speleman	 F	 and	 Van	 Vlierberghe	 P.	 AACR	 meeting	
Hematological	Malignancies,	September	20-23th,	Philadelphia,	Pennsylvania,	
USA	
	
• PHF6	 loss	 compensates	 for	 TLX1	mediated	 repression	 of	 IL7R	 expression	
and	 shows	 a	 functional	 interplay	 with	 the	 SWI-SNF	 remodeling	 complex	
during	T-ALL	formation.	Durinck	K,	Van	de	Walle	I*,	De	Bock	C*,	Rondou	P*,	
Van	Roy	N,	Benoit	Y,	Poppe	B,	Soulier	J,	Taghon	T,Cools	J,	Van	Vlierberghe	P	
and	Speleman	F.	Keystone	meeting,	January	24-30th,	Denver,	USA	
	
• Functional	 genomic	 dissection	 of	 the	 TLX1	 regulome	 in	 T-ALL.	Durinck	 K,	
Van	 Loocke	W,	 Van	 der	 Meulen	 J,	 Van	 de	 Walle	 I,	 Rondou	P,	 de	 Bock	CE,	
Poppe	 B,	 Cools	 J,	 Soulier	 J,	 Taghon	 T,	 Speleman	 F	 and	 Van	 Vlierberghe	 P.	
FASEB	meeting,	July	26th-31st,	Vermont,	Saxtons	River,	USA	
	
• The	 T-ALL	 oncogene	 TLX1	 controls	 enhancer	 lncRNA	 expression.	Durinck	 K,	 Van	
Loocke	W,	Matthijssens	F,	Verboom	K,	Van	de	Walle	I,	Wallaert	A,	Volders	PJ,	Van	
Roy	 N,	 Benoit	 Y,	 Poppe	 B,	 Rondou	 P,	 Mestdagh	 P,	 Vandesompele	 J,	 De	 Laat	W,	
Taghon	 T,	 Soulier	 J,	 Van	 Vlierberghe	 P,	 Speleman	 F.	 AACR	 meeting	 Epigenetics,	
September	24-27th,	Atlanta,	USA	
	
Conferences:	
	
• 7th	European	Zebrafish	Meeting,	July	5th-9th,	2011,	Edinburgh,	Scotland	
• 53th	ASH	Annual	Meeting	and	Exposition,	December	10th-13th,	2011,	San		
					Diego,	USA	
• 12th	BeSHG	Meeting,	March	2nd,	2012,	Liège,	Belgium	
• 1st	Oncopoint	Meeting,	May	23th,	2012,	Ghent,	Belgium	
• 17th	Congress	of	 the	European	Hematology	Association,	 June	14-17th,	 2012,	
Amsterdam,	The	Netherlands	
• Cell	 Symposia:	 Angiogenesis,	 Metabolic	 Regulation	 and	 Cancer	 Biology	 in	
association	with	VIB,	July	6th-8th,	2012,	Leuven,	Belgium	
• Keystone	 Symposia:	 noncoding	 RNAs	 in	 Development	 and	 Cancer,	 January	
20-25th,	2013,	Vancouver,	Canada	
• EHA-ESH:	 Second	 Scientific	Workshop:	 T-cell	 acute	 lymphoblastic	 leukemia,	
March	22nd-24th,	2013,	Lisbon,	Portugal	
• Cell	symposia:	Cancer	Epigenomics,	October	6th-8th,	2013,	Sitges,	Spain	
• 55th	 ASH	 Annual	 Meeting	 and	 Exposition,	 December	 5th-10th,	 2013,	 New	
Orleans,	USA	
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• 2nd	Oncopoint	Meeting,	February	6th,	2014,	Ghent,	Belgium	
• 14th	BeSHG	meeting,	February	7th,	2014,	Antwerp,	Belgium	
• 1st	Masterclass	Hematology	meeting,	9-10th	June,	2014,	Amsterdam,	The	
					Netherlands	
• EMBL	meeting	 on	 Non-coding	 RNAs	 in	 development	 and	 disease,	 22nd-25th	
June,	2014,	Heidelberg,	Germany	
• 56th	Annual	ASH	meeting,	December	6-9th,	2014,	San	Francisco,	USA	
• Keystone	epigenetics	meeting,	January	24-30th,	2015,	Denver,	USA	
• 2nd	Masterclass	Hematology	meeting,	9-10th	June,	2015,	Rottterdam	The	
					Netherlands	
• FASEB	meeting,	July	26th-31st,	Vermont,	Saxtons	River,	USA	
• AACR	meeting	on	Epigenetics,	September	24-27th,	2015,	Atlanta,	USA	
 
 
Courses	
 
• Felasa	C	certificate	for	Laboratory	Anima	science,	academic	year	2011-2012	
Ghent	University,	Belgium	
• BITS	course,	RNA-seq	analysis	for	differential	expression,	April	22nd	and	24th,	2014,	
VIB,	Leuven,	Belgium	
• Wellcome	Trust	Advanced	Course	on	Epigenetics,	November	10-19th,	2014,	Sanger	
Institute,	Cambridge,	UK	
	
Training	
	
• Training	in	4C-sequecing,	host	lab	Wouter	de	Laat,	Hubrecht	Institute,	February	2nd	-	
6th,	Utrecht,	The	Netherlands	
	
 
 
Supervision	of	students:	
 
Z-lijn	 paper,	 2nd	 Bachelor	 of	 Medicine	 2010-2011:	 Sofie	 Demoen,	 Het	
kankerepigenoom:	 potentieel	 doelwit	 voor	 nieuwe	 therapeutische	 strategieën.	
Supervision:	Kaat	Durinck,	promotor:	prof.	Frank	Speleman	
	
Master	Thesis,	2nd	Master	of	Biomedical	Sciences	2011-2012:	Maaike	Van	Hoecke,	
Functionele	analyse	van	PHF6	als	tumor	suppressor	 in	T-cel	acute	 lymfoblastische	
leukemie.	 Supervision:	 Kaat	 Durinck	 and	 Pieter	 Rondou,	 promotor:	 prof.	 Frank	
Speleman	
	
Z-lijn	paper,	2nd	Bachelor	of	Medicine	2011-2012:	Tomas	Paquet,	Deregulatie	van	
het	 epigenetisch	 landschap	 in	 oncogenese	 als	 potentieel	 doelwit	 voor	 nieuwe	
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therapeutische	 strategieën.	 Supervision:	 Kaat	 Durinck,	 promotor:	 prof.	 Frank	
Speleman	
	
Master	 Thesis	 2nd	 Master	 of	 Biomedical	 Sciences	 2012-2013:	 Hannelore	
Haemerlinck,	 Functionele	 analyse	 van	 PHF6	 als	 tumor	 suppressor	 in	 T-cel	 acute	
lymfoblastische	leukemie.	Supervision:	Kaat	Durinck	and	Pieter	Rondou,	promotor:	
prof.	Frank	Speleman	
	
Z-lijn	paper,	 2nd	Bachelor	of	Medicine	2012-2013:	Björn	Tuytens,	Toepassing	van	
epigenetische	 therapeutica	 in	 hematologische	 maligniteiten.	 Supervision:	 Kaat	
Durinck,	promotor:	prof.	Frank	Speleman	
	
Z-lijn	 paper,	 2nd	 Bachelor	 of	 Medicine	 2012-2013:	 Zander	Macharis,	 Toepassing	
van	epigenetische	therapeutica	in	hematologische	maligniteiten.	Supervision:	Kaat	
Durinck,	promotor:	prof.	Frank	Speleman	
	
Z-lijn	 paper,	 2nd	 Bachelor	 of	 Medicine	 2013-2014:	 Siska	 Van	 den	 Hautte,	
Toepassing	 van	 epigenetische	 therapeutica	 in	 hematologische	 maligniteiten.	
Supervision:	Kaat	Durinck,	promotor:	prof.	Frank	Speleman	
	
Z-lijn,	2nd	Bachelor	of	Medicine,	2014-2015:	Tessa	Berben,	Interleukine	7	receptor	
signalisatie	als	therapeutisch	doelwit	 in	T-cel	 leukemie.	Supervision:	Kaat	Durinck,	
promotor:	prof.	Frank	Speleman	
	
Z-lijn,	 2nd	 Bachelor	 of	 Medicine,	 2015-2016:	 Elise	 de	 Cuyper,	 Bromodomein-
inhibitoren	als	nieuwe	epigenetische	therapie	in	kanker.	Supervision:	Kaat	Durinck,	
promotor:	prof.	Frank	Speleman	
	
Z-lijn,	2nd	Bachelor	of	Medicine,	 2015-2016:	Tim	Krols,	Bromodomein-inhibitoren	
als	nieuwe	epigenetische	therapie	in	kanker.	Supervision:	Kaat	Durinck,	promotor:	
prof.	Frank	Speleman	
	
	
		 334	
	
	
	
	
	
	
	
	
	
	
	
	
List	of	main	abbreviations	
	 335	
List	of	main	abbreviations	
	
	
AID  Activation Induced cytidine Deaminase 
AML  Acute myeloid leukemia 
ASO  antisense oligonucleotide 
BFLS  Börjeson-Forssman-Lehmann syndrome 
 CD  Cluster of Differentiation 
ceRNA competing endogenous RNA 
CHD  Chromodomain helicase 
ChIP  Chromatin immunoprecipitation 
CRISPR Clustered regularly interspaced short palindromic sequences 
CSS  Coffin-Siris syndrome 
DNA  DeoxyriboNucleic Acid 
DDR  DNA damage response 
DNMT DNA methyltransferase 
EMT  Epithelial-mesenchymal transition 
ETP  Early T-cell precursor 
FACS  Fluorescence activated cell sorting 
FCS  Fetal Calf Serum 
GFP  Green Fluorescent Protein 
GRAALL Group for Research in Adult Acute Lymphoblastic Leukemia 
GREAT Genomic Regions Enrichment of Annotations 
GSEA  Gene Set Enrichment Analysis 
GSI  gamma-secretase inhibitor 
HSC  Hematopoietic stem cell 
ICN1  Intracellular NOTCH1 fragment 
IGF1R  Insulin Growth factor Receptor 1 
ING  Inhibitor of Growth 
IL7R  Interleukin 7 receptor 
INO80  Inositol requiring 80 
KDM6A Lysine-specific (K) demethylase 6A 
lncRNA long non-coding RNA 
miRNA micro-RNA 
NCBRS Nicolaides-Baraitser syndrome 
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NLS  Nuclear Localization Signal 
NurD  Nucleosome Remodeling and Deacetylation 
MAML Mastermind-like 
MBD  Methyl-Binding Domain 
PHD  Plant Homeodomain 
PRC2  Polycomb group protein complex 2 
shRNA short hairpin RNA 
SWI-SNF Switching defective/Sucrose Non-Fermenting 
PHF6   Plant Homeodomain zinc finger protein 6 
PTM  post-translational modification 
qPCR  quantitative polymerase chain reaction 
TAL1  T-cell acute Lymphocytic Leukemia 1 
T-ALL  T-cell acute lymphoblastic leukemia 
TCR  T-cell receptor 
TDG  thymine DNA glycosylase 
TET  Ten Eleven Translocation 
TLX1  T-cell leukemia homeobox 1 
UBF   Upstream Binding factor 
ZEB2  Zinc finger E-box binding homeobox 2 protein 
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